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Abstract 
 
 
Background and Aim 
Cardiovascular disease is one of the leading causes of death around the world.  Resting 
heart rate has been shown to be a strong and independent risk marker for adverse 
cardiovascular events and mortality, and yet its role as a predictor of risk is somewhat 
overlooked in clinical practice.  With the aim of highlighting its prognostic value, the 
role of resting heart rate as a risk marker for death and other adverse outcomes was 
further examined in a number of different patient populations. 
 
Materials and Methods 
A systematic review of studies that previously assessed the prognostic value of resting 
heart rate for mortality and other adverse cardiovascular outcomes was presented.  
New analyses of nine clinical trials were carried out.  Both the original and extended 
Cox model that allows for analysis of time-dependent covariates were used to evaluate 
and compare the predictive value of baseline and time-updated heart rate 
measurements for adverse outcomes in the CAPRICORN, EUROPA, PROSPER, PERFORM, 
BEAUTIFUL and SHIFT populations.  Pooled individual patient meta-analyses of the 
CAPRICORN, EPHESUS, OPTIMAAL and VALIANT trials, and the BEAUTIFUL and SHIFT 
trials, were also performed.  The discrimination and calibration of the models applied 
were evaluated using Harrell’s C-statistic and likelihood ratio tests, respectively.  
Finally, following on from the systematic review, meta-analyses of the relation between 
baseline and time-updated heart rate, and the risk of death from any cause and from 
cardiovascular causes, were conducted. 
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Results 
Both elevated baseline and time-updated resting heart rates were found to be 
associated with an increase in the risk of mortality and other adverse cardiovascular 
events in all of the populations analysed.  In some cases, elevated time-updated heart 
rate was associated with risk of events where baseline heart rate was not.  Time-
updated heart rate also contributed additional information about the risk of certain 
events despite knowledge of baseline heart rate or previous heart rate measurements.  
The addition of resting heart rate to the models where resting heart rate was found to 
be associated with risk of outcome improved both discrimination and calibration, and in 
general, the models including time-updated heart rate along with baseline or the 
previous heart rate measurement had the highest and similar C-statistics, and thus the 
greatest discriminative ability.  The meta-analyses demonstrated that a 5bpm higher 
baseline heart rate was associated with a 7.9% and an 8.0% increase in the risk of all-
cause and cardiovascular death, respectively (both p<0.001).  Additionally, a 5bpm 
higher time-updated heart rate (adjusted for baseline heart rate in eight of the ten 
studies included in the analyses) was associated with a 12.8% (p<0.001) and a 10.9% 
(p<0.001) increase in the risk of all-cause and cardiovascular death, respectively.   
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Discussion 
These findings may motivate health care professionals to routinely assess resting heart 
rate in order to identify individuals at a higher risk of adverse events.  The fact that the 
addition of time-updated resting heart rate improved the discrimination and calibration 
of models for certain outcomes, even if only modestly, strengthens the case that it be 
added to traditional risk models.  The findings, however, are of particular importance, 
and have greater implications for the clinical management of patients with pre-existing 
disease.  An elevated, or increasing heart rate over time could be used as a tool, 
potentially alongside other established risk scores, to help doctors identify patient 
deterioration or those at higher risk, who might benefit from more intensive monitoring 
or treatment re-evaluation.  Further exploration of the role of continuous recording of 
resting heart rate, say, when patients are at home, would be informative.  In addition, 
investigation into the cost-effectiveness and optimal frequency of resting heart rate 
measurement is required.  One of the most vital areas for future research is the 
definition of an objective cut-off value for the definition of a high resting heart rate. 
  
v 
 
Table of Contents 
 
Abstract ............................................................................................... ii 
Table of Contents .................................................................................... v 
List of Tables......................................................................................... xi 
List of Figures ...................................................................................... xiii 
Acknowledgements ............................................................................... xviii 
Author’s Declaration .............................................................................. xix 
Publications ......................................................................................... xx 
Abbreviations ...................................................................................... xxi 
Summary ........................................................................................... xxiii 
Chapter 1: Introduction ............................................................................ 1 
1.1 Resting Heart Rate and Life Expectancy among Mammals ......................... 1 
1.2 The Current Costs of Cardiovascular Disease and Death ............................ 3 
1.3 The Cardiovascular Disease Continuum ............................................... 4 
1.4 The Prevalence of Risk Factors for Cardiovascular Disease ........................ 6 
1.4.1 High Cholesterol ........................................................................ 6 
1.4.2 Hypertension ............................................................................ 6 
1.4.3 Diabetes ................................................................................. 6 
1.4.4 Obesity ................................................................................... 7 
1.4.5 Chronic Kidney Disease ................................................................ 7 
1.4.6 Cigarette Smoking ...................................................................... 8 
1.4.7 Alcohol Consumption................................................................... 8 
1.4.8 Physical Inactivity ...................................................................... 8 
vi 
 
1.5 The Association between Heart Rate and Risk Factors for Cardiovascular 
Disease ............................................................................................. 9 
1.5.1 Heart Rate and the Development of Hypertension ................................ 9 
1.5.2 Heart Rate and the Development of Diabetes .................................... 10 
1.5.3 The Association between Heart Rate and Obesity ................................ 10 
1.5.4 The Association between Heart Rate and Kidney Disease ....................... 11 
1.5.5 The Effect of Smoking on Heart Rate............................................... 11 
1.5.6 The Effect of Alcohol Consumption on Heart Rate ............................... 12 
1.5.7 The Effects of Physical Activity on Heart Rate .................................... 12 
1.6 Additional Factors that Affect Heart Rate ........................................... 13 
1.7 Methods of Measuring Resting Heart Rate ........................................... 13 
1.8 Interpretation of the Hazard Ratio ................................................... 16 
1.9 Chapter Summary ....................................................................... 19 
Chapter 2: A Systematic Review of Heart Rate as a Prognostic Risk Marker for Mortality 
and Adverse Cardiovascular Outcomes .......................................................... 21 
2.1 Introduction .............................................................................. 21 
2.2 Methods ................................................................................... 22 
2.2.1 Literature Search ...................................................................... 22 
2.2.2 Eligible Studies ........................................................................ 23 
2.2.3 Eligible Heart Rate Measurements and Outcomes ................................ 23 
2.2.4 Eligible Participants ................................................................... 24 
2.2.5 Further Exclusions ..................................................................... 24 
2.2.6 Data Extraction and Organisation of Studies ...................................... 24 
2.2.7 Assessment of Risk of Bias ........................................................... 25 
2.3 Results .................................................................................... 25 
vii 
 
2.3.1 Baseline Heart Rate Studies ......................................................... 26 
2.3.2 Multiple Heart Rate Measurement Studies ......................................... 49 
2.4 Discussion ................................................................................. 55 
2.4.1 Baseline Heart Rate Studies ......................................................... 55 
2.4.2 Multiple Heart Rate Measurement Studies ......................................... 57 
2.4.3 Findings in Relation to Practice and Research .................................... 59 
2.4.4 Strengths and Limitations ............................................................ 61 
2.4.5 Chapter Summary and Conclusions ................................................. 63 
Chapter 3: Materials and Methods ............................................................... 64 
3.1 Introduction .............................................................................. 64 
3.2 Datasets and Trials ...................................................................... 64 
3.2.1 Patients Included in the High Risk MI Database ................................... 67 
3.2.2 EUROPA ................................................................................. 70 
3.2.3 PROSPER ................................................................................ 71 
3.2.4 PERFORM ................................................................................ 72 
3.2.5 BEAUTIFUL .............................................................................. 73 
3.2.6 SHIFT .................................................................................... 74 
3.3 Methods of Analysis Applied in Chapters 4 to 8 ..................................... 74 
3.3.1 Heart Rate Groups..................................................................... 74 
3.3.2 Comparison of Baseline Characteristics ............................................ 76 
3.3.3 Cox Proportional Hazards Regression Analysis .................................... 76 
3.3.4 Linearity ................................................................................ 82 
3.3.5 Model Discrimination and Calibration .............................................. 82 
3.3.6 Subgroup Analyses ..................................................................... 83 
viii 
 
3.3.7 Proportionality of Hazards ........................................................... 84 
3.4 Methods used in the Meta-Analyses Presented in Chapter 9 ...................... 85 
3.5 Chapter Summary ....................................................................... 88 
Chapter 4: Heart Rate and Risk in Post-Acute MI Patients ................................... 89 
4.1 Introduction .............................................................................. 89 
4.2 A Pooled Analysis of the Predictive Value of Baseline Resting Heart Rate in 
Patients after Acute MI, with HF, LVSD or Both ............................................ 90 
4.3 The Predictive Value of Time-Updated Heart Rate Measurements in the 
CAPRICORN Placebo Patients ................................................................. 105 
4.4 Discussion ................................................................................ 116 
4.4.1 Chapter Summary and Conclusions ................................................ 120 
Chapter 5: Heart Rate and Risk in the EUROPA Population ................................. 122 
5.1 Introduction ............................................................................. 122 
5.2 Methods and Results ................................................................... 122 
5.3 Discussion ................................................................................ 134 
5.3.1 Chapter Summary and Conclusions ................................................ 138 
Chapter 6: Heart Rate and Risk in the PROSPER Population ................................ 140 
6.1 Introduction ............................................................................. 140 
6.2 Methods and Results ................................................................... 141 
6.3 Discussion ................................................................................ 156 
6.3.1 Chapter Summary and Conclusions ................................................ 162 
Chapter 7: Heart Rate and Risk in the PERFORM Population ................................ 163 
7.1 Introduction ............................................................................. 163 
7.2 Methods and Results ................................................................... 164 
7.3 Discussion ................................................................................ 177 
ix 
 
7.3.1 Chapter Summary and Conclusions ................................................ 180 
Chapter 8: Heart Rate and Risk in Patients with Left-Ventricular Systolic Dysfunction 181 
8.1 Introduction ............................................................................. 181 
8.2 The Predictive Value of Baseline and Time-Updated Heart Rate Measurements 
in the BEAUTIFUL Placebo Patients .......................................................... 182 
8.3 The Predictive Value of Baseline and Time-Updated Heart Rate Measurements 
in the SHIFT Placebo Patients ................................................................ 194 
8.4 A Pooled Analysis of the Predictive Value of Baseline and Time-Updated Heart 
Rate Measurements in Patients with Left-Ventricular Systolic Dysfunction and Stable 
Coronary Heart Disease, Chronic Heart Failure or Both .................................. 207 
8.5 Discussion ................................................................................ 220 
8.5.1 Chapter Summary and Conclusions ................................................ 226 
Chapter 9: Meta-Analyses of the Associations between Resting Heart Rate and All-Cause 
and Cardiovascular Mortality .................................................................... 228 
9.1 Introduction ............................................................................. 228 
9.2 A Meta-Analysis of 28 Studies that Analysed Baseline Resting Heart Rate as a 
Prognostic Risk Marker for All-Cause and Cardiovascular Mortality ..................... 229 
9.2.1 Study Selection and Data Extraction .............................................. 229 
9.2.2 Results ................................................................................. 229 
9.3 A Meta-Analysis of 10 Studies that Analysed Time-Updated Resting Heart Rate 
as a Prognostic Risk Marker for All-Cause and Cardiovascular Mortality ............... 240 
9.3.1 Study Selection and Data Extraction .............................................. 240 
9.3.2 Results ................................................................................. 241 
9.4 Discussion ................................................................................ 246 
9.4.1 Strengths and Limitations ........................................................... 250 
x 
 
9.4.2 Chapter Summary and Conclusions ................................................ 251 
Chapter 10: Discussion ........................................................................... 252 
10.1 Background, Justification and Overview ......................................... 252 
10.2 Main Findings ......................................................................... 255 
10.2.1 Associations Between Resting Heart Rate and Risk ............................ 255 
10.2.2 Model Discrimination and Calibration ............................................ 262 
10.2.3 Evidence of Non-Proportionality of Hazards .................................... 262 
10.2.4 Meta-Analyses ....................................................................... 263 
10.3 Clinical Implications ................................................................. 263 
10.4 The Recommended Method for Assessing Risk Associated with Resting Heart 
Rate 265 
10.5 Future Research ...................................................................... 266 
10.6 Limitations ............................................................................ 271 
10.7 Summary .............................................................................. 272 
Appendices ......................................................................................... 273 
Appendix 1: Supplementary Tables for Chapter 2 ......................................... 274 
Appendix 2: Supplementary Tables for Chapter 4 ............................................ 316 
Appendix 3: Supplementary Tables for Chapter 5 ............................................ 335 
Appendix 4: Supplementary Tables for Chapter 6 ............................................ 346 
Appendix 5: Supplementary Tables for Chapter 7 ............................................ 367 
Appendix 6: Supplementary Tables for Chapter 8 ............................................ 378 
Appendix 7: Supplementary Tables for Chapter 9 ............................................ 412 
List of References ................................................................................. 423 
 
  
xi 
 
List of Tables 
Table 2-1: A summary of the evidence presented by the ‘baseline heart rate’ studies, on 
the association between baseline resting heart rate and each of the main adverse 
outcomes in the populations of subjects discussed in Section 2.3.1. ...................... 56 
Table 2-2: A summary of the evidence presented by the ‘multiple heart rate 
measurement studies’, on the association between both baseline and multiple resting 
heart rate measurements, and each of the main adverse outcomes in the populations of 
subjects discussed in Section 2.3.2. ............................................................. 58 
Table 3-1: Main features of the nine trials newly analysed in this thesis. ................. 65 
Table 4-1: Characteristics and inclusion criteria of the CAPRICORN, EPHESUS, OPTIMAAL 
and VALIANT trial populations. ................................................................... 91 
Table 4-2: Baseline characteristics of the pooled population of patients included in the 
High Risk MI Database by heart rate group. .................................................... 93 
Table 4-3: The number of first events that occurred in the pooled population of patients 
included in the High Risk MI Database and each of the baseline heart rate groups. ..... 96 
Table 4-4: Baseline characteristics of the CAPRICORN placebo population. ............. 106 
Table 4-5: The number of first events that occurred in the CAPRICORN placebo 
population. ......................................................................................... 108 
Table 5-1: Baseline characteristics of the EUROPA study population. .................... 124 
Table 5-2: The number of first events that occurred in the EUROPA population. ....... 125 
Table 6-1: Baseline characteristics of the PROSPER study population. ................... 144 
Table 6-2: The number of first events that occurred in the PROSPER population. ...... 146 
Table 7-1: Baseline characteristics of the PERFORM study population. ................... 165 
Table 7-2: The number of first events that occurred in the PERFORM population. ..... 168 
Table 8-1: Baseline characteristics of the BEAUTIFUL placebo study population. ....... 184 
Table 8-2: The number of first events that occurred in the BEAUTIFUL placebo 
population. ......................................................................................... 185 
Table 8-3: Baseline characteristics of the SHIFT placebo study population. ............. 195 
xii 
 
Table 8-4: The number of first events that occurred in the SHIFT placebo population. 198 
Table 8-5: Principal characteristics, key inclusion criteria, and main features of the 
BEAUTIFUL and SHIFT populations. ............................................................. 208 
Table 8-6: Baseline characteristics of the pooled left-ventricular dysfunction placebo 
population by heart rate group. ................................................................ 210 
Table 8-7: The number of first events that occurred in the pooled left-ventricular 
dysfunction placebo population and each of the baseline heart rate groups. ........... 212 
Table 10-1: A summary and comparison of the evidence previously identified in the 
systematic review of Chapter 2, and the evidence presented in Chapters 4 to 8 of the 
thesis, on the associations between both baseline and multiple resting heart rate 
measurements, and risk of each of the main adverse outcomes, in the populations of 
subjects discussed in the review and in Chapters 4 to 8. ................................... 260 
  
xiii 
 
List of Figures 
Figure 1-1: The relationship between resting heart rate and life expectancy in 
mammals, adapted from Figure 1 in Levine 19972. ............................................ 1 
Figure 1-2: The updated cardiovascular disease continuum presented by Dzau et al. 
2006, adapted from Figure 2 in Dzau et al. 200614. ............................................ 5 
Figure 2-1: Flow chart of the selection process of the studies included in the systematic 
review. ............................................................................................... 26 
Figure 4-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the five baseline heart rate groups 
greater than or equal to 65bpm, relative to a baseline heart rate <65bpm in the pooled 
population of patients included in the High Risk MI Database. .............................. 98 
Figure 4-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher baseline heart rate in the 
pooled population of patients included in the High Risk MI Database. ..................... 99 
Figure 4-3: The Schoenfeld residuals plots for a 5bpm higher baseline heart rate for 
each outcome in the pooled population of patients included in the High Risk MI 
Database. ........................................................................................... 102 
Figure 4-4: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the five baseline heart rate groups 
greater than or equal to 65bpm, relative to a baseline heart rate <65bpm, in the 
CAPRICORN, EPHESUS, OPTIMAAL and VALIANT populations, for the outcomes that 
showed significant interactions between heart rate and study. ........................... 103 
Figure 4-5: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher baseline heart rate, in the 
CAPRICORN, EPHESUS, OPTIMAAL and VALIANT populations, for the outcomes that 
showed significant interactions between heart rate and study. ........................... 104 
xiv 
 
Figure 4-6: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥75bpm compared to a heart 
rate <75bpm in the CAPRICORN placebo population. ........................................ 109 
Figure 4-7: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the CAPRICORN 
placebo population. ............................................................................... 111 
Figure 4-8: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate 
patterns ‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the 
CAPRICORN placebo population. ................................................................ 113 
Figure 5-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥70bpm compared to a heart 
rate <70bpm in the EUROPA population. ...................................................... 127 
Figure 5-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the EUROPA 
population. ......................................................................................... 128 
Figure 5-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate 
patterns ‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the 
EUROPA population. .............................................................................. 131 
Figure 6-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a ‘high’ heart rate relative to a ‘low’ heart 
rate in the PROSPER population. ................................................................ 148 
Figure 6-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the PROSPER 
population. ......................................................................................... 150 
Figure 6-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate 
xv 
 
patterns ‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the 
PROSPER population. ............................................................................. 152 
Figure 7-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥70bpm compared to a heart 
rate <70bpm in the PERFORM population. ..................................................... 169 
Figure 7-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the PERFORM 
population. ......................................................................................... 171 
Figure 7-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate 
patterns ‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the 
PERFORM population. ............................................................................. 173 
Figure 7-4: The Schoenfeld residuals plot of the effect of a 5bpm higher baseline heart 
rate on the risk of all-cause death in the PERFORM population. ........................... 177 
Figure 8-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥70bpm compared to a heart 
rate <70bpm in the BEAUTIFUL placebo population. ......................................... 187 
Figure 8-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the BEAUTIFUL 
placebo population. ............................................................................... 189 
Figure 8-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate 
patterns ‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the 
BEAUTIFUL placebo population. ................................................................. 190 
Figure 8-4: The Schoenfeld residuals plots for a 5bpm higher baseline heart rate for 
each of the outcomes where evidence of non-proportionality of the effect of heart rate 
over time was observed in the BEAUTIFUL placebo population. ........................... 193 
xvi 
 
Figure 8-5: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥80bpm compared to a heart 
rate <80bpm in the SHIFT placebo population. ............................................... 200 
Figure 8-6: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the SHIFT 
placebo population. ............................................................................... 201 
Figure 8-7: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate 
patterns ‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the 
SHIFT placebo population. ....................................................................... 203 
Figure 8-8: The Schoenfeld residuals plots for a baseline heart rate ≥80bpm for each of 
the outcomes where evidence of non-proportionality of the effect of heart rate over 
time was observed in the SHIFT placebo population. ........................................ 206 
Figure 8-9: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the five baseline heart rate groups 
greater than or equal to 65bpm, relative to <65bpm, and each of the six time-updated 
heart rate groups greater than or equal to 60bpm, relative to <60bpm, in the pooled 
left-ventricular dysfunction placebo population. ............................................ 215 
Figure 8-10: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the six time-updated heart rate 
groups greater than or equal to 60bpm, relative to <60bpm, in the pooled left-
ventricular dysfunction placebo population. .................................................. 216 
Figure 8-11: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the pooled left-
ventricular dysfunction placebo population. .................................................. 217 
Figure 8-12: The Schoenfeld residuals plots for a 5bpm higher baseline heart rate for 
each of the outcomes where evidence of non-proportionality of the effect of heart rate 
over time was observed in the pooled left-ventricular dysfunction placebo population.
 ....................................................................................................... 219 
xvii 
 
Figure 9-1: Flow chart of the selection process of the studies included in the meta-
analysis of baseline resting heart rate. ........................................................ 230 
Figure 9-2: Forest plot representing the individual and pooled risk of all-cause death 
associated with a 5bpm higher baseline resting heart rate. ................................ 234 
Figure 9-3: Forest plot representing the individual and pooled risk of all-cause death 
associated with a 5bpm higher baseline resting heart rate, overall and by patient 
population. ......................................................................................... 235 
Figure 9-4: Forest plot representing the individual and pooled risk of cardiovascular 
death associated with a 5bpm higher baseline resting heart rate. ........................ 236 
Figure 9-5: Forest plot representing the individual and pooled risk of cardiovascular 
death associated with a 5bpm higher baseline resting heart rate, overall and by patient 
population. ......................................................................................... 237 
Figure 9-6: Funnel plots showing the degree of publication bias for all-cause death and 
cardiovascular death, assessed from the results in Table A7-2. ........................... 238 
Figure 9-7: Flow chart of the selection process of the studies included in the meta-
analysis of time-updated resting heart rate. .................................................. 242 
Figure 9-8: Forest plot representing the individual and pooled risk of all-cause death 
associated with a 5bpm higher time-updated resting heart rate. ......................... 243 
Figure 9-9: Forest plot representing the individual and pooled risk of cardiovascular 
death associated with a 5bpm higher time-updated resting heart rate. .................. 245 
 
  
xviii 
 
Acknowledgements 
First, I would like to thank my supervisor Professor Ian Ford.  Despite being constantly busy 
and in demand, you always made time to provide me with your invaluable guidance and 
support, and for that I am profoundly grateful.  It has been a privilege to work with such a 
calm and reassuring supervisor, and to have the opportunity to learn from your wealth of 
knowledge.  To my second supervisor, Dr Sarah Barry, thank you so much for offering me 
your advice and encouragement throughout these three and half years, especially when I 
was feeling slightly stressed and overwhelmed. 
I would also like to thank Servier for funding my PhD, and everyone at the Robertson Centre 
for welcoming me and making me feel part of the team – especially Michelle and Suzanne 
who did so in addition to preparing some data sets for me to analyse.  My greatest thanks 
also go to Professors Graham Teasdale and Tom McMillan, whom I was lucky enough to work 
with on a very interesting side project, which led to my first publication, and an amazing 
trip to San Francisco where I got to present at my first international conference.  To my 
fellow PhD student Jess Wainman-Lefley and sleep researcher Dr Maria Gardani, thank you 
for making this trip such an enjoyable experience.  Sarah, thank you again for your guidance 
on this project, and Alex, thank you for taking over after Sarah went off to have her lovely 
baby Ella. 
To my friend and fellow PhD student Victoria Bianchi, our weekly visits to the library to 
work on our projects were without a doubt one of the highlights of my final year - both 
productive and fun-filled, they made writing up a much more enjoyable experience, and I 
will be sure to be available when your time comes if you need me! 
Finally, to my family – Mum, Dad, Gregor, Nana, Grampa and Nona – thank you for being 
there for me during this time and throughout my life.  Dad, thank you for reading over my 
entire thesis, and Mum, thank you for comforting me during my times of despair and cooking 
me dinner every night.  I wouldn’t be where I am today without all of you and your 
unwavering love and support, and for that I am eternally grateful.    
xix 
 
Author’s Declaration 
This thesis has been composed by myself and has not been submitted in any previous 
application for a degree.  The work reported within was executed by myself, unless 
otherwise stated. 
  
xx 
 
Publications 
Original research publications authored by the candidate on work related to this thesis: 
Hamill V, Ford I, Fox K, Bohm M, Borer JS, Ferrari R, et al.  Repeated heart rate 
measurement and cardiovascular outcomes in left ventricular systolic dysfunction.  Am J 
Med.  2015; 128 (10): 1102-8. 
 
Original research publication authored by the candidate on work not specifically related 
to this thesis: 
Hamill V, Barry SJE, McConnachie A, McMillan TM, Teasdale GM.  Mortality from head 
injury over four decades in Scotland.  J Neurotrauma.  2015; 32(10): 689-703. 
 
Conference proceedings not specifically related to this thesis: 
2014 Tenth World Congress on Brain Injury 
Oral abstract presentation: ‘Mortality from Head Injury 1974-2012 in Scotland’ 
San Francisco, USA. 
  
xxi 
 
Abbreviations 
ACE  Angiotensin Converting Enzyme 
ACS  Acute Coronary Syndrome 
AF  Atrial Fibrillation 
ANOVA  Analysis of Variance 
ARB  Angiotensin-II Receptor Blocker 
BMI   Body Mass Index 
CABG  Coronary Artery Bypass Graft 
CHD  Coronary Heart Disease 
CCB  Calcium Channel Blocker 
CI  Confidence Interval 
CV  Cardiovascular 
DBP  Diastolic Blood Pressure 
ECG  Electrocardiogram/Electrocardiography 
eGFR  estimated Glomerular Filtration Rate 
EF  Ejection Fraction 
HDL  High Density Lipoprotein 
HF  Heart Failure 
HR  Hazard Ratio 
LDL   Low Density Lipoprotein 
LV  Left-Ventricular 
xxii 
 
LVEF  Left-Ventricular Ejection Fraction 
LVSD  Left-Ventricular Systolic Dysfunction 
MI  Myocardial Infarction 
NSTEMI Non-ST-Elevation Myocardial Infarction 
NYHA  New York Heart Association 
PAD  Peripheral Artery Disease 
PCI  Percutaneous Coronary Intervention 
PTCA  Percutaneous Transluminal Coronary Angioplasty 
OR   Odds Ratio 
RR  Relative Risk 
SBP  Systolic Blood Pressure 
STEMI  ST-Elevation Myocardial Infarction 
TIA  Transient Ischemic Attack 
UK  United Kingdom 
US  United States 
WHO  World Health Organisation  
xxiii 
 
Summary 
It has been previously demonstrated that resting heart rate is a strong and independent 
risk marker for adverse cardiovascular events and mortality.  However, the role of 
resting heart rate as a predictor of risk is perhaps undervalued in clinical practice.  
Compared to the number of studies that have investigated the risk associated with a 
single resting heart rate measurement using standard Cox proportional hazards 
regression, few have assessed the prognostic value of multiple heart rate measurements 
entered into the extended Cox model as a single time-dependent variable, and less have 
performed meta-analyses of the results from different studies.  Furthermore, the 
majority of studies have been of subjects from the general population, often with no 
existing cardiovascular disease. 
The aim of this thesis is to highlight the importance of heart rate as an indicator of risk, 
by further examining the role of resting heart rate as a risk marker for death and other 
adverse cardiovascular outcomes in a number of different patient populations.  In 
particular, the risk associated with multiple resting heart rate measurements is assessed 
using the extended Cox model, and both standard and individual patient meta-analyses 
are performed. 
Chapter 1 begins by presenting the relationship between heart rate and life span in 
mammals, as well as the current human and economic costs of cardiovascular disease.  
The concept of the cardiovascular disease continuum is introduced, and the prevalence 
of the risk factors known to initiate the series of events leading to end-stage heart 
failure is described.  The association between heart rate and such risk factors is 
discussed, and other factors that can affect heart rate are briefly mentioned.  An 
overview of the methods of measuring resting heart rate, along with recent 
recommendations for its measurement, and the methods used in the nine trials newly 
analysed in the thesis, is given.  Finally, hazard ratios are briefly introduced, and it is 
explained that although hazard ratios are often reported as an increase or decrease in 
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risk in the field, and are reported as such throughout the thesis, strictly speaking, it is 
not the risk of death or an event, but the hazard of death or an event, that is increased 
or decreased.  An alternative interpretation is then described to help highlight the 
distinction. 
Chapter 2 presents a systematic review of studies that analysed resting heart rate as a 
risk marker for mortality and other adverse cardiovascular outcomes, distinguishing 
between studies that used a single heart rate measurement to predict risk from those 
that used multiple heart rate measurements.   
New analyses of nine clinical trials are presented in Chapters 4 to 9, and information 
about these trials is given at the beginning of Chapter 3.  Chapters 4 to 8 employ similar 
methods of analysis, and a description of these methods follows.  Finally, the methods 
used in the meta-analyses presented in Chapter 9, including the random-effects 
restricted maximum likelihood method, is described. 
Chapter 4, Section 4.1, investigates the association between baseline resting heart rate 
and adverse outcomes in patients after acute myocardial infarction with  heart failure, 
left-ventricular systolic dysfunction, or both, by performing a pooled individual patient 
meta-analysis of the CAPRICORN, EPHESUS, OPTIMAAL and VALIANT trials, using the High 
Risk Myocardial Infarction Database.  The predictive value of time-updated heart rate 
measurements in the CAPRICORN placebo population is then examined in Section 4.2.  
Chapters 5 to 7 further assess the predictive value of baseline and time-updated heart 
rate measurements for death and other adverse outcomes in the EUROPA, PROSPER, and 
PERFORM trial populations, respectively.  Similar analyses of the BEAUTIFUL and SHIFT 
placebo populations are carried out in Chapter 8 Sections 8.1 and 8.2, respectively.  
Since both studies included patients who had left-ventricular systolic dysfunction, a 
pooled individual patient meta-analysis of the two placebo populations is subsequently 
presented in Chapter 8 Section 8.3. 
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Following on from the systematic review of Chapter 2, a meta-analysis of the published 
prospective evidence on the relationship between baseline heart rate and the risk of 
all-cause and cardiovascular death is presented in Chapter 9 Section 9.2.  A similar 
meta-analysis of time-updated resting heart rate is presented in Section 9.3.  The 
results from Chapters 4 to 8 are also included in the analyses. 
Finally, Chapter 10 discusses the thesis as a whole.  
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Chapter 1 
 
Introduction 
1.1 Resting Heart Rate and Life Expectancy among 
Mammals 
Heart rate among mammals varies considerably between species.  Small animals have 
high heart rates, while larger animals have much lower heart rates.  The heart rate of a 
hamster, for example, is around 400bpm, while that of a horse is around 40bpm1.  
Smaller species of mammals also have shorter lives than larger species.  Hamsters, for 
example, live for around 2-3 years, while horses live for around 25-30 years.  It could be 
surmised that animals with a slow heart rate live longer than those with a fast heart 
rate, and this is indeed the case2,3.  Levine 19972 demonstrated that heart rate is 
negatively correlated with life span in mammals, as shown by Figure 1-1. 
Figure 1-1: The relationship between resting heart rate and life expectancy in mammals, 
adapted from Figure 1 in Levine 19972.   
 
Note that the y-axis was plotted using the natural log values of the heart rates stated on the axis. 
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In fact, overlooking some variations, all mammals excluding humans appear to use the 
same number of heart beats during their lives: interestingly, regardless of species, the 
heart of a mammal beats approximately 1.1 billion times over their lifetime2. 
Figure 1-1 shows that humans are an exception to this rule.  The average resting heart 
rate of a human lies between 60 and 100bpm, similar to that of other large mammals 
such as the polar bear or tiger1.  However, unlike polar bears or tigers who live for 
around 20 years, humans often live long into their 70s and 80s.  Indeed, the human 
heart beats approximately 3 billion times over a lifetime4 – two billion more times than 
that of other mammals.       
A plausible explanation of this difference between humans and other warm-blood 
animals is that humans are able to extend their lives through improvements in living 
standards and use of modern scientific methods.  At the end of the 19th century the 
median age of British men and women was around 47: by the beginning of the 21st 
century it had increased to around 805.  During the 20th century, much of society 
benefited from access to more nutritious diets, cleaner drinking water, and vaccines 
that prevented potentially life-threatening parasitic and infectious diseases, such as 
measles, polio, smallpox and tuberculosis6.  Techniques and treatments found to 
effectively intervene in the process of heart disease were also discovered.  Increased 
knowledge about the effect of diet, smoking, and physical activity on the development 
of atherosclerosis likely contributed to the decrease in its prevalence observed over the 
late 20th century7.  In addition, implementation of procedures such as defibrillation, 
percutaneous coronary intervention (PCI), and pacemaker implantation, along with 
access to a range of pharmacologic drugs such as thrombolytics and beta-blockers, 
means that individuals who develop heart disease are now able to live longer than they 
would have done in the past.    
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1.2 The Current Costs of Cardiovascular Disease and 
Death 
Despite recent advancements in medicine, the human and economic costs of 
cardiovascular (CV) disease are still high across Britain, Europe and the United States 
(US).   
In 2008, CV disease was the primary cause of death worldwide, accounting for 30% of all 
deaths.  At that time, 17.3 million deaths per year were caused by CV disease.  By 2030, 
this number is anticipated to have increased to over 23.6 million8,9. 
CV disease is the main cause of death in Europe and the US.  In Europe, over four 
million deaths each year are due to CV disease10.  In the US, 2,150 Americans die every 
day from some form of the disease, equating to one every 40 seconds8.  In Europe, and 
the US, more lives are lost because of CV disease than all forms of cancer combined. 
Conversely, in 2012, for the first time since the British Heart Foundation was created in 
1961, cancer was responsible for more deaths than CV disease in the United Kingdom 
(UK).  While 29% of British deaths were caused by cancer, 28% were still due to CV 
disease11. 
A significant number of premature deaths, defined as deaths before the age of 75 years 
old, are also due to CV disease.  In Europe, 37% and 38% of premature deaths in men 
and women, respectively, are caused by CV disease10; In Britain, 26% and 18% of men 
and women, respectively, died prematurely because of CV disease in 201211.   
The number of people living with some form of CV disease in these countries is also 
considerable.  Over 2.3 million residents of the UK have coronary heart disease (CHD), 
more than half a million have heart failure (HF), 1.15 million have atrial fibrillation 
(AF), and more than 1.3 million have previously had a stroke11.  Approximately 27% of 
Americans are living with some form of heart disease or the after-effects of a stroke8. 
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Both the direct and indirect costs of CV disease are huge.  In the US, an estimated 
$320.1 billion is spent each year8.  More than £6.8 billion was spent on treatment within 
the National Health Service in England in 2012/1311.  In addition, production losses 
associated with the disease, and informal care, cost the UK over £6 billion and around 
£3.8 billion in 2009, respectively12.  It is estimated that CV disease costs the European 
Union economy almost €196 billion a year: 54% of which is direct health care costs, 24% 
of which is from losses in production, and 22% of which is related to informal care10. 
1.3 The Cardiovascular Disease Continuum 
The progress made in CV research at the end of the 20th century highlighted the 
importance of identifying factors that possibly increased the risk of someone developing 
CV disease.  Dzau et al. 199113 put forward the idea that CV disease was the outcome of 
a chain of events, set in motion by a variety of different risk factors, that could 
ultimately alter the heart and its structure. 
The group of researchers proposed that disrupting this chain of events, perhaps at 
several different stages of the chain, could help to delay and even possibly prevent 
symptomatic heart disease from developing, thus prolonging life.  At this point in time, 
however, there was a lack of pathological evidence and clinical trial data.  They 
acknowledged that further research was required to vindicate their theory. 
Over the next 15 years, new landmark clinical trial data and discoveries relating to the 
fundamental pathology of heart disease, along with the development of pioneering 
drugs, substantiated the notion that CV disease was the result of such a chain of events 
- named the CV disease continuum14,15.  These advancements in the field also reinforced 
the concept that disrupting the chain at any or multiple points could impede the 
progression of heart disease.  Moreover, they indicated that the continuum was set in 
motion earlier in life than initially thought, suggesting that CV disease is established 
over decades. 
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Taking this new evidence into account, Dzau et al. 2006 introduced an updated CV 
disease continuum14,15.  While the initial idea concentrated on risk factors for CHD and 
its sequelae, the updated continuum incorporated additional conditions including 
peripheral artery disease (PAD), cerebrovascular disease, and renal disease, as shown by 
Figure 1-214,15.  Risk factors such as smoking, diabetes, elevated cholesterol, 
hypertension, alcohol consumption and obesity were now known to instigate the 
sequence of events leading to HF.  Dzau et al. 2006 went on to propose that prevention 
or management of these factors through lifestyle adjustments, such as losing weight and 
stopping smoking, was a crucial component of preventative cardiology.   
Figure 1-2: The updated cardiovascular disease continuum presented by Dzau et al. 2006, 
adapted from Figure 2 in Dzau et al. 200614. 
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1.4 The Prevalence of Risk Factors for Cardiovascular 
Disease 
1.4.1 High Cholesterol 
High cholesterol is the one of the leading physiological risk factors for CHD16.  The World 
Health Report 2002 approximated that 60% and 40% of CHD and ischemic stroke in 
developed countries, respectively, was attributable in part to high cholesterol10,17.  The 
World Health Organisation (WHO) Global Status Report on Noncommunicable Diseases 
2010 reported that prevalence of raised cholesterol (≥5.0mmol/L or 190mg/L) was 
greatest in the European Region, at 54%, followed by the Region of Americas, at 48%9.  
Approximately 53.4% of Americans adults had high cholesterol in 2011 to 20128.  
Increased physical activity and adjustments to diet – particularly reducing the 
consumption of saturated fats – can lower cholesterol.  
1.4.2 Hypertension 
High blood pressure, also known as hypertension, is directly linked to an increased risk 
of developing CV disease16.  The World Health Report 2002 approximated that more than 
50% of CHD and almost 75% of stroke in developed countries was due in part to the 
condition10,17.  An estimated 972 million people worldwide had hypertension in 200018.  
The National Health and Nutrition Examination Survey data from 2009 to 2012 found 
that approximately 32.6% of American adults had high blood pressure8.  In England, the 
prevalence in 2012 was 31% and 27% among men and women, respectively19.  Similar to 
high cholesterol, increased physical activity, weight loss, and an improvement in diet 
can effectively lower blood pressure20.  
1.4.3 Diabetes 
Diabetes also increases the risk of CV disease.  In addition, people with diabetes are 
about three times more likely to have a heart attack compared to those who do not21.  
Not only that, but the effects of other risk factors, such as high cholesterol and 
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hypertension, are amplified by the presence of the condition10.  In 2010, the prevalence 
of diabetes across the globe was estimated to be 6.4%, equating to approximately 285 
million individuals; it is projected to increase to 7.7%, equating to 439 million 
individuals, by 20308.  The National Health and Nutrition Survey further revealed that 
21.1 million and 8.1 million American adults had diagnosed and undiagnosed diabetes, 
respectively8.  Around 3.2 million people living in the UK have been diagnosed with the 
disease11.  Being overweight is one of the primary causes of the onset of type 2 
diabetes22.  In a small study conducted by Newcastle University, 11 people with diabetes 
were limited to 600 calories each day for 8 weeks: after three months, 7 of the 11 
people no longer had diabetes23. 
1.4.4 Obesity 
Obesity, in particular abdominal obesity, majorly increases the risk of CV disease, 
including CHD, stroke, AF and congestive HF24-27.  It is also one of the key risk factors for 
raised cholesterol, hypertension, and diabetes10.  In 2008, approximately 1.46 billion 
adults were overweight or obese worldwide8.  Recently gathered data from across the 
UK and US revealed that 24.8% of British adults were obese11, and that 69% of American 
adults were obese or overweight8.  WHO data from 2008 showed that national mean 
body mass index (BMI) levels for men and women across Europe varied between 24 and 
28 km/m2 – considerably higher than the ideal mean BMI of a population, 21km/m2 10. 
1.4.5 Chronic Kidney Disease 
People with chronic kidney disease and end-stage renal disease are at an extremely high 
risk of experiencing CV disease-related events8.  End-stage renal disease is defined as 
the need to receive chronic renal replacement therapy, such as haemodialysis or kidney 
transplantation; chronic kidney disease is the last stage before end-stage renal disease.  
Whether chronic kidney disease is an independent risk factor for CV disease is still being 
disputed8.  However, those with chronic kidney disease are more likely to die from a 
CV-related cause than to progress to end-stage renal disease8.  Over 26 million 
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Americans have chronic kidney disease28; in 2008, 547,982 were found to have end-stage 
renal disease, 70% of whom were being treated with haemodialysis8. 
1.4.6 Cigarette Smoking 
In spite of 50 years of strong evidence that smoking is a very harmful habit, it is still 
commonplace.  It is also one of the leading modifiable risk factors for premature death 
and CV disease16.  Among its many negative health-related effects, it raises blood 
pressure which in turn increases the risk of developing CHD11.  The World Health Report 
2002 estimated that more than 20% of CV disease in developed countries was 
attributable to smoking17.  According to estimates from 2011, 20% and 18% of English 
men and women, respectively, were regular smokers11.  Similarly, data from 2013 found 
that 20.4% and 15.5% of American men and women smoked8. 
1.4.7 Alcohol Consumption 
High levels of alcohol consumption increase the risk of CV disease10.  Excessive drinking 
increases blood pressure as well as the levels of fat in the blood, known as triglycerides, 
which leads to an increased risk of developing atherosclerosis11,17.  In England, the 
percentage of men and women exceeding the recommended daily allowance of alcohol 
(up to four units for men and three for women12) on their heaviest day’s drinking was 
37% and 28%, respectively, in 201211,19.  Similarly , in Wales, 48% of men and 36% of 
women disclosed drinking more than the recommended amount in 201329.   
1.4.8 Physical Inactivity 
Another primary risk factor for CV disease is physical inactivity.  A sedentary lifestyle 
can lead to obesity, hypertension, high cholesterol and diabetes30.  Conversely, an 
active lifestyle corresponds with a decrease in the risk of CV-related death31.  In 
England in 2012, 33% and 45% of men and women did not meet physical activity 
guidelines, respectively19.  Across the European Union, 39% of adults reported that they 
never participated in exercise or sport10.  Moreover, in 2013 it was discovered that 
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30.5% of American adults did not partake in any form of physical activity in their leisure 
time8. 
1.5 The Association between Heart Rate and Risk Factors 
for Cardiovascular Disease 
As yet, resting heart rate has only been established as a true modifiable risk factor for 
adverse CV-related outcomes in patients with a resting heart rate of at least 70bpm, in 
sinus rhythm, with left-ventricular systolic dysfunction (LVSD) and chronic HF32.  
However, resting heart rate has been shown to be significantly associated with all of the 
risk factors discussed in Section 1.4, excluding cholesterol: it appears that there have 
not yet been any studies of the association between resting heart rate and cholesterol.   
1.5.1 Heart Rate and the Development of Hypertension 
Heart rate is a significant and independent predictor of the onset of hypertension33-41.  
Palatini et al. 2006 showed that both baseline and changes in clinic heart rate over the 
following 6 months independently predicted long-term hypertension (a systolic blood 
pressure (SBP) >140mmHg or a diastolic blood pressure (DBP) >90mmHg10) in young 
people39.  Those who had a heart rate ≥85bpm throughout the study were found to be at 
twice the risk (95% confidence interval (CI) 1.4 to 2.9) of acquiring long-term 
hypertension requiring blood pressure medication compared to those with a heart rate 
<85bpm.  Similarly, Inoue et al. 2007 revealed that normotensive middle-aged subjects 
with a heart rate ≥71bpm were 1.61 times more likely (95% CI 1.10 to 2.37) to become 
hypertensive compared to those with a heart rate <59bpm40.  More recently, Wang et al. 
2014 found that a 10bpm higher resting heart rate was significantly and independently 
associated with an 8% increase in the risk of new-onset hypertension in an Asian 
population41. 
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1.5.2 Heart Rate and the Development of Diabetes 
An elevated resting heart rate is also known to be associated with an increase in risk of 
diabetes42-48.  Bemelmans et al. 2012, for example, demonstrated that an elevated 
resting heart rate was independently associated with an increase in risk of type 2 
diabetes in patients with different forms of vascular disease (CHD, PAD, cerebrovascular 
disease and abdominal aortic aneurysm)47.  Firstly, subjects with a heart rate ≥70bpm 
were discovered to be at a 65% higher risk (95% CI 15 to 136%) of developing diabetes 
compared to those with a heart rate <55bpm.  Secondly, a 10bpm higher resting heart 
rate was borderline significantly associated with a 10% increase in risk (95% CI 0 to 21%).  
When subjects were stratified by age (<55, 55-63 and >63 years), the risk was found to 
be especially high in the 55-63 year-old group: a 10bpm higher resting heart rate was 
associated with a 22% (95% CI 4 to 43%) increase in risk.  Grantham et al. 2013 also 
recently showed that participants in a large population-based cohort with a heart rate 
≥80bpm were 1.89 times (95% CI 1.07 to 3.35) more likely to develop diabetes compared 
to those with a heart rate below 60bpm48.  When the subjects were divided by sex and 
obesity, non-obese men with a raised heart rate were found to be an especially high 
5.61 times more at risk (95% CI 1.75 to 17.98). 
1.5.3 The Association between Heart Rate and Obesity 
Furthermore, a high heart rate has been shown to be an independent predictor of being 
overweight and obese43,49.  Shigetoh et al. 2009 showed that a high resting heart rate 
predicted future obesity in a general population of subjects independent of age, sex and 
initial BMI43.  Those who had a baseline resting heart rate ≥80bpm were 2.34 times (95% 
CI 1.09 to 5.90, p<0.05) more likely to be obese 20 years later, compared to those who 
had a heart rate <60bpm.  Palatini et al. 2011 demonstrated that both baseline resting 
heart rate, and change in resting heart rate over follow-up, independently predicted 
being overweight or obese approximately 7 years later49.  In the population of young 
subjects screened for stage 1 hypertension, both heart rate measurements were 
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independent predictors of BMI at the end of follow-up (p = 0.007 for baseline and p = 
0.036 for change).  Additionally, after adjustment for a variety of other baseline risk 
factors including BMI, blood pressure, smoking, and alcohol consumption, a 10bpm 
higher baseline heart rate and change in heart were associated with a 30% (95% CI 10 to 
50%, p = 0.0003) and 17% (95% CI 6 to 28%, p = 0.003) increase in the risk of being 
overweight or obese, respectively. 
1.5.4 The Association between Heart Rate and Kidney Disease 
Moreover, it has recently been shown that heart rate is a predictor of kidney 
disease50,51.  Bohm et al. 2008 revealed that a higher heart rate was significantly 
associated with an increase in the risk of microalbuminuria - an indicator of impaired 
renal function50.  In the population of high-risk patients with hypertension, subjects 
with a heart rate between 80 and 100bpm were found to be 1.47 times (95% CI 1.29 to 
1.68, p<0.0001) more likely to have impaired renal function, compared to those who 
had a heart rate <60bpm.  Subjects with a heart rate above 100bpm were found to be at 
an even higher risk of 1.56 times (95% CI 1.22 to 1.99, p = 0.0004).  In a large general 
population of men and women, Inoue et al. 2009 showed that subjects with a baseline 
heart rate ≥72bpm were 1.29 (95% CI 1.06 to 1.57) times more at risk of developing 
chronic kidney disease after around 5 years compared to subjects with a heart rate 
<60bpm51.  When the population was split by age (≤48 years and >48 years) an increase 
in heart rate category was associated with a 15% (95% CI 5 to 25%, p = 0.0016) increase 
in the risk of chronic kidney disease in the older subjects (using the fully adjusted 
model), but no significant association was observed in the younger subjects. 
1.5.5 The Effect of Smoking on Heart Rate 
Smoking is known to increase heart rate52-54.  While the most noticeable effect occurs 
shortly after use, if smoking is a regular habit then the heart rate is continually 
increased52.  A study of both young and middle-aged smokers by Hering et al. 2006 
showed that cigarette smoking substantially increased the heart rate in both groups.  
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The increases in the younger group (22 ± 2bpm) were found to be significantly higher 
than those in the middle-aged group (13 ± 2bpm, p<0.001), suggesting that the effect is 
age-dependent.  In response to this finding, Papathanasiou et al. 2013 focused on the 
effect in young people54.  Resting heart rate was significantly lower among the young 
people who did not smoke compared to those who smoked 20 or more cigarettes a day, 
regardless of sex.  The mean resting heart rate of the women who did not smoke was 
70, while that of the women who did was 76.4 (p<0.001).  Among the men, those who 
did not smoke had a mean resting heart rate of 66.3, while the heart rate of those who 
did was 72.8 (p<0.001). 
1.5.6 The Effect of Alcohol Consumption on Heart Rate 
A few studies have shown that alcohol consumption is positively associated with heart 
rate55,56.  Ryan and Howes 2002 found that alcohol consumption was an independent 
predictor of 24-hour heart rate (p = 0.008)55.  Ohira et al. 2009 further demonstrated 
that habitual alcohol intake was associated with increased 24-hour heart rate, as well as 
heart rate while awake and asleep56.  The heavy drinkers had significantly higher mean 
24-hour, awake and asleep heart rates than the non-drinkers, light drinkers and 
moderate drinkers.  The mean 24-hour heart rate of the non-drinkers, for example, was 
68.2bpm, while that of the heavy drinkers was 72.2bpm (p<0.01). 
1.5.7 The Effects of Physical Activity on Heart Rate 
Physical activity can decrease resting heart rate57-59.  Wilmore et al. 2001 found that a 
20-week endurance training program decreased resting heart rate by 4.6 to 2.7bpm in a 
group of healthy subjects who previously led sedentary lifestyles57.  Huang et al. 2005 
performed a meta-analysis of controlled aerobic training on resting heart rate among 
sedentary older adults and discovered that the overall mean reduction in heart rate was 
6bpm, ranging from 2 to 12bpm58.  The analysis also revealed that training of more than 
30 weeks results in a larger statistically significant decrease.  A study by Genovesi et al. 
2007 compared the awake and asleep heart rates of trained athletic and sedentary 
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young males and females, and found that the athletic subjects had significantly lower 
heart rates than the sedentary ones, irrespective of sex59.  The physically active group 
of males, for example, had a mean sleeping heart rate of 51bpm, while the sedentary 
groups’ mean was 59bpm (p<0.001).  Similarly, the physically active group of females 
had a mean sleeping heart rate of 61bpm, while the sedentary group had a mean of 
69bpm (p = 0.002). 
1.6 Additional Factors that Affect Heart Rate 
Aside from smoking, alcohol consumption and physical activity, a number of other 
factors can influence resting heart rate.  As well as being an independent predictor of 
hypertension, heart rate is positively correlated with blood pressure60,61.  Furthermore, 
several studies have found that female gender is a determinant of elevated heart rate62-
64.  Various medical conditions, such as anxiety, pain, dehydration, and fever, can also 
cause the heart rate to increase65.  In addition, CV diseases, such as CHD, myocardial 
infarction (MI) and HF can result in the heart beating faster than normal.  If blood 
cannot travel as easily through the vessels because of plaque, for example, or if the 
heart muscle has been damaged and cannot pump as effectively as it once could, the 
heart attempts to maintain adequate cardiac output by increasing the heart rate66,67.   
1.7 Methods of Measuring Resting Heart Rate 
Resting heart rate can be measured using the following methods: pulse palpation; 
auscultation (using a stethoscope to listen to the heart beat); using an ECG; or using an 
electronic heart rate monitor68.  Pulse palpation is the simplest method of measuring 
resting heart rate.  The pulse rate can be felt at any location on the body where an 
artery is near the surface: commonly the temporal, carotid, radial, and brachial 
arteries, located at the temple, the neck below the jaw, the wrist, and the inside of the 
forearm at the elbow, respectively68,69.  Once the pulse rate is located, the number of 
beats can be counted over a certain length of time, such as 30 or 60 seconds, and then 
multiplied if necessary to estimate the number of beats per minute.  This is the method 
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of heart rate measurement used by clinicians and other healthcare professional in daily 
practice, and can potentially be performed by anyone, in any setting.  Auscultation is a 
similar method of measurement.  It involves listening to and counting the number of 
heart beats over a certain length of time using a stethoscope, and then multiplying the 
number counted to estimate the number of beats per minute if required.  An ECG, on 
the other hand, uses electrodes attached to the skin to record the electrical activity of 
the heart over a certain length of time.  It is the method normally used in critical care 
medicine, such as when a patient is admitted to hospital in an emergency setting with 
suspected HF68.  Finally, electronic heart rate monitors are generally made up of two 
parts: a transmitter that is placed over an artery, and a receiver such as a wrist watch 
that displays the heart rate, sometimes along with other information such as the 
average or maximum heart rate over some period of time68.  These devices are not 
commonly used to measure resting heart rate; they are mainly used by athletes and 
other sportspeople to monitor their fitness and performance68.  ECGs and electronic 
heart rate devices provide more precise measurements of heart rate compared to 
palpation and auscultation, and allow for the heart rate to be monitored over longer 
lengths of time. 
There is uncertainty as to whether ECG should be preferred to pulse palpation since ECG 
is a more accurate method of measurement.  It is used in the majority of clinical trials 
for this reason, whereas in epidemiological studies, around 50% of measurements are 
acquired using palpation, and 50% are acquired using ECG68.  The use of ECG, however, 
is implicitly more expensive than pulse palpation.  Furthermore, there is no evidence 
that the added precision of ECG renders more meaningful data, or is advantageous in 
clinical practice or research.  In addition, the studies by Erikssen and Rodahl 197970, and 
Sbarouni et al. 201571, found a strong correlation between the two measurements in 
healthy men, and in patients with stable CHD, respectively, with correlation 
coefficients of more than 0.9 in both studies. 
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Moreover, ECG is executed in the lying (supine) position, whereas pulse palpation can 
be performed in the sitting position, along with blood pressure72.  The panel of experts 
who recently took part in the second consensus conference endorsed by the European 
Society of Hypertension, deemed that the sitting position should be favoured since 
blood pressure is normally measured in such a position, and thus heart rate can be 
measured directly after each blood pressure measurement72.  The panel therefore 
recommended that pulse palpation be used, with the pulse rate counted over 30 
seconds, and stated that while ECG measurement is permitted, it is not recommended 
even for research72; in some cases, such as when a patient has AF, heart rate should be 
measured using auscultation, since some heart beats can be missed using palpation68.   
Since heart rate can be affected by various factors, as discussed in Section 1.6, 
including the position of the body, mental stimuli, and environmental factors, the panel 
made further recommendations for the measurement of resting heart rate, with the aim 
of minimising the effect of such confounding factors72.  Firstly, individuals should refrain 
from exercising, smoking, and drinking alcohol or coffee in the hours before 
measurement.  Secondly, they should be permitted to sit and relax as much as possible 
prior to measurement, for at least five minutes: a longer relaxation period may be 
required if the individual is anxious, for example.  In addition, the individual should be 
instructed to avoid talking during measurement.  The room, and the temperature of the 
room, should be comfortable, and any sources of noise should be eliminated where 
possible.  Finally, the individual should be seated comfortably, with their legs 
uncrossed, and at least two heart rate measurements should be taken, the average of 
which should be calculated.  If blood pressure is also being measured, heart rate should 
be measured after each blood pressure reading; these recommendations are very similar 
to those for measurement of blood pressure.  The panel further advocated that all 
scientific studies focusing on heart rate supply the following information: the length of 
time of rest prior to measurement; the conditions of the environment where 
measurement was performed, such as the temperature; the method used for 
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measurement; the number of measurements taken; the duration of each measurement; 
the time interval between measurements; the position of the individual, such as 
whether they were sitting or lying down; and details about the observer, such as 
whether they were a doctor or a nurse, or whether an electronic heart rate monitor was 
used72. 
The majority of scientific publications, however, do not even state the method used for 
heart rate measurement, let alone any of the additional information listed above, even 
when heart rate is one of the main variables of interest73.  In regards to the trials newly 
analysed in this thesis, information about the method of resting heart rate 
measurement was not available for five of the nine trials, in any of their related 
publications.  In three of the trials, resting heart rate was measured using ECG, and in 
one, resting heart rate was measured using palpation, auscultation, or ECG, according 
to the investigator’s decision (see Section 3.2 for details).   
1.8 Interpretation of the Hazard Ratio 
Section 1.5 discussed the associations between heart rate and risk factors for CV 
disease.  In Section 1.5.2 for example, it was stated that subjects with a heart rate 
≥70bpm were found to be at a 65% higher risk (95% CI 15 to 136%) of developing 
diabetes compared to those with a heart rate <55bpm in the study by Bemelmans et al. 
201247.  This association between resting heart rate and risk, along with the others 
described in Section 1.5.2, was quantified using Cox proportional hazards analysis74, 
which is introduced in detail in Chapter 3 Section 3.3.3.  Cox proportional hazards 
analysis is used in situations where the total number of events that occur, as well as 
their timing, are of interest75.  It allows the effect that a baseline measurement (such 
as resting heart rate) has on the risk of a future event (such as the development of 
diabetes or hypertension) to be estimated; this effect is expressed by the hazard ratio 
(HR).   
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The HR, sometimes called the relative hazard, describes the relative risk of 
experiencing an event, such as death or the development of diabetes, given that an 
individual has survived, or not yet experienced the event, up to a certain point in 
time76.  In other words, it is the probability of experiencing an event in the next time 
interval, given that it has not already occurred, divided by the length of the next time 
interval76,77.  Thus, the length of time that the individual is followed-up for is 
conceptually divided into intervals: these intervals are made very short, however, so 
that in effect the HR represents an instantaneous rate77.  One of the main assumptions 
of Cox proportional hazards analysis is that the HR is approximately the same for each 
time interval, and so is essentially constant over the duration of follow-up (see Sections 
3.3.3 and 3.2.6).  The HR therefore represents the risk of experiencing an event over 
the follow-up period, at any point in time. 
In Section 1.5, and throughout the following chapters, HRs were, and are, generally 
reported as an increase or decrease in risk of death or the event of interest.  This is 
commonly how HRs are reported in the field.  In the study by Bemelmans et al. 201247, 
for example, the HR for the development of diabetes associated with a heart rate 
≥70bpm, compared to a heart rate <55bpm, was 1.65 (95% CI 1.15 to 2.36), which was 
reported in Section 1.5.2 as a 65% higher risk (95% CI 15 to 136%) of developing 
diabetes.  In the original publication47, it was stated that “subjects in the highest 
quartile of resting heart rate (Q4) had a 65% higher risk of incident type 2 diabetes 
mellitus compared with those in the reference Q1 (HR 1.65, 95% CI 1.15 to 2.36) based 
on the fully adjusted model.”  Similarly, the study by Palatini et al. 201149 found that 
the HR for becoming overweight or obese associated with a 10bpm higher baseline heart 
rate was 1.30 (95% CI 1.10 to 1.50), which was reported in Section 1.5.3 as a 30% (95% 
CI 10 to 50%, p = 0.003) increase in the risk of being overweight or obese.  In the 
original publication49, it was stated that “there was a 30% increase in the risk of Ov-Ob 
(overweight or obesity) for a 10bpm increment in baseline clinic heart rate (HR 1.30, 
confidence interval = 1.10-1.50)”.  The articles by Barraclough et al. 201178 and 
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Sedgwick et al. 201576, entitled “What a Clinician Ought to Know: Hazard Ratios” and 
“Interpreting Hazard Ratios”, respectively, also recommend this interpretation of the 
HR.  Barraclough et al. 2011, for example, advise that an HR of 0.75 for death, 
associated with taking a new medication compared to an old medication, be interpreted 
as a 25% lower risk of death, assuming proportionality of hazards78.  Furthermore, 
Sedgwick et al. 2015, using as an example a trial which investigated the impact of 
isoniazid prophylaxis on mortality in children with HIV, and discovered that the HR for 
death associated with treatment compared to placebo was 0.46 (95% CI 0.22 to 0.95), 
advise that the HR be interpreted as a 54% lower risk of mortality76.   
Although this interpretation of the HR is frequently used, strictly speaking, it is not the 
risk of death or an event, but the hazard of death or an event, that is increased or 
decreased.  Thus, going back to the study by Bemelmans et al. 201247, technically the 
HR for the development of diabetes of 1.65 means that subjects with a heart rate 
≥70bpm had a 65% higher hazard of developing diabetes compared to subjects with a 
heart rate <55bpm, or, in other words, had a 65% higher risk of developing diabetes 
specifically during follow-up.  HR results should only be applied to the subjects studied 
over the duration of follow-up: using them to make broad inferences should be done 
with caution, and is not generally recommended78.  One reason for this is that 
proportionality of hazards may no longer hold outwith the follow-up period.  As the 
standard interpretation is used throughout the thesis, this should be kept in mind. 
An alternative interpretation, which may highlight the distinction, is described as 
follows77.  In the context of the study by Bemelmans et al. 201247, the HR of 1.65 is 
equivalent to the odds that a subject with a heart rate ≥70bpm develops diabetes 
before a subject with a heart rate <55bpm. 
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The odds of developing diabetes, is equal to the probability of developing diabetes, 
divided by the probability of not developing diabetes, which can be calculated using the 
formula 
    𝑂𝑑𝑑𝑠 =  
𝑝
1−𝑝
     (1-1) 
 
where 𝑝 is the probability of developing diabetes. 
As the HR is equivalent to the odds, it follows that 
    𝐻𝑅 =  
𝑝
1−𝑝
      (1-2) 
 
Rearranging Equation 1-2 so that 𝑝 becomes the subject of the formula gives 
    𝑝 =  
𝐻𝑅
1+𝐻𝑅
      (1-3) 
 
Thus, a subject with a heart rate ≥70bpm who is at a 65% higher hazard of developing 
diabetes compared to a subject with a heart rate <55bpm, has a 62% chance of 
developing diabetes before a subject with a heart rate <55bpm.   
1.9 Chapter Summary 
This chapter began by presenting the negatively correlated relationship between heart 
rate and life expectancy among mammals.  It was demonstrated that humans are the 
exception to this rule: the human species has a much longer lifespan than expected 
given their average heart rate, perhaps because human lives can be extended through 
improvements in living standards and the application of modern scientific techniques.  A 
summary of the current human and economic costs of CV disease - one of the leading 
causes of death in the Western world – was then given, and the concept of the CV 
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disease continuum was introduced.  The prevalence of the risk factors known to set the 
chain of events leading to end-stage HF in motion was described.  Evidence on the 
association between resting heart rate and these risk factors was subsequently 
presented, and additional factors than can affect heart rate were briefly mentioned.  
An overview of the methods of measuring resting heart rate, along with recent 
recommendations for its measurement, and the methods used in the nine trials newly 
analysed in the thesis, was then given.  Finally, a brief introduction to hazard ratios was 
provided, and it was explained that although hazard ratios are often reported as an 
increase or decrease in risk in the field, and were reported as such throughout the 
thesis, strictly speaking, it is not the risk of death or an event, but the hazard of death 
or an event, that is increased or decreased.  An alternative interpretation was then 
described to help highlight the distinction. 
A considerable number of observational studies and post-hoc clinical trial analyses have 
also examined the association between resting heart rate and adverse CV events and 
mortality: Chapter 2 presents a review of such studies.    
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Chapter 2 
 
A Systematic Review of Heart Rate as a 
Prognostic Risk Marker for Mortality and Adverse 
Cardiovascular Outcomes 
2.1 Introduction 
As well as being independently associated with established risk factors for CV disease, 
as discussed in Chapter 1, over the past three decades extensive evidence from 
epidemiological studies and clinical trials designed for other purposes have 
demonstrated that heart rate is a strong and independent prognostic risk marker of 
adverse CV events and mortality.  At the moment, however, the predictive value of 
resting heart rate is given less consideration in clinical practice than perhaps it should 
be, in view of the evidence and the fact that it is straightforward and inexpensive to 
measure. 
There are a multitude of discursive (non-systematic) reviews available on the subject, 
most of which include discussion of the pathophysiological mechanisms linking heart 
rate and CV disease, and the experimental effects of heart rate reduction79-93.  The 
majority of the reviews that discuss heart rate as a risk marker are limited to studies of 
the predictive value of resting heart rate measured at a single point in time at the 
beginning of follow-up.  The recent review by Inoue et al. 201392 distinguished some 
studies that used multiple heart rate measurements updated after the beginning of the 
study period to assess the risk of adverse events.   
This chapter provides a systematic review of observational studies and post-hoc clinical 
trial analyses that focused on the prognostic value of resting heart rate for mortality 
and adverse CV outcomes in a number of different populations, available at the end of 
April 2015, specifically distinguishing between studies that used a single heart rate 
measurement from those that used more than one heart rate measurement.  The aim 
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was to provide a comprehensive guide of the predictive value of resting heart rate, thus 
highlighting its importance as an indicator of risk, as well as avenues for future 
research.  Subsequently, in Chapter 9, meta-analyses of the risk of death from any 
cause and death from CV causes are presented, including the published prospective 
evidence identified in the review, as well as the results from Chapters 4 to 8 of this 
thesis. 
2.2 Methods 
2.2.1 Literature Search 
The systematic review followed the PRISMA guidelines94,95 as extensively as possible; the 
PRISMA 2009 checklist is given in Table A1-1 provided in Appendix 1.  MEDLINE (1946-
present) and Embase (1947-present) were searched for relevant studies.  Ovid was used 
to search MEDLINE and Embase simultaneously.   
The focus of the review was the prognostic value of resting heart rate for death and 
adverse CV outcomes.  They key concepts were therefore “heart rate”, “death”, and 
“adverse CV outcomes”.  Thus, the first search term to be decided upon was “heart 
rate”: “resting heart rate” was not used as it was thought to be too specific. 
Corresponding MeSH terms of “heart rate” are “pulse” and “pulse rate”, and so they 
were included in the search term as well.  As studies focusing on the prognostic value of 
heart rate were of interest, “prognos**” was chosen as a search term, along with its 
synonym “predict**”.  Note that adding ** to the end of a search term in Ovid retrieves 
unlimited suffix variations i.e. “predict**” searches for “prediction”, “predictive”, 
“predictor”, and so on.  “Outcome**” was additionally chosen to be included, along 
with “event**”, as the two are often used synonymously.  “Adverse” was also included, 
in addition to “death”, its statistical synonym “mortality”, and “survival”, which is the 
corresponding MeSH term for “mortality”. 
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 Thus, the final search term used was (“heart rate” OR “pulse” OR “pulse rate”) AND 
(“risk” OR “hazard” OR “prognos**” OR “predict**” OR “event**” OR “outcome**” OR 
“adverse” OR “death” OR “mortality” OR “survival”), and a Title search was specified.  
A Title as opposed to a Keyword or Topic search was used since only studies that 
specifically focused on the prognostic value of heart rate were of interest.  The Ovid 
search also specified the following limits: English Language; Full Text; Human and 
Humans.  The set of results was then automatically de-duplicated, and search terms 
were used to exclude irrelevant groups of studies; details of the search strategy are 
given in Table A1-2 provided in Appendix 1.  Reference and citation lists of included 
studies were searched for additional relevant publications: Web of Science was used to 
search citations.  The census date for the search was the end of April 2015.   
2.2.2 Eligible Studies 
Studies were accepted for inclusion in the systematic review if the full-text PDF version 
of the article was available online in English; conference abstracts and other forms of 
publications such as letters and reviews, were excluded, as were studies for which no 
PDF could be obtained.  Eligibility assessment was performed independently in an 
unblinded standardised manner.  No other investigators took part in the literature 
search, or eligibility assessment and selection of studies. 
2.2.3 Eligible Heart Rate Measurements and Outcomes 
Only studies which specifically focused on the association between the risk of at least 
death or an adverse CV outcome and resting heart rate (measured by pulse or 
electrocardiography (ECG)) were of interest.  Studies which analysed admission, 
discharge, or in-hospital heart rate were also included, but studies focusing only on 
short-term heart rate variability, response, pattern, exercise heart rate, or heart rate 
measured by Holter over a period of say, 24 hours, were excluded.  Studies of heart rate 
measured during an episode of angina or MI were excluded.  Studies that assessed heart 
rate and the risk of conditions such as the development of hypertension or diabetes 
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were also excluded, as were studies which only analysed a non-CV endpoint such as 
cancer death, or the association between heart rate and physiological measurements. 
2.2.4 Eligible Participants 
The selection of studies was also restricted to adult populations that were generally 
healthy or had been drawn from the general population and those with diabetes, 
hypertension, CHD, HF, kidney disease/failure or any other form of vascular disease 
(including those who had previously experienced an acute coronary syndrome (ACS) 
event such as an MI, a stroke, or a coronary artery bypass graft (CABG)).   
Studies which analysed some other specific groups of subjects were excluded, such as 
those with asymptomatic aortic stenosis, suspected myocarditis without known HF, AF 
(and none of the other included conditions listed above), multiple organ damage, or 
those who had undergone a transplant. 
2.2.5 Further Exclusions 
Further exclusions were made for: studies that looked at determinants of heart rate; 
studies that only used a log-rank test to evaluate the relationship between heart rate 
and outcomes as opposed to some form of regression analysis; and studies involving only 
babies or children. 
2.2.6 Data Extraction and Organisation of Studies 
Where possible, the following data were extracted from each publication: the first 
author’s last name; the year of publication; the name of the study if it had one; details 
about the study population including age, sex, location, and any underlying diseases or 
conditions; the number of subjects included in the final analysis; the mean or median 
length of follow-up; the type of heart rate measurement used; the type of model used 
to analyse the association between heart rate and risk; and outcomes relevant to the 
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review (death or adverse CV-related outcomes) that were analysed.  No other 
investigators assisted in the data extraction process. 
Studies chosen for inclusion were grouped by whether they analysed the risk associated 
with a single heart measurement obtained at the beginning of the follow-up period, or 
with at least one or more heart rate measurements obtained after the beginning of the 
study. The first of these two types of studies are referred to as ‘baseline heart rate’ 
studies, and the latter as ‘multiple heart rate measurement’ studies.   
The baseline heart rate studies found were further grouped according to the common 
condition of the participants.  The multiple heart rate measurement studies, which 
were fewer in number, were classified into two groups: those which included a general 
population of subjects, or those which included subjects with a specific pre-existing 
disease or condition. 
2.2.7 Assessment of Risk of Bias 
Study quality was appraised using the 9-star Newcastle-Ottawa Scale96, which is widely 
used for assessing the quality of observational studies and post-hoc clinical trial 
analyses.  It awards a maximum of nine stars to each study being assessed, with higher 
quality studies attaining a greater number of stars.  Stars are awarded in relation to the 
following three categories: selection (4 stars); comparability (2 stars); and outcome (3 
stars). 
2.3 Results 
As shown by Figure 2-1, the search of Ovid returned 3,330 studies.  After exclusion of 
duplicates using the de-duplicate function in Ovid, and irrelevant groups of studies using 
search terms (see Table A1-2), 556 studies remained.   The remaining studies were 
screened by title and abstract, and a further 470 were excluded for the reasons outlined 
in Figure 2-1.  Thus, 86 full-text articles remained to be reviewed.  Of the remaining 86 
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articles, 6 were excluded for the reasons outlined in Figure 2-1, which left 80 studies to 
be included.  Searching the reference and citation lists of each of these remaining 80 
studies identified a further 37 studies for inclusion, and 1 other publication was found 
through academic contacts.  Thus, 118 studies were included in this systematic review, 
published as far back as 1980. 
Figure 2-1: Flow chart of the selection process of the studies included in the systematic 
review. 
 
2.3.1 Baseline Heart Rate Studies 
A total of 98 of the 118 studies chosen for inclusion analysed the risk associated with a 
single heart rate measurement obtained at the beginning of follow-up.  They were 
grouped into the following 11 categories and are discussed accordingly: (1) general 
populations of participants; (2) subjects with diabetes; (3) subjects with hypertension; 
(4) subjects with CHD; (5) post-MI/ACS subjects; (6) subjects with HF; (7) subjects with 
left-ventricular (LV) dysfunction; (8) CABG subjects; (9) subjects with mixed types of 
vascular disease; (10) post-stroke subjects; and (11) subjects with kidney disease.  The 
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quality of each study, appraised using the Newcastle-Ottawa Scale96, is given in Table 
A1-3 provided in Appendix 1.  Study quality was high, ranging from 5 to 9 stars: 95 out 
of the 98 studies were awarded 7 stars or more.  
2.3.1.1 General Populations 
A total of 42 of the 98 single heart rate measurement studies found analysed baseline 
heart rate as a predictive risk marker for adverse events in subjects drawn from the 
general population, often with no evidence of existing CV disease or CHD.  An overview 
of each of these studies is given in Table A1-4 provided in Appendix 1.  The length of 
follow-up ranges from three years97 to 40 years98.  The number of subjects included 
ranged from 13199 to 379,843100. 
The earliest study included in the review was published in 1980 by Dyer et al.101 and 
included one group of middle-aged white men with no known heart disease from the 
Chicago Peoples Gas Company study.  After adjustment for age, cholesterol, blood 
pressure, weight and smoking, an elevated baseline resting heart rate predicted an 
increase in the risk of sudden and all-cause death in the Gas Company cohort.  Since 
then, elevated resting heart rate has also been found to be independently associated 
with an increase in the risk of all-cause death in middle-aged French102, Jewish-
Israeli103, Italian104, Japanese105 and Danish men106.  Shaper et al. 1993 further examined 
the risk of sudden death in middle-aged British men with and without pre-existing CHD, 
and found that an elevated heart rate predicted an increase in risk in those with no 
evidence of CHD, but was not associated with risk in those with pre-existing CHD107.   
Dyer et al. 1980 did not find any significant associations between heart rate and CV 
death or CHD death in any of the three cohorts101.  Similarly, Shaper et al. 1993 found 
no association between heart rate and risk of CHD death, or major CHD events, in either 
group of subjects analysed107.  However, Kristal-Boneh et al. 2000103 and Seccareccia et 
al. 2001104 found that a baseline resting heart rate ≥90bpm was associated with a 95% 
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(95% CI 10 to 280%) and a 154% (95% CI 25 to 416%) increase in the risk of CV death 
compared to a heart rate <70bpm, and <60bpm, respectively.   
Batty et al. 2010 examined the risk of all-cause, CHD and stroke death in middle-aged 
government employees from London, but found no associations between heart rate and 
risk98.  Compared to a heart rate ≤64bpm, a heart rate >75bpm was borderline 
significantly associated with an increase in risk of all-cause death (HR 1.17, 95% CI 0.99 
to 1.37), so there may have been an insufficient number of events for the result to 
reach significance (n = 942).  The number of CHD and stroke deaths were also relatively 
small (n = 307 and n = 90, respectively).  Of the 42 studies, a total of 16 analysed 
outcomes in both men and women, but did so separately for each gender100,108-122. 
In contrast to the studies discussed previously, Benetos et al. 1999112 and Tverdal et al. 
2008100 found that an elevated heart rate was associated with an increase in the risk of 
CHD death in middle-aged men from France, and Norway, respectively.  For example, a 
10bpm higher baseline heart rate was associated with a 12% increase in the risk of CHD 
death (95% CI 6 to 18%), after adjustment for cholesterol, triglycerides, DBP, smoking, 
physical activity and family history100.  Both of these studies further confirmed that 
heart rate is associated with all-cause and CV death, but did not find significant 
associations with stroke death.  Tverdal et al. 2008 also assessed risk of sudden death, 
but no increase in risk with higher heart rate was observed (note that the subjects had 
no history of CV disease)100.  Reunanen et al. 2000 examined associations between heart 
rate and risk of all-cause, CV, CHD and stroke death in middle-aged Finnish men with 
and without pre-existing heart disease, and found that heart rate was not associated 
with any of the outcomes in men free of heart disease, but was associated with all-
cause and CV death in men with heart disease, despite the number of events being 
much higher in those without heart disease113.   
The relationship between heart rate and risk has also been evaluated in older men.  
While some studies have found that an elevated heart rate is associated with an 
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increase in risk of all-cause death111,122, CV death111 and CHD death118,122 in older men, 
others have not110,114,115.  For example, Okamura et al. 2004 found that a heart rate 
≥78bpm was associated with a 155% (p = 0.01), 299% (p = 0.03) and 45% (p = 0.02) 
increase in the risk of CV death, CHD or HF death, and all-cause death, respectively, in 
young to middle-aged men, but found no associations in older men, despite the number 
of events being higher in the older age group of men115.   
While earlier studies examined only fatal endpoints, and found no associations between 
heart rate and stroke death, the more recent study by Mao et al. 2010 found that an 
elevated heart rate was associated with an increase in risk of fatal and non-fatal CV 
disease, heart disease, CHD, and haemorrhagic stroke in a large population of Chinese 
men aged 40 years or older120.  A 10bpm higher resting heart rate was associated with 
an 8% increase (95% CI 1 to 16%) in fatal or non-fatal haemorrhagic stroke after 
multivariate adjustment.  The association between an elevated continuous heart rate 
and the risk of all fatal or non-fatal stroke was also borderline significant: a 10bpm 
increment was associated with a 4% increase (95% CI 0 to 8%) in risk.  No significant 
association was observed in relation to fatal or non-fatal ischemic stroke, however the 
number of such events was much smaller than all of the other events analysed.   
The association between heart rate and the risk of adverse outcomes are less consistent 
among women drawn from the general population.  An elevated resting heart rate has 
been found to be associated with an increase in risk of all-cause death in younger to 
middle-aged women in some studies100,110,112,115 but not in others113,122.  Similarly, the 
majority of studies that have assessed the risk of CV death have not found any 
associations with heart rate100,112,113,115.  Greenland et al. 1999, on the other hand, found 
that a 12bpm higher heart rate was associated with a 13% increase in the risk of CV 
death (95% CI 2 to 25%) in the middle-aged subgroup of women analysed110.  The risk of 
CHD death has also been found to be related to heart rate in some studies of younger to 
middle-aged women110,115,118, but not in others100,112,113,122. 
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In older women, heart rate has similarly been associated with all-cause death in some 
studies97,114,122,123 but not others.  For example, in women aged 67 years or older who 
were referred for coronary angiography, but did not necessarily have CV disease, 
Vassalle et al. 2014 showed that a resting heart rate ≥76bpm was associated with a 70% 
increase in the risk of all-cause death (p<0.05)122.  On the other hand, no significant 
association between heart rate and the risk of cardiac death was observed.  In contrast, 
Kado et al. 2002 discovered that a 10bpm higher heart rate was associated with a 17% 
increase in the risk of CHD (95% CI 5 to 30%, p = 0.003) in white American women aged 
65 or older123.  However, other studies that have analysed the heart rate-risk 
relationship in older women found no association with any of the outcomes 
assessed111,115,118. 
The study by Mao et al. 2010, which included Chinese women aged 40 years or older, 
found that an elevated resting heart rate was associated with a higher risk of fatal and 
non-fatal CV disease, heart disease, and CHD after adjustment for multiple other 
covariates120.  In addition, Cooney et al. 2010 demonstrated that heart rate was 
associated with all-cause, CV, and CHD death, as well as fatal and non-fatal CHD, in 
women aged 25 to 74 from Finland119.  Hsia et al. 2009 further discovered that a heart 
rate ≥76bpm was associated with a 26% increase (95% CI 11 to 42%) in the risk of MI or 
coronary death124.  So far, no significant associations between heart rate and the risk of 
sudden death100, stroke death100,112,113,123 or fatal or non-fatal stroke events120,124 have 
been observed among women-only populations.   
A reason why an association between heart rate and risk of outcome is often not found 
in women when it is in men may be because the number of events that occur in female 
subjects are often less than the number that occur in male subjects, because less 
females are included than males100,110,112,113.  For example, in the study population of 
Benetos et al. 1999, 2036, 664, 370 and 125 all-cause, CV, CHD and stroke deaths, 
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respectively, occurred among the men, of whom there were 12123, whereas only 610, 
180, 66 and 63 of each event occurred among the women, of whom there were 7263112.   
A total of 15 of the studies analysed outcomes in combined populations of men and 
women from the general population66,99,125-136.  The first such study was carried out in 
2007125.   
In such populations, heart rate has been shown to be associated with all-cause 
death126,128,130-135, CV death126,128,130,135, sudden death137 and HF death135.  For example, 
after adjustment for markers of inflammation as well as conventional risk factors, 
Jensen et al. 2012 found that a 10bpm higher resting heart rate was associated with a 
9% (95% CI 5 to 14%) and 14% (95% CI 7 to 22%) increase in the risk of all-cause and CV 
death, respectively128.  In a case-control study, Teodorescu et al. 2013137 discovered 
that a 10bpm higher heart rate was associated with an 18% increase in the risk of 
sudden death (p = 0.005) after adjustment for risk factors including beta-blocker use 
and severe LVSD, and Woodward et al. 2014135 found that an elevated heart rate was 
associated with a 106% (95% CI 5 to 302%) increase in the risk of HF death after 
adjustment for multiple variables. 
Aladin et al. 2014133 further examined the relationship between heart rate and the risk 
of major adverse cardiac events (all-cause death, MI, or revascularisation), MI and 
revascularisation in men and women without known CHD or AF, by gender, even though 
it presented results for all-cause death for both sexes analysed together.  After 
adjustment for conventional risk factors, a heart rate ≥90bpm was associated with a 
higher risk of major CV events in both sexes, and of revascularisation in women.  No 
significant associations between heart rate and the risk of MI were observed in either 
sex, which may have been due to a small number of events (n = 166 in men and n = 77 
in women). Interestingly, no significant association with revascularisation was observed 
in men, even though the number of events was higher among men than women (n = 312 
in men and n = 74 in women).  When models were additionally adjusted for estimated 
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exercise capacity, all associations were attenuated.  However, in a larger population of 
men and women from China, analysed together, a 10bpm higher heart rate was 
associated with a 10% increase in the risk of MI (95% CI 1 to 20%) in the most adjusted 
model134.  The study also assessed the risk of all CV disease, any stroke, ischemic stroke, 
and haemorrhagic stroke, but no significant associations with heart rate were observed 
when the most adjusted model was used.  In contrast, in an even larger study, 
Woodward et al. 2014 found that an elevated heart rate was associated with a higher 
risk of fatal and non-fatal CV disease, all stroke, haemorrhagic stroke, ischemic stroke, 
and unclassified stroke135. 
Jensen et al. 2011 investigated the association between heart rate and all-cause and CV 
death in relation to smoking status127.  Time-dependent Cox models which accounted for 
changes in use of hypertensive medication, heart medication, and whether or not 
subjects had AF, revealed that a continuously higher heart rate was associated with a 
higher increase in risk of both all-cause and CV death in heavy, moderate and former 
smokers, compared to subjects who had never smoked.  A 10bpm higher heart rate was 
associated with a 6%, 11% and 13% increase in the risk of all-cause death in subjects who 
had never smoked, were former smokers, and were current smokers, respectively.  
Similarly, a 10bpm increase was not found to be associated with risk of CV death in 
those who had never smoked (HR 1.06, 95% CI 0.99 to 1.13), but was associated with an 
11%, 15% and 13% increase in risk in former, moderate and heavy smokers, respectively.   
Cacciatore et al. 2007125 and Pittaras et al. 2013131 specifically evaluated the 
relationship between heart rate and all-cause death in older individuals.  In a 
population of Italian subjects aged 65 years or older, Cacciatore et al. 2007 assessed 
whether the presence or absence of cognitive impairment affected the heart rate-risk 
relationship125.  An elevated heart rate was not found to be associated with a higher risk 
of death in the whole study population (relative risk (RR) 0.69, 95% CI 0.27 to 1.73) or in 
those with cognitive impairment (RR 0.91, 95% CI 0.81 to 1.02).  However, in those free 
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of cognitive impairment, an elevated heart rate was associated with a 10% increase in 
risk.  Pittaras et al. 2013 found that subjects aged 60 years or older with a heart rate 
≥70bpm were at a higher risk of death compared to those with a heart rate <60bpm131. 
Three recent studies focused on the risk of developing HF in relation to heart 
rate129,66,136.  Pfister et al. 2012129 and Opdahl et al. 201466 demonstrated that a 10bpm 
higher heart rate was associated with an 11% (95% CI 5 to 17%) and a 48% (95% CI 22 to 
79%) increase in the risk of developing HF after multivariate adjustment, respectively.  
Opdahl et al. 2014 further found that a 10bpm increase was associated with a 97% 
(p<0.001) and 34% (p = 0.028) increase in risk in women and men, respectively66.   
Khan et al. 2015 was an interesting study136.  In an individual participants pooled 
analysis of three population-based cohorts including some subjects on beta-blockers and 
with a history of CV disease, it was discovered that a 10bpm higher heart rate above 
60bpm was associated with a 13% (95% CI 7 to 18%, p<0.001) increase in the risk of 
developing HF.  Differences in the relationship between subjects with preserved and 
reduced ejection fraction (EF) were assessed, but none were found.  A meta-analysis 
including the three population-based cohorts, as well as the results previously presented 
by Pfister et al. 2012129 and Opdahl et al. 201466, and two other previously published 
studies (Nanchen et al. 2013138 included in Section 2.3.1.9 and Nanchen et al. 2013139 
included in Section 2.3.2.1), was subsequently performed.  This analysis showed that 
overall, an elevated heart rate was associated with a 40% increase in the risk of 
developing HF (95% CI 19 to 64%).   
2.3.1.2 Subjects with Diabetes 
Three of the studies found investigated the relationship between heart rate and adverse 
outcomes in subjects with diabetes.  An overview of each of these studies is given in 
Table A1-5 provided in Appendix 1. 
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Stettler et al. 2007140 and Hillis et al. 2012141 demonstrated that an elevated baseline 
resting heart rate was associated with an increase in risk of all-cause and CV death in 
subjects with type 2 diabetes.  In addition, Stettler et al. 2007 found that a 10bpm 
higher resting heart rate was associated with a 45% and 52% increase in the risk of 
cardiac death and CHD death, respectively, in subjects with type 2 diabetes140.  
Moreover, Hillis et al. 2012 found that the risk of a major CV event (CV death, non-fatal 
MI, or stroke) was 8% higher (p = 0.009) per 10bpm increment in heart rate141.   
While Stettler et al. 2007 found that an elevated heart rate was associated with an 
increase in risk of each of the endpoints analysed, no such associations were observed in 
the subjects with type 1 diabetes included in the study140.  However, the number of 
events that occurred in the type 1 diabetes subjects, of whom there were 221, were 
smaller than those that occurred in the type 2 subjects, of whom there were 302, which 
may explain this.  For example, the total number of deaths that occurred in type 2 
subjects was 158, whereas the total number that occurred in type 1 subjects was 107; in 
regards to CHD death, the number of events that occurred in the type 2 subjects was 
more than double the number that occurred in the type 1 subjects.   
Hillis et al. 2012 also performed competing risk analyses which adjusted for all-cause 
death as the competing event140.  In this case, the sub-distribution HRs of CV death and 
all major CV events were 1.15 (95% CI 1.07 to 1.25, p<0.001) and 1.07 (95% CI 1.01 to 
1.13, p = 0.01), respectively.  Miot et al. 2012 similarly assessed whether resting heart 
rate was a predictor of the cumulative incidence of the combined primary outcome of 
CV death, non-fatal MI, non-fatal stroke, hospitalisation for HF, or onset of end-stage 
renal disease, adjusting for non-CV death as a competing risk, in type 2 diabetes 
subjects142.  The analysis was stratified by whether or not subjects had CV disease at 
baseline, and the Fine and Gray model143 was used.  A baseline resting heart rate 
≥70bpm was found to be associated with a higher risk of the primary endpoint in 
patients with CV disease (p = 0.026) but not in those without (p = 0.628).   
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2.3.1.3 Subjects with Hypertension 
Four of the studies found evaluated the relationship between heart rate and adverse 
outcomes in subjects with hypertension.  An overview of each of these studies is given 
in Table A1-6 provided in Appendix 1. 
In a population of hypertensive subjects not taking anti-hypertensive medication at 
baseline, Gillman et al. 1993 assessed the association of heart rate with all-cause 
death, CV disease death, CHD death, sudden death, and incidence of CV disease and 
CHD144.  The male and female subjects were analysed separately.  The analysis 
demonstrated that a 40bpm higher heart rate was associated with a 98% (95% CI 52 to 
159%) and an 87% (95% CI 37 to 156%) increase in the risk of all-cause death in men and 
women, respectively.  An higher risk of CV disease death and CHD death was only 
observed in the male subjects.  This may have been because the numbers of events 
among the women were smaller than those among the men: the number of CV disease 
and CHD deaths among the men were 267 and 187, respectively, whereas among the 
women there were only 151 and 78.  In addition, elevated heart rate was not associated 
with sudden death, CV disease, or CHD in either sex, but again the numbers of events 
were small.   
King et al. 2006 further analysed the risk of incident CHD and all-cause mortality in 
subjects with pre-hypertension with no evidence of CHD145.  Pre-hypertension is defined 
as an SBP between 120 and 139mmHg or a DBP between 80 and 89mmHg, and can be 
seen as a warning that you may become hypertensive in the future.  A heart rate 
≥80bpm was found to be associated with a 47% increase (95% CI 2 to 114%) in the risk of 
all-cause mortality.  Due to differences in hypertension and prognosis between men and 
women, the analysis was subsequently stratified by gender.  However, the association 
was not maintained when men and women were analysed separately.  Conversely, a 
heart rate ≥80bpm was associated with a 188% increase (95% CI 8 to 342%) in the risk of 
incident CHD in women, but not in men or when both sexes were analysed together.   
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In a small population of 528 subjects with resistant hypertension (already stable on 
three or more antihypertensive treatment drugs), Salles et al. 2013 analysed the 
association between both slow (<60bpm) and fast (>75bpm) ECG and clinic (pulse) heart 
rates and the risk of all-cause death, CV death and the composite of all fatal or non-
fatal CV events146.  Compared to a heart rate between 60 and 75bpm, only a slow ECG 
heart rate was associated with a higher risk of the combined endpoint after multivariate 
adjustment (HR 4.40, 95% CI 1.06 to 8.37).  However, only a small number of events 
occurred in the population (n = 94, 62 and 44 of the combined endpoint, all-cause 
death, and CV death respectively) which may be a reason for no other associations 
being observed.   
In elderly subjects with isolated systolic hypertension, a baseline heart rate >79bpm has 
been shown to be associated with an 89% increase in risk of all-cause death (p<0.001) 
and a 60% increase in the risk of CV death (p<0.05)147.  
2.3.1.4 Subjects with CHD 
Four of the studies found examined the relationship between baseline resting heart rate 
and adverse outcomes in subjects with CHD.  An overview of these studies is given in 
Table A1-7 provided in Appendix 1. 
Both Diaz et al. 2005148 and Ho et al. 2010149 found that an elevated resting heart rate 
at baseline was associated with a higher risk of all-cause death and HF hospitalisation in 
subjects with CHD.  A small percentage of the subjects included in the study by Ho et 
al. 2010 had a history of HF, but models were adjusted for this149.  Neither study found 
an association between heart rate and the risk of MI or stroke, and Diaz et al. 2005 
found no association between heart rate and hospitalisation due to angina.  On the 
other hand, Diaz et al. 2005 established that a heart rate ≥83bpm was associated with a 
31% (95% CI 15 to 48%) and a 14% (95% CI 2 to 27%) increase in the risk of CV death and 
CV hospitalisation (hospitalisation due to MI, angina, stroke, revascularisation or rhythm 
disturbance), respectively148.  Similarly, Ho et al. 2010 ascertained that a 10bpm higher 
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baseline heart rate was associated with an 8% (p = 0.01) increase in the risk of major CV 
events, defined as CHD death, non-fatal MI, stroke, or a resuscitated cardiac arrest149.   
Anselmino et al. 2010 assessed the association with risk of all-cause death and CV 
events (all-cause death, non-fatal MI or stroke) in subjects with CHD with or without 
diabetes, some of whom had prior congestive HF150.  A 10bpm higher heart rate was 
shown to be associated with a 34% (p = 0.015) increase in the risk of all-cause death in 
subjects with diabetes after adjustment for confounding variables, but not in those 
without.  However, the number of deaths was slightly less in subjects without diabetes 
(49 in subjects with diabetes and 37 in those without).  No associations between heart 
rate and the risk of the CV events endpoint were observed in either group of subjects.   
In a broad unselected population of patients with stable CHD, Ortiz et al. 2010 found no 
associations between heart rate and the risk of major CV events (all-cause death, ACS, 
coronary revascularisation, stroke or admission to hospital for HF), coronary events (ACS 
or revascularisation) or all-cause death151.  This may have been because the population 
was at low risk of CV events, or because the number of events was too small for 
significant differences to be detected (222 major CV events, 161 coronary events, and 
33 all-cause deaths).   
2.3.1.5 Post-MI/ACS Subjects 
The risk associated with heart rate measured at a single point in time was evaluated in 
19 studies of subjects who had experienced an ACS, six of which were conducted in the 
pre-PCI era152-157.  The term ACS refers to any event that is caused by the blood supply 
to the heart muscle becoming suddenly blocked, and includes unstable angina, non-ST-
elevation MI (NSTEMI), and ST-elevation MI (STEMI)158.  An overview of each of these 
studies is given in Table A1-8 provided in Appendix 1. 
A total of 15 of the 19 studies assessed the predictive value of admission heart rate152-
155,157,159-168,.  Elevated admission heart rate has been shown to be associated with a 
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higher risk of in-hospital mortality in patients hospitalised with MI153,154,157,164,165 and 
ACS160.  Honda et al. 2010, for example, demonstrated that an admission heart rate 
≥93bpm was associated with an increased risk of in-hospital mortality (odds ratio (OR) 
8.5, 95% CI 1.4 to 49, p = 0.018), in patients hospitalised within 24 hours of acute MI157.  
In patients who were hospitalised with non-ST-segment elevation ACS, and were part of 
the CRUSADE study, which encompassed 550 hospitals across the US, Bangalore et al. 
2010 found that a heart rate >130bpm was associated with a 93% increase in the risk of 
in-hospital mortality (compared to an admission heart rate between 60 and 69bpm), 
using generalised estimating equations to account for within-hospital clustering160. 
Bangalore et al. 2010 also discovered that a heart rate <50bpm was associated with a 
61% increase in the risk of in-hospital mortality160.  Similarly, Asaad et al. 2014 showed 
that an admission heart rate <60bpm was associated with a higher risk of in-hospital 
mortality in patients diagnosed with unstable angina, NSTEMI or STEMI/left bundle 
branch block167.   
In addition, elevated admission heart rate has been shown to be associated with an 
increase in risk of some other in-hospital endpoints in patients hospitalised for MI and 
ACS.  Salwa et al. 2015 showed that an elevated admission heart rate was associated 
with a higher risk of in-hospital CV mortality (OR 1.51, 95% CI 1.25 to 1.82), in patients 
with STEMI (it is not clear from the publication what cut-off value of heart rate was 
associated with this result)168.  Honda et al. 2010157 demonstrated that an admission 
heart rate ≥93bpm was associated with a higher risk of poor LV function (left-ventricular 
ejection fraction (LVEF) <50% before discharge) (OR 2.2, 95% CI 1.1 to 4.7, p = 0.033), 
while Asaad et al. 2014167 discovered that a heart rate >89bpm was associated with a 
higher risk of in-hospital HF (OR 2.2, 95% CI 1.39 to 3.32, p = 0.001).  Moreover, 
Bangalore et al. 2010 found that both high and low admission heart rates were 
associated with an elevated risk of in-hospital stroke160.  For example, a heart rate 
<50bpm was associated with a 98% increase in the risk of in-hospital stroke, and a heart 
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rate >130bpm was associated with a 79% increase in risk.  The study also evaluated the 
relationship between heart rate and the risk of in-hospital re-infarction, but no 
significant associations were observed. 
The risk of post-discharge mortality has also been shown to increase with elevated 
admission heart rate in patients hospitalised with MI152-154,159,162,164,166 and ACS155,161,163.  
For example, Parodi et al. 2010 showed that a 5bpm higher admission heart rate was 
associated with a 32% increase in the risk of 6-month post-discharge mortality in a 
population of patients with STEMI undergoing PCI159.  In a population of patients with 
ACS, Facila et al. 2012 found that an admission heart rate (measured three to seven 
days after the occurrence of ACS) ≥70bpm was associated with a 150% increase in the 
risk of 1-year post-discharge mortality (95% CI 26 to 397%, p = 0.009), independent of 
other known risk factors163.   
The relationship between admission heart rate and risk has further been examined 
specifically in patients with AF, and with and without diabetes.  Li et al. 2013 studied 
the association between admission heart rate and the risk of one-year post-discharge 
mortality in post-STEMI and non-STEMI patients in AF166.  The analysis found that 
patients with an admission heart rate ≥95bpm were at 4.69 times (95% CI 1.47 to 15.01, 
p = 0.01) the risk of 1-year mortality compared to patients with a heart rate <95bpm 
after adjustment for confounders.  In patients with anterior wall STEMI without 
diabetes, Davidovic et al. 2013 demonstrated that an admission heart rate ≥80bpm was 
associated with an 8% increase in the risk of in-hospital mortality (95% CI 1 to 15%, p = 
0.033)165.  Han et al. 2012 examined the association between admission heart rate and 
30-day all-cause mortality, and CV events (all-cause mortality, re-infarction or stroke) 
in relation to the presence of type 2 diabetes, in patients admitted to hospital for 
STEMI162.  In patients without type 2 diabetes, each of the three heart rate groups above 
66bpm (67-76bpm, 77-88bpm, and >88bpm) were associated with a higher risk of both 
30-day mortality and CV events.  In patients with type 2 diabetes, only heart rates 
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between 77 and 88bpm, and >88bpm, were associated with a higher risk of 30-day 
events.  Only a heart rate >88bpm was associated with an increased risk of 30-day 
mortality.  The insignificance of the other heart rate groups may have been due to the 
small number of diabetic subjects included in the analysis (820 with diabetes, 6474 
without).  However, a significant interaction between heart rate and diabetes was 
observed for 30-day CV events (p = 0.035).  This indicated that an elevated heart rate 
had greater adverse effect in subjects with type 2 diabetes, since the HRs in each heart 
rate group were larger in those subjects, than in those without diabetes.  For example, 
a heart rate >88bpm was associated with a 130% increase in 30-day CV events in those 
without diabetes (95% CI 87 to 183%, p<0.001), and a 200% increase in those with 
diabetes (95% CI 76 to 414%, p<0.001).  No significant interaction was observed for 30-
day all-cause mortality (p = 0.126). 
The remaining four of the 19 studies evaluated the predictive value of discharge heart 
rate156,169-171.  Antoni et al. 2012169 and Seronde et al. 2014171 discovered that an 
elevated discharge heart rate was associated with a higher risk of post-discharge 
mortality in patients admitted to hospital with MI.  For example, a 10bpm higher 
discharge heart rate was associated with a 9% increase in the risk of 5-year post-
discharge mortality (p = 0.015)171.  In subjects with stable or unstable ACS treated with 
PCI followed-up for two years, Jensen et al. 2013 further demonstrated that a 1bpm 
higher discharge heart rate was associated with a 4.1% (p<0.001) increase in mortality 
post-discharge170.   
The risk of other post-discharge outcomes has also been evaluated in relation to 
discharge heart rate.  Mauss et al. 2005 revealed that elevated discharge heart rate was 
an independent predictor of the combined endpoint of all-cause mortality and 
arrhythmic events (such as sudden death and resuscitated ventricular fibrillation) (p = 
0.008) in patients presenting with acute MI156.  The risk of CV mortality at one and four 
years after discharge has been shown to increase by 29% and 26% (both p<0.001) in 
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relation to a 5bpm higher heart rate in patients admitted with STEMI treated with 
PCI169.  Jensen et al. 2013 further discovered that a 1bpm higher heart rate was 
associated with a 2.9% increase in risk of the composite of CV mortality or non-fatal MI 
(p = 0.011)170.   
Finally, subgroup analyses performed by Seronde et al. 2014 showed significant 
differences in the association between discharge heart rate and risk of death in STEMI 
and non-STEMI patients (p = 0.002), and patients with LV dysfunction (p <0.001)171.  A 
heart rate ≥75bpm was associated with an 82% (95% CI 39 to 138%, p<0.001) increase in 
the risk of 5-year post-discharge mortality in non-STEMI patients, whereas no 
association between heart rate and risk was observed in STEMI patients (p = 0.62).  
Similarly, a heart rate ≥75bpm was associated with a 79% (95% CI 49 to 115%, p<0.001) 
increase in risk in patients with LV dysfunction, whereas no association was observed in 
those with preserved LV function (p = 0.89).   
2.3.1.6 Subjects with HF 
The risk associated with elevated heart rate measured at the beginning of follow-up was 
analysed in ten studies of subjects with HF.  An overview of each of these studies is 
given in Table A1-9 provided in Appendix 1. 
Of the ten studies, five evaluated the heart rate-risk association in subjects with 
chronic HF172-176.  Among subjects with chronic HF in sinus rhythm with preserved EF, an 
elevated baseline resting heart rate has been shown to be associated with an increase in 
the risk of all-cause death172,174-176, CV death175,176, HF death176 and HF 
hospitalisation174,175.  For example, Takada et al. 2014 demonstrated that the highest 
third of the distribution of heart rate was associated with an 82% (95% CI 23 to 169%) 
and a 96% (95% CI 5 to 272%) increase in the risk of all-cause and CV death, 
respectively176.  The middle third of heart rate was found to be associated with a 229% 
(95% CI 5 to 933%) increase in the risk of HF death, and the highest third was borderline 
significantly associated with an increase in risk (HR 3.16, 95% CI 0.99 to 10.10).  There 
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were only 32 HF deaths in the total study population, however, (including the subjects 
with reduced EF) which may explain the large CIs and borderline significant association.  
The study did not observe any association between elevated heart rate and risk of HF 
hospitalisation.  On the other hand, Bohm et al. 2014 illustrated that a 12.4bpm (one 
standard deviation) higher heart rate was associated with an 18% (p = 0.001) increase in 
the risk of HF hospitalisation175.    
An elevated baseline resting heart rate has also been discovered to be associated with 
an increase in the risk of all-cause death174,176 and HF hospitalisation174 among subjects 
with chronic HF in sinus rhythm with reduced EF.  For example, Maeder and Kaye 2012 
found that a heart rate >87bpm was associated with a 16% (p = 0.02) and a 31% 
(p<0.001) increase in the risk of all-cause death and HF hospitalisation, respectively, 
compared to a heart rate <71bpm174.  In addition, Takada et al. 2014 established that 
the highest third of the distribution of heart rate was associated with an 80% (% CI 17 to 
178%) increase in the risk of all-cause death176.  However, no associations between heart 
rate and the risk of CV death, HF death or HF hospitalisation were observed.   
Castagno et al. 2012 further discovered that a 10bpm higher heart rate was associated 
with a 6% (95% CI 2 to 10%) and a 7% (95% CI 3 to 10%) increase in the risk of all-cause 
death, and the combined endpoint of CV death or HF hospitalisation, respectively, in a 
population of subjects in either sinus rhythm or AF, with an LVEF ≤40%173.  No 
association between heart rate and risk of all-cause death was observed in subjects with 
an LVEF >40%, and a borderline significant association between heart rate and the 
combined endpoint was found (HR 1.06, 95% CI 1.00 to 1.12).  The interaction of effect 
between heart rate and LVEF was tested, but no significant interaction was discerned (p 
= 0.80 for all-cause death; p = 0.88 for CV death or HF hospitalisation).   
Castagno et al. 2012 additionally stratified subjects by whether they were in sinus 
rhythm or AF173.  In subjects in sinus rhythm with either reduced or preserved EF, a 
10bpm higher heart rate was associated with an 8% (95% CI 4 to 12%) and a 10% (95% CI 6 
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to 13%) increase in the risk of all-cause death, and CV death or HF hospitalisation, 
respectively.  Conversely, no associations between heart rate and the risk of either 
endpoint were established in subjects in AF.  A significant interaction of effect between 
heart rate and rhythm was observed for both outcomes (p<0.001 for both).  Bohm et al. 
2014 also analysed the relationship between heart rate and outcome in subjects 
specifically in AF with a preserved EF175.  In this population, no associations between 
heart rate and risk of any of the endpoints assessed were observed.  In contrast, an 
elevated heart rate was found to be associated with a higher risk of all of the endpoints 
in the subjects in sinus rhythm.  However, the number of subjects in AF included in the 
analysis (n = 696) was less than a quarter of the number of subjects in sinus rhythm (n = 
3,271) which may be a reason for such a result. 
The other five studies yet to be discussed evaluated the heart rate-risk relationship in 
patients with acute HF177-181.  Admission heart rate was analysed by three of the 
studies177,179,180 and discharge heart rate was analysed by the remaining two178,181.   
Elevated admission heart rate has been shown to be associated with an increase in the 
risk of in-hospital mortality in acute HF patients in sinus rhythm or AF, analysed as a 
combined group177,179, and in subjects in sinus rhythm177,180 and AF177 analysed 
separately.  For example, Bui et al. 2013 demonstrated that a 10bpm higher heart rate, 
in subjects with an admission heart rate between 70 and 105bpm, was associated with a 
23% (95% CI 19 to 27%) increase in the risk of in-hospital mortality in patients in either 
AF or sinus rhythm177.  Similarly, a 10bpm increase was associated with a 21% (95% CI 15 
to 28%) increase in risk in sinus rhythm patients, and was associated with a 20% (95% CI 
14 to 27%) increase in risk in AF patients.  Kaplon-Cieslicka 2014 similarly established 
that a 10bpm higher admission heart rate was associated with a 59.4% (95% CI 6.1 to 
139.5%) increase in the risk of in-hospital HF in a population of Polish patients in either 
AF or sinus rhythm179.  However, when the sinus rhythm and AF patients were analysed 
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separately, heart rate was not found to be associated with risk.  This may have been 
due to the fact that only 21 in-hospital deaths occurred. 
In patients hospitalised for HF in sinus rhythm, Habal et al. 2014 discovered that a 
discharge heart rate >90bpm was associated with a 56% (p = 0.007), 65% (p = 0.017), 
26% (p = 0.021) and 29% (p = 0.004) increase in the risk of 30-day post-discharge all-
cause death, CV death, readmission for HF, and readmission for CV disease, 
respectively178.  The risks of the same outcomes at 1-year post-discharge were also 
evaluated.  A discharge heart rate >90bpm was similarly associated with a 41% (p<0.001) 
and 47% (p = 0.005) increase in the risk of all-cause and CV death, respectively, but no 
significant associations were observed for readmission for HF or CV disease.  The risk of 
30-day and 1-year post-discharge readmission for CHD was also evaluated, but no 
associations between heart rate and risk were observed at either time point.   
Laskey et al. 2015 assessed the relationship between discharge heart rate and risk in 
patients hospitalised for HF either in sinus rhythm or AF181.  A 10bpm higher heart rate 
in patients in sinus rhythm with a discharge heart rate ≥75bpm was associated with an 
18.5% (p<0.001) and 6.3% (p<0.001) increase in the risk of 1-year post-discharge all-
cause death, and all-cause readmission, respectively.  Similarly, a 10bpm increase in 
patients in AF with a discharge heart rate ≥75bpm was associated with an 8.8% 
(p<0.001) and a 3.3% (p = 0.0046) increase in each of the endpoints, respectively.  The 
effect of LVEF was also explored in the sinus rhythm and AF patients separately.  No 
significant interactions between heart rate and LVEF were observed in the sinus rhythm 
patients in relation to either of the endpoints.  On the other hand, significant 
interactions between heart rate and LVEF were observed in the AF patients for both of 
the endpoints (p = 0.01 for all-cause death and p = 0.003 for all-cause readmission).   
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2.3.1.7 Subjects with LV Dysfunction 
Three of the studies found assessed the relationship between baseline resting heart rate 
and risk of adverse outcomes in subjects all of whom had LV dysfunction.  An overview 
of each of these studies is given in Table A1-10 provided in Appendix 1. 
In subjects with LV dysfunction, an elevated resting heart rate at baseline has been 
found to be associated with an increase in the risk of all-cause death182,183, CV 
death182,184, and hospital admission for HF182,184.  Bohm et al. 2010, for example, 
ascertained that a baseline heart rate ≥87bpm was associated with an 86% (p<0.001), an 
85% (p<0.001), and a 199% (p<0.001) increase in the risk of all-cause death, CV death, 
and hospital admission for HF, respectively, compared to a heart rate <72bpm182.  The 
study also showed that a heart rate ≥87bpm was associated with a 134% (p<0.001) 
increase in the risk of death due to HF.  Fox et al. 2008 previously demonstrated that 
the risk of hospital admission for MI and coronary revascularisation are also related to 
resting heart rate.  A baseline resting heart rate ≥70bpm was associated with a 46% (p = 
0.0066) and a 38% (p = 0.037) increase in the risk of hospital admission for MI, and 
coronary revascularisation, respectively, compared to a heart rate <70bpm184. 
Fosbol et al. 2010 assessed differences in the effect of resting heart rate on long-term 
mortality (follow-up was at least ten years) in patients with LVEF ≤35% who had 
previously been hospitalised due to an MI or HF183.  A 10bpm higher heart rate was 
associated with a 16% (p<0.001) increase in the risk of mortality in the subgroup of post-
MI patients, and a 9% (p<0.001) increase in the subgroup of patients with HF.  No 
significant interaction of effect between resting heart rate and HF or MI was observed in 
relation to long-term mortality (p = 0.2).  Conversely, when one-year mortality was 
investigated, a significant interaction effect was observed (p<0.001).  While an elevated 
heart rate remained associated with an increase in the risk of one-year mortality in the 
MI patients, no such association was observed in the HF patients.   
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2.3.1.8 CABG Subjects 
Three of the studies found analysed the association between heart rate measured at a 
single point in time and risk in subjects who were about to have, or had previously 
underwent, CABG surgery.  An overview of each of these studies is given in Table A1-11 
provided in Appendix 1.   
In patients about to undergo CABG surgery, Fillinger et al. 2002 discovered that an 
elevated pre-induction heart rate was associated with an increase in the rate of in-
hospital mortality (p for trend < 0.001)185.  The risk of intra- or post-operative stroke 
was also assessed, but no association with heart rate was observed (p = 0.091).  In a 
similar population of patients, Aboyans et al. 2008 demonstrated that a 10bpm higher 
pre-operative admission heart rate was associated with a 17% (p = 0.029) increase in the 
risk of experiencing the primary endpoint of the study (all-cause death, non-fatal MI or 
non-fatal stroke or transient ischemic attack (TIA)) within 30-days after CABG, after 
adjustment for age, sex, SBP, LVEF and beta-blocker use186.  No association between an 
elevated admission heart rate and risk of the secondary endpoint (all-cause death or 
non-fatal stroke or TIA) was observed.  This may have been because of the smaller 
number of events. 
In patients who had recently undergone CABG surgery, followed-up for just over 3 years, 
Frank et al. 2010 found that a post-operative heart rate (measured at the first 
outpatient visit after surgery) ≥90bpm was associated with a 316% (p = 0.04) and a 128% 
(p = 0.04) increase in the risk of all-cause mortality, and the composite secondary 
endpoint of the study (all-cause death, secondary coronary revascularisation, non-fatal 
ACS, non-fatal stroke or TIA, or vascular surgery), respectively187.  After adjustment for 
additional risk factors such as off-pump surgery and use of statins, the association with 
all-cause death was was no longer significant (HR 3.57, 95% CI 0.90 to 14.17, p = 0.07), 
but remained in regards to the composite secondary endpoint (HR 2.26, 95% CI 1.04 to 
4.91, p = 0.04). 
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2.3.1.9 Subjects with Vascular Disease 
Three of the studies were carried out in mixed populations of subjects with some form 
of vascular disease.  An overview of each of these is given in Table A1-12 provided in 
Appendix 1. 
An elevated resting heart rate at baseline has been shown to be associated with an 
increase in the risk of all-cause death188,189, CV death138,188, vascular events188 and HF 
hospitalisation138 in such populations.  For example, Bemelmans et al. 2013 
demonstrated that a 10bpm higher heart rate was associated with a 15% increase in 
both the risk of all-cause (95% CI 8 to 22%) and CV (referred to as vascular in the 
publication) death (95% CI 6 to 25%), and an 8% (95% CI 1 to 15%) increase in the risk of 
vascular events, in a mixed group of subjects with CHD, cerebrovascular disease, PAD, 
or abdominal aortic aneurysm, in sinus rhythm188.  Additionally, van Kruijsdijk et al. 
2014 showed that a 10bpm increase was associated with a 13% (95% CI 8 to 19%) 
increase in the risk of all-cause death after adjustment for competing mortality, using 
the Fine and Gray model143, in the same population189.  Bemelmans et al. 2013 found no 
association between heart rate and the risk of ischemic stroke or MI188.  Nanchen et al. 
2013 further discovered that a baseline heart rate in the highest third of the 
distribution was associated with a 62% (95% CI 9 to 141%)and a 48% (95% CI 3 to 113%) 
increase in the risk of HF hospitalisation and CV death, respectively, compared to a 
heart rate in the lowest third, in subjects with CHD, cerebral disease, or PAD, or who 
had hypertension, diabetes or were smokers, after adjustment for conventional risk 
factors and markers of inflammation and endothelial dysfunction138.   
2.3.1.10 Post-Stroke Subjects 
The relationship between heart rate measured at a single time point and risk was 
evaluated in four studies that included subjects all of whom had recently experienced 
some form of stroke.  An overview of each of these studies in given in Table A1-13 
provided in Appendix 1.  
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An elevated baseline resting heart rate has been found to be associated with an 
increase in the risk of all-cause death190,191, vascular death190,191 and recurrent 
stroke191,192 in subjects who had previously had a stroke or TIA.  For example, Bohm et 
al. 2012 revealed that a heart rate >82bpm at baseline was associated with a 74% (95% 
CI 48 to 106%) and a 78% (95% CI 44 to 122%) increase in the risk of all-cause and 
vascular death, respectively, when compared to a heart rate ≤64bpm190.  The risk of any 
type of recurrent stroke, MI, and chronic HF were also evaluated, but no associations 
with heart rate were observed.  On the other hand, Fox et al. 2013 discovered that a 
baseline heart rate ≥70bpm, compared to one <70bpm, was associated with a 32% (p = 
0.029) and an 11% (p = 0.040) increase in the risk of all fatal or non-fatal MI, and all 
fatal or non-fatal stroke, respectively191.  No associations with a heart rate ≥70bpm 
were observed for non-fatal MI, all fatal or non-fatal ischemic stroke, or non-fatal 
ischemic stroke.  However, a 5bpm higher heart rate was associated with a 9% increase 
in the risk of non-fatal MI.   
Erdur et al. 2014 assessed the association between admission heart rate and the risk of 
in-hospital mortality in a population of ischemic stroke patients admitted to hospital 
within 72 hours after onset of symptoms, and found that a 10bpm higher admission 
heart rate was associated with a 40% (p = 0.003) increase in the risk of in-hospital 
mortality193.   
2.3.1.11 Subjects with Kidney Disease 
Three of the studies found assessed the relationship between baseline heart rate and 
risk in subjects who had kidney disease.  An overview of each of these studies is given in 
Table A1-14 provided in Appendix 1. 
After adjustment for demographics, comorbidities, haemoglobin, physical activity, 
estimated glomerular filtration rate (eGFR) and baseline medications, Beddhu et al. 
2009 showed that a heart rate ≥90bpm was associated with a 264% (95% CI 83 to 612%) 
increase in the risk of all-cause death in American subjects with chronic kidney 
49 
 
disease194.  When the same model was used to evaluate the risk of CV events, no 
association with heart rate was observed.  However, only a small number of CV events 
occurred (n = 110) which may explain this.  In a much larger study, including 147,702 
Japanese subjects receiving haemodialysis three times a week, Iseki et al. 2011 
demonstrated that subjects with a heart rate ≥70bpm were at a higher risk of death 
compared to those with a heart rate between 60 and 69bpm195.  For example, patients 
with a heart rate between 80 and 89bpm were at a 46% (p<0.001) higher risk of 
mortality. 
In a similar but much smaller study of Japanese subjects receiving haemodialysis three 
times a week, Inoue et al. 2012 found that a heart rate ≥80bpm was associated with a 
101% (95% CI 1 to 322%) increase in the risk of the composite of all-cause death, ACS, 
stroke or any other CV event (the secondary endpoint of the study)196.  The primary 
endpoint was the same, excluding any other CV events.  No association between heart 
rate and the primary endpoint was observed.  However, this may again have been due 
to the very small number of events that occurred: a total of 14 primary and 18 
secondary endpoints. 
2.3.2 Multiple Heart Rate Measurement Studies 
Of the 118 studies chosen for inclusion in the review, 20 analysed the risk associated 
with at least one additional heart rate measurement obtained after the beginning of the 
study, and are thus referred to as multiple heart rate measurement studies.  They were 
grouped into those which included a general population of subjects, and those which 
included subjects all of whom had a specific pre-existing disease or condition, and are 
discussed accordingly.  The quality of each study, appraised using the Newcastle-Ottawa 
Scale96, is given in Table A1-15 provided in Appendix 1.  Study quality was high, ranging 
from 7 to 9 stars. 
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2.3.2.1 General Populations 
A total of eleven of the multiple heart rate measurement studies investigated the 
association between heart rate and risk in subjects from the general population, often 
with no existing CV disease or CHD.  An overview of each of these studies is given in 
Table A1-16 provided in Appendix 1. 
Five of the studies analysed the prognostic value of a change in resting heart rate197-201.  
Jouven et al. 2009, for example, assessed the magnitude and direction of change in 
resting heart rate from baseline to 5-years post-baseline in middle-aged French men 
who had no known CV disease198.  Compared to subjects with a baseline heart rate 
between 64 and 70bpm whose heart rate was unchanged after five years (had decreased 
by at the most 4bpm or had increased by at the most 3bpm), subjects with an elevated 
heart rate at baseline (>70bpm) that had increased by at least 4bpm over the five years 
were at a 64% (95% CI 34 to 100%, p<0.001) higher risk of mortality.  In contrast, 
subjects who had a low heart rate at baseline (<64bpm) that had decreased by at least 
5bpm were at a 29% (95% CI 11 to 44%, p = 0.003) lower risk.   
The association between change in resting heart rate and death was further explored by 
Nauman et al. 2011 in a population of Norwegian men and women aged 20 years or 
older who had participated in both the first and second waves of the HUNT study 
(HUNT-1 and HUNT-2), the second of which occurred approximately 10 years after the 
first199.  Compared to participants who had a heart rate <70bpm at both HUNT-1 and 
HUNT-2, participants who had a heart rate <70bpm at HUNT-1 that had increased to 
>85bpm by HUNT-2 were at a 50% (95% CI 20 to 90%) higher risk of all-cause death.  
Moreover, participants with a heart rate >85bpm at both waves of the study were at a 
30% (95% CI 10 to 50%) higher risk.  Similarly, compared to participants with a low heart 
rate at both waves, participants whose heart rate was between 70 and 85bpm at HUNT-
1 that had increased to >85bpm by HUNT-2 were at an 80% (95% CI 20 to 180%) higher 
risk of CHD death.   
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On the other hand, in a population of unselected primary care patients from Germany 
without known CV disease, Leistner et al. 2012 found that neither baseline or change in 
resting heart rate over the following year were associated with risk of all-cause 
mortality, CV mortality, major CV events (non-fatal MI, revascularisation or CV 
mortality), or CV events (non-fatal MI or revascularisation)200.  However, the number of 
events was small (137 deaths and 121 CV events, for example), so there may have been 
insufficient statistical power to detect associations.   
Both Jouven et al. 2001202 and Floyd et al. 2015203 evaluated the relationship between 
the mean of five heart rate measurements gathered annually over time and the risk of 
adverse events in subjects without any known CV disease.  Jouven et al. 2001 found 
that a 10.2bpm higher baseline heart rate was associated with a 28% (p = 0.003) 
increase in the risk of sudden death in middle-aged French men, and while the result 
obtained using mean heart rate was not explicitly stated, it was said to be very similar 
to the baseline result202.  Floyd et al. 2015 found that a 10bpm higher mean heart rate 
was associated with a 12% (95% CI 5 to 20%) increase in the risk of all-cause death in 
American men and women203.  Neither study found an association between heart rate 
and the risk of MI, but this may have been due to an insufficient number of events.  For 
example, in the population studied by Floyd et al. 2015, there were only 262 MI events 
compared to 1,326 all-cause deaths203.  Ho et al. 2014 also investigated the relationship 
between the mean of multiple heart rate measurements obtained over time and risk in 
American men and women with no evidence of prior MI, HF or AF204.  In this case, the 
heart rate measurements were gathered over 8 years prior to baseline.  After 
multivariable adjustment, a 10bpm higher baseline heart rate was associated with a 17% 
(p<0.001), 18% (p = 0.001), 15% (p<0.001) and 32% (p<0.001) increase in the risk of all-
cause death, CV death, CV disease and HF, respectively.  Similar to Jouven et al. 2001, 
the results obtained using mean heart rate were not explicitly provided, but were 
stated as showing similar associations to baseline.  No associations between baseline or 
mean heart rate and the risk of CHD or stroke were observed. 
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Four of the studies assessed the prognostic value of multiple heart rate measurements 
entered into the extended Cox model205 as a single time-updated variable, referred to 
as time-updated heart rate139,204,206,207.  Legeai et al. 2011206, Ho et al. 2014204, and 
O’Hartaigh et al. 2015207 each found that an elevated time-dependent heart rate was 
associated with an increase in the risk of all-cause death.  Ho et al. 2014, for example, 
found that an 11bpm higher time-updated heart rate was associated with an 18% 
(p<0.001) increase in the risk of all-cause death204.  The study also found that an 11bpm 
higher time-updated heart rate was associated with an 18% (p = 0.005), 22% (p<0.001) 
and 41% (p<0.001) increase in the risk of CV death, CV disease, and HF, respectively.  
While no association between baseline or mean heart rate and the risk of CHD was 
observed, an 11bpm higher time-updated heart rate was associated with a 19% 
(p<0.001) increase in risk of CHD.  No association between time-updated heart rate and 
the risk of stroke was observed.  Nanchen et al. 2013 further explored the association 
between time-updated heart rate and risk of HF in men and women separately139.  A 
10bpm higher time-updated heart rate was associated with a 13% (p = 0.017) increase in 
the risk of HF in men, but no such association was observed in women. 
2.3.2.2 Disease-Specific Populations 
The remaining nine of the multiple heart rate measurement studies examined the 
relationship between heart rate and risk in subjects who had some form of pre-existing 
disease or condition.  An overview of each of these studies is given in Table A1-17 
provided in Appendix 1. 
Five of the studies included subjects all of whom had hypertension208-212.  In a 
population of subjects with stable CHD as well as hypertension, Kolloch et al. 2008 
demonstrated that an increase in the mean of multiple heart rate measurements 
gathered over follow-up was associated with an increase in the risk of the composite of 
all-cause death, non-fatal MI, or non-fatal stroke, even after adjustment for baseline 
heart rate208.  Paul et al. 2010 investigated the relationship between baseline heart 
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rate, final visit heart rate, and change in heart rate from baseline to the final visit, and 
all-cause, CV, and CHD death in Scottish men and women with hypertension, in sinus 
rhythm209.  No associations between baseline heart rate and risk of any of the endpoints 
were observed.  A final visit heart rate between 81 and 90bpm was associated with a 
64% (p = 0.026) increase in the risk of all-cause death, compared to a final visit heart 
rate ≤60bpm, but again no associations between final visit heart rate and the risk of CV 
or CHD death were observed.  Conversely, a 1bpm increase in heart rate from baseline 
to the final visit was associated with a 1% increase in the risk of all-cause death (p = 
0.028), CV death (p = 0.035) and CHD death (p = 0.007).  Furthermore, compared to 
subjects who had a heart rate <80bpm at both baseline and the final study visit, those 
who had a heart rate ≥80bpm at both visits were at a 78% (p<0.001), 92% (p = 0.004) and 
94% (p = 0.035) higher risk of all-cause, CV and CHD death, respectively.  Subjects with 
a heart rate <80bpm at baseline that had increased to ≥80bpm by the final study visit 
were additionally found to be at a 91% (p = 0.025) higher risk of CV death.   
Both Okin et al. 2010210 and Okin et al. 2012211 assessed the association between time-
updated resting heart rate and risk of adverse events in patients with hypertension and 
ECG LV hypertrophy who took part in the LIFE study.  Okin et al. 2010 revealed that a 
10bpm higher time-updated heart rate was associated with a 25% (p<0.001) and 16% 
(p<0.001) increase in the risk of all-cause and CV death, respectively, after adjustment 
for conventional risk factors as well as baseline heart rate210.  Excluding subjects with 
prior HF, Okin et al. 2012 further showed that a 10bpm higher time-updated heart rate 
was associated with a 45% (p<0.001) increase in the risk of developing HF211.   
In a population of patients hospitalised for MI in sinus rhythm who survived the first 
year, Jabre et al. 2014 determined that both an elevated admission heart rate, and an 
elevated heart rate measured during the first year of follow-up, were associated with 
an increase in the risk of all-cause and CV death213.  For example, an admission heart 
rate ≥90bpm was associated with a 62% (95% CI 25 to 109%) and a 66% (95% CI 14 to 
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142%) increase in the risk of all-cause and CV death, respectively, compared to an 
admission heart rate ≤60bpm.  Similarly, a heart rate ≥90bpm measured during the first 
year was associated with a 116% (95% CI 64 to 184%) and a 93% (95% CI 27 to 194%) 
increase in risk, respectively, compared to a heart rate ≤60bpm within the first year. 
Two of the studies included subjects all of whom had HF214,215.  In a population of 
patients hospitalised for worsening HF, with LVEF ≤40% in sinus rhythm, no association 
between baseline (admission) heart rate and all-cause death was observed214.  However, 
a 5bpm increase in heart rates ≥70bpm measured at one and four weeks after discharge 
were associated with a 13% (p = 0.002) and 12% (p = 0.001) increase in the risk of death, 
respectively.  Furthermore, a 5bpm increase in heart rate from baseline to discharge 
was associated with a 6% (p = 0.046) increase in risk. 
Vazir et al. 2014 examined the association between baseline heart rate, time-updated 
heart rate, and time-updated change in heart rate, and risk of a number of adverse 
outcomes, in subjects with chronic HF, in sinus rhythm or AF215.  Time-updated change 
in heart rate was the difference in heart rate from one visit to the next, entered as a 
single time-dependent variable in the extended Cox model205.  An elevated baseline 
heart rate was found to be associated with an increase in the risk of all-cause death, CV 
death and hospitalisation for HF.  However, no associations between baseline heart rate 
and the risk of fatal or non-fatal MI, and fatal or non-fatal stroke were observed.  On 
the other hand, a 5bpm higher time-updated heart rate, additionally adjusted for 
baseline heart rate, was associated with a 9% (p<0.001), 8% (p<0.001), 7% (p<0.001), 5% 
(p = 0.031) and 8% (p = 0.002) increase in the risk of all-cause death, CV death, 
hospitalisation for HF, fatal or non-fatal MI, and fatal or non-fatal stroke, respectively.  
Similarly, a 5bpm increase in time-updated change in heart rate, additionally adjusted 
for the previous heart rate measurement, was associated with a 9% (p<0.001), 9% 
(p<0.001), 6% (p<0.001), 6% (p = 0.014) and 7% (p = 0.009) increase in the risk of all-
55 
 
cause death, CV death, hospitalisation for HF, fatal or non-fatal MI, and fatal or non-
fatal stroke, respectively. 
Finally, Lonn et al. 2014 evaluated the relationship between baseline and mean follow-
up resting heart rate (referred to as “in-trial heart rate” in the publication), and risk, in 
subjects with CHD, PAD, cerebrovascular disease, or diabetes with end-stage organ 
damage216.  An elevated continuous baseline heart rate was associated with an increase 
in the risk of major vascular events (CV death, MI, stroke or hospitalisation for HF), all-
cause death, CV death and hospitalisation for HF.  No associations between baseline 
heart rate and risk of MI or stroke were observed.  Conversely, a 10bpm higher mean 
follow-up heart rate was associated with a 12% (p = 0.0006) increase in the risk of 
stroke, and a 22%, 33%, 33%, and 48% (all p<0.0001) increase in the risk of major 
vascular events, all-cause death, CV death and hospitalisation for HF, respectively.  
Again, no association between mean follow-up heart rate and risk of MI was observed. 
2.4 Discussion 
2.4.1 Baseline Heart Rate Studies 
A total of 118 studies were included in the review, 98 of which analysed the risk 
associated with heart rate measured at a single point in time at the beginning of follow-
up, referred to as ‘baseline heart rate’ studies.  The majority of these studies used Cox 
proportional hazards regression models to estimate the association between heart rate 
and risk, and demonstrated that an elevated heart rate was associated with an increase 
in the risk of death and adverse CV outcomes, regardless of the population of subjects, 
independent of other risk factors.  Table 2-1 provides a simplified illustration of the 
evidence in relation to each of the main adverse outcomes and population of subjects, 
as discussed in Section 2.3.1.  The cells that contain a black rectangle indicate where 
an association between baseline resting heart rate and risk has been established, using 
a multivariate-adjusted model; the blank cells indicate where an association has yet to 
be established using such a model. 
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Table 2-1: A summary of the evidence presented by the ‘baseline heart rate’ studies, on the association between baseline resting heart rate and each of the 
main adverse outcomes in the populations of subjects discussed in Section 2.3.1. 
Outcome 
Category of Subjects 
General 
 
42 Studies 
Diabetes 
 
3 Studies 
Hypertension 
 
4 Studies 
CHD 
 
4 Studies 
Post-MI/ACS 
 
19 Studies 
HF 
 
10 Studies 
LV 
Dysfunction 
3 Studies 
CABG 
 
3 Studies 
Vascular 
Disease 
3 Studies 
Post-Stroke  
 
4 Studies 
Kidney 
Disease 
3 Studies 
Deaths             
All-cause death            
CV/vascular death            
Cardiac death            
CHD death            
HF death            
Sudden death            
Other 
 
           
CV disease/event             
CHD            
MI            
Revascularisation            
HF            
Stroke            
The cells that contain a black rectangle indicate where an association between baseline resting heart rate and risk has been established, using a multivariate-adjusted model; the blank cells indicate where an 
association has yet to be established using such a model.  The ‘Other’ events include combinations of both fatal and non-fatal events, and non-fatal events only. 
ACS = Acute Coronary Syndrome; CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; CV = Cardiovascular; HF = Heart Failure; LV = Left-Ventricular; MI = Myocardial Infarction. 
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2.4.2 Multiple Heart Rate Measurement Studies 
Only 20 of the 118 studies analysed the risk associated with baseline and at least one 
additional heart rate measurement obtained after the beginning of the study, referred 
to as ‘multiple heart rate measurement’ studies.  Table 2-2 provides a summary of the 
evidence presented by these studies, in relation to each of the main adverse outcomes 
and populations of subjects, as discussed in Section 2.3.2.  The cells that contain one or 
more black shapes indicate where an association between some form of resting heart 
rate variable and risk has been established, using a multivariate-adjusted model; the 
blank cells indicate where an association has yet to be established using such a model.  
Each shape represents a different resting heart rate variable: a rectangle represents 
baseline resting heart rate; a circle represents a change in resting heart rate over time; 
a triangle represents the mean of multiple resting heart rate measurements gathered 
over time; and a star represents time-updated resting heart rate. 
A number of the multiple heart rate measurement studies demonstrated that multiple 
heart rate measurements predicted outcomes that were not found to be associated with 
baseline heart rate.  Paul et al. 2010, for example, did not observe any associations 
between baseline heart rate and risk of any of the endpoints assessed, which were all-
cause death, CV death, and CHD death209.  Conversely, a 1bpm increase in heart rate 
from baseline to the final visit was associated with a 1% increase in risk of each of the 
endpoints (all p<0.04).  Similarly, while Lonn et al. 2014 demonstrated that an elevated 
baseline heart rate was associated with an increase in the risk of major vascular events, 
all-cause death, CV death and CHD death, no association between baseline heart rate 
and risk of stroke was observed216.  On the other hand, a 10bpm increase in the mean of 
multiple heart rate measurements gathered over follow-up was associated with a 12% (p 
= 0.0006) increase in the risk of stroke.  
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Table 2-2: A summary of the evidence presented by the ‘multiple heart rate measurement studies’, on the association between both baseline and multiple 
resting heart rate measurements, and each of the main adverse outcomes in the populations of subjects discussed in Section 2.3.2. 
Outcome 
Category of Subjects 
General 
 
11 Studies 
Hypertension 
 
5 Studies 
Post-MI/ACS 
 
1 Studies 
HF 
 
2 Studies 
Vascular Disease 
 
1 Study 
Deaths       
All-cause death 
             
CV/vascular death 
           
Cardiac death      
CHD death      
HF death      
Sudden death      
Other 
 
 
    
CV disease/event  
   
   
  
Cardiac event      
CHD 
 
    
MI  
 
 
 
 
Revascularisation      
HF 
     
 
    
Stroke      
The cells that contain one or more black shapes indicate where an association between some form of resting heart rate variable and risk has been established, using a multivariate-adjusted model; the blank 
cells indicate where an association has yet to be established using such a model.  Each shape represents a different resting heart rate variable: a rectangle represents baseline resting heart rate; a circle 
represents a change in resting heart rate over time; a triangle represents the mean of multiple resting heart rate measurements gathered over time; and a star represents time-updated resting heart rate.  The 
‘Other’ events include combinations of both fatal and non-fatal events, and non-fatal events only. 
ACS = Acute Coronary Syndrome; CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; CV = Cardiovascular; HF = Heart Failure; LV = Left-Ventricular; MI = Myocardial Infarction. 
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Seven of these studies assessed the prognostic value of multiple heart rate 
measurements entered into the extended Cox model205 as a single time-dependent 
variable, often referred to as time-updated heart rate139,204,206,207,210,211,215.  Some of 
them also showed that time-updated heart rate was able to predict events where 
baseline heart rate was not.  Vazir et al. 2014, for example, found no association 
between baseline heart rate and the risk of fatal or non-fatal MI, or fatal or non-fatal 
stroke215.  In contrast, a 5bpm higher time-updated heart rate, adjusted for baseline 
heart rate, was associated with a 5% (p = 0.031) and an 8% (p = 0.002) increase in the 
risk of MI and stroke, respectively.  Furthermore, while Ho et al. 2014 observed no 
association between baseline heart rate or mean follow-up heart rate and risk of CHD, 
an 11bpm higher time-updated heart rate was associated with a 19% (p<0.001) increase 
in risk204 
2.4.3 Findings in Relation to Practice and Research 
Despite the abundance of evidence and the fact that it is straightforward and easy to 
measure, resting heart rate as a risk marker is given less consideration in clinical 
practice than perhaps it should be.  The ESC guidelines relating to CV disease 
prevention in clinical practice31, diabetes217, arterial hypertension218, stable CHD219, 
STEMI220, and HF221, as well as the ACC/AHA guidelines for stable CHD222 and CABG 
surgery223, currently recognise elevated heart rate as an indicator of risk.  However, 
only the ESC guidelines for CV disease prevention in clinical practice, and the 
management of arterial hypertension, recommend that heart rate be measured as part 
of the routine physical examination for risk assessment31,218.  In addition, only the NICE 
guidelines for the management of ACS, and unstable angina and NSTEMI, mention that 
formal assessment of risk should include a physical examination where heart rate is 
measured, alongside blood pressure224,225.   
One of the reasons physicians may overlook heart rate is because it is influenced by 
factors such as stress, physical activity and illness.  A single baseline heart rate 
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measurement may not sufficiently predict the risk of experiencing an adverse event 
many years in the future.  Taking updated measurements of heart rate into account 
could provide a more reliable estimate of the risk, which may be more closely related 
to newly measured levels, as has been illustrated.  The prognostic value of time-
updated heart rate measurements may therefore be more relevant to clinical practice 
than that of a single heart rate measurement.   
Compared to the number of studies that have investigated the risk associated with a 
single resting heart rate measurement, few have assessed the prognostic value of time-
updated measurements.  In the current review, no time-updated heart rate 
measurement studies were identified of specific groups of subjects with diabetes, CHD, 
ACS, or who had previously experienced an MI, LV dysfunction, who had undergone, or 
were about to undergo, CABG surgery, had some form of vascular disease, had 
previously experienced a stroke or TIA, or who had kidney disease.  Further studies of 
the relationship between time-updated heart rate measurements and risk could 
encourage health care providers to give more consideration to routine monitoring of 
heart rate as an indicator of risk.   
Another reason that heart rate may not be given much consideration in clinical practice 
is perhaps because studies often include very specific populations of subjects, and so 
general conclusions about its effect as a risk marker cannot be made.  Moreover, studies 
that did not find an association between heart rate and risk of certain outcomes often 
included only a small number of events, and hence may have lacked the statistical 
power required to detect significant differences.  Meta-analysis, defined as the 
statistical analysis of a collection of analytic results for the purpose of integrating 
findings226, can be used to help overcome both of these issues.  It can be used to 
calculate a single more powerful estimate of the effect of a risk marker for example, by 
combining the results from different studies, and also look for consistency of effect 
across sub-populations.   
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Khan et al. 2015 was the only study found in the current review that used meta-analysis 
techniques to assess the association between heart rate and risk136.  Combining and re-
analysing individual patient data from three previous cohort studies in what is known as 
an individual patient meta-analysis, Khan et al. 2015 discovered that a 10bpm increase 
in heart rate above 60bpm was associated with a 13% (p<0.001) increase in the risk of 
developing HF, in a large population of subjects from the general population, some of 
whom had a history of CV disease and some of whom were taking beta-blockers.  A 
aggregate data meta-analysis was subsequently performed, which extracted results 
from the previously published Pfister et al. 2012129, Opdahl et al. 201466, and Nanchen 
et al. 2013138,139, and combined them with the results from the three previous cohort 
studies.  It demonstrated that overall, an elevated resting heart rate was associated 
with a 40% increase in the risk of developing HF (95% CI 19 to 64%).  Further meta-
analyses of heart rate could lead to more general conclusions about its effect as a risk 
marker being drawn, thus emphasising its potential for assessing risk in both healthy 
individuals, and those with pre-existing conditions.   
The majority of studies of single and multiple heart rate measurements analysed the 
risk associated with an elevated heart rate in subjects from the general population, 
often with no evidence of existing CV disease or CHD.  Thus, further analyses of 
subjects with specific conditions could be informative.   
2.4.4 Strengths and Limitations 
The review has several strengths and limitations.  Firstly, it was limited to full-text 
articles that were available in English, and made no attempt to include unpublished 
material.  Further, it did not search for, or include, studies of risk models that may 
have included heart rate, but did not highlight its inclusion in the title of the paper.  In 
addition, there was no review protocol, and the objectives and methods of the review 
were not formally pre-specified: not having a protocol increases the likelihood of bias, 
such as selective outcome reporting95.  Moreover, MEDLINE and Embase were the only 
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databases searched initially for studies, and while they are two of the most 
comprehensive sources of healthcare information worldwide, like any database, their 
coverage is somewhat limited.  However, reference and citation lists of include studies 
were searched for additional relevant publications, by hand and through Web of 
Science, respectively.  The literature search, eligibility assessment, selection of studies, 
and data extraction process, was carried out by only one investigator.  Ideally, two or 
more independent investigators take part in each of these steps, so that objectivity is 
enhanced, and disagreements can be explored and resolved by consensus.  The 
contribution of at least two investigators can decrease the probability of rejecting 
relevant studies227.  When only one investigator conducts each stage of the review, 
mistakes in study selection and data extraction, and bias, are much more likely.  
Furthermore, no data extraction sheet was formally developed or piloted before the 
review began.  The studies included in the review were also considerably heterogeneous 
with respect to definition of outcomes, length of follow-up, variables adjusted for in 
multivariate models applied, and methods used to measure subjects’ heart rate.  
Heterogeneity also existed in regard to the types of heart rate measurements and 
variables used to evaluate associations between resting heart rate and risk: for 
example, some studies assessed the risk associated with resting heart rate as a 
continuous variable, some compared risk between subjects in two different heart rate 
groups, and some compared risk between subjects in multiple different heart rate 
groups.  Additionally, the studies that compared risk between subjects in different 
heart rate groups used varying cut-off points to define the groups.  The review did, 
however, follow the PRISMA guidelines94,95 as extensively as possible.  The search was 
extensive, the quality of studies was high, and a number of studies that found no 
association between heart rate and risk were included: thus bias should be limited.  The 
discussion of studies by patient population, and whether single or multiple heart rate 
measurements were used, should aid in accentuating where knowledge is lacking, thus 
helping researchers extend previous analysis and develop the field.   
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2.4.5 Chapter Summary and Conclusions 
This chapter presented a review of observational studies and post-hoc clinical trial 
analyses that evaluated resting heart rate as a risk marker for mortality and adverse CV 
outcomes, in a variety of populations, distinguishing between studies that used a single 
heart rate measurement to predict risk from those that used multiple heart rate 
measurements.    
The majority of studies included in this systematic review demonstrated that an 
elevated heart rate is associated with an increase in the risk of adverse events.  Despite 
this, heart rate is not routinely used as a risk marker for CV disease.  The relatively 
recent findings that time-updated heart rate measurements have increased prognostic 
value, may encourage physicians to give more consideration to regular assessment of 
heart rate as an indicator of risk.  Further multiple heart rate measurement studies, 
meta-analyses of heart rate as a risk marker, and additional analyses of subjects with 
specific conditions would be instructive.  
Accordingly, the role of resting heart rate as a risk marker is further explored in 
Chapters 4 to 8; new analyses of data from nine clinical trials was undertaken.  
Following on from this review, meta-analyses of the risk of death from any cause and 
death from CV causes are presented in Chapter 9, including the published prospective 
evidence identified in the review as well as the results from Chapters 4 to 8.  Chapter 3 
details the specific methods of analysis that were applied, and the trials which were 
newly explored. 
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Chapter 3 
 
Materials and Methods 
3.1 Introduction 
This chapter describes the trials which were newly analysed in this thesis, and the 
methods of analysis that were employed.  Specifically, new analyses of nine trials are 
presented in Chapters 4 to 8 and these trials are described in Section 3.2.  The role of 
resting heart rate as a risk marker for death and other adverse outcomes is further 
investigated in Chapters 4 to 9.  In Chapter 4, Section 4.3, and Chapters 5 to 8, both the 
original74 and extended Cox model205 were employed to explore the predictive value of 
baseline and time-updated resting heart rate for adverse outcomes in a number of 
different patient populations.  In Chapter 4, Section 4.2, and Chapter 8, Section 8.4, 
pooled individual patient meta-analyses are described.  The discrimination and 
calibration of the models applied in Chapters 4 to 8 were evaluated using Harrell’s C-
statistic228,229 and likelihood ratio tests, respectively.  Finally, following on from the 
systematic review presented in Chapter 2, meta-analyses of the risk of death from any 
cause and death from CV causes are presented in Chapter 9 Sections 9.2 and 9.3.  Since 
similar methods of analysis were applied in Chapters 4 to 8, they are presented in 
Section 3.3.  Finally, Section 3.4 describes the methods used to conduct the meta-
analyses presented in Chapter 9.  All analyses were executed using the statistical 
software package R230.   
3.2 Datasets and Trials 
Nine trials are newly analysed in this thesis in Chapters 4 to 8.  Table 3-1 provides an 
overview of the main features of each of these trials: they are described in greater 
detail in Sections 3.2.1 to 3.2.6.   
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Table 3-1: Main features of the nine trials newly analysed in this thesis. 
Trial and 
Section Where 
Described 
CAPRICORN 
Section 
3.2.1.1 
EPHESUS 
Section 
3.2.1.2 
OPTIMAAL 
Section 
3.2.1.3 
VALIANT 
Section 
3.2.1.4 
EUROPA 
Section  
3.2.2 
PROSPER 
Section  
3.2.3 
PERFORM 
Section  
3.2.4 
BEAUTIFUL 
Section  
3.2.5 
SHIFT 
Section  
3.2.6 
Trial 
Characteristics 
         
No. of patients 
randomised 
1959 6632 5477 14703 12218 5804 19100 10917 6505 
Length of 
follow-up 
1.3 years 1.3. years 2.7 years 2.1 years 4.2 years 3.2 years 2.4 years 1.6 years 1.9 years 
Study 
treatments 
Carvedilol and 
placebo 
Eplerenone and 
placebo 
Losartan and 
captopril 
Valsartan and 
captopril 
Perindopril and 
placebo 
Pravastatin and 
placebo 
Terutroban and 
aspirin 
Ivabradine and 
placebo 
Ivabradine and 
placebo 
Patient 
Characteristics 
         
Main inclusion 
criteria 
Post-MI with 
LVEF ≤40%, 
aged at least 
18 years 
Post-MI with 
LVEF ≤40%, and 
HF or diabetes, 
aged at least 
21 years 
Post-MI with 
LVEF <35% or 
HF, aged at 
least 50 years 
Post-MI with 
HF, LVEF ≤40%, 
or both, aged 
at least 18 
years  
Stable CHD 
(without HF) 
aged at least 
18 years 
Pre-existing 
vascular 
disease, or 
hypertension, 
diabetes, or 
currently 
smoking, 
without HF, 
aged 70 to 82 
years  
Post-stroke or 
TIA aged at 
least 55 years 
CHD with LVEF 
<40%, and 
resting heart 
rate ≥60bpm, 
in sinus 
rhythm, aged 
at least 55 
years 
Chronic HF 
with LVEF 
≤35%, and 
resting heart 
rate ≥70bpm, 
in sinus 
rhythm, aged 
at least 18 
years  
Mean age  63 years 64 years 67 years 65 years 60 years 75 years 67 years 65 years 60 years 
Percentage of 
men 
74% 71% 71% 69% 85% 48% 63% 83% 77% 
Table continued and footnote provided on the following page. 
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Table 3-1 (Cont.): Main features of the nine trials newly analysed in this thesis. 
Trial and 
Section Where 
Described 
CAPRICORN 
Section 
3.2.1.1 
EPHESUS 
Section 
3.2.1.2 
OPTIMAAL 
Section 
3.2.1.3 
VALIANT 
Section 
3.2.1.4 
EUROPA 
Section  
3.2.2 
PROSPER 
Section  
3.2.3 
PERFORM 
Section  
3.2.4 
BEAUTIFUL 
Section  
3.2.5 
SHIFT 
Section  
3.2.6 
Information on 
Resting Heart 
Rate 
         
Resting heart 
rate 
measurements 
available 
Baseline and at 
visits 
throughout 
follow-up 
Baseline only Baseline only Baseline only Baseline and at 
visits 
throughout 
follow-up 
Baseline and at 
visits 
throughout 
follow-up 
Baseline and at 
visits 
throughout 
follow-up 
Baseline and at 
visits 
throughout 
follow-up 
Baseline and at 
visits 
throughout 
follow-up 
Method of heart 
rate 
measurement 
Information on 
method not 
available 
Information on 
method not 
available 
Information on 
method not 
available 
Information on 
method not 
available 
Information on 
method not 
available, but 
likely pulse 
palpation (see 
Section 3.2.2) 
ECG ECG, 
auscultation, 
or pulse 
palpation, 
according to 
decision of 
investigator 
ECG ECG 
The follow-up duration is the mean length of follow-up in regards to CAPRICORN, EPHESUS, OPTIMAAL, EUROPA, PROSPER and PERFORM, and the median length in regards to VALIANT, BEAUTIFUL 
and SHIFT. 
CHD = Coronary Heart Disease; ECG = Electrocardiography; HF = Heart Failure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction; TIA = Transient Ischemic Attack.  
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3.2.1 Patients Included in the High Risk MI Database 
The individual patient meta-analysis presented in Chapter 4 Section 4.2 was carried out 
using the High Risk MI Database.  The High Risk MI Database Initiative231 created a 
database that pooled data of the CAPRICORN, EPHESUS, OPTIMAAL and VALIANT trials, 
each of which was a double-blind, randomised, controlled trial that enrolled patients 
after acute MI, with HF, LVSD, or both.  The database contains a total of 28,771 
patients, followed-up for a mean of 2.7 years.  The mean age of the patients was 65 
years and 70% were male.  Patients’ heart rates were recorded in each of the four trials 
at baseline: details of the method of measurement used in each trial are given in 
Sections 3.1.1.1 to 3.1.1.4.   
3.2.1.1 CAPRICORN 
The Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) study was a 
multi-centre, double blind, randomised controlled trial of carvedilol versus placebo 
involving 17 countries and 163 centres worldwide, which investigated whether 
carvedilol improved outcomes in patients with LV dysfunction after acute MI232,233.  
Eligible patients were aged 18 years or older with a stable, definite MI occurring 3-21 
days before randomisation, with LVEF ≤40%.  Participants were receiving concurrent 
treatment with angiotensin converting enzyme (ACE) inhibitors for at least 48 hours, 
and with a stable dose for more than 24 hours, unless there was a proven intolerance of 
ACE inhibitors.  The trial included 1,959 patients who were followed-up for a mean of 
1.3 years.  The mean age of the patients was 63 years, 73.5% were men, and mean LVEF 
was 32.8%.  There was no evidence of a difference between carvedilol and placebo for 
the first primary endpoint, which was the composite of all-cause mortality or CV cause 
hospital admission (p = 0.30).  However, treatment with carvedilol did reduce the 
frequency of the second primary endpoint of all-cause mortality by 23% (95% CI 2 to 
40%, p = 0.031).   
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Resting heart rate was recorded at baseline, and was also measured at 3-month 
intervals during the first year of follow-up, and at 4-month intervals thereafter.  The 
method of heart rate measurement is not stated in the original trial publication233, or 
the design and methodology publication232.  Chapter 4 Section 4.3 presents an analysis 
of data from the CAPRICORN trial. 
3.2.1.2 EPHESUS 
The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival 
Study (EPHESUS) was a multi-centre, double-blind, randomised controlled trial involving 
37 countries and 674 centres worldwide that evaluated the effect of eplerenone on 
adverse outcomes among patients with acute MI, complicated by LV dysfunction and HF, 
who were receiving optimal medical therapy234,235.  Eligible patients had experienced an 
acute MI 3-14 days before randomisation, were aged 21 years or older, with an LVEF 
≤40%, along with documented HF or diabetes.  The trial included 6,632 patients who 
were followed-up for a mean of approximately 1.3 years.  The mean age of the patients 
was 64 years, 71% were male, 14.5% had HF, 32% had diabetes, and mean LVEF was 33%.  
The majority of patients received optimal medical therapy for acute MI complicated by 
LV dysfunction and HF, including ACE inhibitors or angiotensin-II receptor blockers 
(ARBs) (in 87% of the patients), diuretics (in 60%), beta-blockers (in 75%), and aspirin (in 
88%).  The two primary endpoints of the trial were all-cause death, and CV death or 
hospitalisation for a CV event (including HF, recurrent acute MI, stroke, or ventricular 
arrhythmia).  Eplerenone reduced the risk of all-cause death by 15% (95% CI 4 to 25%, p 
= 0.008), and CV death or hospitalisation for a CV event by 13% (95% CI 5 to 21%, p = 
0.002).   
Resting heart rate was measured at baseline; the method of heart rate measurement is 
not stated in the original trial publication235, or the background, design, and 
organisation of the trial publication234.   
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3.2.1.3 OPTIMAAL 
The Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan 
(OPTIMAAL) was an investigator-initiated, multinational, double-blind, randomised, 
parallel-group trial involving seven European countries and 320 centres, which 
compared the effects of the ARB losartan with those of the ACE inhibitor captopril on 
adverse events in patients with acute MI and evidence of HF or LV dysfunction236,237.  
Eligible patients were 50 years or older with an acute MI occurring 10 days before 
randomisation, with signs or symptoms of HF during the acute phase, or an LVEF <35%, a 
new Q-wave anterior infarction or re-infarction.  The trial included 5,477 patients who 
were followed-up for a mean of 2.7 years.  The mean age of the patients was 67 years, 
71% were male, and 6.2% had congestive HF.  A non-significant difference in total 
mortality with a trend in favour of captopril was observed (p = 0.07), although losartan 
was better tolerated, and was associated with significantly fewer discontinuations 
(p<0.001).    
Resting heart rate was measured at baseline; the method of heart rate measurement is 
not stated in the original trial publication237, or the trial design publication236.   
3.2.1.4 VALIANT 
The Valsartan in Acute Myocardial Infarction (VALIANT) trial was a multi-centre, 
international, double-blind, randomised clinical trial involving 931 centres in 24 
countries, that compared the effect of valsartan, captopril, and the combination of the 
two on mortality in patients with MI complicated by LVSD, HF or both238,239.  Eligible 
patients were aged 18 years or older with an acute MI occurring between 12 hours and 
10 days prior to randomisation with evidence of HF, evidence of LVSD (an LVEF ≤35% on 
echocardiography or contrast angiography, and ≤40% as assessed by radionuclide scan), 
or both.  The trial included 14,703 patients who were followed-up for a median of 
approximately 2.1 years.  The mean age of the patients was 65 years, 69% were male, 
15% had HF and mean LVEF was 35%.  The trial revealed that valsartan was as effective 
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as captopril, but that combining valsartan with captopril increased the rate of adverse 
events without improving survival239.  
Resting heart rate was measured at baseline; the method of heart rate measurement is 
not stated in the original trial publication239, or the rationale and design of the trial 
publication238.   
3.2.2 EUROPA 
Data from the EUropean trial on Reduction Of cardiac events with Perindopril in 
patients with stable coronary Artery disease (EUROPA) trial is analysed in Chapter 5.  
EUROPA was a randomised, double-blind, placebo controlled, multi-centre trial 
involving 424 centres in 24 countries, that assessed the ability of the ACE inhibitor 
perindopril to reduce CV events in a broad, low-risk population of patients with stable 
CHD without HF240,241.  Men and women aged at least 18 years without clinical evidence 
of HF and with evidence of CHD, documented by previous MI (>3 months before 
screening), percutaneous or surgical coronary revascularisation (>6 months before 
screening), or angiographic evidence of at least 70% narrowing of one or more major 
coronary arteries, were eligible for inclusion in the trial.  Men could also be recruited if 
they had a history of chest pain and a positive ECG, echo, or nuclear stress test.  The 
trial included 12,218 patients who were followed-up for a mean of 4.2 years.  The mean 
age of the patients was 60 years, 85% were male, and a total of 92%, 62% and 58% were 
taking platelet inhibitors, beta-blockers, and lipid-lowering therapies, respectively.  
Treatment with perindopril was associated with a 20% (95% CI 9 to 29%, p = 0.0003) 
reduction in the primary endpoint, which was the composite of CV mortality, non-fatal 
MI, or cardiac arrest with successful resuscitation.   
Patients underwent a run-in period, where they received 4mg oral perindopril twice 
daily, in the morning, for 2 weeks in addition to their normal medication, followed by 
8mg oral perindopril once daily, in the morning, for 2 weeks if the lower dose was well 
71 
 
tolerated.  Patients aged 70 years or older were given 2 mg perindopril in the first week 
of screening, followed by 4mg daily in the second week, and 8mg daily in the last 2 
weeks.  At the end of the run-in period, patients were randomly assigned to receive 
perindopril 8mg (two tablets) or placebo once daily for at least 3 years.  If this dose was 
not tolerated, it could be reduced to 4mg once daily or matching placebo.  Heart rate 
was measured twice during the run-in period (at Study Visits 1 and 2) and at 
randomisation (Study Visit 3) in the supine position.  The method of heart rate 
measurement is not stated in the original trial publication, but the publication does 
state that it was measured in the sitting position240.  This suggests that heart rate may 
have been measured by pulse palpation, since it is normally performed with the subject 
in the sitting position, whereas ECG is performed with the subject lying down72.  Follow-
up visits took place at 3, 6 and 12 months after randomisation, and at 6-monthly 
intervals thereafter, at which heart rate was also recorded if possible. 
3.2.3 PROSPER 
Chapter 6 analyses data from the PROspective Study of Pravastatin in the Elderly at Risk 
(PROSPER) trial.  The PROSPER trial was a randomised, double-blind, placebo controlled 
trial that recruited elderly men and women with existing, or at high risk of developing, 
vascular disease from Scotland, Ireland and the Netherlands.  The aim of the trial was 
to determine if pravastatin reduced the risk of cardiac events, stroke, cognitive decline, 
and disability in this cohort of patients242,243.  Eligible patients were aged 70-82 years 
old with pre-existing vascular disease (coronary, cerebral, or peripheral) or raised risk 
of such disease because of smoking, hypertension, or diabetes.  Participants with 
symptomatic congestive HF (New York Heart Association (NYHA) class III or IV) or 
evidence of AF were excluded, as well as those with poor cognitive function (Mini 
Mental State Examination score <24).  The trial included 5,804 patients who were 
followed-up for a mean of 3.2 years.  The mean age of the patients was 75 years and 
48% were male.  Treatment with pravastatin reduced the incident of the primary 
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endpoint, which was the composite of death from CHD, non-fatal MI, or fatal or non-
fatal stroke, by 15% (95% CI 3 to 26%, p = 0.014).   
Resting heart rate was measured from a 12-lead ECG at baseline (as part of the first 
enrolment visit), and annually thereafter. 
3.2.4 PERFORM 
Data from the Prevention of cerebrovascular and cardiovascular Events of ischaemic 
origin with teRutroban in patients with a history oF ischaemic strOke or tRansient 
ischaeMic attack (PERFORM) trial is analysed in Chapter 7.  The PERFORM trial was an 
international, multi-centre, randomised, double-blind, parallel-group trial that was 
undertaken in 802 centres in 46 countries that compared terutroban with aspirin in the 
prevention of cerebral and CV ischemic events in patients who had experienced a recent 
non-cardioembolic ischemic event244,245.  Eligible patients were men or women, aged 55 
years or older, who had experienced an ischemic stroke or arterial retinal ischemic 
event more than 48 hours and less than 3 months preceding inclusion, or a TIA in the 
previous 8 days.  The trial included 19,100 patients followed-up for a mean of 
approximately 2.4 years.  The mean age of the patients was 67.2 years and 63% were 
men.  The trial was stopped prematurely on the grounds of futility245.  There was no 
evidence of a difference between terutroban and aspirin for the primary endpoint, 
which was the composite of fatal or non-fatal ischemic stroke, fatal or non-fatal MI, or 
other vascular death (excluding haemorrhagic death), or for any of the other endpoints 
assessed.   
Heart rate was measured at baseline after a 10-minute rest in the supine position by 
palpation, auscultation, or 12-lead ECG, according to the investigator’s decision.  
Follow-up visits took place at 1, 3 and 6 months after randomisation and at 6-monthly 
intervals thereafter until closure of the study, and heart rate was recorded at each of 
these visits if possible. 
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3.2.5 BEAUTIFUL 
Chapter 8 analyses data from the morBidity-mortality EvAlUaTion of the If inhibitor 
ivabradine in patients with coronary disease and left ventricULar dysfunction 
(BEAUTIFUL) trial.  The BEAUTIFUL trial was a randomised, double-blind, placebo-
controlled, parallel-group trial, across 781 centres in 33 countries that assessed whether 
the addition of ivabradine (a pure heart-rate-lowering drug) to standard treatment 
could reduce adverse CV events in patients with CHD and LVSD246-248.  Eligible patients 
were men and women aged 55 years or older with CHD, LVEF of less than 40% and end-
diastolic short-axis internal dimension larger than 56mm, identified by 
echocardiography.  Patients had to be in sinus rhythm, with a resting heart rate of 
60bpm or greater.  Any angina or symptoms of HF should have been stable for at least 
three months and patients should have received appropriate conventional CV 
medication at stable doses for at least one month.  The trial included 10,917 patients, 
followed-up for a median of approximately 1.6 years.  The mean age of the patients was 
65.2 years, 83% were male, 87% were receiving beta-blockers, mean LVEF was 32.4% and 
mean resting heart rate was 71.6bpm.  After one year, ivabradine had reduced heart 
rate by 6bpm.  Reduction in heart rate with ivabradine did not reduce risk of the 
primary endpoint, which was the composite of CV death or admission to hospital for MI 
or new-onset or worsening HF (HR 1.00, 95% CI 0.91 to 1.10, p = 0.94), or any of the 
other endpoints.  However, in a pre-specified subgroup of patients with baseline heart 
rate ≥70bpm, the risk of admission to hospital for MI, admission to hospital for MI or 
unstable angina, and coronary revascularisation was reduced by 36% (p = 0.001), 22% (p 
= 0.023) and 30% (p = 0.016), respectively.   
Resting heart rate was measured at baseline and follow-up visits in the supine position 
by 12-lead ECG.  After randomisation, visits were scheduled at 2 weeks; 1, 3 and 6 
months; and every 6 months thereafter and heart rate measurements were recorded at 
each of these visits if possible. 
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3.2.6 SHIFT 
Results from the Systolic Heart failure treatment with the If inhibitor ivabradine Trial 
(SHIFT) are also presented in Chapter 8.  SHIFT was a randomised, double-blind, 
placebo-controlled, multinational trial across 677 centres in 37 countries, that assessed 
whether the addition of ivabradine to guidelines-based treatment could reduce adverse 
events in patients with chronic HF and LVSD32,249.  Men and women aged 18 years or 
older, with symptomatic chronic HF, an LVEF of 35% or lower, who were in sinus rhythm 
with a heart rate of 70bpm or higher, had been admitted to hospital for HF within the 
previous year before randomisation, and were on stable background treatment including 
a beta-blocker if tolerated, were eligible for inclusion in the study. The trial included a 
total of 6,505 participants followed-up for a median of approximately 1.9 years.  The 
mean age of the patients was 60 years, 76.5% were male, 89.5% were taking beta-
blockers, and mean LVEF was 29%.  Treatment with ivabradine was associated with an 
18% reduction (95% CI 10 to 25%, p<0.001) in the primary endpoint, which was the 
composite of CV death or hospital admission for worsening HF.   
Resting heart rate was measured at baseline and follow-up visits in the supine position 
by 12-lead ECG.  After randomisation, visits were scheduled at 28 days post-baseline, 
and every four months thereafter, and heart rate was recorded at each of these visits if 
possible. 
3.3 Methods of Analysis Applied in Chapters 4 to 8 
3.3.1 Heart Rate Groups 
Firstly, the study populations were divided into groups according to their baseline heart 
rate values.  In the previously published PERFORM and BEAUTIFUL baseline heart rate 
analyses191,184, the populations of patients were divided into two groups according to 
whether their baseline resting heart rates were less than, or greater than or equal to, 
70bpm.  In each case, the cut-off of 70bpm was selected on the basis that it was very 
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close to the median heart rate of each population, and because published evidence has 
suggested that the risk associated with heart rate rises greatly above this value148,156,208.  
Thus, to make the current results as comparable as possible to the previously published 
results, the heart rate cut-off of 70bpm was also used in the current analyses of the 
PERFORM and BEAUTIFUL populations.  For consistency of approach, in each of the other 
analyses that involved a single trial, excluding the analysis of the PROSPER patient 
population, the study population was divided into two groups, according to whether 
baseline resting heart was less than, or greater than or equal to, a certain baseline 
heart rate cut-off value that was chosen individually for each trial in a similar manner 
to that of PERFORM and BEAUTIFUL.  The median heart rate of each population was 
found, and was rounded up or down to the nearest multiple of five or ten.  In 
CAPRICORN, the median heart rate of the placebo population was 76bpm, which was 
rounded down to 75bpm; in EUROPA, the median heart rate was 65bpm, but because 
risk has been shown to increase above 70bpm, it was rounded up to 70bpm; and in 
SHIFT, the median heart rate of the placebo population was 77bpm, which was rounded 
up to 80bpm, since the SHIFT patients with a heart rate greater than the median had 
previously been found to be at higher risk of an event32.     
In the PROSPER analysis, the study population was divided into three groups according 
to the tertiles of the distribution of baseline heart rate values, since this was the 
method employed in the original PROSPER baseline heart rate publication138.  This was 
done separately for women and men because women have a higher resting heart rate 
than men250.  The male participants were divided into ‘low’, ‘medium’ and ‘high’ 
baseline heart rate groups according to the tertiles of their distribution of baseline 
heart rate, and the female participants were divided in the same way.  The participants 
in the ‘low’, ‘medium’, and ‘high’ groups were then combined to produce three groups 
of subjects both male and female.  
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In the analysis that involved pooling individual patient data from two or more trials, it 
was not appropriate to divide the pooled population into two groups based on the 
median heart rate value of the population, since the distribution of baseline heart rate 
in each trial population differed.  The patients in BEAUTIFUL, for example, were 
required to have a heart rate of at least 60bpm to be enrolled in the trial, whereas in 
SHIFT they were required to have a heart rate of at least 70bpm.  Thus, it was decided 
that the pooled study population would be divided into multiple baseline heart rate 
groups, which also allowed the observation of a finer relationship between heart rate 
and risk.  The heart rate distributions of the pooled populations were explored, and it 
was decided that each would be divided into six groups, as this resulted in a similar 
number of patients being assigned to each category.  Again, for consistency of 
approach, both pooled populations were categorised into the same six heart rate 
groups: <65bpm, 65-69bpm, 70-74bpm, 75-79bpm, 80-84bpm, and ≥85bpm. 
3.3.2 Comparison of Baseline Characteristics 
Baseline characteristics were compared between the subjects in each of the baseline 
heart rate groups.  For continuous variables, unpaired two-sample t-tests or analysis of 
variance (ANOVA) were used depending on whether baseline characteristics were being 
compared between two groups, or more than two groups, respectively.  For categorical 
variables, chi-squared tests were used.  Continuous variables are reported as means 
along with the corresponding standard deviation, and categorical variables are reported 
as counts along with the corresponding percentage. 
3.3.3 Cox Proportional Hazards Regression Analysis 
3.3.3.1 Associations Between Elevated Baseline Heart Rate and Risk 
In each individual analysis presented in Chapters 4 to 8, associations between baseline 
resting heart rate and risk of certain outcomes were assessed using the standard Cox 
proportional hazards regression model74, adjusted for a number of other covariates, 
specified in each individual section or chapter.  Since associations between baseline 
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resting heart rate and risk had been previously examined in the PROSPER, PERFORM, 
BEAUTIFUL and SHIFT populations, the Cox regression models applied in the analyses of 
these populations were adjusted for the same variables adjusted for in the respective 
baseline heart rate studies138,191,184,182 to make the current results as comparable as 
possible to the previously published results.  In the PROSPER and SHIFT baseline 
analyses138,182, along with the majority of other studies identified in the review of 
Chapter 2, the variables adjusted for in the models appeared to be selected purely at 
the discretion of the researchers, based on their clinical relevance and potential 
influence on outcome.  In the PERFORM and BEAUTIFUL baseline analyses191,184, on the 
other hand, subjects were divided into groups according to their heart rate values at 
baseline, and the models were adjusted for the variables which were significantly 
different between the groups.  Thus, for consistency of approach, the Cox models 
applied in the analyses of the CAPRICORN and EUROPA populations, and the pooled 
populations of patients included in the High Risk MI Database and placebo patients from 
BEAUTIFUL and SHIFT, were similarly adjusted for the variables which were significantly 
different between the heart rate groups at baseline.    
Standard Cox proportional hazards regression models allow the effect that a baseline 
measurement has on the risk of a future event to be estimated.  The model allows for 
other prognostic variables to be adjusted for to take into account potential confounding 
factors. 
The hazard function for the Cox proportional hazards model is 
   ℎ(𝑡, 𝑿) = ℎ0(𝑡)𝑒𝑥𝑝(∑ 𝛽𝑖𝑋𝑖 
𝑛
𝑖=1 )   (3-1) 
 
where 𝑿 = (𝑋1, 𝑋2, … , 𝑋𝑛) are the prognostic variables and ℎ0(𝑡) is the baseline 
hazard.   
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It is a semi-parametric model, because the form of the baseline hazard does not need to 
be specified to estimate the effect of the coefficients.  On the other hand, the 
coefficients themselves have to satisfy certain assumptions: firstly, that they are 
independent of time (the proportional hazards assumption); and secondly, that they are 
linear.   
The HR of an individual with covariates 𝑿 compared to an individual with covariates 𝑿∗ 
is 
ℎ(𝑡, 𝑿)
ℎ(𝑡, 𝑿∗)
=
ℎ0(𝑡)𝑒𝑥𝑝(∑ 𝛽𝑖𝑋𝑖 
𝑛
𝑖=1 )
ℎ0(𝑡)𝑒𝑥𝑝(∑ 𝛽𝑖𝑋𝑖
∗𝑛
𝑖=1 )
 
=  
𝑒𝑥𝑝(∑ 𝛽𝑖𝑋𝑖 
𝑛
𝑖=1 )
𝑒𝑥𝑝 (∑ 𝛽𝑖𝑋𝑖
∗𝑛
𝑖=1 )
 
     = 𝑒𝑥𝑝(∑ 𝛽𝑖(𝑋𝑖 − 𝑋𝑖
∗)𝑛𝑖=1 )  (3-2) 
 
The HR does not depend on time. 
Risk was compared between subjects in the baseline heart rate groups with the lowest 
heart rate group used as the reference group.  The risk associated with baseline heart 
rate as a continuous variable was also assessed and presented as HRs associated with a 
5bpm higher heart rate.  To obtain the HR associated with a 5bpm higher baseline heart 
rate, the exponential of the coefficient for a 1 unit (i.e. 1bpm) higher baseline heart 
rate from the Cox model was raised to the power of 5; to obtain the HR associated with 
a 10 or 20bpm higher heart rate, it would be raised to the power of 10 or 20, and so on.  
In each analysis, estimated HRs were calculated with associated 95% CIs and p-values, 
calculated using the Wald test251. 
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3.3.3.2 Associations Between Elevated Time-Updated Resting Heart Rate 
and Risk 
In Chapter 4, Section 4.3, and Chapters 5 to 8, associations between time-updated 
resting heart rate and risk was assessed using the extended Cox proportional hazards 
regression model205, adjusted for the same covariates as in the baseline heart rate 
analysis.  This was not done in Chapter 4, Section 4.2, because multiple heart rate 
measurements gathered over follow-up were not available in the High Risk MI 
Database231.   
The extended Cox proportional hazards regression model allows for multiple 
measurements of a variable gathered over a prolonged period of time to be entered into 
the model as a single time-dependent variable.   
The hazard function for the extended Cox model is 
 ℎ(𝑡, 𝑿(𝑡)) =  ℎ0(𝑡)𝑒𝑥𝑝[∑ 𝛽𝑖𝑋𝑖
𝑚
𝑖=1 + ∑ 𝛿𝑗𝑋𝑗(𝑡)
𝑛
𝑗=1 ] (3-3) 
  
where 𝑿(𝑡) = (𝑋1, 𝑋2, … , 𝑋𝑚, 𝑋1(𝑡), 𝑋2(𝑡), … , 𝑋𝑛(𝑡)) denotes all of the prognostic 
variables, 𝑋𝑖 denotes the 𝑖
𝑡ℎ time-fixed variable (the form that all variables take in the 
standard Cox proportional hazards model described previously), 𝑋𝑗(𝑡) denotes the 𝑗
𝑡ℎ 
time-dependent variable, and ℎ0(𝑡) is the baseline hazard. 
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The extended HR of an individual with covariates 𝑿 in relation to an individual with 
covariates 𝑿∗ at time t is  
ℎ(𝑡, 𝑿(𝑡))
ℎ(𝑡, 𝑿∗(𝑡))
=
ℎ0(𝑡)𝑒𝑥𝑝(∑ 𝛽𝑖𝑋𝑖 − ∑ 𝛿𝑗𝑋𝑗(𝑡)
𝑛
𝑗=1
𝑚
𝑖=1 )
ℎ0(𝑡)𝑒𝑥𝑝(∑ 𝛽𝑖𝑋𝑖
∗ − ∑ 𝛿𝑗𝑋𝑗
∗(𝑡)𝑛𝑗=1
𝑚
𝑖=1 )
 
=  
𝑒𝑥𝑝 (∑ 𝛽𝑖𝑋𝑖 − ∑ 𝛿𝑗𝑋𝑗(𝑡)
𝑛
𝑗=1
𝑚
𝑖=1 )
𝑒𝑥𝑝 (∑ 𝛽𝑖𝑋𝑖
∗ − ∑ 𝛿𝑗𝑋𝑗
∗(𝑡)𝑛𝑗=1
𝑚
𝑖=1 )
 
  = 𝑒𝑥𝑝 [∑ 𝛽𝑖 (𝑋𝑖 − 𝑋𝑖
∗
) + ∑ 𝛿𝑗 (𝑋𝑗(𝑡) − 𝑋𝑗
∗(𝑡))𝑛𝑗=1
𝑚
𝑖=1 ]  (3-4) 
 
Time-updated heart rate represents the most recent available heart rate value for each 
patient at any point over the course of follow-up.  A patient’s baseline heart rate is 
carried forward until the day of the first follow-up visit, at which time the new 
‘current’ value is used, and then subsequently carried forward until the next visit, and 
so on across all visits.  Since resting heart rate is evaluated as a time-updated risk 
marker, the most immediate value is consistently used for prognostic estimation, 
thereby potentially enhancing clinical relevance. 
Risk was compared between the time-updated heart rate groups, and the risk associated 
with continuous time-updated heart rate was also assessed.  Relating this back to 
Equation 3-3, 𝑋1(𝑡𝑣𝑖𝑠𝑖𝑡𝑘) was included as the only heart rate variable, and the only 
time-dependent variable, in the model, where 𝑣𝑖𝑠𝑖𝑡𝑘 denotes the heart rate 
measurement obtained at the 𝑘𝑡ℎ visit during the trial.  For heart rate as a categorical 
outcome, the heart rate group a subject was in was updated each time they had their 
heart rate measured throughout follow-up.  Estimated HRs of each higher time-updated 
heart rate group relative to the lowest heart rate group, and a 5bpm higher time-
updated heart rate (the exponential of the coefficient for a 1 unit (i.e. 1bpm) higher 
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time-updated heart rate from the Cox model raised to the power of 5), were again 
calculated with associated 95% CIs and p-values, calculated using the Wald test251.   
Additional models were fitted with adjustment for (i) baseline resting heart rate group 
or baseline heart rate as appropriate, and (ii) the previous heart rate group or the 
previous measurement.  In other words, in relation to Equation 3-3, additional models 
were fitted where (i) 𝑋1(𝑡𝑣𝑖𝑠𝑖𝑡𝑘) was included as the only time-dependent variable in 
the model, where 𝑣𝑖𝑠𝑖𝑡𝑘 denotes the heart rate measurement obtained at the 𝑘
𝑡ℎ visit 
during the trial, and 𝑋𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 was also included as a time-fixed variable in the model, 
where 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 denotes the baseline heart rate measurement; and (ii) 𝑋1(𝑡𝑣𝑖𝑠𝑖𝑡𝑘) was 
included as a time-dependent variable, and 𝑋2(𝑡𝑣𝑖𝑠𝑖𝑡𝑘−1) was also included as a time-
dependent variable, where 𝑣𝑖𝑠𝑖𝑡𝑘−1 denotes the heart rate measurement obtained at 
the visit immediately prior to the  𝑘𝑡ℎ visit during the trial.  This was done to determine 
whether the updated heart rate measurements added prognostic value to the 
information already provided by the baseline or previous heart rate measurement.   
3.3.3.3 Associations Between Time-Updated Categorical Heart Rate Patterns 
and Risk  
Finally, in order to assess the risk associated with the direction of change in heart rate 
at each follow-up visit, in a similar manner to previous studies such as Jouven et al. 
2009198, Paul et al. 2010209, and Nauman et al. 2011199, models were fitted for ‘time-
updated categorical heart rate patterns’.  Subjects were classified into a group at each 
time point, depending on their current and previous heart rate measurement. Those 
whose heart rate had: remained below a defined cut-off (such as 70bpm) were classified 
as being in the ‘low-low’ group; decreased from above the cut-off to below the cut-off 
were classified as being in the ‘high-low’ group; increased from below the cut-off to 
above the cut-off were classified as being in the ‘low-high’ group; and remained above 
the cut-off were classified as being in the ‘high-high’ group.  This analysis takes into 
account the change in heart rate between visits, while also adjusting for the previous 
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visit measurement (which is absorbed into the grouping).  Estimated HRs for a time-
updated high-high, low-high, and high-low heart rate relative to a low-low heart rate 
were calculated with associated 95% CIs and p-values, calculated using the Wald test251.  
3.3.4 Linearity  
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  This is the recommended method for assessing the 
linearity of a variable in a Cox proportional hazards regression model252.   
3.3.5 Model Discrimination and Calibration 
While associations between resting heart rate and risk of death and adverse CV 
outcomes have been well studied, as illustrated by the review of Chapter 2, information 
on the prognostic value of resting heart rate beyond measures of association is lacking.  
Lonn et al. 2014216 appeared to be the only study included in the review that examined 
both associations between heart rate and risk of adverse events, and the discrimination 
and calibration of the models applied.  The discrimination of a model is its ability to 
differentiate between subjects who experience an event from those who do not; the 
calibration of a model is how accurately its predictions match the observed event 
rates254.   
It is important to assess model discrimination and calibration, since a risk marker that is 
strongly and significantly associated with risk of an outcome may not necessarily be 
adept at predicting risk of that outcome255.  Thus, in a similar manner to Lonn et al. 
2014216, the discrimination and calibration of the models applied in Chapters 4 to 8 were 
evaluated using Harrell’s C-statistic228,229 and likelihood ratio tests, respectively.  
Specifically, Harrell’s C-statistic was calculated for each resting heart rate model, as 
well as for the model excluding resting heart rate.  Harrell’s C-statistic can range from 
0 to 1, with a value of 0 indicating that the model has no predictive ability, a value of 1 
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indicating that the model has perfect predictive ability, and a value of 0.5 indicating 
that the model has average predictive ability, equivalent to that of random 
prediction256.  Similarly, the likelihood ratio test statistic of each heart rate model 
compared to the model excluding resting heart rate was calculated and tested for 
significance using the likelihood ratio 𝛸2 test.  A significant likelihood ratio 𝛸2 value 
indicates that the addition of the heart rate variable of interest to the model notably 
improves the calibration (or goodness-of-fit) of the model.  The C-statistics were only 
observationally, and not computationally, compared between models – Harrell 
recommends against the computational comparison of competing models by their C-
statistics due to the lack of statistical power in such tests, and states instead that 
comparison of models using the powerful likelihood ratio test is both sufficient and 
ideal257,258. 
3.3.6 Subgroup Analyses 
In the pooled individual patient meta-analyses presented in Chapter 4 Section 4.2, and 
Chapter 8 Section 8.4, interactions between heart rate and study were added to the Cox 
models and tested for significance using likelihood ratio tests to check whether the 
relationships between heart rate and outcome were different between the studies. 
Similarly, in the PROSPER analysis presented in Chapter 6, interactions between time-
updated heart rate and use of anti-arrhythmic drugs (details of the specific drugs 
included in this category were not available) and/or beta-blockers were added to the 
models that were additionally adjusted for baseline heart rate, and tested for 
significance.  Patients were classified as ‘taking anti-arrhythmic drugs and/or beta-
blockers’ if they were taking an anti-arrhythmic drug, a beta-blocker, or both at 
randomisation.  This was done in order to examine whether the relationships between 
heart rate and outcome were different in patients who were or were not taking anti-
arrhythmic drugs and/or beta-blockers at randomisation (drugs which can directly affect 
heart rate).  HRs, 95% CIs, and p-values were also estimated for a 5bpm higher time-
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updated heart rate adjusted for baseline heart rate, separately in patients who were or 
were not taking anti-arrhythmic drugs and/or beta-blockers.   
3.3.7 Proportionality of Hazards 
A key assumption of the Cox model is that proportionality of hazards is maintained over 
time, as mentioned in Section 3.3.3.1.  Although there are visual methods for the 
diagnosis of non-proportionality of hazards, a standard diagnostic is a residuals-based 
test259.  Therneau, Grambsch and Fleming 1990 developed a test based on the absolute 
value of the summed Schoenfeld residuals253, which are the residuals from a Cox model 
defined as the value of each covariate minus its expected value, for each individual who 
experienced an event259.   
Grambsch and Therneau 1994 modified this test by using scaled Schoenfeld residuals260.  
In principle, the scaled Schoenfeld residuals are the Schoenfeld residuals adjusted by 
the inverse of their covariance matrix261.  Grambsch and Therneau 1994, however, 
proposed that this adjustment could be executed using the variance-covariance matrix 
of the parameter estimates, divided by the number of events, under the assumption 
that the distribution of the covariates is similar in each of the different risk sets260,261.   
This test has both a global and covariate specific form, and is the standard diagnostic 
test for non-proportionality of hazards in the Cox model.  The covariate specific test 
statistic is 
    𝑇𝑘 =
{∑ (𝛿𝑘𝑖𝑔𝑘𝑖−?̅?)
𝑛
𝑖=1 𝑠𝑘
∗ }
2
𝑑𝐼𝑘 ∑ (𝛿𝑘𝑖𝑔𝑘𝑖−?̅?)
2
𝑛
𝑖=1
   (3-5) 
 
where 𝛿𝑘𝑖 and 𝑔𝑘𝑖 are the indicator variable and time of the event for the 𝑖
𝑡ℎ 
observation (with 𝑛 representing the total number of observations), respectively, 𝑠𝑘
∗  are 
the scaled Schoenfeld residuals for covariate 𝑘, ?̅? is the average pre-defined time scale 
(either linear or log-linear), 𝑑 is the number of events, and 𝐼𝑘 is the information matrix 
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of variance estimates of the parameter estimates for covariate 𝑘261,262.  Under the null 
hypothesis, this test statistic follows a chi-squared distribution with one degree of 
freedom for the covariate-specific version of the test.  It can be interpreted as a 
measure of the correlation between the covariate-specific residual, and event times.  
Test statistics that exceed 5% critical values are viewed as possible evidence that the 
non-proportional hazards assumption has been violated. 
The assumption of proportionality of hazards was tested for each of the models fitted in 
Chapters 4 to 8 using the Grambsch and Therneau 1994 test.  If the test showed 
evidence of non-proportionality, the smoothed curve and corresponding 95% CIs of the 
Schoenfeld residuals were plotted and examined to determine how the effect of heart 
rate on risk changed over the period of follow-up. 
3.4 Methods used in the Meta-Analyses Presented in 
Chapter 9 
Available HRs and 95% CIs for all-cause mortality and CV mortality were converted to 
the HR and 95% CI associated with a 5bpm higher heart rate (either ‘baseline’ or ‘time-
updated’).  HRs were then combined using random-effects meta-analysis with inverse 
variance weighting - where weights are assigned to each study based on the inverse of 
their within-study variance - to compensate for expected heterogeneity between 
studies226.   
Fixed-effects meta-analysis assumes that all the studies included in the analysis are 
essentially identical.  Thus, the results of a fixed-effects meta-analysis only apply to the 
specific population studied, and are not generalisable to other populations263.  
Differences between studies, such as the types of subjects included, are better taken 
into account using random-effects models.  Random-effects models allow the size of the 
effect of interest to differ between studies, but assumes that they are drawn from a 
common distribution of effect sizes.  This distribution is usually assumed to be the 
Normal distribution, with a variance determined by the data226,263,264.  Thus, random-
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effects meta-analysis is the more suitable method when the aim is to generalise the 
results across a variety of populations or circumstances, which is more often the case263.  
Generally, a test for heterogeneity is performed before conducting a random-effects 
meta-analysis, such as the Q and I2 statistic265-267.  Both of these statistics were used in 
Chapter 9 to assess heterogeneity across the studies. 
Three of the most commonly used methods for fitting random-effects models are the 
DerSimonian and Laird method226, and the maximum and restricted maximum likelihood 
methods265,268,269.  Regardless of which model is used, the between-study variance 𝜏2 is 
approximated first, followed by the overall effect estimate, ?̂?263.  The key difference 
between each of these methods is their calculation of 𝜏2 265.  The DerSimonian and 
Laird method uses a non-iterative technique to approximate 𝜏2, whereas the maximum 
and restricted maximum likelihood methods use an iterative technique265,268,269.  
Additionally, while both the maximum and restricted maximum likelihood methods 
assume that the within and between-study effects are normally distributed, the 
DerSimonian and Laird method does not263,269.   
It would appear that the restricted maximum likelihood method is increasingly being 
used in published meta-analyses over the DerSimonian and Laird method269.  Moreover, 
Thompson and Sharp 1999 recommended its use over the maximum likelihood 
method265.  The log-likelihood function for the maximum likelihood method is: 
𝑙𝑜𝑔𝑀𝐿(𝜃, 𝜏
2) = −
1
2
[∑ 𝑙𝑜𝑔{2𝜋(?̂?𝑖
2 + 𝜏2)} + ∑
(?̂?𝑖−𝜃)
(?̂?𝑖
2+𝜏2)
𝑘
𝑖=1
𝑘
𝑖=1 ]  (3-6) 
 
 
where 𝑘 is the number of studies being combined, 𝜃𝑖 and ?̂?𝑖
2 are the effect and variance 
estimates from study 𝑖, and 𝜃 is the overall effect268.  It assumes that 𝜃 is known, when 
in actual fact it is estimated from the data, and thus does not take into consideration 
the degrees of freedom used in the estimation of 𝜃263,265,270.  This results in a tendency 
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of the maximum likelihood method to underestimate 𝜏2 and standard errors, especially 
when there are only a small number of studies included in the analysis263,265,270.  The 
restricted maximum likelihood method, on the other hand, does not assume that 𝜃 is 
known, and excludes it from the estimation - in this way, it is restricted271.  The log-
likelihood function for the restricted maximum likelihood is: 
𝑙𝑜𝑔𝑅𝐸𝑀𝐿(𝜃, 𝜏
2)  
= −
1
2
[∑ 𝑙𝑜𝑔{2𝜋(?̂?𝑖
2 + 𝜏2)} + ∑
(?̂?𝑖−?̂?)
(?̂?𝑖
2+𝜏2)
𝑘
𝑖=1
𝑘
𝑖=1 ] −
1
2
𝑙𝑜𝑔 ∑
1
(?̂?𝑖
2+𝜏2)
𝑘
𝑖=1  (3-7) 
 
where 𝑘 is the number of studies being combined, 𝜃𝑖 and ?̂?𝑖
2 are the effect and variance 
estimates from study 𝑖, and 𝜃 is the overall effect estimate with 
     𝜃 =
∑ [𝜃𝑖/(?̂?𝑖
2+𝜏2)]𝑘𝑖=1
∑ [1/(?̂?𝑖
2+𝜏2)]𝑘𝑖=1
 .     (3-8) 
 
 
Non-negativity for 𝜏2 is enforced at each iteration, and iteration continues until 
convergence or until the maximum number of iterations is reached269.  It is considered 
an improvement over maximum likelihood, since it does adjust for the degrees of 
freedom used in the estimation of the overall effect 𝜃226,263.  Thus, the random-effects 
restricted maximum likelihood method was applied in Chapter 9226,269.   
In the meta-analysis of baseline resting heart rate, presented in Chapter 9 Section 9.2, 
publication bias was assessed using the random-effects version of Egger’s test272,273, and 
funnel plots.  If publication bias was observed, trim and fill analysis was carried out to 
determine the possible impact of missing studies, using both the L0 and R0 estimators of 
the number of missing studies274.  Duval and Tweedie 2000 recommend using both 
estimators to optimally evaluate the number of studies that are potentially missing274. It 
was not appropriate to assess publication bias in the time-updated heart rate meta-
88 
 
analysis, presented in Section 9.3, since too few published studies were included – tests 
for publication bias should only be applied when ten or more studies are included in the 
analysis275. 
Study quality was assessed using the 9-star Newcastle-Ottawa Scale96, which is widely 
used for assessing the quality of observational studies and post-hoc clinical trial 
analyses.  It awards a maximum of nine stars to each study being assessed, with higher 
quality studies attaining a greater number of stars.  Stars are awarded in relation to the 
following three categories: selection (4 stars); comparability (2 stars); and outcome (3 
stars). 
3.5 Chapter Summary 
This chapter began by outlining the analyses that were carried out in the following 
Chapters 4 to 9.  As the analyses involved new investigation of data from nine clinical 
trials, an overview of their main features was provided in Table 3-1, and each were 
described in greater detail in Section 3.2.  The rest of the chapter set out the specific 
methods of analyses that were employed.  As similar methods were used in Chapters 4 
to 8, they were presented in Section 3.3.  Lastly, Section 3.4 detailed the methods used 
to conduct the meta-analyses presented in Chapter 9. 
The first analysis chapter, Chapter 4, explores the associations between baseline and 
time-updated resting heart rate, and long-term adverse events, in post-MI patients with 
HF, LVSD, or both. 
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Chapter 4 
 
Heart Rate and Risk in Post-Acute MI Patients 
4.1 Introduction 
A raised resting heart rate measured at a single point in time has been associated with 
an increase in the risk of all-cause death164,169-171,183,213, CV death169,213, the combinations 
of all-cause death and arrhythmic events156, and CV death or non-fatal MI170, in patients 
with ACS followed-up for more than one year.  However, information on the relationship 
between resting heart rate and other endpoints, such as hospitalisation for HF, 
subsequent MI, and stroke, does not yet appear to be available in this population of 
patients.   
Previous studies have indicated that the association between heart rate and risk may be 
stronger in patients with LVSD171,173.  However, the systematic review of Chapter 2 
identified only one study that evaluated the heart rate-risk relationship in post-MI 
patients with LVSD183.  None of the studies assessed the prognostic value of resting heart 
rate in post-MI patients with HF, LVSD, or both. 
Using the High Risk MI Database231, an individual patient meta-analysis of the association 
between baseline resting heart rate and risk of death and a number of adverse CV 
outcomes in post-MI patients with HF, LVSD, or both was performed.  Differences 
between the CAPRICORN233, EPEHSUS235, OPTIMAAL237 and VALIANT239 trials that made up 
the database, in relation to the effect of baseline heart rate, were also examined.   
Since CAPRICORN patients also had their heart rates measured throughout follow-up, 
additional data from the trial made it possible to further investigate the prognostic 
value of baseline and time-updated heart rate for long-term adverse outcomes in post-
MI patients specifically with LVSD.  The systematic review of Chapter 2 did not identify 
any studies of time-updated heart rate in post-MI patients.   
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4.2 A Pooled Analysis of the Predictive Value of Baseline 
Resting Heart Rate in Patients after Acute MI, with HF, 
LVSD or Both 
The pooled analysis of individual trial data from the CAPRICORN, EPHESUS, OPTIMAAL 
and VALIANT trials included 28,691 patients (99.7% of the 28,771 randomised in total) 
who had a baseline heart rate measurement available (1,955 from CAPRICORN (99.8% of 
the 1,959), 6,606 from EPHESUS (99.5% of the 6,642), 5,461 from OPTIMAAL (99.7% of 
the 5,477) and 14,669 from VALIANT (just less than 100% of the 14,703 randomised)).  
Ideally, only the placebo group of CAPRICORN would have been included in the analysis, 
since carvedilol has heart rate lowering effects, however the High Risk MI Database did 
not contain the randomised study treatment231 so it was not possible to exclude the 
treatment group subjects.  
The publications reporting the primary results of each trial included in the database did 
not report the same outcomes.  However, the High Risk MI Database provided simplified 
information on the following 12 endpoints, all of which were evaluated in the current 
analysis: (1) all-cause death; (2) CV death; (3) CV hospitalisation; (4) HF hospitalisation; 
(5) fatal or non-fatal MI; (6) fatal or non-fatal stroke; (7); CV death or non-fatal MI; (8) 
CV death or non-fatal stroke; (9) CV death or HF hospitalisation; (10) CV death, non-
fatal MI or non-fatal stroke; (11) CV death, non-fatal MI, non-fatal stroke or HF 
hospitalisation; and (12) CV death or CV hospitalisation.   
Table 4-1 shows the characteristics and inclusion criteria of each trial.  CAPRICORN was 
the smallest trial in terms of number of patients randomised, which was just under 
2,000; EPHESUS and OPTIMAAL were larger, randomising on average approximately 
6,000 patients each; and VALIANT randomised over seven times the number of patients 
randomised in CAPRICORN, and was by far the largest of the four trials.  CAPRICORN and 
EPHESUS had similar lengths of follow-up of approximately just over one year, while 
OPTIMAAL had the longest of approximately three years.  CAPRICORN, EPHESUS and 
VALIANT were similar in that they accepted young patients into the trial, whereas 
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OPTIMAAL included only middle-aged or older subjects.  CAPRICORN included the 
highest percentage of men.  Patients in all four trials had very recently experienced an 
acute MI prior to randomisation: OPTIMAAL and VALIANT randomised subjects as little as 
12 hours after the event, while the subjects randomised to CAPRICORN and EPHESUS 
had experienced the event at least three days prior. 
Table 4-1: Characteristics and inclusion criteria of the CAPRICORN, EPHESUS, OPTIMAAL 
and VALIANT trial populations. 
n = 28691 CAPRICRON 
n = 1955 
EPHESUS 
n = 6606 
OPTIMAAL 
n = 5461 
VALIANT 
n = 14669 
Trial 
Characteristics 
    
No. of patients 
randomised 
1959 6632 5477 14703 
Follow-up 
(months) 
15.6 16.0 32.4 25.9 
Study treatments Carvedilol and 
placebo 
Eplerenone and 
placebo 
Losartan and 
captopril 
Valsartan and 
captopril 
Patient 
Characteristics 
    
Mean age (years) 63 64 67 65 
Percentage of 
males 
75% 71% 71% 69% 
Mean LVEF 33% 33% - 35% 
Inclusion Criteria     
Primary diagnosis Acute MI Acute MI Acute MI Acute MI 
Age ≥18 years >21 years ≥50 years ≥18 years 
MI criteria LVEF ≤40% Clinical evidence of 
HF, or diabetes, and 
LVEF ≤40% 
Clinical evidence of 
HF or evidence of 
LV dysfunction 
(LVEF ≤35%) or new 
Q-wave anterior 
infarct 
Clinical evidence of 
HF or evidence of 
LV dysfunction 
(LVEF ≤40%) 
Randomisation 
after onset of 
symptoms 
3 to 21 days 3 to 14 days 12h to 10 days 12h to 10 days 
The number of subjects given in the first row of the table are the number that had baseline heart rate measurements 
available who are included in the present analysis.  The follow-up duration is the mean length of follow-up in regards to 
CAPRICORN, EPHESUS, and OPTIMAAL, and the median length in regards to VALIANT.  Mean LVEF was not reported in 
the OPTIMAAL trial publication and OPTIMAAL did not collect information about patients’ LVEF.   
HF = Heart Failure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction.  
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Patients were categorised into the following six heart rate groups: <65bpm, 65-69bpm, 
70-74bpm, 75-79bpm, 80-84bpm, and ≥85bpm.  The baseline characteristics of the 
patients in each of the six baseline heart rate groups are shown in Table 4-2.   
Not all patients had every baseline measurement available.  CAPRICORN did not report 
any information on whether patients were taking beta-blockers at randomisation.  
EPHESUS did not report any information on whether patients had previously undergone a 
percutaneous transluminal coronary angiography (PTCA) or CABG procedure, or were 
taking anti-aldosterone agents at randomisation.  OPTIMAAL did not report any 
information about patients’ LVEF, or whether they were on antiplatelet agents 
(excluding aspirin), ACE inhibitors, ARBs, anti-aldosterone agents, or other lipid 
lowering medications (excluding statins) at randomisation.  VALIANT did not report any 
information on whether patients were taking anti-aldosterone agents at randomisation.  
Therefore, percentages and means were calculated using the number of subjects with 
non-missing data as the denominator.   
There were significant differences between the six groups of patients for all of the 
baseline characteristics except renal insufficiency, cerebrovascular accident, previous 
PTCA, SBP, and intake of calcium channel blockers (CCBs).  Patients in the highest heart 
rate group (≥85bpm) were more likely to be younger, with a higher BMI and a lower 
LVEF.  They were also more likely to be female and black, and have diabetes (in terms 
of both type 1 and type 2), AF, HF, chronic obstructive pulmonary disease, and a Killip 
class of above 2.  They were less likely to have angina, or have previously experienced 
an MI (prior to the most recent one).  In terms of intake of drugs at randomisation, 
those in the highest heart rate group were less likely to be taking aspirin and beta-
blockers, and were more likely to be taking other antiplatelets (excluding aspirin), 
vitamin K antagonists, diuretics and cardiac glycosides.    
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Table 4-2: Baseline characteristics of the pooled population of patients included in the High 
Risk MI Database by heart rate group.   
n = 28691 Group 1 
<65bpm 
 
n = 5724 
Group 2 
65-69bpm 
 
n = 3278 
Group 3 
70-74bpm 
 
n = 5250 
Group 4 
75-79bpm 
 
n = 3740 
Group 5 
80-84bpm 
 
n = 4558 
Group 6 
≥85bpm 
 
n = 6141 
P-
Value 
Demographic 
Characteristics 
       
Age (years) 65.7  
(11.2) 
64.9  
(11.2) 
64.9  
(11.4) 
64.9  
(11.6) 
64.7  
(11.6) 
64.6  
(11.6) 
<0.001 
Sex (male) 4306  
(75%) 
2345 
(72%) 
3726 
(71%) 
2583 
(69%) 
3091 
(68%) 
4086 
(67%) 
<0.001 
Race       <0.001 
Caucasian 5461 
(95%) 
3111 
(95%) 
4914 
(94%) 
3496 
(93%) 
4258 
(93%) 
5675 
(92%) 
- 
Black 68 
(1%) 
50 
(2%) 
77 
(1%) 
66 
(2%) 
81 
(2%) 
161 
(3%) 
- 
Asian 41 
(1%) 
28 
(1%) 
58 
(1%) 
41 
(1%) 
41 
(1%) 
78 
(1%) 
- 
Other 154 
(3%) 
89 
(3%) 
201 
(4%) 
137 
(4%) 
178 
(4%) 
227 
(4%) 
- 
BMI (kg/m²) 27.2  
(4.5) 
27.4  
(4.5) 
27.4  
(4.7) 
27.6  
(4.9) 
27.6  
(4.7) 
27.7  
(5.5) 
<0.001 
Smoking 
history 
      <0.001 
Never 1879 
(33%) 
1191 
(36%) 
1956  
(37%) 
1463  
(39%) 
1693  
(37%) 
2294  
(37%) 
- 
Current 1960 
(34%) 
1094  
(33%) 
1679  
(32%) 
1172  
(31%) 
1461  
(32%) 
1809  
(29%) 
- 
Past 1881 
(33%) 
993  
(30%) 
1607  
(31%) 
1105  
(30%) 
1398  
(31%) 
2053  
(33%) 
- 
Medical History        
Diabetes 1146 
(20%) 
783  
(24%) 
1273 
(24%) 
1026 
(27%) 
1258 
(28%) 
1878 
(31%) 
<0.001 
Type 1 diabetes 207  
(4%) 
171  
(5%) 
280  
(5%) 
213  
(6%) 
292  
(6%) 
517  
(8%) 
 
Type 2 diabetes 939  
(16%) 
612  
(19%) 
993  
(19%) 
813  
(22%) 
966  
(21%) 
1361  
(22%) 
 
Hypertension 2972  
(52%) 
1811  
(55%) 
2906  
(55%) 
2116  
(57%) 
2442  
(54%) 
3294  
(54%) 
<0.001 
Angina 2561  
(45%) 
1494  
(46%) 
2374  
(45%) 
1620  
(43%) 
1978  
(43%) 
2395  
(39%) 
<0.001 
Previous MI 1617  
(28%) 
931  
(28%) 
1357  
(26%) 
979  
(26%) 
1097  
(24%) 
1483  
(24%) 
<0.001 
AF 695  
(12%) 
345  
(11%) 
660  
(13%) 
453  
(12%) 
614  
(13%) 
969  
(16%) 
<0.001 
Dyslipidaemia 2833  
(50%) 
1482  
(45%) 
2387  
(46%) 
1734  
(46%) 
2106  
(46%) 
2856  
(47%) 
<0.001 
Renal 
insufficiency 
187  
(3%) 
96  
(3%) 
181  
(3%) 
112  
(3%) 
159  
(3%) 
199  
(3%) 
0.63 
Heart failure 1906  
(33%) 
1212  
(37%) 
1984  
(38%) 
1440  
(39%) 
1864  
(41%) 
2748  
(45%) 
<0.001 
COPD 379  
(7%) 
244  
(7%) 
387  
(7%) 
320  
(9%) 
422  
(9%) 
630  
(10%) 
<0.001 
Cerebrovascular 
accident 
455  
(8%) 
243  
(7%) 
408  
(8%) 
283  
(8%) 
375  
(8%) 
492  
(8%) 
0.77 
Previous CABG 315  
(6%) 
157  
(5%) 
241  
(5%) 
185  
(5%) 
216  
(5%) 
397  
(6%) 
<0.001 
Previous PTCA 803  
(14%) 
458  
(14%) 
726  
(14%) 
553  
(15%) 
759  
(17%) 
1107  
(18%) 
0.21 
Table continued and footnote provided on the following pages. 
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Table 4-2 (Cont.): Baseline characteristics of the pooled population of patients included in 
the High Risk MI Database by heart rate group.   
n = 28691 Group 1 
<65bpm 
 
n = 5724 
Group 2 
65-69bpm 
 
n = 3278 
Group 3 
70-74bpm 
 
n = 5250 
Group 4 
75-79bpm 
 
n = 3740 
Group 5 
80-84bpm 
 
n = 4558 
Group 6 
≥85bpm 
 
n = 6141 
P-
Value 
Cardiac 
Parameters 
       
SBP (mm HG) 121.6 
(17.0) 
121.8 
(17.0) 
121.7 
(16.5) 
122.1 
(16.5) 
121.8 
(17.1) 
121.6 
(17.3) 
0.89 
DBP (mm Hg) 70.8  
(11.0) 
71.8  
(11.0) 
72.4  
(10.6) 
72.5  
(10.8) 
73.0  
(10.7) 
72.6  
(11.7) 
<0.001 
Heart rate 
(bpm) 
59.5  
(4.3) 
67.1  
(1.3) 
71.6  
(1.4) 
76.6  
(1.2) 
81.3  
(1.6) 
94.2  
(8.7) 
- 
Killip Class       <0.001 
1 1983  
(35%) 
1037  
(32%) 
1503  
(29%) 
1064  
(28%) 
1175  
(26%) 
1398  
(23%) 
- 
2 2975  
(52%) 
1717  
(52%) 
2783  
(53%) 
1953  
(52%) 
2440  
(54%) 
3154  
(51%) 
- 
3 574  
(10%) 
405  
(12%) 
741  
(14%) 
571  
(15%) 
737  
(16%) 
1181  
(19%) 
- 
4 166  
(3%) 
107  
(3%) 
205  
(4%) 
137  
(4%) 
184  
(4%) 
448  
(7%) 
- 
LVEF 35.3  
(8.9) 
35.0  
(8.5) 
34.9  
(9.1) 
34.3  
(8.4) 
33.9  
(8.8) 
32.9  
(9.1) 
<0.001 
Medication at 
Randomisation 
       
Aspirin 5101  
(89%) 
2892  
(88%) 
4567  
(87%) 
3251  
(87%) 
3939  
(86%) 
5262  
(86%) 
<0.001 
Antiplatelet 
(excluding 
aspirin) 
1117  
(20%) 
626  
(19%) 
1093  
(21%) 
815 
(22%) 
977  
(21%) 
1465  
(24%) 
<0.001 
ACE inhibitor 2510  
(44%) 
1504  
(46%) 
2488  
(47%) 
1710  
(46%) 
2035  
(45%) 
2642  
(43%) 
<0.001 
ARB 60  
(1%) 
47  
(1%) 
49  
(1%) 
56  
(1%) 
54  
(1%) 
79  
(1%) 
<0.001 
Anti-
aldosterone 
agents 
2  
(0.03%) 
1  
(0.03%) 
4  
(0.08%) 
6  
(0.2%) 
10  
(0.2%) 
9  
(0.1%) 
<0.001 
Beta-blocker 4152  
(73%) 
2230  
(68%) 
3386  
(64%) 
2236  
(60%) 
2683  
(59%) 
3080  
(50%) 
<0.001 
Statin 2226  
(39%) 
1062  
(32%) 
1761  
(34%) 
1224  
(33%) 
1499  
(33%) 
2016  
(33%) 
<0.001 
Other lipid 
lowering agent 
(excluding 
statin) 
71  
(1%) 
44  
(1%) 
84  
(2%) 
49  
(1%) 
63  
(1%) 
90  
(1%) 
<0.001 
Vitamin K 
antagonist 
508  
(9%) 
292  
(9%) 
531  
(10%) 
375  
(10%) 
479  
(11%) 
707  
(12%) 
<0.001 
CCB 475  
(8%) 
279  
(9%) 
403  
(8%) 
270  
(7%) 
383  
(8%) 
542  
(9%) 
0.058 
Any diuretic 2176  
(38%) 
1381  
(42%) 
2296  
(44%) 
1666  
(45%) 
2168  
(48%) 
3284  
(53%) 
<0.001 
Cardiac 
glycosides 
410  
(7%) 
245  
(7%) 
518  
(10%) 
350  
(9%) 
587  
(13%) 
1027  
(17%) 
<0.001 
This table shows the clinical and demographic characteristics of the patients in each of the six baseline heart rate groups, 
including only patients who had their baseline resting heart rate measured.  Data are the number of patients with the 
corresponding percentage, or the mean with the standard deviation, depending on whether the variable was categorical or 
continuous, respectively.  The values of each characteristic were compared between the six baseline heart rate groups of 
patients using ANOVA and chi-square tests for continuous and categorical variables, respectively. 
ACE = Angiotensin-Converting Enzyme; AF = Atrial Fibrillation; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass 
Index; CABG = Coronary Artery Bypass Graft; CCB = Calcium Channel Blocker; COPD = Chronic Obstructive Pulmonary 
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Disease; DBP = Diastolic Blood Pressure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction; PTCA = 
Percutaneous Transluminal Coronary Angioplasty; SBP = Systolic Blood Pressure. 
Not all patients had every baseline measurement available.  CAPRICORN did not report any information on whether 
patients were taking beta-blockers at randomisation.  EPHESUS did not report any information on whether patients had 
previously undergone a PTCA or CABG procedure, or were taking anti-aldosterone agents at randomisation.  OPTIMAAL 
did not report any information about patients’ LVEF, or whether they were on antiplatelet agents (excluding aspirin), ACE 
inhibitors, ARBs, anti-aldosterone agents, or other lipid lowering medications (excluding statins) at randomisation.  VALIANT 
did not report any information on whether patients were taking anti-aldosterone agents at randomisation.  Therefore, 
percentages and means were calculated using the number of subjects with non-missing data as the denominator.    
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The number of events that occurred in each of the six baseline heart rate groups, as 
well as in the total pooled population, is presented in Table 4-3. 
Table 4-3: The number of first events that occurred in the pooled population of patients 
included in the High Risk MI Database and each of the baseline heart rate groups. 
  Subjects Separated by Baseline Heart Rate  
 Pooled 
Population 
 
n = 28691 
Group 1 
<65bpm 
 
n = 5724 
Group 2 
65-69bpm 
 
n = 3278 
Group 3 
70-74bpm 
 
n = 5250 
Group 4 
75-79bpm 
 
n = 3740 
Group 5 
80-84bpm 
 
n = 4558 
Group 6 
≥85bpm 
 
n = 6141 
Mortality-
Related 
Endpoints 
       
All-cause death 5108 (18%) 780 (14%) 494 (15%) 836 (16%) 658 (18%) 864 (19%) 1476 (24%) 
CV death 4387 (15%) 650 (11%) 426 (13%) 700 (13%) 570 (15%) 746 (16%) 1295 (21%) 
Hospitalisation
-Related 
Endpoints 
       
CV 
hospitalisation 
13111 (46%) 2623 (46%) 1488 (45%) 2327 (44%) 1698 (45%) 2051 (45%) 2924 (48%) 
HF 
hospitalisation 
3375 (12%) 484 (8%) 343 (10%) 554 (11%) 439 (12%) 582 (13%) 973 (16%) 
Other 
Individual 
Endpoints 
        
Subsequent MI 
(fatal or non-
fatal) 
3116 (11%) 619 (11%) 368 (11%) 520 (10%) 383 (10%) 474 (10%) 752 (12%) 
Stroke (fatal or 
non-fatal) 
937 (3%) 179 (3%) 99 (3%) 164 (3%) 133 (6%) 147 (3%) 215 (4%) 
Composite 
Endpoints 
       
CV death or 
non-fatal MI 
6104 (21%) 1050 (18%) 642 (20%) 1019 (19%) 763 (20%) 1001 (22%) 1629 (27%) 
CV death or 
non-fatal 
stroke 
4939 (17%) 757 (13%) 492 (15%) 794 (15%) 659 (18%) 757 (17%) 1417 (23%) 
CV death or HF 
hospitalisation 
6646 (23%) 986 (17%) 655 (20%) 1091 (19%) 855 (23%) 1130 (25%) 1929 (31%) 
cv death, non-
fatal MI, or 
non-fatal 
stroke 
6597 (23%) 1146 (20%) 699 (21%) 1103 (21%) 843 (23%) 1066 (23%) 1740 (28%) 
CV death, non-
fatal MI, non-
fatal stroke or 
HF 
hospitalisation 
8457 (29%) 1413 (25%) 884 (27%) 1434 (27%) 1074 (29%) 1397 (31%) 2255 (37%) 
CV death or CV 
hospitalisation 
15017 (52%) 2880 (50%) 1649 (50%) 2630 (50%) 1943 (52%) 2379 (52%) 3536 (58%) 
This table shows the total number of patients included in the High Risk MI Database with available baseline resting heart 
rate data who experienced any pre-specified events of interest, as well as the number in relation to baseline heart rate 
group.  Data are number of patients who experienced each event as a first event, with the corresponding percentage.  Note 
that first event refers to the first event of each type: for example, a patient may have been hospitalised for a CV cause, and 
then subsequently been hospitalised for HF at a later date. 
CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction.  
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The Cox models were adjusted for the variables which were significantly different 
between the heart rate groups at baseline (p<0.05), and were available for all four 
individual studies: age; sex; race; BMI; smoking history; diabetes; hypertension; angina; 
prior MI; AF; dyslipidaemia; HF; chronic obstructive pulmonary disease; DBP; Killip 
class; and intake of certain drugs at randomisation which were aspirin, statins, vitamin 
K antagonists, diuretics and cardiac glycosides.  Models were also adjusted for study.     
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
Comparing the risk of the outcomes between the heart rate groups greater than or 
equal to 65bpm, versus <65bpm, produced the HRs, 95% CIs and p-values shown by 
Figure 4-1 and in Table A2-1 provided in Appendix 2. Compared to patients with a 
baseline heart rate <65bpm, patients in each of the baseline heart rate groups ≥65bpm 
were at a higher risk of HF hospitalisation, and the combined endpoints CV mortality or 
non-fatal stroke, CV death or HF hospitalisation, and CV mortality, non-fatal MI, stroke 
or HF hospitalisation.  Patients in each heart rate group ≥70bpm were at a higher risk of 
all-cause and CV death.  Those in each heart rate group ≥75bpm were at a higher risk of 
the combined endpoints CV death or non-fatal MI, and CV death, non-fatal MI or stroke.  
Finally, patients with a baseline heart rate ≥85bpm were at a higher risk of CV 
hospitalisation, fatal or non-fatal MI, and the combined endpoint of CV death or CV 
hospitalisation.  No significant increases in risk of fatal or non-fatal stroke were 
observed.     
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Figure 4-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the five baseline heart rate groups 
greater than or equal to 65bpm, relative to a baseline heart rate <65bpm in the pooled 
population of patients included in the High Risk MI Database.   
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction.   
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; intake of certain drugs at randomisation which were aspirin, 
statins, vitamin K antagonists, diuretics and cardiac glycosides; and study.  
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Analysing continuous baseline heart rate produced the HRs, 95% CIs and p-values shown 
by Figure 4-2 and in Table A2-2 provided in Appendix 2.  Elevated baseline heart rate 
was associated with an increase in risk of all of the endpoints except fatal or non-fatal 
stroke (p = 0.062).  The smallest increases in risk were observed for CV hospitalisation 
and fatal or non-fatal MI.  A 5bpm higher baseline heart rate was associated with a 1% 
(p = 0.0059) and 2% (p = 0.0086) increase in the risk of CV hospitalisation and fatal or 
non-fatal MI, respectively.  The largest increase in risk was observed for CV death, HF 
hospitalisation, and the composite of the two.  A 5bpm higher heart rate was associated 
with an 8% increase in risk of each of these endpoints. 
Figure 4-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher baseline heart rate in the pooled 
population of patients included in the High Risk MI Database. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction.   
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; intake of certain drugs at randomisation which were aspirin, 
statins, vitamin K antagonists, diuretics and cardiac glycosides; and study.  
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The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A2-3 provided in Appendix 2 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the model 
including the baseline heart rate group variable, for each outcome.  Regardless of 
whether resting heart rate group was included, the models had the greatest predictive 
ability for all-cause death, CV death, HF hospitalisation, and the combined endpoints of 
CV death or non-fatal stroke, and CV death or HF hospitalisation: the C-statistics of the 
models both excluding and including resting heart rate ranged from 0.703 to 0.735 for 
these outcomes.  On the other hand, the models had the least predictive ability for CV 
hospitalisation, and the combined endpoint of CV death or CV hospitalisation, with C-
statistics ranging from 0.581 to 0.591.  The addition of the baseline heart rate groups 
variable improved discrimination for all of the outcomes.  The largest improvements in 
discrimination were observed for CV death and HF hospitalisation, with the C-statistics 
increasing from 0.715 to 0.723, and 0.727 to 0.735, respectively, when baseline heart 
rate group was added to the model.  The smallest improvements were observed for CV 
hospitalisation, and fatal or non-fatal MI, with the C-statistics increasing from 0.581 to 
0.582, and 0.650 to 0.652, respectively.  The likelihood ratio test statistics and 
corresponding p-values for the addition of the baseline heart rate group variable to the 
models are also presented in Table A2-3.  The addition of baseline heart rate group 
resulted in statistically significant improvements in the calibration of the models for all 
of the outcomes excluding fatal or non-fatal stroke.   
Harrell’s C-statistics for the model excluding resting heart rate, and the model including 
the continuous baseline heart rate variable, for each outcome, are shown in Table A2-4 
provided in Appendix 2, along with the likelihood ratio test statistics and corresponding 
p-values for the addition of the continuous baseline heart rate variable to the models.  
The results were very similar to those observed for baseline resting heart rate group.   
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All of the models with the exception of the heart rate groups model for fatal or non-
fatal stroke exhibited evidence of non-proportionality of the effect of heart rate on the 
hazard over time (see Table A2-5 and A2-6 in Appendix 2 for the p-values of the 
Grambsch and Therneau 1994 test for non-proportionality).  The previously presented 
HRs therefore represent the ‘average’ effect of heart rate on the hazard over the 
duration of follow-up. Examination of the plots of the smoothed curve and 
corresponding 95% CIs of the Schoenfeld residuals for each model and outcome 
suggested that the effect of heart rate was highest at the beginning of follow-up, and 
then decreased over time.  Figure 4-3 shows the Schoenfeld residual plots for a 5bpm 
higher baseline heart rate, along with the previously calculated ‘average’ hazard ratio 
of each outcome, represented by the horizontal dotted line, and provides an illustration 
of this finding. 
Table A2-1 and Table A2-2 in Appendix 2 also provide the p-values for the likelihood 
ratio tests for the interaction term of heart rate with study. Significant interactions 
between heart rate group and study were observed for CV death (p = 0.040), CV 
hospitalisation (p = 0.0025), and the combined endpoints CV death or HF hospitalisation 
(p = 0.027), and CV death or CV hospitalisation (p = 0.034).  When continuous heart rate 
was analysed, significant interactions between heart rate and study were observed for 
CV hospitalisation (p<0.001), fatal or non-fatal MI (p = 0.0045) and CV death or CV 
hospitalisation (p = 0.0027).  This indicates that the effect of heart rate is different 
depending on study for these outcomes. To gain insight into these differences, HRs for 
categorical heart rate were calculated for the four outcomes that showed significant 
interaction for each of the four individual trials.  These are shown by Figure 4-4 and 
given in Table A2-7 provided in Appendix 2.  Similarly, HRs for a 5bpm higher heart rate 
were calculated and are shown by Figure 4-5 and in Table A2-8 provided in Appendix 2. 
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Figure 4-3: The Schoenfeld residuals plots for a 5bpm higher baseline heart rate for each 
outcome in the pooled population of patients included in the High Risk MI Database. 
 
The horizontal dotted lines represent the previously calculated ‘average’ hazard ratio of each outcome.  AC = All-Cause; CV 
= Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
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Figure 4-4: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the five baseline heart rate groups 
greater than or equal to 65bpm, relative to a baseline heart rate <65bpm, in the CAPRICORN, 
EPHESUS, OPTIMAAL and VALIANT populations, for the outcomes that showed significant 
interactions between heart rate and study. 
 
CV = Cardiovascular; HF = Heart Failure. 
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; and intake of certain drugs at randomisation which were 
aspirin, statins, vitamin K antagonists, diuretics and cardiac glycosides.  
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Figure 4-5: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher baseline heart rate, in the 
CAPRICORN, EPHESUS, OPTIMAAL and VALIANT populations, for the outcomes that 
showed significant interactions between heart rate and study.  
CV = Cardiovascular; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; and intake of certain drugs at randomisation which were 
aspirin, statins, vitamin K antagonists, diuretics and cardiac glycosides. 
 
Patients in each of the heart rate groups were shown to be at a similar risk of CV death 
and the combined endpoint of CV death or HF hospitalisation across all four studies.  
The significant interactions observed are therefore likely to be due to a difference in 
the strength of the associations, with a suggestion of a significant but weaker gradient 
in the risk in the largest study, VALIANT.  In contrast, for CV hospitalisation and the 
combination of CV death or CV hospitalisation, there was no evident association 
between heart rate and risk in OPTIMAAL, with a clear gradient of risk in EPHESUS and 
evidence of an association in the smaller CAPRICORN trial.  While there was also no 
association between heart rate and risk of CV hospitalisation in the VALIANT population, 
VALIANT patients with a baseline heart rate ≥85bpm were found to be at a 15% higher 
risk of CV death or CV hospitalisation compared to those with a baseline heart rate 
<65bpm.  Similar results were found when heart rate was analysed as a continuous 
variable for the outcomes of CV hospitalisation and CV death or CV hospitalisation.  For 
the outcome of fatal or non-fatal MI, it appears that the OPTIMAAL study is an outlier 
with a trend to a negative association with risk for an elevated heart rate (a 5bpm 
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higher heart rate was associated with a borderline significant decrease in the risk of MI: 
HR 0.97, 95% CI 0.95 to 1.00, p = 0.077). 
4.3 The Predictive Value of Time-Updated Heart Rate 
Measurements in the CAPRICORN Placebo Patients 
A total of 981 of the patients assigned to the CAPRICORN placebo group (98.7% of the 
984 placebo-assigned patients) had baseline heart rate measurements available and 
were included in the present analysis.  Patients who were randomised to the treatment 
group were excluded since carvedilol has heart rate lowering effects and could possibly 
interfere with any association between heart rate and outcomes.   
The current analysis evaluated all of the outcomes that were assessed in the original 
CAPRICORN trial publication233: all-cause death (the first primary endpoint of 
CAPRICORN); all-cause death or CV hospital admission (the second primary endpoint of 
CAPRICORN); sudden death; hospital admission for HF; CV death; HF death; non-fatal 
MI; and all-cause death or non-fatal MI.   
The heart rate cut-off of 75bpm was selected on the basis that it was very close to the 
median heart rate of 76bpm of the CAPRICORN placebo population.  The baseline 
characteristics of the placebo-assigned CAPRICORN patients, overall and categorised 
into groups depending on whether their baseline resting heart rate was less than, or 
greater than or equal to, 75bpm, are shown in Table 4-4.  There were significant 
differences between the two groups of patients in terms of sex, whether or not they 
had diabetes, their LVEF (borderline), the site of their MI, and whether or not they were 
treated with intravenous diuretics post-MI.  Patients in the higher heart rate group were 
more likely to be female and have diabetes.  They were also more likely to have had an 
anterior MI, and to have been treated with intravenous diuretics. 
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Table 4-4: Baseline characteristics of the CAPRICORN placebo population. 
  Baseline Heart Rate  
 All Subjects 
n = 981 
<75bpm 
n = 449 
≥75bpm 
n = 532 
p-value 
Demographic Characteristics     
Age (years) 63.2 (11.7) 63.0 (11.4) 63.3 (12.0) 0.62 
Sex    0.042 
Men 721 (74%) 344 (77%) 377 (71%)  
Women 260 (27%) 105 (23%) 155 (29%)  
Smoking    0.64 
Current 319 (33%) 153 (34%) 166 (31%)  
Previous 242 (25%) 109 (24%) 133 (25%)  
Never 417 (43%) 186 (41%) 231 (43%)  
Medical History     
Previous MI 290 (30%) 131 (29%) 159 (30%) 0.81 
Previous angina 531 (54%) 249 (55%) 282 (53%) 0.44 
Previous hypertension 512 (52%) 231 (51%) 281 (53%) 0.67 
Previous diabetes 229 (23%) 85 (19%) 144 (27%) 0.0027 
Other vascular disease 159 (16%) 70 (16%) 89 (17%) 0.63 
Previous revascularisation 107 (11%) 48 (11%) 59 (11%) 0.84 
Hyperlipidaemia 322 (33%) 139 (31%) 183 (34%) 0.25 
Infarct Characteristics     
LVEF (%) 32.7 (6.4) 33.1 (6.2) 32.3 (6.6) 0.050 
SBP (mmHg) 120.7 (16.1) 121.4 (15.6) 120.1 (16.5) 0.21 
DBP (mmHg) 73.4 (10.0) 73.7 (9.6) 73.1 (10.4) 0.39 
Heart rate (bpm) 77.2 (11.3) 67.8 (4.3) 85.1 (9.0) - 
Site of MI    0.025 
Anterior 533 (54%) 234 (52%) 299 (56%)  
Inferior 205 (21%) 111 (25%) 94 (18%)  
Other 243 (25%) 104 (23%) 139 (26%)  
Treatment for Index MI     
Nitrates 714 (73%) 331 (74%) 383 (72%) 0.54 
Intravenous beta-blockers 99 (10%) 43 (10%) 56 (11%) 0.62 
Intravenous heparin 632 (64%) 290 (65%) 342 (64%) 0.92 
Subcutaneous heparin 481 (49%) 221 (49%) 260 (49%) 0.91 
Intravenous diuretics 319 (33%) 110 (24%) 209 (39%) <0.001 
Thombolysis/primary angioplasty 463 (47%) 208 (46%) 255 (48%) 0.62 
Medications at Time of Randomisation     
ACE inhibitor 953 (97%) 439 (98%) 514 (97%) 0.28 
Aspirin 845 (86%) 382 (85%) 463 (87%) 0.38 
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This table shows the clinical and demographic characteristics of the CAPRICORN placebo patients who had baseline 
resting heart rate measurements available.  Values are given for the total placebo population, as well as separately for 
patients who had a baseline resting heart rate <75bpm, and patients who had a baseline resting heart rate ≥75bpm.  Data 
are the number of patients with the corresponding percentage, or the mean with the standard deviation, depending on 
whether the variable was categorical or continuous.  Not all patients had every baseline measurement available.  Therefore, 
percentages and means were calculated using the number of subjects with non-missing data as the denominator.  The 
values of each characteristic were compared between the two different baseline resting heart rate groups using unpaired 
two-sample t-tests and chi-squared tests, for continuous and categorical variables, respectively. 
ACE = Angiotensin-Converting Enzyme; DBP = Diastolic Blood Pressure; LVEF = Left-Ventricular Ejection Fraction; MI = 
Myocardial Infarction; SBP = Systolic Blood Pressure.   
  
108 
 
The total number of events that occurred in the placebo group is presented in Table 
4-5, along with the number that occurred in each of the baseline heart rate groups of 
patients.  The percentage of patients in the greater than or equal to 75bpm baseline 
heart rate group who experienced an event was higher for every event compared to the 
less than 75bpm baseline heart rate group of patients.   
Table 4-5: The number of first events that occurred in the CAPRICORN placebo population.   
  Subjects Separated by Baseline 
Heart Rate 
 Total Placebo 
Population 
n = 981 
<75bpm 
n = 449 
≥75bpm 
n = 532 
Primary Endpoints    
All-cause mortality 150 (15%) 55 (12%) 95 (18%) 
All-cause mortality or cardiovascular cause 
hospital admission 
366 (37%) 141 (31%) 225 (42%) 
Secondary Endpoints    
Sudden death 68 (7%) 26 (6%) 42 (8%) 
Hospital admission for heart failure 138 (14%) 42 (9%) 96 (18%) 
Other Endpoints    
Cardiovascular-cause mortality 138 (14%) 52 (12%) 86 (16%) 
Death due to heart failure 30 (3%) 7 (2%) 23 (4%) 
Non-fatal myocardial infarction 57 (6%) 19 (4%) 38 (7%) 
All-cause mortality or non-fatal myocardial 
infarction 
191 (19%) 70 (16%) 121 (23%) 
This table shows the total number of CAPRICORN placebo patients with available baseline resting heart rate data who 
experienced any pre-specified events of interest, as well as the number in relation to baseline heart rate, partitioned at 
75bpm.  Data are number of patients who experienced each event as a first event, with the corresponding percentage.  
Note that first event refers to the first event of each type: for example, a patient may have experienced a non-fatal MI, and 
then subsequently been admitted to hospital for HF at a later date. 
 
The Cox regression models adjusted for the variables which were significantly different 
between the two baseline heart rate groups (p≤0.05); sex, previous diabetes, LVEF, site 
of MI, and in-hospital treatment with intravenous diuretics.   
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
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Comparing the risk of each of the outcomes between patients with a baseline or time-
updated heart rate greater than or equal to 75bpm, or less than 75bpm, produced the 
HRs and CIs shown by Figure 4-6 and in Table A2-9 provided in Appendix 2. 
Figure 4-6: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥75bpm compared to a heart rate 
<75bpm in the CAPRICORN placebo population. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction.   
Models were additionally adjusted for: sex; previous diabetes; left-ventricular ejection fraction (LVEF); site of MI; and in-
hospital treatment with intravenous diuretics. 
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A heart rate ≥75bpm was associated with an increase in risk of the combined endpoint 
of all-cause death or CV-cause hospital admission, and hospital admission for HF in all 
models fitted (time-updated heart rate adjusted for baseline was borderline significant 
for all-cause death or CV-cause hospital admission (p = 0.067)).  A baseline resting heart 
rate ≥75bpm was not associated with an increase in risk of all-cause mortality, CV 
mortality or the combined endpoint of all-cause mortality or non-fatal MI.  However, 
time-updated resting heart rate ≥75bpm was associated with a 62% (p = 0.0058) increase 
in risk of all-cause mortality, and a 57% increase in risk of CV mortality (p = 0.013), with 
the association remaining even after adjustment for baseline or the previous heart rate 
category.  Similarly, time-updated heart rate ≥75bpm was associated with a 43% (p = 
0.019) increase in risk of all-cause mortality or non-fatal MI, but after adjustment for 
baseline heart rate or the previous heart rate category, the association was attenuated 
slightly (p = 0.058 and p = 0.082 for adjustment for baseline, and the previous category, 
respectively).  Conversely, a baseline heart rate ≥75bpm was associated with a 78% (p = 
0.042) increase in risk of experiencing a non-fatal MI, while none of the time-updated 
heart rate variables were.  No significant associations between heart rate and risk were 
observed for sudden death or death due to HF in any of the models. 
Analysing continuous heart rate measurements produced the HRs and CIs shown by 
Figure 4-7 and in Table A2-10 provided in Appendix 2.  The pattern of results was 
generally very similar to those for the categorical heart rate analysis, with the 
exceptions that baseline heart rate was no longer associated with risk of MI, and a 5bpm 
higher baseline heart rate was associated with a 17% (p = 0.018) increase in the risk of 
death due to HF.   
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Figure 4-7: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the CAPRICORN 
placebo population. 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: sex; previous diabetes; left-ventricular ejection fraction (LVEF); site of MI; and in-
hospital treatment with intravenous diuretics. 
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Figure 4-8 and Table A2-11 show the adjusted HRs and 95% CIs estimated using the time-
updated categorical heart rate patterns models.  Comparing the current heart rate 
measurement at each visit to the previous heart rate measurement, those who had a 
heart rate ≥75bpm at both visits (high-high) were found to be at a higher risk of all-
cause mortality (67%, 95% CI 12 to 149%, p = 0.012), the combined endpoint of all-cause 
mortality or CV cause hospital admission (36%, 95% CI 6 to 76%, p = 0.017), CV-cause 
mortality (59%, 95% CI 5 to 142%, p = 0.028), and all-cause death or non-fatal MI (54%, 
95% CI 9 to 119%, p = 0.015), compared to those patients who had a heart rate <75bpm 
at both visits (low-low).  Patients with a high heart rate at both visits (high-high), and 
an increase in heart rate from below 75bpm at the previous visit, to greater than or 
equal to 75bpm at the current visit (low-high), were at a significantly higher risk of 
hospital admission for HF compared to those patients with a low heart rate at both visits 
(low-high: 80%, 95% CI 3 to 213%, p = 0.038; high-high: 114%, 95% CI 38 to 233%, 
p<0.001).  There were no significant increases in the risk of sudden death, death due to 
HF, or non-fatal MI. 
The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A2-12 provided in Appendix 2 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the heart rate variables that categorised subjects according to whether they 
had a heart rate less than, or greater than or equal to, 75bpm for each outcome.  
Regardless of whether any resting heart rate category variables were included, the 
models had the greatest predictive ability for hospital admission for HF and death due 
to HF: the C-statistics of the models both excluding and including resting heart rate 
ranged from 0.682 to 0.703, and 0.733 to 0.768 for each of these outcomes, 
respectively.  The C-statistics of the models for the other outcomes ranged from 0.604 
to 0.657.  The addition of resting heart rate category improved discrimination for all of 
the outcomes compared to the model excluding heart rate.  For all-cause death, 
hospitalisation for HF, death due to HF, and the combined endpoints of all-cause death  
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Figure 4-8: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate patterns 
‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the CAPRICORN 
placebo population.   
 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 75bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 75bpm, and so on.     
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction.   
Models were additionally adjusted for: sex; previous diabetes; left-ventricular ejection fraction (LVEF); site of MI; and in-
hospital treatment with intravenous diuretics. 
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or CV hospital admission, and all-cause death or non-fatal MI, the model including time-
updated resting heart rate category additionally adjusted for baseline heart rate 
category had the best discrimination.  The greatest improvement in discrimination was 
observed for death due to HF, with the C-statistic increasing from 0.733 to 0.768.  The 
model including time-updated heart rate category additionally adjusted for the previous 
heart rate category had the best discrimination for sudden death, and both of the time-
updated heart rate models adjusted for either baseline or the previous heart rate 
category had the best for CV death.  Conversely, the model including baseline resting 
heart rate only, had the best predictive ability for non-fatal MI, which corresponds with 
the fact that a baseline heart rate ≥75bpm was associated with an increase in risk of MI, 
while none of the time-updated heart rate variables were.  The likelihood ratio test 
statistics and corresponding p-values for the addition of the heart rate category 
variables to the models are also presented in Table A2-12.  The addition of any of the 
heart rate category variables resulted in statistically significant improvements in the 
calibration of the models for all-cause death, the combined endpoint of all-cause death 
or CV hospital admission, and hospital admission for HF.  Only the addition of the time-
updated heart rate category variable, with or without adjustment for baseline or the 
previous heart rate category, improved the calibration of the models for CV death, and 
the combined endpoint of all-cause death or non-fatal MI.  On the other hand, only the 
addition of baseline heart rate category improved the calibration of the model for non-
fatal MI.  There were no significant improvements in model calibration for sudden death 
or death due to HF with the addition of any of the heart rate category variables.    
Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the continuous heart rate variables, for each outcome, are shown in Table A2-
13 provided in Appendix 2, along with the likelihood ratio test statistics and 
corresponding p-values for the addition of the different continuous heart rate variables.  
The results were very similar to those observed for the heart rate categories according 
to whether subjects had a heart rate less than, or greater than or equal to 75bpm, with 
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a few exceptions.  First, the model including continuous time-updated heart rate 
additionally adjusted for baseline heart rate had the best discrimination for non-fatal 
MI, as opposed to the model including only baseline heart rate, but there were no 
significant improvements in model calibration for MI with the addition of any of the 
continuous heart rate variables.  Second, the addition of baseline heart rate, or time-
updated heart rate (but not in combination with baseline or previous heart rate) 
improved the calibration of the model for death due to HF. 
Table A2-14 provided in Appendix 2 shows Harrell’s C-statistics for the model excluding 
resting heart rate, and the models including the time-updated categorical heart rate 
patterns variable for each outcome.  Again, irrespective of whether resting heart rate 
was included, the models had the greatest predictive ability for hospital admission for 
HF and death due to HF.  The addition of time-updated categorical heart rate pattern 
improved discrimination for all of the outcomes.  The largest improvements in 
discrimination were observed for sudden death and death due to HF, with the C-
statistics increasing from 0.622 to 0.640, and 0.733 to 0.752, respectively, when time-
updated heart rate pattern was added to the models.  The smallest were observed for 
the composite of all-cause death or CV hospital admission, and non-fatal MI, with the C-
statistics increasing from 0.604 to 0.611, and 0.632 to 0.638, respectively.  The 
likelihood ratio test statistics and corresponding p-values for the addition of the heart 
rate patterns variable to the models are also presented in Table A2-14.  The addition of 
heart rate pattern only resulted in statistically significant improvements in the 
calibration of the models for all-cause death and hospital admission for HF; there were 
no significant improvements in model calibration for any of the other outcomes.   
Tables A2-15, A2-16 and A2-17 in Appendix 2 show the p-values of the Grambsch and 
Therneau 1994 test for non-proportionality of hazards for all of the models and 
outcomes.  There were no violations of the proportional hazard assumption for any of 
the heart rate variables that were associated with risk of outcome.  
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4.4 Discussion 
In the large pooled population of patients after MI with HF, LVSD, or both, an elevated 
baseline resting heart rate was associated with an increase in the risk of all of the 
endpoints evaluated, except for fatal or non-fatal stroke.  The addition of baseline 
heart rate also resulted in statistically significant improvements in the calibration of the 
models for all of the outcomes except fatal or non-fatal stroke.  However, adding 
baseline heart rate to the models improved discrimination for every outcome.  The 
associations were similar for all-cause death, CV death, and HF hospitalisation, but 
were weaker for CV hospitalisation and subsequent MI.  The models had the greatest 
predictive ability for the three former endpoints, and the least for CV hospitalisation.  
Evidence of non-proportionality of the effect of an elevated heart rate was observed for 
all outcomes (excluding higher heart rate group for fatal or non-fatal stroke).  It 
appeared that the association between elevated heart rate and risk of each outcome 
was highest immediately after MI, and decreased over time.  
When differences between each of the four cohorts were examined, it was discovered 
that the relationship between heart rate and CV hospitalisation, the combined endpoint 
of CV death or CV hospitalisation, and the individual endpoint of subsequent MI, were 
particularly different in the OPTIMAAL population.  For example, a raised resting heart 
rate was associated with an increase in the risk of CV death or CV hospitalisation in all 
of the populations except OPTIMAAL, despite the fact that the number of CV death or 
CV hospitalisation events that occurred in OTPIMAAL (n = 3215) were similar to the 
number that occurred in EPHESUS (n = 3116).  Similarly, a raised resting heart rate was 
associated with an increase in the risk of subsequent MI in the EPHESUS and VALIANT 
populations, but was not associated with risk in either CAPRICORN or OPTIMAAL.  Few 
recurrent MI events occurred in CAPRICORN (n = 118), however, which could explain the 
insignificant association, whereas the number that occurred in OPTIMAAL (n = 657) was 
again similar to the number that occurred in EPHESUS (n = 604).   
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In the small placebo population of patients with MI and LVSD from CAPRICORN, an 
elevated resting heart rate was associated with an increase in the risk of all the 
endpoints evaluated, except for sudden death.  The addition of resting heart rate also 
resulted in statistically significant improvements in the calibration of the models for all 
of the outcomes except sudden death.  However, adding resting heart rate to the 
models improved discrimination for all of the endpoints.   
Both an elevated baseline and time-updated heart rate, unadjusted and adjusted for 
the baseline or previous heart rate measurement, were associated with an increase in 
the risk of hospital admission for HF; the addition of any of the heart rate variables also 
resulted in statistically significant improvements in the calibration of the models. 
While no associations between baseline heart rate and risk of all-cause or CV death 
were observed, an elevated time-updated heart rate was similarly associated with an 
increase in risk of both endpoints.  When heart rate was treated as a continuous 
variable, only the addition of the time-updated heart rate variables, with or without 
adjustment for baseline or the previous heart rate measurement, improved the 
calibration of the models for all-cause and CV death (the addition of any of the heart 
rate category variables resulted in statistically significant improvements in the 
calibration of the models for all-cause death).  Generally, the models including time-
updated heart rate additionally adjusted for the baseline or previous heart rate 
measurement had the best discrimination for hospital admission for HF, all-cause death 
and CV death.  This suggests that, despite knowing the baseline or previous heart rate 
measurement, the current measurement contributes significant additional information 
about risk of each of these endpoints.   
Only an elevated continuous baseline heart rate, and a baseline heart rate ≥75bpm, 
were associated with an increase in the risk of death due to HF, and non-fatal MI, 
respectively.  The model including baseline heart rate category also had the best 
discrimination for non-fatal MI, and was the only model found to have a significantly 
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better calibration than the model excluding heart rate.  The model including continuous 
baseline heart rate was also found to have a significantly better calibration than the 
model excluding heart rate for death due to HF.  Conversely, the time-updated heart 
rate model adjusted for baseline heart rate had the greatest discriminative ability for 
death due to HF, regardless of whether heart rate was treated as a categorical or 
continuous variable.   
The results found using baseline heart rate in the pooled analysis were similar to those 
found using time-updated heart rate in the CAPRICORN placebo analysis for all-cause 
and CV death.  Furthermore, using time-updated heart rate appeared to strengthen the 
associations, despite less than 200 deaths occurring in the CAPRICORN placebo 
population, compared to more than 4000 occurring in the pooled population.  For 
example, in the pooled analysis, a 5bpm higher baseline heart rate was associated with 
a 7% (p<0.001) and an 8% (p<0.001) increase in risk of all-cause and CV death, 
respectively; in the CAPRICORN analysis, a 5bpm higher time-updated heart rate 
adjusted for baseline was associated with a 12% (p<0.001) and a 10% (p = 0.0031) 
increase in risk, respectively. 
Previous studies of post-MI patients have found similar increases in the risk of all-cause 
death164,171,183.  In addition, Fox et al. 2008184 and Bohm et al. 2010182 found that a 5bpm 
higher baseline heart rate was associated with a similar 8% (p = 0.05) and 16% (p<0.001) 
increase in the risk of CV death in patients with LVSD who had CHD, or HF, respectively.  
In contrast, Antoni et al. 2012 demonstrated that a 5bpm higher discharge heart rate 
was associated with a much higher 26% (p<0.001) and 24% (p<0.001) increase in the risk 
of all-cause death and CV death four years after discharge, respectively, in STEMI 
patients treated with PCI169. 
The results found using baseline heart rate in regards to hospital admission for HF were 
similar between the two analyses, despite only 138 events occurring in the CAPRICORN 
population compared to 3375 in the pooled population.  Again, the association was 
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apparently strengthened when time-updated heart resting heart rate was used.  For 
example, a 5bpm higher baseline heart rate was associated with an 8% (p<0.001) and a 
9% (p = 0.012) increase in hospitalisation for HF in the pooled and CAPRICORN analysis, 
respectively, and a 5bpm higher time-updated heart rate adjusted for baseline was 
associated with an 11% (p<0.001) increase in risk.   
None of the studies of ACS patients identified in the review of Chapter 2 evaluated risk 
of long-term HF hospitalisation.  However, Bohm et al. further illustrated that a 5bpm 
higher baseline heart rate was associated with a similar 16% increase in the risk of 
hospital admission for HF in patients with chronic HF and LVSD182. 
It is not clear why OPTIMAAL was an outlier in the pooled analysis.  The main 
differences between it and the other studies were that it followed patients up for 
around three years, while each of the others followed patients up for around one or two 
years, and only recruited patients aged 50 years or older.  Further examination of 
OPTIMAAL would be required to understand if and how these differences affect the 
relationship between heart rate and outcome.   
No association between an elevated baseline heart rate and the risk of fatal or non-fatal 
stroke was observed in the pooled analysis.  Although discrimination of the model 
improved slightly with the addition of baseline heart rate (from 0.675 to 0.679 and 
0.676 for categorical and continuous heart rate, respectively), there were no 
improvements in model calibration.  However, the number of stroke events that 
occurred was less than 1000 (n = 937), whereas at least 3000 of each of the other 
endpoints occurred.  In addition, a 5bpm higher baseline heart rate was borderline 
significantly associated with an increase in risk (HR 1.02, 95% CI 1.00 to 1.05), so there 
may have been an insufficient number of events for the association to reach 
significance.  Similarly, no association between any of the heart rate variables and the 
risk of sudden death was observed in the CAPRICORN placebo population analysis.  
Again, discrimination of the models was improved with the addition of resting heart 
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rate, but there were no improvements in model calibration.  However, the number of 
sudden deaths was also relatively small (n = 68).  Moreover, both a 5bpm higher time-
updated heart rate unadjusted and adjusted for baseline were borderline significantly 
associated with an increase in risk of sudden death (unadjusted for baseline: HR 1.08, 
95% CI 0.99 to 1.19, p = 0.087; adjusted for baseline: HR 1.09, 95% CI 0.99 to 1.20, p = 
0.094), so again there may have been an insufficient number of events for the 
association to reach significance.  None of the studies of subjects with ACS identified in 
Chapter 2, or those that included subjects all of whom had LVSD, investigated the 
relationship between heart rate and stroke or sudden death.  Thus, further analyses of 
the relationship between resting heart rate and risk of these endpoints including a 
greater number of events could be insightful.   
None of the time-updated heart rate variables were able to predict risk of death due to 
HF, or non-fatal MI in the CAPRICORN placebo population analysis.  This is likely due to 
there being only 30 deaths due to HF, and 57 non-fatal MI events.  A 5bpm higher time-
updated heart rate was borderline significantly associated with an increase in risk of 
both death due to HF (HR 1.12, 95% CI 1.00 to 1.25, p = 0.060) and non-fatal MI (HR 
1.09, 95% CI 0.99 to 1.20, p = 0.089).  Future studies of the relationship between time-
updated heart rate and risk of HF death and non-fatal MI could be illuminating.   
4.4.1 Chapter Summary and Conclusions 
This chapter examined the associations between baseline and time-updated resting 
heart rate, and long-term adverse CV events, in post-MI patients with HF, LVSD, or 
both.  Firstly, using the High Risk MI Database, a pooled individual patient meta-analysis 
of the CAPRICORN, EPHESUS, OPTIMAAL and VALIANT trials, assessing the predictive 
value of baseline resting heart rate, was carried out.  Secondly, the prognostic value of 
both baseline and time-updated heart rate measurements in the CAPRICORN placebo 
population was evaluated.   
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An elevated baseline resting heart rate was shown to be a risk marker for all-cause 
death, CV death, CV hospital admission, HF hospital admission, subsequent MI and HF 
death in the population of post-MI patients with LVSD, HF or both who were included in 
the High Risk MI Database.  In the CAPRICORN population of post-MI patients with LVSD, 
time-updated resting heart rate also carried additional prognostic information for all-
cause death, CV death and hospitalisation for HF, regardless of whether baseline resting 
heart rate or the previous heart rate measurement were known.   
Chapter 5 further assesses the predictive value of baseline and time-updated resting 
heart rate for adverse CV outcomes and mortality in the EUROPA population of patients, 
who had stable CHD without HF.   
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Chapter 5 
 
Heart Rate and Risk in the EUROPA Population 
5.1 Introduction 
The prognostic value of baseline resting heart rate for death and adverse CV outcomes 
has previously been assessed in patients with stable CHD, some of whom had a history of 
HF148-151,184,208.  An elevated baseline resting heart rate has been associated with an 
increase in the risk of all-cause death148,149, CV death148,184, and hospital admission for 
HF148,149,184 in different populations of CHD patients.  However, from the review of 
Chapter 2 it seems that associations between heart rate and risk of MI and coronary 
revascularisation have only been observed in CHD patients specifically with LVSD184.  
Furthermore, a relationship between heart rate and risk of stroke or angina has yet to 
be established, and risk of cardiac arrest has not yet been evaluated.   
Using data from the EUROPA trial240, this analysis examined the prognostic value of 
baseline and time-updated resting heart rate for death and adverse CV outcomes, 
including stroke, angina and cardiac arrest, in patients with stable CHD with no 
apparent HF.  The systematic review of Chapter 2 did not identify any studies of time-
updated heart rate in patients with CHD. 
5.2 Methods and Results 
Data of patients from both treatment arms of EUROPA (perindopril or placebo) were 
pooled for this analysis since perindopril does not directly affect heart rate.  Baseline 
heart rate is defined as the heart rate the subjects had measured at their randomisation 
visit, Visit 3.  12,208 of the patients (99.9% of the 12,218 patients included in the trial) 
had a baseline heart rate measurement available and were included in the present 
analysis.   
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The following outcomes were assessed: the composite of CV mortality, non-fatal MI or 
cardiac arrest with successful resuscitation (the primary endpoint of EUROPA); its 
individual components (CV mortality, fatal or non-fatal MI, and cardiac arrest); the 
composite of total mortality, non-fatal MI, unstable angina or cardiac arrest with 
successful resuscitation (the first secondary endpoint of EUROPA); total mortality; 
unstable angina; stroke; revascularisation; and HF requiring hospital admission.   
The heart rate cut-off of 70bpm was selected since prior published research has 
suggested that the risk associated with heart rate rises greatly above this value148,156,208.  
The baseline characteristics of the EUROPA population, overall and categorised into 
groups depending on whether their baseline resting heart rate was less than, or greater 
than or equal to, 70bpm are shown in Table 5-1.  There were significant differences 
between the two groups of patients in terms of age, sex, history of PCI and CABG, PAD, 
diabetes, hypercholesterolemia, SBP, DBP, and treatment with platelet inhibitors, lipid-
lowering agents, beta-blockers, CCBs, and diuretics.  Patients with a heart rate of 
70bpm or greater at baseline were younger, with a higher SBP and DBP than those with 
a baseline heart rate of less than 70bpm.  They were also more likely to be female, 
have previously had a CABG procedure, PAD, and diabetes, and less likely to have had a 
PCI and have hypercholesterolemia.  Patients in the higher heart rate group were also 
more likely to be treated with CCBs and diuretics, and less likely to be treated with 
platelet inhibitors, lipid-lowering agents, and beta-blockers. 
The total number of events that occurred in the EUROPA population is presented in 
Table 5-2, along with the number that occurred in each of the baseline heart rate 
groups of patients.  The percentage of patients with a baseline heart rate of 70bpm or 
greater who experienced an event was higher for every event compared to the patients 
with a baseline heart rate less than 70bpm.    
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Table 5-1: Baseline characteristics of the EUROPA study population. 
  Baseline Heart Rate  
 All Subjects 
n = 12208 
<70bpm 
n = 7631 
≥70bpm 
n = 4577 
p-value 
Demographic Characteristics     
Age (years) 60.7 (9.3) 60.9 (9.2) 60.2 (9.5) <0.001 
Sex (female) 1779 (15%) 1019 (13%) 760 (17%) <0.001 
History of Coronary Heart Disease     
History of MI 7913 (65%) 4909 (64%) 3004 (66%) 0.14 
History of PCI 3568 (29%) 2322 (30%) 1246 (27%) <0.001 
History of CABG 3582 (29%) 2104 (28%) 1478 (32%) <0.001 
Other Medical History     
Previous stroke or TIA 407 (3%) 245 (3%) 162 (4%) 0.33 
Peripheral artery disease 882 (7%) 519 (7%) 363 (8%) 0.020 
Hypertension 3312 (27%) 2086 (27%) 1226 (27%) 0.51 
Diabetes mellitus 1502 (12%) 843 (11%) 659 (14%) <0.001 
Hypercholesterolemia 7730 (63%) 4891 (64%) 2839 (62%) 0.022 
Medication at Randomisation (Visit 3)     
Platelet inhibitors 11266 (92%) 7126 (93%) 4140 (90%) <0.001 
Lipid-lowering therapy 7026 (58%) 4462 (58%) 2564 (56%) 0.0080 
Beta-blockers 7530 (62%) 5392 (71%) 2138 (47%) <0.001 
Calcium-channel blockers 3822 (31%) 2319 (30%) 1503 (33%) 0.0047 
Nitrates 5241 (43%) 3328 (44%) 1913 (42%) 0.050 
Diuretics (potassium-sparing and other) 1028 (8%) 557 (7%) 471 (10%) <0.001 
Cardiac Parameters at Randomisation 
(Visit 3) 
    
Mean Heart Rate (bpm) 66.4 (10.4) 59.9 (5.9) 77.1 (7.0) - 
Mean SBP (mm Hg) 129.5 (16.2) 129.1 (16.4) 130.2 (16.0) <0.001 
Mean DBP (mm Hg) 78.1 (8.9) 77.6 (8.9) 78.9 (8.8) <0.001 
This table shows the clinical and demographic characteristics of the EUROPA patient population.  Values are given for the 
overall population, as well as separately for patients who had a baseline resting heart rate <70bpm, and patients who had a 
baseline resting heart rate ≥70bpm.  Data are the number of patients with the corresponding percentage, or the mean with 
the standard deviation, depending on whether the variable was categorical or continuous, respectively.  Not all patients had 
every baseline measurement available.  Therefore, percentages and means were calculated using the number of subjects 
with non-missing data as the denominator.  The values of each characteristic were compared between the two different 
baseline resting heart rate groups using unpaired two-sample t-tests and chi-squared tests, for continuous and categorical 
variables, respectively.   
Hypertension was defined as a blood pressure >160/95 mm Hg or receiving antihypertensive treatment. 
Hypercholesterolemia was defined as a total cholesterol >6.5 mmol/L or receiving lipid-lowering treatment. 
Subjects had their blood pressure measured twice at baseline and the mean of both SBP and DBP values was taken as 
their overall baseline value.  The overall mean for each heart rate group was then calculated using the mean baseline SBP 
and DBP values of each patient. 
CABG = Coronary Artery Bypass Graft; DBP = Diastolic Blood Pressure; MI = Myocardial Infarction; PCI = Percutaneous 
Coronary Intervention; SBP = Systolic Blood Pressure; TIA = Transient Ischemic Attack. 
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Table 5-2: The number of first events that occurred in the EUROPA population. 
  Baseline Heart Rate 
 Total Population 
n = 12208 
<70bpm 
n = 7631 
≥70bpm 
n = 4577 
Primary Composite Endpoint    
Cardiovascular mortality, MI, or cardiac arrest  1091 (9%) 422 (6%) 669 (15%) 
Individual Components of the Primary Composite Endpoint    
Cardiovascular mortality  464 (4%) 193 (3%) 271 (6%) 
Fatal or non-fatal MI  738 (6%) 268 (4%) 470 (10%) 
Cardiac arrest  17 (0.1%) 7 (0.1%) 10 (0.2%) 
Other Composite Endpoints    
Total mortality, MI, unstable angina or cardiac arrest 1946 (16%) 748 (10%) 1198 (26%) 
Other Mortality Endpoints    
Total mortality 795 (7%) 338 (4%) 457 (10%) 
Other Individual Endpoints    
Unstable Angina 708 (6%) 251 (3%) 457 (10%) 
Stroke 199 (2%) 73 (1%) 126 (3%) 
Revascularisation 1177 (10%) 392 (5%) 785 (17%) 
Heart failure requiring hospital admission 166 (1%) 78 (1%) 88 (2%) 
This table shows the total number of EUROPA patients with available baseline resting heart rate data who experienced any 
pre-specified events of interest, as well as the number in relation to baseline heart rate, partitioned at 70bpm.  Data are 
number of patients who experienced the event as a first event and the corresponding percentage of the particular group.  
Note that first event refers to the first event of each type: for example, a patient may have experienced a stroke, and then 
subsequently been admitted to hospital for HF at a later date. 
MI = Myocardial Infarction. 
 
The Cox regression models were adjusted for the variables which were significantly 
different between the two baseline heart rate groups (p<0.05): age; sex; history of PCI; 
history of CABG; PAD; diabetes mellitus; hypercholesterolemia; treatment with platelet 
inhibitors; lipid-lowering therapies; beta-blockers; CCBs; and diuretics (potassium-
sparing and other); and SBP and DBP. 
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
Comparing the risk of each of the outcomes between patients with a baseline or time-
updated heart rate greater than or equal to 70bpm versus patients with a heart rate less 
than 70bpm produced the HRs and CIs shown by Figure 5-1 and in Table A3-1 provided in 
126 
 
Appendix 3.  The CIs of the HRs for cardiac arrest were much wider than the others due 
to the small number of events which is why they are plotted individually. 
A heart rate ≥70bpm was associated with an increase in risk of total mortality in all 
models fitted.  A baseline resting heart rate ≥70bpm was not associated with an 
increase in risk of CV mortality, the combined endpoint of total mortality, MI, unstable 
angina or cardiac arrest, or HF requiring hospital admission.  However, time-updated 
resting heart rate ≥70bpm predicted a 30% (p = 0.0059) increase in risk of CV mortality, 
and a 16% (p = 0.0017) increase in risk of the combined endpoint of total mortality, MI, 
unstable angina or cardiac arrest, with the association remaining even after adjustment 
for baseline or the previous heart rate category.  Similarly, time-updated heart rate 
≥70bpm predicted a 47% (p = 0.015) increase in risk of HF requiring hospital admission, 
with the association remaining after adjustment for baseline (p = 0.042) but being 
attenuated after adjustment for the previous heart rate category (p = 0.46).  Despite 
there being only 17 cardiac arrest events over the length of follow-up, a time-updated 
heart rate ≥70bpm adjusted for baseline, and adjusted for the most previous 
measurement, was found to be associated with a 220% (p = 0.041) and 219% (p = 0.013) 
increase in risk of cardiac arrest, respectively. A baseline heart rate ≥70bpm was 
associated with a 14% (p = 0.020) decrease in risk of revascularisation, while none of the 
time-updated heart rate variables were associated with an increase or decrease in risk.  
There was no significant increase in risk observed with elevated heart rate for the 
combined endpoint of CV mortality, MI or cardiac arrest, or the individual endpoints 
fatal or non-fatal MI, unstable angina, or stroke. 
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Figure 5-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥70bpm compared to a heart rate 
<70bpm in the EUROPA population. 
 
The confidence intervals of the hazard ratios for cardiac arrest were much wider than the others due to the small number of 
events which is why they are plotted individually.  CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; history of percutaneous coronary intervention (PCI); history of coronary 
artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; hypercholesterolemia; treatment with 
platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers (CCBs); and diuretics (potassium 
sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP).  
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Analysing continuous heart rate measurements produced the HRs and CIs shown by 
Figure 5-2 and in Table A3-2 provided in Appendix 3.  A 5bpm higher heart rate was 
associated with higher risk of CV mortality, the combined endpoint of total mortality, 
MI, unstable angina or cardiac arrest, and the individual endpoints of total mortality and 
HF requiring hospital admission in all models (baseline heart rate was borderline 
significant for HF requiring hospital admission (p = 0.052)).   
Figure 5-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the EUROPA 
population. 
 
CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; history of percutaneous coronary intervention (PCI); history of coronary 
artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; hypercholesterolemia; treatment with 
platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers (CCBs); and diuretics (potassium 
sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
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An elevated continuous baseline heart rate was not associated with an increase in risk 
of the combined endpoint of CV mortality, MI or cardiac arrest, and cardiac arrest 
analysed individually.  However, a 5bpm higher time-updated heart rate was associated 
with a 3% (p = 0.019) increase in risk of CV mortality, MI or cardiac arrest; the 
association was attenuated when time-updated heart rate was adjusted for baseline or 
the previous measurement.  On the other hand, a 5bpm higher time-updated heart rate 
was not associated with an increase in risk of cardiac arrest, but time-updated heart 
rate adjusted for baseline and the previous measurement was associated with a 25% (p = 
0.045) and a 27% (p = 0.035) increase in risk of cardiac arrest, respectively.  Both a 5pm 
higher baseline resting heart rate, and a 5bpm higher time-updated heart were found to 
be associated with a 4% (p = 0.0070 for baseline and p = 0.011 for time-updated) lower 
risk of revascularisation.  There were no significant associations between elevated 
continuous heart rate and risk of fatal or non-fatal MI, unstable angina, or stroke 
(although time-updated heart rate adjusted for baseline was borderline significant for 
stroke (p = 0.051)).   
Figure 5-3 and Table A3-3 provided in Appendix 3 show the adjusted HRs and 95% CIs 
estimated using the time-updated categorical heart rate patterns models.  Comparing 
the current heart rate measurement at each visit to the previous heart rate 
measurement, patients who had a heart rate ≥70bpm at both visits (high-high) were 
found to be at a higher risk of CV mortality (38% increase in risk, 95% CI 11 to 72%, p = 
0.0040) and HF requiring hospitalisation (98%, 38 to 184%, p<0.001), compared to 
patients who had a heart rate <70bpm at both visits (low-low).  In contrast, subjects 
with a persistently high heart rate were shown to be at a lower risk of revascularisation 
(22% decrease in risk, 95% CI 10 to 33%, p = 0.0010), compared to patients who had a 
heart rate <70bpm at both visits (low-low).  Patients with a high heart rate at both 
visits (high-high), and an increase in heart rate from below 70bpm at the previous visit, 
to ≥70bpm at the current visit (low-high), were at a higher risk of the combined 
endpoint of total mortality, MI, unstable angina or cardiac arrest (low-high: 16%, 95% CI 
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1 to 34%, p = 0.035; high-high: 19% 95% CI 7 to 32%, p = 0.0020), as well as total 
mortality analysed individually (low-high: 48%, 95% CI 19 to 84%, p<0.001; high-high: 
75%, 95% CI 48 to 107%, p<0.001), compared to those patents who had a heart rate 
<70bpm at both visits (low-low).  No significant associations between time-updated 
heart rate pattern and risk were observed for the combined endpoint CV mortality, MI 
or cardiac arrest, or the individual endpoints fatal or non-fatal MI, unstable angina, and 
stroke.  There were not enough cardiac arrest events to allow HRs to be calculated 
using the time-updated categorical heart rate patterns models. 
The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A3-4 provided in Appendix 3 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the heart rate variables that categorised subjects according to whether they 
had a heart rate less than, or greater than or equal to 70bpm, for each outcome.  
Regardless of whether any resting heart rate category variables were included, the 
models had the greatest predictive ability for cardiac arrest and HF requiring hospital 
admission: the C-statistics of the models both excluding and including resting heart rate 
ranged from 0.808 to 0.850, and 0.754 to 0.768 for each of these outcomes, 
respectively.  The models had the least predictive ability for unstable angina, with C-
statistics ranging from 0.587 to 0.585.  The C-statistics of the models for the other 
outcomes ranged from 0.602 to 0.721.  The addition of baseline or time-updated resting 
heart rate category improved discrimination for CV mortality, total mortality, and HF 
requiring hospital admission, compared to the model excluding heart rate.  The same 
was true for unstable angina and revascularisation, although the C-statistics increased 
by only 0.001 or 0.002 with the addition of one of the heart rate category variables.  
The model including time-updated heart rate category additionally adjusted for the 
previous heart rate category had the best discrimination for the former three endpoints.  
Only the addition of the time-updated heart rate category variable, with or without  
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Figure 5-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate patterns 
‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the EUROPA 
population. 
 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.  There were not enough cardiac arrest 
events to allow HRs to be calculated using these models, hence why it is not included here.     
CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction.   
Models were additionally adjusted for: age; sex; history of percutaneous coronary intervention (PCI); history of coronary 
artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; hypercholesterolemia; treatment with 
platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers (CCBs); and diuretics (potassium 
sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
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adjustment for baseline or the previous heart rate category, improved the 
discrimination of the models for stroke, cardiac arrest, and the combined endpoints of 
CV mortality, MI or cardiac arrest, and total mortality, MI, unstable angina or cardiac 
arrest.  While discrimination was substantially improved for cardiac arrest, the C-
statistics for stroke and the two composite outcomes increased by only 0.001 or 0.002 
with the addition of time-updated heart rate category.  Again, the model including 
time-updated heart rate category additionally adjusted for the previous heart rate 
category had the best discrimination for cardiac arrest.  There was no improvement in 
discrimination for fatal or non-fatal MI with the addition of any of the heart rate 
category variables.  The likelihood ratio test statistics and corresponding p-values for 
the addition of the heart rate category variables to the models are also presented in 
Table A3-4.  The addition of any of the heart rate category variables resulted in 
statistically significant improvements in the calibration of the model for total mortality.  
Similarly, the addition of baseline or time-updated heart rate category, but only when 
additionally adjusted for baseline or the previous heart rate category, improved the 
calibration of the model for revascularisation.    Only the addition of the time-updated 
heart rate category variable, with or without adjustment for baseline or the previous 
heart rate category, improved the calibration of the models for CV mortality, HF 
requiring hospital admission, and the combined endpoint of total mortality, MI, unstable 
angina or cardiac arrest.  Furthermore, only the time-updated heart rate model 
adjusted for previous heart rate category had a significantly better calibration 
compared to the model not including heart rate for cardiac arrest.  There were no 
significant improvements in model calibration for the combined endpoint of CV 
mortality, MI, or cardiac arrest, or the individual endpoints of fatal or non-fatal MI, 
unstable angina, and stroke with the addition of any of the heart rate category 
variables. 
Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the continuous heart rate variables, for each outcome, are shown in Table A3-
133 
 
5 provided in Appendix 3, along with the likelihood ratio test statistics and 
corresponding p-values for the addition of the different continuous heart rate variables.  
The results were very similar to those observed for the heart rate categories according 
to whether subjects had a heart rate less than, or greater than or equal to 70bpm, 
although the addition of the time-updated heart rate category variable, with or without 
adjustment for baseline or the previous heart rate category, improved the 
discrimination of the model for fatal or non-fatal MI, whereas previously there was no 
improvement with the addition of any of the heart rate category variables. 
Table A3-6 provided in Appendix 3 shows Harrell’s C-statistics for the model excluding 
resting heart rate, and the models including the time-updated categorical heart rate 
patterns variable for each outcome.  Again, irrespective of whether resting heart rate 
was included, the models had the greatest and least predictive ability for HF requiring 
hospital admission and unstable angina, respectively (there were not enough cardiac 
arrest events to allow HRs to be calculated using the time-updated categorical heart 
rate patterns models).  The addition of time-updated categorical heart rate pattern 
improved discrimination for all of the outcomes excluding fatal or non-fatal MI.  
However, the C-statistics for unstable angina, stroke, revascularisation, and the two 
composite endpoints, increased by only 0.001 or 0.002 with the addition of time-
updated heart rate pattern.  The likelihood ratio test statistics and corresponding p-
values for the addition of the heart rate patterns variable to the models are also 
presented in Table A3-6.  The addition of heart rate pattern resulted in statistically 
significant improvements in the calibration of the models for CV mortality, total 
mortality, revascularisation, HF requiring hospital admission, and the composite of total 
mortality, MI, unstable angina or cardiac arrest; there were no significant improvements 
in model calibration for any of the other outcomes. 
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None of the models exhibited evidence of non-proportionality of hazards associated 
with heart rate over time (see Table A3-7, Table A3-8 and Table A3-9 in Appendix 3 for 
the p-values of the Grambsch and Therneau 1994 test for non-proportionality).   
5.3 Discussion 
In this large population of patients with stable CHD and no evidence of HF, an elevated 
resting heart rate was associated with an increase in risk of the majority of the 
endpoints evaluated, including all-cause death, CV death, HF requiring hospital 
admission, and cardiac arrest.  Unexpectedly, an elevated baseline heart rate was 
associated with a decrease in the risk of coronary revascularisation.  No significant 
associations between heart rate and the risk of fatal or non-fatal MI, stroke, or unstable 
angina were observed.   
Both an elevated baseline and time-updated heart rate, analysed categorically or 
continuously, unadjusted and adjusted for the baseline or previous heart rate 
measurement, were associated with an increase in the risk of all-cause death.  
Incorporating time-updated heart rate strengthened the association.  The same was true 
for CV death when heart rate was analysed continuously (a baseline heart rate ≥70bpm 
did not predict risk of CV death).  For example, a 5bpm higher baseline heart rate, and 
time-updated heart rate adjusted for baseline, was associated with a 9% (p<0.001) and 
16% (p<0.001) increase in the risk of all-cause death, and a 6% (p=0.058) and a 10% 
(p<0.001) increase in the risk of CV death, respectively.  Thus, even if the baseline or 
previous heart rate measurement is known, the updated heart rate measurement offers 
significant additional information in regards to the risk of death from all causes and CV 
causes in CHD patients without HF.  The addition of baseline or time-updated resting 
heart rate improved discrimination for all-cause and CV mortality, compared to the 
model excluding heart rate, although the time-updated heart rate models were the best 
at differentiating between subjects who experienced such deaths from those that that 
did not.  While the addition of baseline heart rate category did not improve calibration 
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of the model for CV death, the addition of any of the continuous heart rate variables 
resulted in statistically significant improvements in model calibration for both 
outcomes, as did the addition of any of the categorical heart rate variables for all-cause 
death. 
While no associations between baseline heart rate and risk of hospital admission for HF 
were observed, an elevated time-updated heart rate, analysed categorically or 
continuously, was associated with an increase in risk.  An elevated continuous time-
updated heart rate retained its prognostic value even after adjustment for baseline 
heart rate or the previous heart rate measurement.  A time-updated heart rate ≥70bpm 
was similarly predictive after adjustment for baseline heart rate group, but was no 
longer predictive after adjustment for the previous heart rate group.  These results 
further imply that, if heart rate is analysed as a continuous measurement, the current 
measurement adds prognostic value to the prediction of hospital admission for HF, even 
if the baseline and previous measurement are known, although note that the confidence 
intervals did overlap substantially across the models.  The discrimination of the model 
for hospital admission for HF improved with the addition of any of the resting heart rate 
variables; on the other hand, only the addition of the time-updated heart rate 
variables, with or without adjustment for baseline or the previous heart rate 
measurement, significantly improved calibration.  The time-updated heart rate model 
adjusted for previous heart rate measurements was found to have the greatest 
discriminative ability for hospital admission for HF regardless of whether heart rate was 
treated as a categorical or continuous variable. 
Despite only 17 cardiac arrest events occurring during follow-up, a time-updated heart 
rate adjusted for baseline, or the previous heart rate measurement, was associated 
with an increase in the risk of cardiac arrest, whether analysed as a categorical or a 
continuous variable.  No associations between time-updated heart rate and risk were 
observed when it was not additionally adjusted for either of the other heart rate 
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variables.  Only the addition of the time-updated heart rate variables, with or without 
adjustment for baseline or the previous heart rate, improved the discrimination of the 
models; the time-updated model adjusted for previous heart rate yielded the highest C-
statistic.  The categorical time-updated heart rate model adjusted for previous heart 
rate category was the only model found to have a significantly better calibration 
compared to the model not including heart rate for cardiac arrest. 
The present findings for all-cause death are similar to those previously found by Diaz et 
al. 2005148(heart rate ≥83bpm: HR 1.32, 95% CI 1.19 to 1.47), Ho et al. 2010149 (in which 
a small percentage of the patients had HF, some of whom may have had LVSD) (heart 
rate ≥70bpm: HR 1.40, 95% CI 1.14 to 1.71), and Anselmino et al. 2010 (in the subgroup 
of CHD patients with diabetes) (10bpm higher heart rate: HR 1.34, 95% CI 1.06 to 
1.69)150.  The results in relation to CV death and hospital admission for HF are also 
similar to those previously found by Diaz et al. 2005148 (heart rate ≥83bpm: HR 1.31, 95% 
CI 1.15 to 1.48 for CV death; HR 1.32, 95% CI 1.01 to 1.75 for HF), as well as those 
found by Fox et al. 2008184 (heart rate ≥70bpm: HR 1.34, 95% CI 1.10 to 1.63 for CV 
death; HR 1.53, 95% CI 1.25 to 1.88 for HF) where all patients had LVSD, many of whom 
also had HF.  Ho et al. 2010 contrastingly found that patients with a baseline heart rate 
≥70bpm were at a much higher risk of HF hospitalisation (HR 2.30, 95% CI 1.80 to 
2.95)149.  However, the present analysis did find that patients whose heart rates were 
≥70bpm at two or more consecutive visits over time were at a 98% (95% CI 1.38 to 2.84, 
p<0.001) higher risk of HF hospital admission compared to those whose heart rates were 
<70bpm at two or more consecutive visits. 
The current analysis found that patients with a baseline heart rate ≥70bpm were at a 
14% (p = 0.020) lower risk of revascularisation compared to those with a heart rate 
<70bpm.  Additionally, a 5bpm higher baseline heart rate, and time-updated heart rate, 
were associated with a 4% (p = 0.0070 for baseline and p = 0.011 for time-updated) 
decrease in risk.  Although discrimination was improved when the resting heart rate 
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variables were added to the model, the C-statistic increased by a maximum of only 
0.003.  However, the addition of any of the heart rate variables resulted in statistically 
significant improvements in the calibration of the model (borderline significant for the 
time-updated categorical heart rate model not adjusted for baseline or the previous 
heart rate measurement (p = 0.051)).   
In contrast to the current findings, Fox et al. 2008 demonstrated that CHD patients with 
LVSD, many of whom had HF, with a baseline heart rate ≥70bpm, were at a 38% (p = 
0.037) higher risk of revascularisation compared to those with a heart rate <70bpm184.  
In addition, a 5bpm higher baseline heart rate was shown to be associated with an 8% (p 
= 0.034) increase in risk184.  It is not clear why an elevated resting heart rate was 
associated with a decrease in risk of revascularisation in this analysis and an increase in 
risk in the BEAUTIFUL analysis.  EUROPA recruited patients from 1997 to 2000, whereas 
BEAUTIFUL recruited patients from 2004 to 2006.  In the 1990s, revascularisation was 
mainly used to treat angina, whereas from 2000 onwards it began to be used more 
frequently as a treatment for acute MI276.  It could therefore be that revascularisation 
was a marker of different conditions in EUROPA and BEAUTIFUL.  However further 
exploration would need to be carried out to better understand the reasons for the 
differences in findings. 
No associations between any of the heart rate variables and the risk of fatal or non-fatal 
MI, stroke, or unstable angina were observed.  Moreover, there were no significant 
improvements in model calibration, and only very small improvements in model 
discrimination (a maximum increase in the C-statistic of 0.002) for these endpoints with 
the addition of resting heart rate.  The number of fatal or non-fatal MI and unstable 
angina events were relatively large (n = 738 and n = 708, respectively).  Moreover, none 
of the results relating to these two outcomes showed any evidence of significant 
differences.  The studies by Diaz et al. 2005148 and Ho et al. 2010149 similarly observed 
no associations between baseline heart rate and risk of MI, despite there being high 
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numbers of subjects included in the analyses.  Additionally, Diaz et al. 2005 observed no 
significant association between heart rate and risk of hospital admission due to angina, 
although a heart rate ≥83bpm was borderline significantly associated with an increase in 
risk (HR 1.12, 95% CI 0.99 to 1.27)148.  In contrast, in patients with CHD and LVSD, many 
of whom had HF, Fox et al. 2008 showed that a heart rate ≥70bpm was associated with 
a 46% (95% CI 11 to 91%, p = 0.0066) increase in the risk of admission to hospital for 
fatal or non-fatal MI, and a 5bpm increase was also borderline significantly associated 
with a 7% increase in risk (95% CI 0 to 14%, p = 0.052), despite only 226 MI events 
occurring184.  These results suggest that heart rate is not associated with risk of MI or 
unstable angina in CHD patients without HF or a reduced LVEF, but further studies are 
required to confirm this. 
Diaz et al. 2005148 and Ho et al. 2010149 also examined the relationship between baseline 
heart rate and stroke, and neither observed any association.  Only 199 stroke events 
occurred in the EUROPA population.  A 5bpm higher time-updated heart rate, 
unadjusted and adjusted for baseline, and adjusted for the previous measurement, was 
borderline significantly associated with an increase in the risk of stroke (time-updated: 
HR 1.05, 95% CI 0.99 to 1.12, p = 0.12; time-updated adjusted for baseline: HR 1.07, 
95% CI 1.00 to 1.16, p = 0.051; time-updated adjusted for previous: HR 1.07, 95% CI 0.99 
to 1.15, p = 0.10).  Thus, there may have not have been enough events for the 
associations to reach significance.  Further analyses of the relationship between resting 
heart rate and risk of stroke including a greater number of events could be informative.   
5.3.1 Chapter Summary and Conclusions 
This chapter evaluated both baseline and time-updated resting heart rate as risk 
markers for death and adverse CV outcomes in the EUROPA population. 
Raised time-updated heart rate was found to be predictive of an elevated risk of all-
cause death, CV death, hospital admission for HF, and cardiac arrest in the EUROPA 
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population of CHD patients without HF.  Despite knowledge of the baseline or previous 
heart rate measurement, the most recent heart rate measurement provided significant 
additional information about the risk of each of these endpoints.  On the contrary, an 
elevated time-updated heart rate was associated with a decrease in risk of 
revascularisation in this population of patients.  
Chapter 6 further explored the associations between baseline and time-updated resting 
heart rate and risk of adverse outcomes in the PROSPER population of elderly individuals 
with, or at an increased risk of, vascular disease. 
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Chapter 6 
 
Heart Rate and Risk in the PROSPER Population 
6.1 Introduction 
A higher baseline resting heart rate has been associated with an increase in the risk of 
all-cause death188,189,216, CV death138,188,216 and hospitalisation for HF138,216 among mixed 
populations of subjects with, or at an increased risk of, vascular disease.  Nanchen et 
al. 2013, for example, demonstrated that participants of the PROSPER trial with a 
baseline heart rate in the highest third of the distribution were at a 73% and 80% higher 
risk of CV death and HF hospitalisation, respectively, compared to those with a heart 
rate in the lowest third138.  An elevated baseline heart rate has also been associated 
with an increase in the risk of all-cause death141,147 and CV death141 in older individuals 
with diabetes and hypertension.    
On the other hand, studies of such populations have yet to establish an association 
between baseline heart rate and the risk of stroke or MI188,216.  Lonn et al. 2014, for 
example, observed no association between baseline heart rate and the risk of MI or 
stroke within a model that adjusted for conventional baseline variables (p = 0.090 for 
MI; p = 0.57 for stroke)216.  However, a 10bpm higher mean follow-up heart rate was 
associated with a 12% (p = 0.0006) increase in the risk of stroke. 
The mean of multiple heart rate measurements gathered over time, however, is 
calculated using different numbers of heart rate measurements at different points 
during follow-up, and so interpreting the estimated association in practice can be 
difficult.  Furthermore, it does not necessarily reflect localised increases or decreases 
in heart rate, whereas time-updated individual heart rate measurements do.  Ho et al. 
2014 demonstrated that an 11bpm (one standard deviation) increase in time-updated 
heart rate was associated with a 19% (p<0.001) increase in risk of CHD in a population of 
subjects from the general population with no evidence of prior MI, HF or AF, whereas no 
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associations between baseline or mean follow-up heart rate and risk of CHD were 
observed204.   
Using data from the PROSPER trial, which enrolled elderly individuals with, or at an 
increased risk of, vascular disease, the first objective of this analysis was to examine 
the association between baseline heart rate and risk of each of the other 15 endpoints 
that were assessed in the original PROSPER trial publication243, such as stroke and non-
fatal MI, that were not previously studied by Nanchen et al. 2013138.  The second 
objective was to determine whether or not time-updated heart rate would strengthen 
the associations for each of these outcomes, as well as CV death and HF hospitalisation, 
which were previously studied by Nanchen et al. 2013 in relation to baseline heart rate 
only138.   The systematic review of Chapter 2 did not identify any studies of time-
updated heart rate in patients with, or at an increased risk of, vascular disease.   
Differences between participants who were and were not taking anti-arrhythmic 
medications and/or beta-blockers at baseline in relation to the effect of heart rate, 
were also assessed.   
6.2 Methods and Results 
The following 17 outcomes were thus assessed: (1) the composite of CHD death, non-
fatal MI or any stroke (the primary endpoint of PROSPER); (2) the composite of CHD 
death or non-fatal MI; (3) fatal or non-fatal stroke; (4) non-fatal MI; (5) non-fatal 
stroke; (6); TIA; (7) PTCA or CABG; (8) peripheral arterial surgery/angioplasty; (9) any 
CV event; (10) fatal or non-fatal stroke or TIA; (11); HF hospitalisation; (12); CHD death; 
(13) stroke death; (14) vascular death; (15) non-vascular death; (16) cancer death; and 
(17) all-cause death. 
Data of patients from both treatment arms of PROSPER (pravastatin or placebo), were 
pooled for this analysis since pravastatin does not directly affect heart rate.  5,684 of 
the patients (97.9% of the 5,804 patients included in the original trial) had baseline 
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heart rate measurements available.  The original baseline heart rate analysis138 
excluded four participants with baseline AF, 149 taking anti-arrhythmic drugs and 1,447 
taking beta-blockers, because of the effects of anti-arrhythmic drugs and beta-blockers 
on heart rate.  The participants with baseline AF were similarly excluded in the current 
analysis, but those on anti-arrhythmic drugs or beta-blockers were not, so that 
differences between participants who were and were not taking anti-arrhythmic 
medications and/or beta-blockers at baseline in relation to the effect of heart rate 
could be explored.  Hence 5,680 subjects were included in the present analysis. 
To make the current results as comparable as possible to the previously published 
results by Nanchen et al. 2013138, the study population was divided into three groups 
according to the tertiles of the distribution of baseline heart rate values, since this was 
the method employed in their analysis of baseline heart rate in the PROSPER 
population.  This was done separately for women and men because women have a 
higher resting heart rate than men250.  The male participants were divided into ‘low’, 
‘medium’ and ‘high’ baseline heart rate groups according to the tertiles of their 
distribution of baseline heart rate, and the female participants were divided in the 
same way.  The participants in the ‘low’, ‘medium’, and ‘high’ groups were then 
combined to produce three groups of subjects both male and female.  
The tertiles of the distribution of male and female baseline heart rate values were 
59bpm and 68bpm, and 62bpm and 72bpm, respectively.  Male participants with a 
baseline heart rate less than or equal to 59bpm, between 60 and 68bpm, and greater 
than 68bpm, were classed as being in the ‘low’, ‘medium’ and ‘high’ heart rate thirds, 
respectively.  Similarly, female participants with a baseline heart rate less than or 
equal to 62bpm, between 63 and 72bpm, and greater than 72bpm were classed as being 
in the ‘low’, ‘medium’ and ‘high’ heart rate thirds.  The baseline characteristics of the 
PROSPER patients, overall and categorised into ‘low’, ‘middle’ and ‘high’ heart rate 
groups depending on their baseline resting heart rate are shown in Table 6-1.   
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There were significant differences between the groups of patients in terms of age, sex, 
smoking status, alcohol consumption, history of hypertension and diabetes, history of 
vascular disease, CHD and angina, Mini Mental State Examination score, SBP, DBP, 
height, BMI, low density lipoprotein (LDL) and high density lipoprotein (HDL) 
cholesterol, fasting glucose, creatinine, eGFR, thyroid stimulating hormone and 
treatment with beta-blockers, aspirin, nitrates and ACE inhibitors.  Patients in the 
‘high’ heart rate group were older, more likely to be current smokers, and drank more 
alcohol each week than those in the ‘low’ heart rate group.  Those with a ‘high’ 
baseline heart rate were more likely to have a history of diabetes and a lower Mini 
Mental State Examination score, but less likely to have a history of hypertension, 
vascular disease, CHD and angina, compared with the ‘low’ heart rate group subjects.  
Patients in the ‘high’ group were also more likely to be treated with ACE inhibitors, and 
less likely to be treated with beta-blockers, aspirin and nitrates.  Compared to patients 
in the ‘low’ baseline group, they had a higher SBP, DBP, BMI, HDL cholesterol, fasting 
glucose and eGFR, but a lower LDL cholesterol, creatinine and thyroid stimulating 
hormone. 
The total number of events that occurred in the PROSPER population is presented in 
Table 6-2, along with the number that occurred in each of the baseline heart rate 
groups.   
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Table 6-1: Baseline characteristics of the PROSPER study population. 
  Baseline Heart Rate  
 All Subjects 
n = 5680 
Low Heart 
Rate Third 
n = 1976 
Middle Heart 
Rate Third 
n = 1877 
High Heart 
Rate Third 
n = 1827 
p-value 
Demographics      
Age, years 75.3 (3.4) 75.2 (3.3) 75.4 (3.4) 75.4 (3.4) 0.013 
Female 2929 (52%) 987 (50%) 1030 (45%) 912 (50%) 0.0021 
Smoking status     <0.001 
Never 1930 (34%) 698 (35%) 652 (35%) 580 (32%)  
Former 2228 (39%) 860 (44%) 685 (36%) 683 (37%)  
Current 1522 (27%) 418 (21%) 540 (29%) 564 (31%)  
Alcohol consumption, 
drinks/week 
5.2 (9.3) 5.1 (9.1) 4.9 (8.8) 5.6 (9.9) 0.046 
Co-morbidities      
Hypertension 3509 (62%) 1288 (65%) 1137 (61%) 1084 (59%) <0.001 
Diabetes 611 (11%) 149 (8%) 205 (11%) 257 (14%) <0.001 
History of vascular 
disease 
2496 (44%) 967 (49%) 773 (41%) 756 (41%) <0.001 
History of coronary heart 
disease 
875 (15%) 346 (18%) 252 (13%) 277 (15%) 0.0020 
History of angina 1530 (27%) 656 (33%) 450 (24%) 424 (23%) <0.001 
History of cerebrovascular 
disease 
628 (11%) 218 (11%) 201 (11%) 209 (11%) 0.78 
History of peripheral 
artery disease 
437 (8%) 131 (7%) 149 (8%) 157 (9%) 0.068 
Lower MMSE score 1813 (32%) 573 (29%) 603 (32%) 637 (35%) <0.001 
Objective Measures      
Heart rate, bpm 66.3 (11.7) 54.6 (5.0) 65.8 (3.2) 79.5 (8.0) - 
SBP, mmHg 154.7 (21.9) 153.0 (22.0) 154.6 (21.9) 156.7 (21.6) <0.001 
DBP, mmHg 83.8 (11.5) 82.4 (11.5) 83.9 (11.3) 85.2 (11.5) <0.001 
Weight, kg 73.4 (13.4) 73.7 (12.7) 72.9 (13.2) 73.6 (14.2) 0.48 
Height, cm 1.7 (0.09) 1.7 (0.09) 1.7 (0.10) 1.6 (0.09) <0.001 
BMI, kg/m2 26.8 (4.2) 26.8 (3.9) 26.7 (4.1) 27.0 (4.5) 0.0018 
Total cholesterol, mmol/L 5.7 (0.9) 5.7 (0.9) 5.7 (0.9) 5.7 (0.9) 0.42 
LDL-cholesterol, mmol/L 3.8 (0.8) 3.8 (0.8) 3.8 (0.8) 3.7 (0.8) <0.001 
HDL-cholesterol, mmol/L 1.3 (0.3) 1.2 (0.3) 1.3 (0.4) 1.3 (0.4) <0.001 
Triglycerides, mmol/L 1.5 (0.7) 1.6 (0.7) 1.5 (0.7) 1.5 (0.7) 0.52 
Fasting glucose, mmol/L 5.4 (1.4) 5.3 (1.2) 5.3 (1.3) 5.5 (1.6) <0.001 
Creatinine, μmol/L 101.3 (22.4) 103.0 (22.6) 99.8 (22.3) 101.1 (22.1) <0.001 
eGFR, mL/min 60.1 (14.6) 59.2 (14.2) 60.6 (14.9) 60.5 (14.6) <0.001 
TSH, mIU/L 2.3 (2.1) 2.3 (1.9) 2.4 (2.4) 2.2 (2.1) <0.001 
Randomised Treatment      
Pravastatin 2833 (50%) 1,004 (51%) 935 (50%) 894 (49%) 0.51 
Table continued and footnote provided on following page. 
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Table 6-1 (Cont.): Baseline characteristics of the PROSPER study population. 
  Baseline Heart 
Rate 
   
 All Subjects 
n = 5680 
Low Heart 
Rate Third 
n = 1976 
Middle Heart 
Rate Third 
n = 1877 
High Heart 
Rate Third 
n = 1827 
p-value 
Medication use      
Anti-arrhythmic drugs 152 (3%) 57 (3%) 43 (2%) 52 (3%) 0.45 
Beta-blockers 1,472 (26%) 905 (46%) 381 (20%) 186 (10%) <0.001 
Aspirin 2,066 (36%) 825 (42%) 636 (34%) 605 (33%) <0.001 
Nitrates 1,073 (19%) 477 (24%) 318 (17%) 278 (15%) <0.001 
Diuretics 2,301 (41%) 779 (39%) 753 (40%) 769 (42%) 0.23 
CCBs 1,428 (25%) 503 (25%) 468 (25%) 457 (25%) 0.92 
ACE inhibitors 929 (16%) 309 (16%) 274 (15%) 346 (19%) <0.001 
ARBs 113 (2%) 35 (2%) 42 (2%) 36 (2%) 0.58 
Other antihypertensive 
drugs 
233 (4%) 70 (4%) 82 (4%) 81 (4%) 0.30 
This table shows that clinical and demographic characteristics of the PROSPER patients who had baseline resting heart 
rate measurements available, and who were in sinus rhythm.  Values are given for the total population, as well as according 
to gender-specific heart rate thirds.  Data are the number of patients with the corresponding percentage, or the mean with 
the standard deviation, depending on whether the variable was categorical or continuous.  Not all patients had every 
baseline measurement available.  Therefore, percentages and means were calculated using the number of subjects with 
non-missing data as the denominator.  The values of each characteristic were compared between the three different 
baseline resting heart rate groups using one-way ANOVA and chi-squared tests, for continuous and categorical variables, 
respectively.   
Vascular disease is defined as a history of coronary heart disease, angina, cerebrovascular disease, or peripheral artery 
disease. 
Coronary heart disease is defined as a history of myocardial infarction, percutaneous coronary intervention, or coronary 
artery bypass surgery. 
Cerebrovascular disease is defined as a history of stroke or transient ischemic attack.   
Peripheral artery disease is defined as a history of claudication or peripheral vascular surgery. 
ACE = Angiotensin-Converting Enzyme; ARB = Angiotensin II Receptor Block; BMI = Body Mass Index; CCB = Calcium 
Channel Blocker; DBP = Diastolic Blood Pressure; eGFR = estimated Glomerular Filtration Rate; HDL = High Density 
Lipoprotein; LDL = Low Density Lipoprotein; MMSE = Mini Mental State Examination; SBP = Systolic Blood Pressure; TSH 
= Thyroid-Stimulating Hormone. 
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Table 6-2: The number of first events that occurred in the PROSPER population. 
  Subjects Separated by Gender-Specific 
Baseline Heart Rate Thirds 
 Total 
Population 
n = 5680 
Low Heart 
Rate Third 
n = 1976 
Middle Heart 
Rate Third 
n = 1877 
High Heart 
Rate Third 
n = 1827 
Primary Endpoint     
CHD death or non-fatal MI or fatal or non-fatal 
stroke 
868 (15%) 308 (16%) 262 (14%) 298 (16%) 
Secondary Endpoints     
CHD death or non-fatal MI 639 (11%) 227 (11%) 194 (10%) 218 (12%) 
Fatal or non-fatal stroke 261 (5%) 96 (5%) 73 (4%) 92 (5%) 
Other Outcomes     
Non-fatal MI 471 (8%) 172 (9%) 143 (8%) 156 (9%) 
Non-fatal stroke 231 (4%) 86 (4%) 65 (3%) 80 (4%) 
TIA 177 (3%) 74 (4%) 48 (3%) 55 (3%) 
PTCA or CABG 87 (2%) 42 (2%) 29 (2%) 16 (1%) 
Peripheral arterial surgery/angioplasty 79 (1%) 30 (2%) 23 (1%) 26 (1%) 
All cardiovascular events 963 (17%) 350 (18%) 292 (16%) 321 (18%) 
Fatal or non-fatal stroke or TIA 409 (7%) 159 (8%) 112 (6%) 138 (8%) 
HF hospitalisation 232 (4%) 61 (3%) 79 (4%) 92 (5%) 
Deaths     
CHD 212 (4%) 66 (3%) 65 (3%) 81 (4%) 
Stroke 35 (1%) 12 (1%) 9 (0.5%) 14 (1%) 
Vascular 287 (5%) 89 (5%) 83 (4%) 115 (6%) 
Non-vascular 303 (5%) 87 (4%) 85 (5%) 131 (7%) 
Cancer 199 (4%) 60 (3%) 63 (3%) 76 (4%) 
All-causes 590 (10%) 176 (9%) 168 (9%) 246 (13%) 
This table shows the total number of PROSPER patients with available baseline resting heart rate data who experienced 
any pre-specified events of interest, as well as the number according to gender-specific heart rate thirds.  Data are number 
of patients who experienced the event as a first event, with the corresponding percentage.  Note that first event refers to the 
first event of each type: for example, a patient may have experienced a non-fatal MI, and then subsequently been 
hospitalised for HF at a later date. 
All cardiovascular events is defined as the primary endpoint, CABG, PTCA, peripheral arterial surgery, or angioplasty.   
Vascular death is defined as CHD death, fatal stroke, or other vascular death, and is equivalent to the cardiovascular death 
endpoint analysed in the original baseline heart rate paper138. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
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The previous study by Nanchen et al. 2013138, which examined the associations between 
baseline heart rate and risk of CV death and HF hospitalisation in the PROSPER 
population, fitted a “basic” multivariate adjusted model, as well as this “basic” 
multivariate adjusted model additionally adjusted for drug use at baseline and 
treatment group in the trial, referred to in the publication as the “multivariate-
adjusted model additionally adjusted for treatment”.  To make the current results as 
comparable as possible to the previously published results by Nanchen et al. 2013138, the 
Cox regression models adjusted for the same variables adjusted for in the “multivariate-
adjusted model additionally adjusted for treatment”, excluding history of angina: age; 
smoking status; diabetes; history of vascular disease; hypertension; BMI; HDL-
cholesterol; thyroid stimulating hormones; eGFR; treatment group (pravastatin or 
placebo); and intake of aspirin, nitrates, diuretics, ACE inhibitors and ARBs.  History of 
angina was not adjusted for individually as it was included in history of vascular disease 
in the current analysis.  
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
Comparing the risk of each of the outcomes between patients with a baseline or time-
updated heart rate in the ‘high’ category and the ‘low’ category produced the HRs and 
95% CIs shown by Figure 6-1 and in Table A4-1 provided in Appendix 4.  The HRs, 95% CIs 
and p-values comparing patients with a heart rate in the ‘middle’ category and the 
‘low’ category are also given in Table A4-1, but were omitted from Table 6-1 because 
the majority of them were not significant.   
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Figure 6-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a ‘high’ heart rate relative to a ‘low’ heart rate in 
the PROSPER population. 
 
Male participants with a baseline heart rate less than or equal to 59bpm, between 60 and 68bpm, and greater than 68bpm, 
were classed as being in the ‘low’, ‘medium’ and ‘high’ heart rate thirds, respectively.  Similarly, female participants with a 
baseline heart rate less than or equal to 62bpm, between 63 and 72bpm, and greater than 72bpm were classed as being in 
the ‘low’, ‘medium’ and ‘high’ heart rate thirds. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; CV = Cardiovascular; HF = Heart Failure; MI = 
Myocardial Infarction; PAS = Peripheral Artery Surgery; PTCA = Percutaneous Transluminal Coronary Angiography; TIA = 
Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs).  
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A ‘high’ heart rate was associated with an increase in risk of HF hospitalisation, CHD 
death, vascular death, non-vascular death, and all-cause death in all models fitted.  
Patients with a ‘high’ baseline heart rate were not found to be at a higher risk of the 
combined endpoints of CHD death, non-fatal MI or fatal or non-fatal stroke, and CHD 
death or non-fatal MI, or the individual endpoints non-fatal MI, all CV events, and 
cancer death.  However, a ‘high’ time-updated resting heart rate predicted an increase 
in risk of each of these endpoints, even after adjustment for baseline or the previous 
heart rate category.  In contrast, a ‘high’ baseline heart rate was also not associated 
with an increase in risk of TIA, but a ‘high’ time-updated heart rate, and time-updated 
heart rate adjusted for the previous category, was associated with a 32% (p = 0.038) and 
a 43% (p = 0.031) lower risk of TIA.  No significant differences in risk of fatal or non-
fatal stroke, non-fatal stroke, PTCA or CABG, peripheral arterial surgery/angioplasty, 
fatal or non-fatal stroke or TIA, and stroke death between patients with a ‘high’ heart 
rate compared to a ‘low’ heart rate were observed using any of the models.   
Analysing continuous heart rate measurements produced the HRs and CIs shown by 
Figure 6-2 and in Table A4-2 provided in Appendix 4.  In regards to the individual 
endpoints, 5bpm higher heart rate was associated with an increase in risk of HF 
hospitalisation, CHD death, vascular death, non-vascular death and all-cause death in 
all models.  An elevated continuous baseline heart rate was not associated with an 
increase in risk of non-fatal MI, all CV events, or cancer death.  However, a 5bpm higher 
time-updated heart rate was associated with a 4% (p = 0.0024) increase in risk of all CV 
events, and a 12% (p<0.001) increase in risk of cancer death.  These associations 
remained significant even after adjustment for baseline or previous heart rate.    
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Figure 6-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the PROSPER 
population. 
 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; CV = Cardiovascular; HF = Heart Failure; MI = 
Myocardial Infarction; PAS = Peripheral Artery Surgery; PTCA = Percutaneous Transluminal Coronary Angiography; TIA = 
Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs).  
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A 5bpm higher time-updated heart rate was borderline significantly associated with an 
increase in risk of non-fatal MI (p = 0.050), but time-updated heart rate adjusted for 
baseline heart rate was associated with a 9% (p<0.001) increase in risk, and time-
updated heart rate adjusted for previous heart rate was associated with a 7% increase in 
risk (p = 0.0097).  A 5bpm higher baseline resting heart rate, and time-updated heart 
rate, were associated with a 14% lower risk of PTCA or CABG.   
In regards to the composite endpoints, an elevated continuous baseline heart rate was 
not associated with an increase in risk of the combined endpoint of CHD death, non-
fatal MI or fatal or non-fatal stroke, the combined endpoint of CHD death or non-fatal 
MI.  However, a 5bpm higher time-updated heart rate was associated with a 5% 
(p<0.001) increase in risk of CHD death, non-fatal MI or fatal and non-fatal stroke, a 6% 
(p<0.001) increase in risk of CHD or non-fatal MI.  These associations also remained 
significant even after adjustment for baseline or previous heart rate. 
No significant associations between continuous heart rate and risk were observed for 
fatal or non-fatal stroke, non-fatal stroke, TIA, peripheral artery surgery/angioplasty, 
the combination of fatal or non-fatal stroke or TIA, or stroke death.  
Figure 6-3 and Table A4-3 provided in Appendix 4 show the adjusted HRs and 95% CIs 
estimated using the time-updated categorical heart rate patterns models.  The heart 
rate cut-off of 70bpm was selected since prior published research has suggested that 
the risk associated with heart rate rises greatly above this value148,208,156.   
Comparing the current heart rate measurement at each visit to the previous heart rate 
measurement, patients who had a heart rate ≥70bpm at both visits (high-high), and an 
increase in heart rate from below 70bpm at the previous visit, to ≥70bpm at the current 
visit (low-high), were at a higher risk of the combined endpoint of CHD death, non-fatal 
MI or fatal or non-fatal stroke, the combined endpoint of CHD death or non-fatal MI, all 
CV events (high-high borderline significant (p = 0.057)), HF hospitalisation, CHD death,   
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Figure 6-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate patterns 
‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the PROSPER 
population. 
 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; CV = Cardiovascular; HF = Heart Failure; MI = 
Myocardial Infarction; PAS = Peripheral Artery Surgery; PTCA = Percutaneous Transluminal Coronary Angiography; TIA = 
Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs).  
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vascular death, non-vascular death, cancer death and all-cause death, compared to 
patients who had a heart rate <70bpm at both visits (low-low).  No significant 
associations between any of the time-updated categorical heart rate patterns were 
observed for fatal or non-fatal stroke, non-fatal MI, non-fatal stroke, TIA, PTCA or 
CABG, peripheral arterial surgery/angioplasty, the combined endpoint of fatal or non-
fatal stroke or TIA, and stroke death.   
The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A4-4 provided in Appendix 4 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the gender-specific heart rate thirds variables, for each outcome.  Regardless 
of whether any resting heart rate third variables were included, the models had the 
greatest predictive ability for PTCA or CABG, and stroke death: the C-statistics of the 
models both excluding and including resting heart rate ranged from 0.769 to 0.774, and 
0.794 to 0.799 for each of these outcomes, respectively.  The models had the last 
predictive ability for non-fatal stroke, with the C-statistics ranging from 0.595 to 0.603.  
The C-statistics of the models for the other outcomes ranged from 0.614 to 0.757.  The 
addition of baseline or time-updated resting heart rate third improved discrimination 
for all of the outcomes, compared to the model excluding heart rate, except for non-
fatal MI, peripheral artery surgery/angioplasty, and CHD death: only the addition of the 
time-updated heart rate thirds variable, with or without adjustment for baseline or the 
previous heart rate group, improved the discrimination of these latter three outcomes.  
The greatest improvements in discrimination were observed for CHD death, vascular 
death, and all-cause death: the models not including resting heart rate had a C-statistic 
of 0.702, 0.701 and 0.673, whereas the models including time-updated resting heart 
rate had a C-statistic of 0.721 (increase of 0.019), 0.720 (increase of 0.019), and 0.679 
(increase of 0.016), for each of these outcomes, respectively.  The smallest 
improvements in discrimination were observed for PTCA or CABG, peripheral arterial 
surgery/angioplasty, and fatal or non-fatal stroke or TIA: the models not including 
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resting heart rate had a C-statistic of 0.769, 0.755, and 0.620, whereas the models 
including time-updated heart rate (adjusted for the previous heart rate third for first 
two endpoints and baseline heart rate third for the last) had a C-statistic of 0.774 
(increase of 0.005), 0.757 (increase of 0.002) and 0.625 (increase of 0.005).  The 
likelihood ratio test statistics and corresponding p-values for the addition of the heart 
rate thirds variables to the models are also presented in Table A4-4.  The addition of 
any of the heart rate thirds variables to the models resulted in statistically significant 
improvements in the calibration of the models for HF hospitalisation, vascular death, 
non-vascular death and all-cause death.  Only the addition of the time-updated heart 
rate thirds variable, with or without adjustment for baseline or the previous heart rate 
third, improved the calibration of the models for the combined endpoints of CHD death, 
non-fatal MI or fatal or non-fatal stroke, and CHD death or non-fatal MI, and the 
individual endpoints of non-fatal MI, all CV events, CHD death and cancer death.  On 
the other hand, only the addition of baseline heart rate third improved the calibration 
of the models for fatal or non-fatal stroke, and fatal or non-fatal stroke or TIA.  There 
were no significant improvements in model calibration for non-fatal stroke, TIA, PTCA 
or CABG, peripheral arterial surgery/angioplasty, or stroke death with the addition of 
any of the heart rate thirds variables.   
Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the continuous heart rate variables, for each outcome, are shown in Table A4-
5 provided in Appendix 4, along with the likelihood ratio test statistics and 
corresponding p-values for the addition of the different continuous heart rate variables.  
The results were very similar to those observed for the heart rate thirds, with the 
exception that addition of any of the continuous heart rate variables resulted in 
statistically significant improvements in the calibration of the model for PTCA or CABG, 
whereas previously there was no improvement with the addition the heart rate thirds 
variables. 
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Table A4-6 provided in Appendix 4 shows Harrell’s C-statistics for the model excluding 
resting heart rate, and the models including the time-updated categorical heart rate 
patterns variable for each outcome.  Again, irrespective of whether resting heart rate 
was included, the models had the greatest predictive ability for PTCA or CABG and 
stroke death, and the least for non-fatal stroke.  The addition of time-updated 
categorical heart rate pattern improved discrimination for all of the outcomes except 
fatal or non-fatal stroke, peripheral arterial surgery/angioplasty, and stroke death.  
However, the C-statistics for non-fatal MI, non-fatal stroke, PTCA or CABG, and fatal or 
non-fatal stroke or TIA only increased by 0.001 or 0.002 with the addition of time-
updated heart rate pattern.  The likelihood ratio test statistics and corresponding p-
values for the addition of the heart rate patterns variable to the models are also 
presented in Table A4-6.  The addition of heart rate pattern resulted in statistically 
significant improvements in the calibration of the models for HF hospitalisation, CHD 
death, vascular death, non-vascular death, cancer death, all-cause death, and the 
combined endpoints of CHD death, non-fatal MI, or fatal or non-fatal stroke, and CHD 
death or non-fatal MI; there were no significant improvements in model calibration for 
any of the other outcomes. 
Table A4-7, Table A4-8 and Table A4-9 in Appendix 4 show the p-values for the 
Grambsch and Therneau 1994 test for non-proportionality for all of the models and 
outcomes.  Neither a ‘high’ heart rate, an elevated continuous heart rate, nor any of 
the time-updated categorical heart rate patterns exhibited evidence of non-
proportionality of hazards over time for any of the outcomes.  
Table A4-10 provided in Appendix 4 shows the HRs, 95% CIs, and p-values for a 5bpm 
higher time-updated heart rate adjusted for baseline heart rate calculated separately 
for subjects who were or were not taking anti-arrhythmics and/or beta-blockers at 
randomisation, along with the p-values for the interactions calculated using likelihood 
ratio tests.  Significant interactions between continuous time-updated heart rate and 
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intake of beta-blockers or anti-arrhythmics at randomisation were observed for fatal or 
non-fatal stroke (p = 0.042), non-fatal stroke (p = 0.041) and fatal or non-fatal stroke or 
TIA (p = 0.0078).   
In each case, no significant associations were observed between an elevated continuous 
time-updated heart rate and risk in those not taking beta-blockers or anti-arrhythmics 
at baseline (p = 0.99, p = 0.93 and p = 0.23, respectively).  On the other hand, in 
patients who were taking either or both drugs at randomisation, a 5bpm higher time-
updated heart rate adjusted for baseline heart rate was associated with a 13% increase 
(95% CI 3 to 25%, p = 0.013) in risk of fatal or non-fatal stroke, a 13% increase (95% CI 2 
to 25%, p = 0.022) in risk of non-fatal stroke, and an 11% increase (95% CI 2 to 20%, p = 
0.0017) in risk of fatal or non-fatal stroke or TIA.  In each case the number of events 
that occurred in the group of patients who were taking beta-blockers or anti-
arrhythmics at randomisation was smaller than the number of events that occurred in 
the group of patients who were not.   
6.3 Discussion 
In this population of elderly individuals with vascular disease (coronary disease, cerebral 
disease or PAD), or who were at an increased risk of vascular disease (because they 
smoked, or had diabetes or hypertension), an elevated resting heart rate was associated 
with a higher risk of the majority of endpoints studied, including all-cause, cancer, non-
vascular, vascular and CHD death, as well as HF hospitalisation, and non-fatal MI.  An 
elevated heart rate was associated with a decrease in the risk of TIA and PTCA or CABG.  
While an elevated heart rate was not found to be associated with risk of any of the 
stroke-related endpoints in the overall study population, an elevated time-updated 
heart rate adjusted for baseline was associated with an increase in each of the stroke 
related endpoints, excluding stroke death, in the subgroup of participants taking anti-
arrhythmic medications and/or beta-blockers at randomisation, despite fewer events 
occurring in this subgroup.  No significant associations between heart rate and stroke 
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death or peripheral arterial surgery/angioplasty were observed, although the numbers 
of these events were low. 
Both an elevated baseline and time-updated resting heart rate, analysed categorically 
or continuously, were associated with an increase in the risk of all-cause death, vascular 
death (equivalent to CV death), non-vascular death, CHD death and HF hospitalisation.  
Time-updated heart rate remained a significant predictor for each of these outcomes 
after adjustment for baseline heart rate or the previous heart rate measurement.  This 
indicates that updated measurements of heart rate contribute additional information 
about the risk of each of these endpoints in individuals with, or at an increased risk of, 
vascular disease, regardless of whether the baseline or previous heart rate 
measurement is known.  Using time-updated heart rate strengthened the associations 
found for all of these outcomes.   The addition of the baseline or time-updated resting 
heart rate variables also improved discrimination for each of these outcomes.  In 
general, the time-updated heart rate models, unadjusted or adjusted for baseline or 
the previous heart rate measurement, yielded the highest and similar C-statistics, and 
thus had the best discriminative ability for each of these endpoints.  Moreover, the 
addition of any of the heart rate variables to the models resulted in statistically 
significant improvements in their calibration, although when heart rate was analysed as 
a categorical variable, only the addition of the time-updated heart rate tertiles 
variable, with or without adjustment for baseline or the previous heart rate third, 
improved the calibration of the model for CHD death.  
While no associations between baseline heart rate and risk of non-fatal MI or cancer 
death were observed, patients with a time-updated heart rate ≥70bpm were at a higher 
risk of both endpoints compared to those with a time-updated heart rate <70bpm.  An 
elevated continuous time-updated heart rate was also associated with an increase in the 
risk of cancer death, and was borderline significantly associated with an increase in risk 
of non-fatal MI (p = 0.05).  However, time-updated heart rate, adjusted for baseline or 
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the previous heart rate measurement, was a significant predictor of both endpoints, 
whether analysed categorically or continuously.  For example, a 5bpm higher time-
updated heart rate adjusted for baseline was associated with a 9% (p<0.001) and a 14% 
(p<0.001) increase in the risk of non-fatal MI and cancer death, respectively.   
The addition of any of the resting heart rate variables improved the discrimination of 
the model for cancer death, and resulted in significantly better calibration when heart 
rate was analysed as a continuous variable: in regards to the heart rate tertiles 
variables, only the addition of the time-updated variable, with or without adjustment 
for baseline or the previous heart rate third, significantly improved calibration.  Each of 
the time-updated models performed similarly well at discriminating between subjects 
who experienced cancer death from those that did not, and did so better than the 
baseline heart rate model.  For non-fatal MI, only the addition of time-updated resting 
heart rate, analysed categorically or continuously, with or without adjustment for 
baseline or the previous heart rate, improved the discrimination of the model.  Each of 
the three time-updated heart rate tertiles models were also found to have a 
significantly better calibration than the model excluding resting heart rate.  When heart 
rate was analysed as a continuous variable, however, only the time-updated heart rate 
model additionally adjusted for baseline heart rate had significantly improved 
calibration.  The model including time-updated heart rate alongside baseline heart rate 
was found to have the greatest predictive ability for MI, for both categorical and 
continuous resting heart rate. 
The current findings for all-cause death correspond to those previously found by: Hillis 
et al. 2012141 and Palatini et al. 2002147, studies which included older subjects all of 
whom had diabetes and hypertension, respectively; Bemelmans et al. 2013188, which 
included subjects all of whom had vascular disease; and Lonn et al. 2014216, which 
included subjects who had vascular disease or diabetes with end-organ damage.  The 
results for CV death and HF hospitalisation are also similar to those previously found by 
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Hillis et al. 2012141, Bemelmans et al. 2013188, and Lonn et al. 2014216.  Excluding those 
taking anti-arrhythmic medications and/or beta-blockers at baseline, Nanchen et al. 
2013 previously found that the PROSPER participants with a ‘high’ baseline heart rate 
were at a 73% (95% CI 22 to 145%) and 80% (95% CI 22 to 165%) higher risk of CV death 
and HF hospitalisation, respectively, compared to those with a ‘low’ baseline heart 
rate, after adjustment for conventional baseline risk factors and medications138.  
Including subjects taking anti-arrhythmic medications and/or beta-blockers at baseline, 
the current analysis exhibited that those with a ‘high’ baseline heart rate were at a 45% 
(p = 0.0099) and a 77% (p<0.001) higher risk of CV death and HF hospitalisation, 
respectively, compared to those with a ‘low’ baseline heart rate.  Those with a high 
time-updated heart rate, adjusted for baseline heart rate group, were at a 64% (p = 
0.0095) and a 94% (p = 0.0024) higher risk, respectively, compared to those with a ‘low’ 
time-updated heart rate.  
Neither Bemelmans et al. 2013188 or Lonn et al. 2014216 found a significant association 
between heart rate and MI after adjustment for baseline risk factors.  Moreover, van 
Kruijsdijk et al. 2014189 found no association between an elevated baseline heart rate 
and risk of cancer death using the Fine and Gray model143, adjusting for competing 
mortality, in the same population of patients as Bemelmans et al. 2013188.   
While Bemelmans et al. 2013188 and Lonn et al. 2014216 previously observed no 
associations between baseline heart rate and risk of stroke, Lonn et al. 2014 
demonstrated that a 5bpm higher mean follow-up heart rate was associated with a 6% 
(p = 0.0006) increase in the risk of stroke in the total study population, 57% of whom 
were taking beta-blockers.  In the present analysis, a higher time-updated heart rate 
adjusted for baseline was associated with a 13% increase in the risk of both fatal and 
non-fatal stroke, and non-fatal stroke (p = 0.013 and p = 0.022, respectively), and an 
11% (p = 0.017) increase in the risk of the combined endpoint of fatal or non-fatal stroke 
or TIA, in the subgroup of participants taking anti-arrhythmic medications and/or beta-
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blockers at randomisation, but not in the overall study population, or those not taking 
such drugs at baseline.  In the study population as a whole, only small increases in the 
C-statistic were observed when the resting heart rate variables were added to the 
models for these outcomes.  In addition, only the model including baseline resting heart 
rate tertiles had a significantly improved calibration compared to the model not 
including the heart rate thirds variables for each of the three stroke-related endpoints.  
Similarly, only the model including continuous baseline heart rate had a significantly 
improved calibration for fatal or non-fatal stroke, and no improvements in calibration 
were observed for non-fatal stroke, or fatal or non-fatal stroke or TIA, with the addition 
of any of the continuous heart rate variables.  Only 26%, and 3% of the PROSPER 
subjects were taking beta-blockers and anti-arrhythmic drugs at baseline, respectively.  
Further exploration into the relationship between heart rate, stroke-related endpoints, 
and anti-arrhythmic medications and/or beta-blockers could assist in explaining such 
findings. 
In the current analysis, an elevated heart rate was associated with a decrease in the 
risk of TIA and PTCA or CABG.  The addition of baseline or time-updated heart rate 
improved discrimination of the models for both endpoints.  All of models including heart 
rate yielded similar C-statistics for PTCA or CABG, and the same was true for the 
continuous heart rate models for TIA: the time-updated heart rate model adjusted for 
baseline heart rate yielded the highest C-statistic for TIA when heart rate was treated 
as a categorical variable.  However, there were no improvements in calibration when 
any of the heart rate tertiles variables were added to the models for both outcomes, or 
when the continuous heart rate variables were added to the model for TIA.  On the 
other hand, the addition of any of the continuous heart rate variables resulted in 
significantly improved calibration for PTCA or CABG.   
No prior studies of subjects with vascular disease, or of older subjects with diabetes or 
hypertension, were identified in the systematic review of Chapter 2 that examined 
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associations between heart rate and the risk of TIA or revascularisation.  However, the 
analysis of the relationship between heart rate and risk in the EUROPA population of 
patients who had stable CHD with no HF, described in Chapter 5, also found that an 
elevated baseline and time-updated heart rate were associated with a decrease in the 
risk of revascularisation.  On the other hand, elevated baseline heart rate was 
associated with an increase in the risk of revascularisation in the BEAUTFIUL population 
of patients who had CHD and LVSD, many of whom also had HF184.  In Chapter 5, it was 
suggested that this may have been because revascularisation was a marker for different 
conditions in these studies, since in the 1990s revascularisation was mainly used to treat 
angina, whereas from 2000 onwards it began to be used more frequently as a treatment 
for acute MI276.  EUROPA recruited patients from 1997 to 2000, and PROSPER recruited 
patients from 1997 to 1999, whereas BEAUTIFUL recruited patients from 2004 to 2006.  
However, further exploration would need to be carried out to better understand the 
reasons for the differences in findings, and to understand why elevated heart rate 
would be associated with a decrease in risk of TIA. 
No associations between any of the heart rate variables and the risk of peripheral 
arterial surgery/angioplasty or stroke death were observed.  Furthermore, there were 
no significant improvements in model calibration for either endpoint with the addition 
of any of the heart rate variables, and only very small improvements in model 
discrimination were observed.  However, only 79 peripheral arterial surgery/angioplasty 
events and 35 stroke deaths occurred, whereas over 170 of each of the other endpoints 
occurred (ranging from 177 TIA events to 963 all CV events) with the exception of PTCA 
or CABG (of which there were only 87).  Thus, there may have been an insufficient 
number of events for the associations to reach significance.  None of the studies 
identified in Chapter 2 of subjects with vascular disease, or of older subjects with 
diabetes or hypertension, evaluated the risk of stroke death or peripheral arterial 
surgery/angioplasty, so further analysis including a greater number of events could be 
illuminating. 
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6.3.1 Chapter Summary and Conclusions 
This chapter investigated the prognostic value of baseline and time-updated resting 
heart rate for adverse outcomes in the PROSPER population.   
An elevated time-updated heart rate was associated with an increase in the risk of all-
cause, cancer, non-vascular, vascular and CHD death, as well as HF hospitalisation, and 
non-fatal MI, in this population of elderly individuals with, or at an increased risk of, 
vascular disease, irrespective of whether or not they were taking anti-arrhythmic drugs 
or beta-blockers.  Updated measurements of heart rate over time contributed 
significant prognostic information about the risk of each of these endpoints, regardless 
of whether the baseline or previous heart rate measurements were known.  Conversely, 
raised time-updated heart rate was predictive of a decrease in risk of TIA and PTCA or 
CABG.  Furthermore, time-updated heart rate was predictive of risk of stroke-related 
outcomes in the subgroup of individuals taking anti-arrhythmic drugs and/or beta-
blockers. 
Chapter 7 similarly examined the predictive value of baseline and time-updated resting 
heart rate for adverse outcomes in the PERFORM population of patients who had 
recently experienced an ischemic stroke or TIA. 
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Chapter 7 
 
Heart Rate and Risk in the PERFORM Population 
7.1 Introduction 
An elevated baseline resting heart rate has been associated with an increase in the risk 
of all-cause death190,191, vascular death190,191, recurrent stroke191,192 and MI191 in subjects 
who had previously had a stroke or TIA.  Associations are less consistent in regards to 
recurrent stroke and MI, compared to all-cause and vascular death, however.  In the 
PERFORM population, for example, Fox et al. 2013 found that an elevated continuous 
baseline heart rate was associated with an increase in the risk of fatal or non-fatal MI, 
and non-fatal MI191.  In addition, patients with a baseline heart rate ≥70bpm were found 
to be at a higher risk of fatal or non-fatal MI (but not non-fatal MI individually), and 
fatal or non-fatal stroke.  However, neither an elevated continuous baseline heart rate, 
nor a baseline heart rate ≥70bpm, were associated with an increase in the risk of 
specifically ischemic stroke. 
Using data from the PERFORM trial245, which enrolled individuals who had recently 
experienced an ischemic stroke or TIA, the first objective was to assess the association 
between baseline heart rate and risk of cardiac death, and hospitalisation due to 
cardiac causes – endpoints not previously evaluated by Fox et al. 2013191, and not 
assessed before in post-stroke subjects.  The second objective was to establish whether 
or not time-updated heart rate would have stronger associations with these outcomes, 
in addition to the outcomes previously evaluated by Fox et al. 2013 for baseline heart 
rate191.  It was of particular interest to see whether time-updated heart rate would be 
associated with risk of ischemic stroke. The systematic review of Chapter 2 did not 
identify any studies of time-updated heart rate in post-stroke or -TIA patients.   
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7.2 Methods and Results 
Ten outcomes were examined: the composite of fatal or non-fatal MI, fatal or non-fatal 
ischemic stroke, or other vascular death (the primary endpoint of PERFORM); fatal or 
non-fatal MI; non-fatal MI; fatal or non-fatal ischemic stroke; non-fatal ischemic stroke; 
all fatal or non-fatal stroke; vascular death; all-cause death; cardiac death; and 
hospitalisation due to cardiac causes.  Note that vascular death did not include 
haemorrhagic death of any origin, as defined in the original trial publication245.   
Data of patients from both treatment arms of PERFORM (terutroban or aspirin) were 
pooled for this analysis since neither treatment directly affects heart rate.  18,993 of 
the patients (99.4% of the 19,100 patients included in the original trial) had a baseline 
heart rate measurement available and were included in the present analysis. 
The baseline heart rate cut-off of 70bpm was selected on the basis that it was the cut-
off used in the previous analysis by Fox et al. 2013191, and was also close to the median 
heart rate of 72bpm.  The baseline characteristics of the population, overall and split by 
baseline resting heart rate less than, or greater than or equal to, 70bpm, are shown in 
Table 7-1.   
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Table 7-1: Baseline characteristics of the PERFORM study population. 
  Baseline Heart Rate  
 All Subjects 
n = 18993 
<70bpm 
n = 7907 
≥70bpm 
n = 11086 
p-value 
Demographic characteristics     
Sex (male) 11888 (63%) 5209 (66%) 6679 (60%) <0.001 
Age (years) 67.2 (7.9) 67.7 (7.9) 66.9 (7.9) <0.001 
Ethnic origin    <0.001 
Caucasian 15928 (84%) 6849 (87%) 9079 (82%)  
Asian 2239 (18%) 735 (9%) 1504 (14%)  
Black 317 (2%) 136 (2%) 181 (2%)  
Other 509 (3%) 187 (2%) 322 (2%)  
Physical examination     
BMI (kg/m²) 27.1 (4.3) 27.0 (4.2) 27.1 (4.4) 0.003 
SBP (mm Hg) 138.3 (16.8) 138.2 (17.3) 138.3 (16.4) 0.538 
DBP (mm Hg) 80.1 (9.4) 79.0 (9.7) 80.9 (9.1) <0.001 
Heart rate (bpm) 71.6 (10.5) 62.1 (5.3) 78.4 (7.6) - 
Smoking habits    <0.001 
Never smoked 9253 (49%) 3629 (46%) 5624 (51%)  
Current smoker 5061 (27%) 2171 (27%) 2890 (26%)  
Stopped smoking >6 months previously 4685 (25%) 2111 (27%) 2574 (23%)  
Medical history     
Hypertension 15877 (84%) 6488 (82%) 9389 (85%) <0.001 
Hypercholesterolaemia 9131 (48%) 3912 (49%) 5219 (47%) 0.001 
Hypertriglyceridemia 1794 (9%) 689 (9%) 1105 (10%) 0.0036 
Diabetes 5275 (28%) 1794 (23%) 3481 (31%) <0.001 
Prior ischemic stroke 2879 (15%) 1130 (14%) 1749 (16%) 0.005 
Prior TIA 1433 (8%) 673 (9%) 760 (7%) <0.001 
Angina pectoris 1806 (10%) 800 (10%) 1006 (9%) 0.016 
Myocardial infarction 1468 (8%) 703 (9%) 765 (7%) <0.001 
Peripheral artery disease 735 (4%) 305 (4%) 430 (4%) 0.940 
Previous treatments     
Antiplatelet agents 17021 (90%) 7216 (91%) 9805 (88%) <0.001 
Statin 10992 (58%) 4804 (61%) 6188 (56%) <0.001 
ACE Inhibitor 10392 (55%) 4213 (53%) 6179 (56%) <0.001 
ARB 2642 (14%) 1157 (15%) 1485 (13%) 0.015 
Diuretic 6820 (36%) 2828 (36%) 3992 (36%) 0.730 
Calcium channel blocker 5267 (28%) 2138 (27%) 3138 (28%) 0.055 
Beta-blocker 5159 (27%) 2658 (34%) 2501 (23%) <0.001 
Antidiabetic agent 4288 (23%) 1430 (18%) 2858 (26%) <0.001 
Modified Rankin Scale    <0.001 
Class 0 (no symptoms) 4212 (22%) 1967 (25%) 2245 (20%)  
Class 1 (no significant disability) 7274 (38%) 3065 (39%) 4209 (38%)  
Class 2 (slight disability) 4284 (26%) 1730 (22%) 2554 (23%)  
Class 3 (moderate disability) 2043 (11%) 733 (9%) 1310 (12%)  
Class 4 (moderately severe disability) 1196 (6%) 420 (5%) 776 (7%)  
This table shows the clinical and demographic characteristics of the PERFORM patients who had baseline resting heart rate 
measurements available.  Values are given for the total population, as well as separately for patients who had a baseline 
resting heart rate <70bpm, and patients who had a baseline resting heart rate ≥70bpm.  Data are the number of patients 
with the corresponding percentage, or the mean with the standard deviation, depending on whether the variable was 
categorical or continuous.  Not all patients had every baseline measurement available.  Therefore, percentages and means 
were calculated using the number of subjects with non-missing data as the denominator.  The values of each characteristic 
were compared between the two different baseline resting heart rate groups using unpaired two-sample t-tests and chi-
squared tests, for continuous and categorical variables, respectively.   
The variable ‘antiplatelet agents’ includes aspirin, dipyridamole, clopidogrel and ticlopidine.   
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ACE = Angiotensin-Converting Enzyme; ARB = Angiotensin II Receptor Block; BMI = Body Mass Index; DBP = Diastolic 
Blood Pressure; SBP = Systolic Blood Pressure; TIA = Transient Ischemic Attack.   
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There were significant differences between the two groups of patients in terms of 
almost all of the baseline characteristics excluding SBP, the presence of PAD, and the 
intake of CCBs and diuretics.  Patients in the ≥70bpm baseline heart rate group were 
more likely to be female and younger; they were also more likely to be Asian and less 
likely to be Caucasian.  Those in the higher heart rate group were also more likely to 
have a higher BMI and DBP, and have never smoked.  Hypertension, 
hypertriglyceridemia and diabetes were more prevalent in the higher heart rate group, 
while hypercholesterolaemia was less prevalent.  It was also less likely that those in the 
higher heart rate group had experienced a prior TIA, angina or an MI, but more likely 
that they had experienced a prior ischemic stroke.  The use of antiplatelet agents, 
statins, ARBs, and beta-blockers was lower in the higher heart rate group, while the use 
of ACE inhibitors and antidiabetic agents was higher.  Finally, patients with a baseline 
heart rate ≥70bpm were more likely to be assessed as Class 2, 3 or 4 by the Modified 
Rankin Scale.   
The total number of events is presented in Table 7-2, along with the number that 
occurred in each of the baseline heart rate groups.  The percentage of patients in the 
greater than or equal to 70bpm heart rate group was higher for: the primary endpoint; 
all fatal and non-fatal MI; vascular death; all-cause death; and cardiac death, compared 
to the less than 70bpm baseline group.  For all other events, the percentage of patients 
in each group who experienced the event was similar. 
The Cox regression models adjusted for the same variables adjusted for in the baseline 
heart rate publication191 with the exception of Country: age; gender; smoking; BMI; 
prior ischemic stroke; prior MI; prior TIA; hypertension; diabetes; and the intake of 
beta-blockers, statins and antiplatelet agents after the qualifying event. 
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Table 7-2: The number of first events that occurred in the PERFORM population. 
  Subjects Separated by Baseline 
Heart Rate 
 Total 
Population 
n = 18993 
<70bpm 
n = 7907 
>=70bpm 
n = 11086 
Primary Composite Endpoint    
Fatal or non-fatal MI, fatal or non-fatal ischemic stroke, or 
other vascular death 
2141 (11%) 835 (11%) 1306 (12%) 
MI-Related Endpoints    
All fatal or non-fatal MI 285 (2%) 108 (1%) 177 (2%) 
Non-fatal MI 251 (1%) 98 (1%) 153 (1%) 
Stroke-Related Endpoints    
All fatal or non-fatal ischemic stroke 1,541 (8%) 631 (8%) 910 (8%) 
Non-fatal ischemic stroke 1,446 (8%) 643 (8%) 843 (8%) 
All fatal or non-fatal stroke 1,667 (9%) 676 (9%) 991 (9%) 
Mortality-Related Endpoints    
Vascular death 436 (2%) 136 (2%) 300 (3%) 
All-cause mortality 1174 (6%) 414 (5%) 760 (7%) 
Cardiac Endpoints    
Cardiac death 103 (1%) 39 (<1%) 64 (1%) 
Hospitalisation due to a cardiac cause 887 (5%) 384 (5%) 503 (5%) 
This table shows the total number of PERFORM patients with available baseline resting heart rate data who experienced 
any pre-specified events of interest, as well as the number in relation to baseline heart rate, partitioned at 70bpm.  Data are 
number of patients who experienced the event as a first event, with the corresponding percentage.  MI = Myocardial 
Infarction.  Note that first event refers to the first event of each type: for example, a patient may have experienced a non-
fatal MI, and then have subsequently experienced a non-fatal ischemic stroke at a later date. 
 
  
169 
 
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
Comparing the risk of each of the outcomes between patients with a baseline or time-
updated heart rate ≥70bpm, or <70bpm, produced the HRs and CIs shown by Figure 7-1 
and in Table A5-1 provided in Appendix 5.   
Figure 7-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥70bpm compared to a heart rate 
<70bpm in the PERFORM population. 
 
AC = All-Cause; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; gender; smoking; body mass index (BMI); prior ischemic stroke; prior myocardial 
infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake of beta-blockers, statins and 
antiplatelet agents after the qualifying event. 
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A heart rate ≥70bpm was associated with a higher risk of the combined endpoint of fatal 
or non-fatal MI, fatal or non-fatal ischemic stroke, or other vascular death, and the 
individual endpoints of vascular death and all-cause death in all models fitted.  A 
baseline resting heart rate ≥70bpm was not associated with a higher risk of all fatal or 
non-fatal ischemic stroke, non-fatal ischemic stroke, or all fatal or non-fatal stroke.  
However, time-updated resting heart rate ≥70bpm was associated with a 16% (p = 
0.0057) increase in risk of all fatal or non-fatal ischemic stroke, a 15% (p = 0.013) 
increase in risk of non-fatal ischemic stroke, and a 16% (p = 0.0044) increase in risk of 
all fatal or non-fatal stroke.  The associations for each of these three outcomes also 
remained after adjustment for baseline heart rate group, but were attenuated when the 
previous time-updated heart rate group was adjusted for (p = 0.069 for fatal or non-
fatal ischemic stroke; p = 0.085 for non-fatal ischemic stroke; and p = 0.054 for all fatal 
or non-fatal stroke).  In regards to all fatal or non-fatal MI, a baseline and a time-
updated heart rate ≥70bpm were associated with a 29% (p = 0.044) and 33% (p = 0.025) 
increase in risk, respectively.  The association between time-updated heart rate and 
risk lost its association when baseline and previous heart rate were adjusted for (p = 
0.094 and p = 0.18, adjusted for baseline and the previous heart rate, respectively).  No 
associations between a heart rate ≥70bpm and risk of non-fatal MI, cardiac death, or 
hospitalisation due to cardiac cause were observed.   
Analysing continuous heart rate measurements produced the HRs and CIs shown by 
Figure 7-2 and in Table A5-2 provided in Appendix 5.   
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Figure 7-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the PERFORM 
population. 
 
AC = All-Cause; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; gender; smoking; body mass index (BMI); prior ischemic stroke; prior myocardial 
infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake of beta-blockers, statins and 
antiplatelet agents after the qualifying event. 
 
 
A 5bpm higher heart rate was associated with higher risk of the combined endpoint of 
fatal or non-fatal MI, fatal or non-fatal ischemic stroke, or other vascular death, and 
the individual endpoints of vascular death and all-cause mortality, in all models.  
Elevated baseline, time-updated and time-updated heart rate adjusted for baseline 
were associated with an increase in risk of cardiac death, but the association was 
attenuated when the previous heart rate measurement was adjusted for (p = 0.26).  A 
5bpm higher baseline heart rate, and time-updated heart rate, were associated with a 
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7% (p = 0.013) and 8% (p = 0.0074) increase in risk of fatal or non-fatal MI, respectively, 
but the association was similarly attenuated after adjustment for baseline (p = 0.077) 
and the previous heart rate measurement (p = 0.10).  An elevated continuous baseline 
heart rate was not associated with an increase in risk of non-fatal MI, fatal or non-fatal 
ischemic stroke, non-fatal ischemic stroke, all fatal or non-fatal stroke, or cardiac 
death.  However, a 5bpm higher time-updated heart rate was associated with an 8% (p = 
0.0074) increase in risk of non-fatal MI, a 5% (p<0.001) increase in risk of fatal or non-
fatal ischemic stroke, a 4% (p = 0.011) increase in risk of non-fatal ischemic stroke, a 5% 
(p<0.001) increase in risk of all fatal or non-fatal stroke, and a 6% (p<0.001) increase in 
risk of hospitalisation due to cardiac cause.  The association between elevated 
continuous time-updated heart rate and risk remained after adjustment for baseline and 
the previous heart rate measurement for fatal or non-fatal ischemic stroke, all fatal or 
non-fatal stroke, and hospitalisation due to cardiac cause.  The association with risk of 
non-fatal ischemic stroke remained after adjustment for baseline (p = 0.012) but was 
attenuated slightly when previous heart rate was adjusted for (p = 0.057).  Elevated 
continuous time-updated heart rate adjusted for baseline or previous heart rate did not 
remain predictive of risk of non-fatal MI (p = 0.13 and p = 0.090 adjusted for baseline 
and the previous heart rate, respectively). 
Figure 7-3 and Table A5-3 provided in Appendix 5 show the adjusted HRs and 95% CIs 
estimated using the time-updated categorical heart rate patterns models.  Comparing 
the current heart rate measurement at each visit to the previous heart rate 
measurement, all patients who did not have a heart rate below 70bpm at both the 
current and previous visit (low-low) were found to be at a higher risk of the combined 
endpoint of fatal or non-fatal MI, ischemic stroke, or other vascular death, and the 
individual endpoints vascular death and all-cause death.  Patients with a heart rate 
≥70bpm at both visits (high-high), and whose heart rate increased from below 70bpm at 
the previous visit to ≥70bpm at the current visit (low-high), were at a higher risk of all 
fatal or non-fatal stroke (low-high: 19%, 95% CI 1 to 40%, p = 0.038; high-high: 22%, 95% 
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CI 8 to 38%, p = 0.0012).  Those with a high heart rate at both visits were at a 51% (p = 
0.0074) higher risk of fatal or non-fatal MI, a 43% (p = 0.026) higher risk of non-fatal MI, 
a 23% (p = 0.0015) higher risk of fatal or non-fatal ischemic stroke, and a 20% higher risk 
of non-fatal ischemic stroke (p = 0.0066).  No significant associations between risk and 
heart rate pattern were observed for either of the cardiac endpoints, although a low-
high heart rate was borderline significantly associated with an increase in risk of 
hospitalisation due to a cardiac cause (p = 0.054).   
Figure 7-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate patterns 
‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the PERFORM 
population. 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.     
AC = All-Cause; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; gender; smoking; body mass index (BMI); prior ischemic stroke; prior myocardial 
infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake of beta-blockers, statins and 
antiplatelet agents after the qualifying event.  
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The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A5-4 provided in Appendix 5 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the heart rate variables that categorised subjects according to whether they 
had a heart rate less than, or greater than or equal to 70bpm, for each outcome.  
Regardless of whether any resting heart rate category variables were included, the 
models had the greatest predictive ability for vascular and cardiac death: the C-
statistics of the models both excluding and including resting heart rate ranged from 
0.711 to 0.731, and 0.748 to 0.753 for each of these outcomes, respectively.  The 
models had the least predictive ability for the three stroke-related endpoints (all 
ischemic strokes, non-fatal ischemic strokes, and all strokes), with C-statistics ranging 
from 0.612 to 0.622.  The C-statistics of the models for the other outcomes ranged from 
0.630 to 0.694.  The addition of baseline or time-updated resting heart rate category 
improved discrimination for all of the endpoints except non-fatal MI and cardiac 
hospitalisation compared to the model excluding heart rate.  However, the C-statistics 
for each of the three stroke-related endpoints increased by up to 0.004 only with the 
addition of the heart rate category variables.  The model including time-updated heart 
rate category additionally adjusted for baseline heart rate category had the best 
discrimination for vascular death and all-cause death; the model including time-updated 
heart rate category additionally adjusted for the previous heart rate category had the 
best discrimination for the combined endpoint of fatal or non-fatal MI, ischemic stroke, 
or other vascular death; and both time-updated heart rate models adjusted for either 
baseline or the previous heart rate category had the best discrimination for fatal or 
non-fatal MI and cardiac death.  Only the addition of the time-updated heart rate 
category variable, with adjustment for baseline or the previous heart rate category, 
improved the discrimination of the model for non-fatal MI.  There was no improvement 
in discrimination for cardiac hospitalisation with the addition of any of the heart rate 
category variables.  The likelihood ratio test statistics and corresponding p-values for 
the addition of the heart rate category variables to the models are also presented in 
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Table A5-4.  The addition of any of the heart rate category variables resulted in 
statistically significant improvements in the calibration of the models for the combined 
endpoint of fatal or non-fatal MI, ischemic stroke, or other vascular death, and the 
individual endpoints of fatal or non-fatal MI, vascular death, and all-cause death.  Only 
the addition of the time-updated heart rate category variable, with or without 
adjustment for baseline or the previous heart rate category, improved the calibration of 
the models for non-fatal MI, each of the three stroke-related endpoints, and cardiac 
hospitalisation.  There were no significant improvements in model calibration for 
cardiac death.   
Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the continuous heart rate variables, for each outcome, are shown in Table A5-
5 provided in Appendix 5, along with the likelihood ratio test statistics and 
corresponding p-values for the addition of the different continuous heart rate variables.  
The results were very similar to those observed for the heart rate categories according 
to whether subjects had a heart rate less than, or greater than or equal to 70bpm, with 
a couple of exceptions.  First, while there was no improvement in discrimination for 
cardiac hospitalisation with addition of any of the heart rate category variables, the 
addition of the continuous time-updated heart rate category variable, with or without 
adjustment for baseline or the previous heart rate category, improved the 
discrimination of the models, but only by 0.001, from 0.662 to 0.663.  Second, the 
addition of any of the continuous heart rate variables resulted in statistically significant 
improvements in the calibration of the models for cardiac death.   
Table A5-6 provided in Appendix 5 shows Harrell’s C-statistics for the model excluding 
resting heart rate, and the models including the time-updated categorical heart rate 
patterns variable for each outcome.  Again, irrespective of whether resting heart rate 
was included, the models had the greatest predictive ability for vascular and cardiac 
death, and the least for the three stroke-related endpoints.  The addition of time-
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updated categorical heart rate pattern improved discrimination for all of the outcomes, 
although the C-statistic increased by only 0.001 for hospitalisation due to a cardiac 
cause, and only 0.003 for each of the stroke-related endpoints.  Other small 
improvements in discrimination were observed for fatal or non-fatal MI, non-fatal MI, 
and cardiac death, with the C-statistics increasing from 0.676 to 0.681, 0.673 to 0.677, 
and 0.748 to 0.753, respectively, when time-updated heart rate pattern was added to 
the models.  The largest improvements were observed for vascular and all-cause death, 
with the C-statistics increasing from 0.711 to 0.727, and 0.678 to 0.693, respectively.  
The likelihood ratio test statistics and corresponding p-values for the addition of the 
heart rate patterns variable to the models are also presented in Table A5-6.  The 
addition of heart rate pattern resulted in statistically significant improvements in the 
calibration of the models for all of the outcomes except cardiac death. 
Table A5-7, Table A5-8 and Table A5-9 in Appendix 5 show the p-values of the Grambsch 
and Therneau 1994 test for non-proportionality for all the models and outcomes.  
Evidence of non-proportionality of the effect of an elevated continuous baseline heart 
rate on the hazard of all-cause death was found.  Examination of the plot of the 
smoothed curve and corresponding 95% CIs of the Schoenfeld residuals for a 5bpm 
higher baseline heart rate and risk of all-cause death, shown by Figure 7-4, suggested 
that the effect of heart rate was highest at the beginning of follow-up, and then 
decreased over time.  No violations of the proportional hazards assumption for any of 
the other heart rate variables that were associated with risk of outcome were observed.   
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Figure 7-4: The Schoenfeld residuals plot of the effect of a 5bpm higher baseline heart rate 
on the risk of all-cause death in the PERFORM population. 
 
The horizontal dotted line represents the previously calculated ‘average’ hazard ratio of all-cause death.   
 
7.3 Discussion 
In this large population of patients aged 55 years or older who had recently experienced 
an ischemic stroke or TIA, an elevated resting heart rate was associated with an 
increase in the risk of all of the endpoints evaluated, including non-fatal MI, all fatal or 
non-fatal ischemic stroke, non-fatal ischemic stroke, cardiac death and hospitalisation 
due to cardiac causes.   
An elevated baseline and time-updated heart rate, both unadjusted and adjusted for 
baseline heart rate or the previous heart rate measurement, analysed as a categorical 
or continuous variable, was associated with an increase in the risk of all-cause and 
vascular death.  Moreover, the addition of any of the heart rate variables improved the 
discriminative ability, and resulted in statistically significant improvements in the 
calibration of the models: the time-updated models adjusted for baseline or the 
previous heart rate measurements yielded the highest C-statistics.  Thus, even if the 
baseline or previous heart rate measurement are known, time-updated heart rate 
supplies significant additional information about the risk of death from all causes or CV 
causes in post-stroke or or-TIA patients.   
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While no associations between baseline heart rate and risk of any of the stroke-related 
endpoints were observed, an elevated time-updated heart rate was associated with an 
increase in risk of each of the stroke-related endpoints.  A time-updated heart rate 
≥70bpm remained a significant predictor of each of the outcomes after adjustment for 
baseline group, but associations were attenuated slightly when previous heart rate 
group was adjusted for.  The same was true of elevated continuous time-updated heart 
rate in regards to non-fatal ischemic stroke.  On the other hand, an elevated continuous 
time-updated heart rate was associated with an increase in risk of fatal or non-fatal 
ischemic stroke, and all fatal or non-fatal ischemic stroke, after adjustment for both 
baseline and the previous heart rate measurement.  While only small improvements in 
discrimination were observed when each of the resting heart rate variables were added 
to the models, the greatest improvements resulted from the inclusion of the time-
updated resting heart rate variables.  Only the addition of the time-updated heart rate 
variables, with or without adjustment for baseline or the previous heart rate 
measurements, improved the calibration of the models for each of the three stroke-
related endpoints. 
Both an elevated baseline and time-updated heart rate were associated with a higher 
risk of all fatal or non-fatal MI.  However, the association with time-updated heart rate 
was attenuated when either baseline heart rate or the previous heart rate measurement 
were adjusted for.  Minor improvements in discrimination were observed when each of 
the resting heart rate variables were added to the models.  The addition of any of the 
heart rate variables resulted in statistically significant improvements in the calibration 
of the models: the improvement appeared to be greatest with the inclusion of time-
updated resting heart rate (all time-updated heart rate models p<0.001 compared to p 
= 0.42 and p = 0.014 for the models including only categorical and continuous baseline 
heart rate, respectively).  No associations between any of the categorical heart rate 
variables and the risk of non-fatal MI were observed.  Conversely, an elevated 
continuous time-updated heart rate was associated with an increase in the risk of non-
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fatal MI, although again, results were attenuated when baseline or the previous heart 
rate measurement were adjusted for.  Only very small improvements in discrimination 
were observed with the addition of some of the resting heart rate variables, and only 
the models including time-updated resting heart rate were found to be better 
calibrated than the model not including resting heart rate for non-fatal MI. 
No associations between any of the categorical heart rate variables and the risk of 
either of the cardiac endpoints were observed.  Although the addition of baseline or 
time-updated resting heart rate category improved discrimination for cardiac death, 
there was no improvement for cardiac hospitalisation with the addition of any of the 
heart rate category variables.  Conversely, there were no significant improvements in 
model calibration for cardiac death, whereas the addition of the time-updated heart 
rate category variable, with or without adjustment for baseline or the previous heart 
rate category, improved the calibration of the models for cardiac hospitalisation.  In 
contrast, an elevated continuous time-updated heart rate was associated with an 
increase in risk of both cardiac death and hospitalisation due to cardiac causes.  An 
elevated continuous time-updated heart rate retained its prognostic value even after 
adjustment for baseline heart rate or the previous heart rate measurement for 
hospitalisation due to cardiac causes, but adjustment for the previous measurement 
attenuated the association with cardiac death.  Again, the addition of baseline or time-
updated resting heart rate improved discrimination of the model for cardiac death, 
however the addition of continuous time-updated heart rate, with or without 
adjustment for baseline or the previous heart rate measurement, also increased the C-
statistic of the model for cardiac hospitalisation, but only by 0.001.  Furthermore, the 
addition of any of the continuous heart rate variables resulted in statistically significant 
improvements in the calibration of the models for cardiac death, while again, the 
addition of the time-updated heart rate variable, with or without adjustment for 
baseline or the previous heart rate measurement, improved the calibration of the 
models for cardiac hospitalisation.   
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The current findings for all-cause death and CV death were generally similar to those 
previously found by Bohm 2012190 and Fox 2013191.  While Bohm et al. 2012 and Fox et 
al. 2013 found no associations between an elevated baseline heart rate and the risk of 
any type of recurrent stroke or MI190, or ischemic stroke191, respectively, this study 
demonstrated that an elevated time-updated resting heart rate was associated with a 
higher risk of both fatal and non-fatal MI and ischemic stroke.  No prior studies of post-
stroke or -TIA subjects were identified in the systematic review of Chapter 2 that 
examined associations between heart rate and the risk of cardiac death or 
hospitalisation due to cardiac causes. 
7.3.1 Chapter Summary and Conclusions 
This chapter assessed the associations between baseline and time-updated resting heart 
rate, and risk of death and adverse CV events, in the PERFORM population. 
Raised time-updated heart rate was associated with an increase in risk of all of the 
adverse events that were studied, including all-cause death, non-fatal MI, cardiac death 
and hospitalisation due to cardiac causes in this population of patients who had recently 
experienced an ischemic stroke or TIA.  While baseline resting heart rate was not found 
to be associated with risk of any of the stroke-related endpoints that were evaluated, 
an elevated time-updated heart rate was associated with an increase in risk of each of 
them. 
Chapter 8 similarly explores baseline and time-updated resting heart rate as risk 
markers in the BEAUTIFUL and SHIFT placebo populations, both individually and pooled: 
each trial enrolled patients with LVSD who were in sinus rhythm.   
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Chapter 8 
 
Heart Rate and Risk in Patients with Left-
Ventricular Systolic Dysfunction 
8.1 Introduction 
In the placebo-randomised patients of the BEAUTIFUL trial, who had CHD and LVSD, 
with a baseline heart rate ≥60bpm (many of whom also had HF), Fox et al. 2008 
established that an elevated baseline resting heart rate was associated with an increase 
in the risk of CV death, hospital admission for HF and MI, and coronary 
revascularisation184.  Patients with a baseline heart rate ≥70bpm, for example, were 
found to be at a 46% (p = 0.0066) higher risk of hospital admission for MI.  A 5bpm 
higher baseline heart rate, however, was only borderline significantly associated with a 
7% (p = 0.052) increase in the risk of hospital admission for MI.   
Similarly, in the placebo-randomised patients of the SHIFT trial, who had chronic HF and 
LVSD, with a baseline heart rate ≥70bpm, Bohm et al. 2010 demonstrated that a raised 
resting heart rate at baseline was associated with an increase in the risk of death from a 
number of different causes, and adverse CV outcomes such as hospital admission for HF 
and MI182.   However, the predictive value of an elevated continuous resting heart rate 
was only evaluated in relation to the primary endpoint – CV death or hospital admission 
for HF – and its individual components.   
Vazir et al. 2014 recently demonstrated that an elevated time-updated heart rate was 
associated with an increase in the risk of adverse events in a population of patients with 
chronic HF215.  However, the systematic review of Chapter 2 did not identify any studies 
of time-updated heart rate in patients specifically with LVSD and either CHD or chronic 
HF.     
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In Section 8.2, data from the BEAUTIFUL trial was used to investigate the association 
between baseline heart rate and risk of the other five endpoints that were assessed in 
the original BEAUTIFUL trial publication248 , such as all-cause and cardiac death, that 
were not previously studied by Fox et al. 2008184.  The analysis also aimed to determine 
whether or not time-updated heart rate would strengthen the associations for each of 
these outcomes, as well as the four originally studied by Fox et al. 2008184. 
In Section 8.3, data from the SHIFT trial was used to explore the associations between 
baseline heart rate and hospital admission for non-fatal MI, and the composite of CV 
death or hospital admission for non-fatal MI - endpoints that were not previously studied 
by Bohm et al. 2010182.  The analysis also aimed to establish whether or not time-
updated heart rate would strengthen the associations for each of these outcomes, as 
well as those originally studied by Bohm et al. 2010182.   
Since both trials enrolled patients with LVSD in sinus rhythm, data from each were 
pooled, and an individual patient meta-analysis of the predictive value of baseline and 
time-updated resting heart rate for common outcomes across the trials was carried out 
in Section 8.4.  Differences between the trials, in relation to the effect of heart rate, 
were also examined.   
8.2 The Predictive Value of Baseline and Time-Updated 
Heart Rate Measurements in the BEAUTIFUL Placebo 
Patients 
Only the placebo group of the BEAUTIFUL trial was included in this analysis since 
ivabradine lowers the heart rate.  All of the patients assigned to the placebo group (n = 
5,438) had baseline heart rate measurements available and were included. 
Nine outcomes were assessed: the composite of CV death or admission to hospital for MI 
or new-onset or worsening HF (the primary endpoint of BEAUTIFUL); all-cause death; CV 
death; cardiac death; admission to hospital for HF; the composite of CV death or 
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admission to hospital for new-onset or worsening HF; admission to hospital for MI; the 
composite of admission to hospital for MI or unstable angina; and coronary 
revascularisation.   
The baseline heart rate cut-off of 70bpm was selected on the basis that it was the cut-
off used in the previous analysis184 and was also very close to the median heart rate of 
69bpm of the BEAUTIFUL placebo patients included in the current analysis.  The 
baseline characteristics of the placebo-assigned BEAUTIFUL patients, overall and 
categorised into groups depending on whether their baseline resting heart rate was less 
than or greater than or equal to 70bpm are shown in Table 8-1.  There were significant 
differences between the two groups of patients in terms of age, smoking status, BMI, 
history of diabetes, previous MI, previous PCI or CABG, PAD, SBP, DBP, LVEF, NYHA 
class, and treatment with aspirin, beta-blockers, statins, diuretics (excluding anti-
aldosterone), organic nitrates, and anti-aldosterone agents at randomisation.  Patients 
with a heart rate of 70bpm or greater were younger, had a higher BMI, SBP and DBP, 
and had a lower LVEF than those with a heart rate of less than 70bpm.  They were also 
more likely to smoke, have diabetes and PAD, and be in NYHA class III, and less likely to 
have had an MI or revascularisation.  Patients in the higher heart rate group were also 
more likely to be treated with diuretics, organic nitrates, and anti-aldosterone agents, 
and less likely to be treated with aspirin, beta-blockers, and statins.  
The total number of events that occurred in the placebo group is presented in Table 
8-2, along with the numbers that occurred in each of the baseline heart rate groups of 
patients.  The percentage of patients with a baseline heart rate of 70bpm or higher who 
experienced an event was higher for every event compared to the patients with a 
baseline heart rate lower than 70bpm.    
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Table 8-1: Baseline characteristics of the BEAUTIFUL placebo study population. 
  Baseline Heart Rate  
 All Subjects 
n = 5438 
<70bpm 
n = 2745 
≥70bpm 
n = 2693 
p-value 
Demographic Characteristics     
Age (years) 65.0 (8.4) 65.6 (8.2) 64.4 (8.6) <0.001 
Sex (male) 4507 (83%) 2298 (84%) 2209 (82%) 0.098 
Smoking (current) 835 (15%) 353 (13%) 482 (18%) <0.001 
BMI (kg/m²) 28.5 (4.4) 28.3 (4.1) 28.7 (4.7) 0.002 
Medical History     
Hypertension 3838 (71%) 1911 (70%) 1927 (72%) 0.117 
Diabetes 2019 (37%) 864 (31%) 1155 (43%) <0.001 
Dyslipidaemia 4278 (79%) 2155 (79%) 2123 (79%) 0.768 
Prior MI 4817 (89%) 2648 (90%) 2349 (87%) 0.002 
Prior PCI or CABG 2824 (52%) 1464 (53%) 1360 (51%) 0.037 
Prior stroke 971 (18%) 468 (17%) 503 (19%) 0.117 
Peripheral artery disease 748 (14%) 346 (13%) 402 (15%) 0.013 
Cardiac Parameters     
Heart rate (bpm) 71.6 (9.9) 64.1 (2.8) 79.2 (8.7) - 
SBP (mm Hg) 127.9 (15.5) 127.2 (15.2) 128.5 (15.7) 0.002 
DBP (mm Hg) 77.5 (9.2) 76.7 (9.2) 78.3 (9.2) <0.001 
LVEF (%) 32.3 (5.5) 32.7 (5.3) 31.9 (5.7) <0.001 
NYHA Class    <0.001 
Class I heart failure 840 (15%) 467 (17%) 373 (14%)  
Class II heart failure 3359 (62%) 1744 (64%) 1615 (60%)  
Class III heart failure 1239 (23%) 534 (19%) 705 (26%)  
Medication at Randomisation     
Aspirin 4588 (84%) 2438 (86%) 2240 (83%) 0.017 
ACE inhibitor, ARB or both 4873 (90%) 2452 (89%) 2421 (90%) 0.488 
Beta-blocker 4738 (87%) 2465 (90%) 2273 (84%) <0.001 
Statin 4032 (74%) 2087 (76%) 1945 (72%) 0.001 
Diuretics (excluding anti-aldosterone) 3194 (59%) 1490 (54%) 1704 (63%) <0.001 
Organic nitrates 2335 (43%) 1133 (41%) 1202 (45%) 0.012 
Anti-aldosterone agents 1466 (27%) 666 (24%) 800 (30%) <0.001 
This table shows the clinical and demographic characteristics of the BEAUTIFUL placebo patients.  Values are given for the 
total placebo population, as well as separately for patients who had a baseline resting heart rate <70bpm, and patients who 
had a baseline resting heart rate ≥70bpm.  Data are the number of patients with the corresponding percentage, or the mean 
with the standard deviation, depending on whether the variable was categorical or continuous.  Not all patients had every 
baseline measurement available.  Therefore, percentages and means were calculated using the number of subjects with 
non-missing data as the denominator.  The values of each characteristic were compared between the two different baseline 
resting heart rate groups using unpaired two-sample t-tests and chi-squared tests, for continuous and categorical variables, 
respectively. 
Aspirin did not include other antithrombotic agents (which it did in the original baseline heart rate paper). 
ACE = Angiotensin-Converting Enzyme; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass Index; CABG = 
Coronary Artery Bypass Graft; DBP = Diastolic Blood Pressure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial 
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Infarction; NYHA = New York Heart Association; PCI = Percutaneous Coronary Intervention; SBP = Systolic Blood 
Pressure.   
 
Table 8-2: The number of first events that occurred in the BEAUTIFUL placebo population. 
  Subjects Separated by Baseline Heart Rate 
 Total Placebo 
Population 
n = 5438 
<70bpm 
n = 2745 
≥70bpm 
n = 2693 
Primary Composite Endpoint    
Cardiovascular death or admission to 
hospital for myocardial infarction or 
new-onset or worsening heart failure 
832 (15%) 334 (12%) 498 (18%) 
Mortality Endpoints    
All-cause death 547 (10%) 223 (8%) 324 (12%) 
Cardiovascular death 435 (8%) 172 (6%) 263 (10%) 
Cardiac death 151 (8%) 54 (2%) 97 (4%) 
Heart Failure Endpoints    
Admission to hospital for heart failure 427 (8%) 156 (6%) 271 (10%) 
Cardiovascular death or admission to 
hospital for new-onset or worsening 
heart failure 
723 (13%) 281 (10%) 442 (16%) 
Coronary Endpoints    
Admission to hospital for myocardial 
infarction 
226 (4%) 95 (3%) 131 (5%) 
Admission to hospital for myocardial 
infarction or unstable angina 
317 (6%) 135 (5%) 182 (7%) 
Coronary revascularisation 186 (3%) 78 (3%) 108 (4%) 
This table shows the total number of BEAUTIFUL placebo patients with available baseline resting heart rate data who 
experienced any pre-specified events of interest, as well as the number in relation to baseline heart rate, partitioned at 
70bpm.  Data are number of patients who experienced the event as a first event, with the corresponding percentage.  Note 
that first event refers to the first event of each type: for example, a patient may have been admitted to hospital for an MI, 
and then subsequently been admitted to hospital for HF at a later date. 
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The Cox regression models adjusted for the same variables adjusted for in the baseline 
heart rate analysis184 (all variables with nominal differences at baseline): age, smoking, 
BMI, history of diabetes, previous MI, previous PCI or CABG, PAD, SBP, DBP, LVEF, NYHA 
class, and treatment with aspirin (not including other antithrombotic agents as it was 
not available in the dataset used for the current analysis), beta-blockers, statins, 
diuretics (excluding anti-aldosterone), organic nitrates, and anti-aldosterone agents at 
randomisation. 
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
Comparing the risk of each of the outcomes between patients with a baseline or time-
updated heart rate greater than or equal to 70bpm, or less than 70bpm, produced the 
HRs and 95% CIs shown by Figure 8-1 and in Table A6-1 provided in Appendix 6.  A heart 
rate ≥70bpm was associated with a higher risk of all of the endpoints in all models 
fitted, with the exceptions of admission to hospital for MI or unstable angina, and 
coronary revascularisation.  Baseline and time-updated heart rates ≥70bpm were 
associated with a 41% (p = 0.0032) and 37% (p = 0.0065) higher risk of admission to 
hospital for MI or unstable angina, respectively, but the association between risk and 
time-updated heart rate was attenuated slightly when adjusted for baseline (p = 0.084) 
and the previous heart rate group (p = 0.12).  Similarly, baseline and time-updated 
heart rate ≥70bpm were associated with a 38% (p = 0.036) and 37% (p = 0.038) increase 
in risk of coronary revascularisation, respectively, but again the association was 
attenuated after adjustment (p = 0.17 and p = 0.13 adjusted for baseline and the 
previous heart rate group, respectively).    
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Figure 8-1: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥70bpm compared to a heart rate 
<70bpm in the BEAUTIFUL placebo population.  
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; smoking; body mass index (BMI); history of diabetes; previous myocardial 
infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); peripheral artery 
disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New 
York Heart Association (NYHA) class; and treatment with aspirin (not including other antithrombotic agents), beta-blockers, 
statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone agents at randomisation.  
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Analysing continuous heart rate measurements produced the HRs and CIs shown by 
Figure 8-2 and in Table A6-2 provided in Appendix 6.  An elevated continuous heart rate 
was associated with an increase in risk of all of the endpoints, with the exceptions of 
admission to hospital for MI, and the combination of admission to hospital for MI or 
unstable angina.  An elevated continuous baseline heart rate was not associated with an 
increase in risk of admission to hospital for MI or admission to hospital for MI or unstable 
angina.  However, a 5bpm higher time-updated heart rate was associated with a 14% 
(p<0.001) increase in risk of admission to hospital for MI, and a 10% (p<0.001) increase 
in risk of admission to hospital for MI or unstable angina.  The association between 
time-updated heart rate and risk of each of the endpoints remained significant even 
after adjustment for baseline and the previous heart rate measurement.   
Figure 8-3 and Table A6-3 provided in Appendix 6 show the adjusted HRs and 95% CIs 
estimated using the time-updated categorical heart rate patterns models. Comparing 
the current heart rate measurement at each visit to the previous heart rate 
measurement, all patients who did not have a heart rate below 70bpm at both the 
current and previous visit (low-low) were found to be at a higher risk of the combined 
endpoint of CV death or admission to hospital for MI or new-onset or worsening HF, and 
the combined endpoint of CV death or admission to hospital for new-onset or worsening 
HF.  Patients with a heart rate ≥70bpm at both visits (high-high), and whose heart rate 
increased from below 70bpm at the previous visit to ≥70bpm at the current visit (low-
high), were at a significantly higher risk of all-cause death, CV death, cardiac death, 
and admission to hospital for new-onset or worsening HF, compared to those patients 
who had a heart rate <70bpm at both visits (low-low).  Subjects with a persistently high 
heart rate (high-high) were at an elevated risk of admission to hospital for MI (HR 1.73, 
95% CI 1.27 to 2.37, p<0.001), admission to hospital for MI or unstable angina (HR 1.54, 
95% CI 1.19 to 2.00, p<0.001) and coronary revascularisation (HR 1.44, 95% CI 1.03 to 
2.02, p = 0.032).    
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Figure 8-2: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the BEAUTIFUL 
placebo population. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; smoking; body mass index (BMI); history of diabetes; previous myocardial 
infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); peripheral artery 
disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New 
York Heart Association (NYHA) class; and treatment with aspirin (not including other antithrombotic agents), beta-blockers, 
statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone agents at randomisation.  
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Figure 8-3: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate patterns 
‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the BEAUTIFUL 
placebo population. 
 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.   
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; smoking; body mass index (BMI); history of diabetes; previous myocardial 
infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); peripheral artery 
disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New 
York Heart Association (NYHA) class; and treatment with aspirin (not including other antithrombotic agents), beta-blockers, 
statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone agents at randomisation. 
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The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A6-4 provided in Appendix 6 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the heart rate variables that categorised subjects according to whether they 
had a heart rate less than, or greater than or equal to 70bpm, for each outcome.  
Regardless of whether any resting heart rate category variables were included, the 
models had the greatest predictive ability for cardiac death and admission to hospital 
for HF: the C-statistics of the models both excluding and including resting heart rate 
ranged from 0.759 to 0.795, and 0.753 to 0.773 for each of these outcomes, 
respectively.  The C-statistics of the models for the other outcomes ranged from 0.648 
to 0.731.  The addition of resting heart rate category improved discrimination for all of 
the outcomes compared to the model excluding heart rate.  For cardiac death, 
admission to hospital for MI, coronary revascularisation, and the combined endpoint of 
admission to hospital for MI or unstable angina, the models including time-updated 
resting heart rate category adjusted for either baseline or the previous heart rate 
category had the best discrimination.  Similarly, for the combined endpoints of CV 
death or admission to hospital for MI or HF, and CV death or admission to hospital for HF 
and the individual endpoint admission to hospital for HF, the model including time-
updated heart rate additionally adjusted for the previous category had the best 
discrimination.  All three of the time-updated heart rate models had the same and the 
best predictive ability for all-cause and CV death, compared to the model not including 
resting heart rate and the model including baseline heart rate only (C-statistic of each 
time-updated heart rate model: 0.710 and 0.716 for all-cause and CV death, 
respectively).  The greatest improvement in discrimination was observed for cardiac 
death, with the C-statistic increasing from 0.759 to 0.795, and the smallest was 
observed for revascularisation, with the C-statistic increasing from 0.651 to only 0.656.  
The likelihood ratio test statistics and corresponding p-values for the addition of the 
heart rate category variables to the models are also presented in Table A6-4.  The 
addition of any of the heart rate category variables resulted in statistically significant 
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improvements in the calibration of the models for all of the outcomes excluding 
revascularisation.  For revascularisation, each of the models including a heart rate 
variable had a significantly better calibration than that of the model excluding heart 
rate, except that which included time-updated heart rate category additionally 
adjusted for the previous heart rate category.   
Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the continuous heart rate variables, for each outcome, are shown in Table A6-
5 provided in Appendix 6, along with the likelihood ratio test statistics and 
corresponding p-values for the addition of the different continuous heart rate variables.  
The results were very similar to those observed for the heart rate categories according 
to whether subjects had a heart rate less than, or greater than or equal to 70bpm, 
although the smallest improvement in discrimination was observed for admission to 
hospital for MI or unstable angina as opposed to revascularisation.  Moreover, the 
addition of any of the continuous heart rate variables resulted in statistically significant 
improvements in the calibration of the model for revascularisation, while only the 
addition the addition of the continuous time-updated heart rate variable, with or 
without adjustment for baseline or the previous heart rate measurement, improved the 
calibration of the model for admission to hospital for MI. 
Table A6-6 provided in Appendix 6 shows Harrell’s C-statistics for the model excluding 
resting heart rate, and the models including the time-updated categorical heart rate 
patterns variable for each outcome.  Again, irrespective of whether resting heart rate 
was included, the models had the greatest predictive ability for cardiac death and 
admission to hospital for HF, and the least for admission to hospital for MI or unstable 
angina, and revascularisation.  The addition of time-updated categorical heart rate 
pattern improved discrimination for all of the outcomes.  Similar to the results for 
categorical and continuous heart rate, the greatest and least improvements in 
discrimination were observed for cardiac death, and hospital admission for MI or 
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unstable angina, respectively.  The likelihood ratio test statistics and corresponding p-
values for the addition of the heart rate patterns variable to the models are also 
presented in Table A6-6.  The addition of heart rate pattern resulted in statistically 
significant improvements in the calibration of the models for all of the outcomes except 
coronary revascularisation.     
Table A6-7, Table A6-8 and Table A6-9 in Appendix 6 show the p-values of the Grambsch 
and Therneau 1994 test for non-proportionality for all the models and outcomes.  
Evidence of non-proportionality of the effect of heart rate over time was observed using 
a number of the different models for the combined endpoint of CV death or admission 
to hospital for MI or HF, hospital admission for HF individually, and the combination of 
CV death or HF hospital admission.  Examination of the plots of the smoothed curve and 
corresponding 95% CIs of the Schoenfeld residuals for each model and outcome showed 
that the effect of elevated heart rate was highest at the beginning of follow-up, and 
then decreased over time.  Figure 8-4 shows the Schoenfeld residual plots for a 5bpm 
higher baseline heart rate, and provides an illustration of this finding.     
Figure 8-4: The Schoenfeld residuals plots for a 5bpm higher baseline heart rate for each of 
the outcomes where evidence of non-proportionality of the effect of heart rate over time was 
observed in the BEAUTIFUL placebo population. 
 
The horizontal dotted lines represent the previously calculated ‘average’ hazard ratio of each outcome.  CV = 
Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
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8.3 The Predictive Value of Baseline and Time-Updated 
Heart Rate Measurements in the SHIFT Placebo 
Patients 
Once again, only the placebo group of the trial was included.  Three of the patients 
assigned to the placebo group received ivabradine in error and were excluded.  The 
remaining 3,261 placebo group patients (99.9% of the 3,264 included in the original 
trial) had baseline heart rate measurements available and were included in the present 
analysis. 
Ten outcomes were evaluated: the combination of CV death or hospital admission for 
worsening HF (the primary endpoint of SHIFT); all-cause mortality; CV mortality; death 
from HF; all-cause hospital admission; hospital admission for worsening HF; any CV 
hospital admission; hospital admission for non-fatal MI; the combination of CV death or 
hospital admission for non-fatal MI; and the combination of CV death, hospital admission 
for worsening HF, or hospital admission for non-fatal MI. 
The baseline heart rate cut-off of 80bpm was selected on the basis that it was close to 
the median baseline heart rate of 77bpm of the SHIFT placebo patients included in the 
current analysis: 80bpm as opposed to 75bpm was chosen because the SHIFT patients 
with a heart rate greater than the median of 77bpm had previously been found to be at 
higher risk of an event32.  The baseline characteristics of the placebo-assigned SHIFT 
patients included in the present analysis, overall and categorised into groups depending 
on whether their baseline resting heart rate was less than, or greater than or equal to, 
80bpm, are shown in Table 8-3.   
  
195 
 
Table 8-3: Baseline characteristics of the SHIFT placebo study population. 
  Baseline Heart Rate  
 
 
All Subjects 
n = 3261 
<80bpm 
n = 1940 
≥80bpm 
n = 1321 
P-value  
Demographic Characteristics     
Age (years) 60.6 (11.5) 61.2 (11.3) 59.6 (11.7) <0.001 
Sex (male) 2506 (77%) 1492 (77%) 1014 (77%) 0.922 
Ethnic Origin    0.016 
Caucasian 2889 (86%) 1747 (90%) 1142 (86%)  
Asian 264 (8%) 135 (7%) 129 (10%)  
Black 43 (1%) 23 (1%) 20 (2%)  
Other 65 (2%) 35 (2%) 30 (2%)  
Current smoking 577 (18%) 308 (16%) 269 (20%) <0.001 
BMI (kg/m²) 28.0 (5.0) 27.8 (4.8) 28.1 (5.3) 0.094 
Cardiac Parameters     
Heart rate (bpm) 80.1 (9.8) 73.8 (2.7) 89.4 (9.0) - 
SBP (mm Hg) 121.4 (15.9) 121.7 (15.5) 121.0 (16.4) 0.231 
DBP (mm Hg) 75.6 (9.4) 75.4 (9.1) 75.8 (9.7) 0.281 
LVEF (%) 29.0 (5.2) 29.3 (5.1) 28.4 (5.2) <0.001 
eGFR (mL/min per 1.73m²) 74.7 (23.0) 74.0 (23.0) 75.6 (22.9) 0.051 
NYHA Class    <0.001 
II 1584 (49%) 1026 (53%) 558 (42%)  
III or IV 1676 (51%) 914 (47%) 763 (58%)  
Medical History     
Duration of Heart Failure (years) 3.5 (4.2) 3.6 (4.3) 3.3 (3.9) 0.078 
Primary Cause of Heart Failure    0.003 
Ischemic 2201 (67%) 1348 (69%) 853 (65%)  
Non-ischemic 1060 (33%) 592 (31%) 468 (35%)  
Myocardial infarction 1836 (56%) 1139 (59%) 697 (53%) <0.001 
Hypertension 2151 (66%) 1307 (67%) 844 (64%) 0.043 
Diabetes 1006 (31%) 572 (29%) 434 (33%) 0.049 
Previous stroke 293 (9%) 152 (8%) 141 (11%) 0.007 
History of AF and/or flutter 259 (8%) 154 (8%) 105 (8%) 0.99 
Table continued and footnote provided on following page. 
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Table 8-3 (Cont.): Baseline characteristics of the SHIFT placebo study population. 
  Baseline Heart Rate 
All Subjects 
n = 3261 
<80bpm 
n = 1940 
≥80bpm 
n = 1321 
P-Value 
Treatment at Randomisation     
Beta-blocker 2921 (90%) 1792 (92%) 1129 (85%) <0.001 
ACE inhibitors 2548 (78%) 1571 (81%) 977 (74%) <0.001 
ARBs 472 (14%) 253 (13%) 219 (17%) 0.006 
Diuretic (excluding anti-aldosterone) 2693 (83%) 1587 (82%) 1106 (84%) 0.170 
Anti-aldosterone agents 1939 (59%) 1114 (57%) 825 (62%) 0.005 
Cardiac glycosides 708 (22%) 366 (19%) 342 (26%) <0.001 
Devices 134 (4%) 73 (4%) 61 (5%)  
CRT 44 (1%) 23 (1%) 21 (2%) 0.408 
ICD 115 (4%) 61 (3%) 54 (4%) 0.181 
This table shows the clinical and demographic characteristics of the SHIFT placebo patients.  Values are given for the total 
placebo population, as well as separately for patients who had a baseline resting heart rate <80bpm, and patients who had 
a baseline resting heart rate ≥80bpm.  Data are the number of patients with the corresponding percentage, or the mean with 
the standard deviation, depending on whether the variable was categorical or continuous.  Not all patients had every 
baseline measurement available.  The values of each characteristic were compared between the two different baseline 
resting heart rate groups using unpaired two-sample t-tests and chi-squared tests, for continuous and categorical variables, 
respectively. 
One patient had an NYHA class that was “missing or Class I” and are not included in the table.  Note that the counts for 
Devices do not necessarily equal the total of CRT plus ICD since certain patients may have both and therefore are only 
counted once in Devices. 
ACE = Angiotensin-Converting Enzyme; AF = Atrial Fibrillation; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass 
Index; CRT = Cardiac Resynchronisation Therapy; DBP = Diastolic Blood Pressure; eGFR = estimated Glomerular Filtration 
Rate; ICD = Implantable Cardioverter Defibrillator; LVEF = Left Ventricular Ejection Fraction; MI = Myocardial Infarction; 
NYHA = New York Heart Association; SBP = Systolic Blood Pressure. 
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There were significant differences between the two groups of patients in terms of age, 
ethnic origin, whether or not they were a current smoker, LVEF, NYHA class, primary 
cause of HF, previous MI, hypertension, diabetes, and stroke, and intake of beta-
blockers, ACE inhibitors, ARBs, anti-aldosterone agents, and cardiac glycosides.  
Patients in the ≥80bpm baseline heart rate group were more likely to be younger, Asian 
or Black, and currently smoking.  They were also more likely to have a lower LVEF, be in 
NYHA class III or IV, and have HF caused primarily by a non-ischemic cause as opposed 
to an ischemic cause.  In terms of medical history, those in the higher heart rate group 
were less likely to have experienced an MI or hypertension in the past, but were more 
likely to have had a stroke, and have diabetes.  The use of ARBs, anti-aldosterone 
agents, and cardiac glycosides was also higher in the ≥80bpm group, while the use of 
beta-blockers and ACE inhibitors was lower.   
The total number of events that occurred in the placebo group is presented in Table 8-4 
along with the number that occurred in each of the baseline heart rate groups of 
patients.  The percentage of patients in the higher heart rate group who experienced an 
event was greater for all of the events, excluding hospital admission for non-fatal MI, 
for which it was smaller, compared to the patients with a baseline heart rate lower 
than 80bpm. 
As Bohm et al. 2010182 had previously explored the relationship between baseline resting 
heart rate and risk in the SHIFT placebo population, the Cox regression models adjusted 
for the same baseline variables that were adjusted for in their baseline rate analysis, to 
make the current results as comparable as possible to their previously published results: 
beta-blocker intake; NYHA class; LVEF; whether the primary cause of HF was ischemic 
or not; age; SBP; and eGFR.   
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Table 8-4: The number of first events that occurred in the SHIFT placebo population. 
  Subjects Separated by 
Baseline Heart Rate 
 Total 
Placebo 
Population 
n = 3261 
<80bpm 
n = 1940 
 ≥80bpm 
n = 1321 
Primary Endpoint    
Cardiovascular death or hospital admission for worsening 
heart failure 
936 (29%) 446 (23%) 490 (37%) 
Mortality Endpoints    
All-cause mortality 551 (17%) 251 (13%) 300 (23%) 
Cardiovascular mortality 491 (15%) 221 (11%) 270 (20%) 
Death from heart failure 151 (5%) 59 (3%) 92 (7%) 
Individual Hospital Admission Endpoints    
All-cause hospital admission 1354 (42%) 739 (38%) 615 (47%) 
Hospital admission for worsening heart failure 671 (21%) 323 (17%) 348 (26%) 
Any cardiovascular hospital admission 1120 (34%) 604 (31%) 516 (39%) 
Hospital admission for non-fatal myocardial infarction 86 (3%) 53 (3%) 33 (2%) 
Other Composite Endpoints    
Cardiovascular death or hospital admission for non-fatal 
myocardial infarction 
550 (17%) 257 (13%) 293 (22%) 
Cardiovascular death, or hospital admission for worsening 
heart failure, or hospital admission for non-fatal myocardial 
infarction 
977 (30%) 470 (24%) 507 (38%) 
This table shows the total number of SHIFT placebo patients with available baseline resting heart rate data who 
experienced any pre-specified events of interest, as well as the number in relation to baseline heart rate, partitioned at 
80bpm.  Data are number of patients who experienced the event as a first event, with the corresponding percentage.  Note 
that first event refers to the first event of each type: for example, a patient may have been admitted to hospital for a CV 
cause, and then subsequently been admitted to hospital for HF at a later date.  
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The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
Comparing the risk of each of the outcomes between patients with a baseline or time-
updated heart rate greater than or equal to 80bpm, or less than 80bpm, produced the 
HRs and CIs shown by Figure 8-5 and in Table A6-10 provided in Appendix 6.  A heart 
rate ≥80bpm was associated with a higher risk of all of the endpoints, except hospital 
admission for non-fatal MI, in all models fitted.  Using time-updated heart rate 
strengthened the association between heart rate and risk of each of these endpoints 
compared to using baseline heart rate.  No association between heart rate and risk of 
hospital admission for MI was observed using any of the models.  However, the 
association did appear to be strengthened by the addition of the time-updated heart 
rate measurements.  For example, the HR for MI associated with a baseline heart rate 
≥80bpm was 0.93 (95% CI 0.60 to 1.45, p =  0.750), while the HR associated with a time-
updated heart rate ≥80bpm adjusted for baseline was 1.25 (95% CI 0.78 to 2.02, p = 
0.354).   
Analysing continuous heart rate measurements produced the HRs and 95% CIs given in 
Figure 8-6 and in Table A6-11 provided in Appendix 6.  An elevated continuous heart 
rate was associated with higher risk of all of the endpoints, with the exception of 
hospital admission for non-fatal MI, in all models fitted. Again, time-updated heart rate 
strengthened the association between heart rate and risk of each of these endpoints 
compared to using baseline heart rate.  An elevated continuous baseline heart rate was 
not associated with a higher risk of hospital admission for non-fatal MI, however, a 
5bpm higher time-updated heart rate was associated with a 9% (p = 0.030) increase in 
risk.  The association remained significant after adjustment for baseline heart rate (p = 
0.010) and the previous heart rate measurement (p = 0.016).   
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Figure 8-5: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a heart rate ≥80bpm compared to a heart rate 
<80bpm in the SHIFT placebo population. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: beta-blocker intake; New York Heart Association (NYHA) class; left-ventricular 
ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; age; systolic blood pressure 
(SBP); and estimated Glomerular Filtration Rate (eGFR).   
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Figure 8-6: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the SHIFT placebo 
population. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: beta-blocker intake; New York Heart Association (NYHA) class; left-ventricular 
ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; age; systolic blood pressure 
(SBP); and estimated Glomerular Filtration Rate (eGFR).   
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Figure 8-7 and Table A6-12 provided in Appendix 6 show the adjusted HRs and 95% CIs 
estimated using the time-updated categorical heart rate patterns models.  Comparing 
the current heart rate measurement at each visit to the previous heart rate 
measurement, all patients who did not have a heart rate below 80bpm at both the 
current and previous visit (low-low) were found to be at a higher risk of all of the 
endpoints, excluding hospital admission for non-fatal MI, compared to those patients 
who did have a heart rate below 80bpm at both visits.  Patients whose heart rate 
increased from below 80bpm at the previous visit to ≥80bpm at the current visit (low-
high) were at an 83% higher risk (95% CI 2 to 225%, p = 0.041) of hospital admission for 
non-fatal MI, compared to those with a heart rate below 80bpm at both visits. 
The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A6-13 provided in Appendix 6 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the heart rate variables that categorised subjects according to whether they 
had a heart rate less than, or greater than or equal to 80bpm, for each outcome.  
Regardless of whether any resting heart rate category variables were included, the 
models had the greatest predictive ability for death from HF, with C-statistics ranging 
from 0.774 to 0.804.  The C-statistics of the models for the other outcomes ranged from 
0.601 to 0.713.  The addition of resting heart rate category improved discrimination for 
all of the outcomes except hospital admission for non-fatal MI, compared to the model 
excluding heart rate.  For all-cause death, death from HF, hospital admission for HF, CV 
hospital admission, and the combined endpoints of CV death or hospital admission for 
HF, and CV death or hospital admission for HF or non-fatal MI, the model including time-
updated resting heart rate category additionally adjusted for the previous heart rate 
category had the best discrimination.  For the other remaining outcomes – CV death, all-
cause hospital admission, and the composite of CV death or hospital admission for non-
fatal MI – both of the time-updated heart rate models adjusted for either baseline or 
the previous heart rate category had the same and the greatest predictive ability.    
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Figure 8-7: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for the time-updated categorical heart rate patterns 
‘high-low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the SHIFT placebo 
population. 
 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 80bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 80bpm, and so on.   
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: beta-blocker intake; New York Heart Association (NYHA) class; left-ventricular 
ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; age; systolic blood pressure 
(SBP); and estimated Glomerular Filtration Rate (eGFR).   
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The greatest improvement in discrimination was observed for hospital admission for HF, 
with the C-statistic increasing from 0.646 to 0.698.  Disregarding hospital admission or 
MI, even the smallest improvement in discrimination, which was observed for CV 
hospital admission, was relatively substantial, with the C-statistic increasing from 0.611 
to 0.639.  There was no improvement in discrimination for hospital admission for non-
fatal MI with the addition of any of the heart rate category variables.  The likelihood 
ratio test statistics and corresponding p-values for the addition of the heart rate 
category variables to the models are also presented in Table A6-13.  The addition of any 
of the heart rate category variables resulted in statistically significant improvements in 
the calibration of the models for all of the outcomes except hospital admission for non-
fatal MI, for which there were no improvements with the addition of any of the heart 
rate variables. 
Harrell’s C-statistics for the model excluding resting heart rate, and the models 
including the continuous heart rate variables, for each outcome, are shown in Table A6-
14 provided in Appendix 6, along with the likelihood ratio test statistics and 
corresponding p-values for the addition of the different continuous heart rate variables.  
The results were very similar to those observed for the heart rate categories according 
to whether subjects had a heart rate less than, or greater than or equal to 80bpm.  
However, while there was no improvement in discrimination or calibration for hospital 
admission for non-fatal MI with the addition of any of the heart rate category variables, 
the addition of continuous time-updated heart rate, with or without adjustment for 
baseline or the previous heart rate measurement, improved discrimination for MI 
(although the C-statistic only increased from 0.713 to 0.716).  Furthermore, the 
addition of continuous time-updated heart rate, with or without adjustment for 
baseline heart rate, but not previous heart rate measurements, significantly improved 
calibration.   
205 
 
Table A6-15 provided in Appendix 6 shows Harrell’s C-statistics for the model excluding 
resting heart rate, and the models including the time-updated categorical heart rate 
patterns variable for each outcome.  The addition of time-updated categorical heart 
rate pattern improved discrimination for all of the outcomes.  The largest improvement 
in discrimination was again observed for hospital admission for HF, with the C-statistic 
increasing from 0.646 to 0.698; the smallest improvement was observed for hospital 
admission for non-fatal MI, with the C-statistic increasing by only 0.011, from 0.713 to 
0.724.  The likelihood ratio test statistics and corresponding p-values for the addition of 
the heart rate patterns variable to the models are also presented in Table A6-15.  The 
addition of heart rate pattern resulted in statistically significant improvements in the 
calibration of the models for all of the outcomes except hospital admission for MI. 
Table A6-16, A6-17 and A6-18 in Appendix 6 show the p-values of the Grambsch and 
Therneau 1994 test for non-proportionality for all the models and outcomes.  Both a 
baseline heart rate ≥80bpm and an elevated continuous baseline heart rate showed 
evidence of non-proportionality of hazards over time for the combined endpoint CV 
death or hospital admission for HF, all-cause hospital admission, CV hospital admission, 
and the combined endpoint CV death, hospital admission for HF, or hospital admission 
for MI.  A baseline heart rate ≥80bpm also exhibited evidence of non-proportionality for 
hospital admission for HF.   
Examination of the plots of the smoothed curve and corresponding 95% CIs of the 
Schoenfeld residuals illustrated that the effect of a baseline heart rate ≥80bpm was 
highest at the beginning of follow-up, and then decreased over time.  The effect of an 
elevated continuous baseline heart rate followed a similar pattern.  Figure 8-8 shows 
the Schoenfeld residual plots for a baseline heart rate ≥80bpm, and provides an 
illustration of this finding.  No violations of the proportional hazard assumption for any 
of the other heart rate variables that were associated with risk of outcome were 
observed.    
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Figure 8-8: The Schoenfeld residuals plots for a baseline heart rate ≥80bpm for each of the 
outcomes where evidence of non-proportionality of the effect of heart rate over time was 
observed in the SHIFT placebo population. 
 
The horizontal dotted lines represent the previously calculated ‘average’ hazard ratio of each outcome.  AC = All-Cause; CV 
= Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
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8.4 A Pooled Analysis of the Predictive Value of Baseline 
and Time-Updated Heart Rate Measurements in 
Patients with Left-Ventricular Systolic Dysfunction 
and Stable Coronary Heart Disease, Chronic Heart 
Failure or Both 
A pooled analysis of individual trial placebo data from the BEAUTIFUL and SHIFT trials 
was carried out to permit a more detailed assessment of the relation of heart rate with 
outcome in subjects with LVSD.  This analysis included 8,699 patients.   
The following outcomes were able to be evaluated in the pooled analysis: all-cause 
mortality; CV mortality; hospital admission for HF; hospital admission for non-fatal MI; 
CV death or hospital admission for HF; CV death or hospital admission for non-fatal MI; 
and CV death or hospital admission for HF or non-fatal MI. 
Table 8-5 shows the characteristics and inclusion criteria of BEAUTIFUL and SHIFT.  Both 
trials were similar in terms of length of follow-up.  BEAUTIFUL was slightly larger than 
SHIFT in regards to the number of patients randomised, had a slightly older population, 
included more males and slightly fewer patients on beta-blockers.  Patients in both 
trials were required to have LV dysfunction, however BEAUTIFUL recruited subjects with 
CHD and an LVEF ≤40%, while SHIFT recruited those in HF with an LVEF ≤35% (although 
many of the BEAUTIFUL subjects also had HF).  The mean LVEF of the SHIFT patients 
was hence slightly lower than that of the BEAUTIFUL patients.  Patients in both trials 
had to be in sinus rhythm, however SHIFT patients had to have a baseline heart rate of 
at least 70bpm, while BEAUTIFUL patients could have a heart rate of 60bpm or greater.  
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Table 8-5: Principal characteristics, key inclusion criteria, and main features of the 
BEAUTIFUL and SHIFT populations. 
n = 8699 BEAUTIFUL 
n = 5438 
SHIFT 
n = 3216 
Trial 
Characteristics 
  
No. of patients 
randomised 
10917 (5479 iabradine, 5438 placebo) 6558 (3268 ivabradine, 3290 placebo 
before exclusions – 3264 after exclusions) 
Follow-up (months) 19 22.9 
Study treatments Ivabradine and placebo Ivabradine and placebo 
Patient 
Characteristics 
  
Mean age (years) 65.2 60 
Percentage of 
males 
83% 76.5% 
Mean LVEF 32.4% 29% 
Percentage 
receiving  
beta-blockers 
87% 89.5% 
Inclusion Criteria   
Primary diagnosis CHD and LVEF ≤40% Chronic HF and LVEF ≤35% 
Age ≥55 years 
 
≥18 years if diabetic 
≥18 years 
Main inclusion 
criteria 
CHD: previous MI; previous percutaneous 
or surgical coronary revascularisation; or 
angiographic evidence that ≥1 major 
coronary artery had narrowed by 50% or 
more 
LVEF ≤40%, end diastolic short-axis internal 
dimension of >56mm by echocardiography, 
in sinus rhythm with a resting heart rate 
≥60bpm 
Any angina or symptoms of HF should have 
received appropriate conventional 
cardiovascular medication at stable doses 
for at least 1 month 
 
Stable symptomatic chronic HF of 4 or 
more weeks’ duration, a previous 
admission to hospital for worsening HF 
within the previous 12 months, and an 
LVEF of ≤35%, in sinus rhythm with a 
resting heart rate ≥70bpm, on stable 
background treatment included a beta-
blocker if tolerated 
The number of the subjects given in the first row of the table are the number that had baseline heart rate measurements 
available who are included in the present analysis.  The follow-up duration is the median length of follow-up.  3,290 patients 
were randomly assigned to the placebo group in SHIFT, but data was only available for 3,264 since 26 patients were 
excluded because the study drug was not dispensed or because of invalid data caused by misconduct at study centres. 
CHD = Coronary Heart Disease; HF = Heart Failure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction.    
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Patients were categorised into the following six baseline heart rate groups: <65bpm, 65-
69bpm, 70-74bpm, 75-79bpm, 80-84bpm and ≥85bpm.  It was not appropriate to divide 
the pooled population of patients into two groups based on the median heart rate value 
of the population, as was done in the individual analyses of BEAUTIFUL and SHIFT 
presented in Sections 8.2 and 8.3, since the distribution of baseline heart rate in each 
trial population differed.  The patients in BEAUTIFUL were required to have a heart rate 
of at least 60bpm to be enrolled in the trial, whereas in SHIFT they were required to 
have a heart rate of at least 70bpm.  Thus, it was decided that the pooled population 
would be divided into multiple baseline heart rate groups, which also allows the 
observation of a finer relationship between heart rate and risk.  The baseline heart rate 
distribution of the pooled population was explored, and the six groups were decided 
upon as they resulted in a similar number of patients being assigned to each category. 
The baseline characteristics of the patients in each of the six baseline heart rate groups 
are shown by Table 8-6.  There were significant differences among the six groups of 
patients for all of the baseline characteristics excluding hypertension and intake of 
ARBs.  Patients in the highest heart rate group (≥85bpm) were younger, with a lower 
SBP, a higher DBP, and a lower LVEF.  They were more likely to smoke, and be in NYHA 
class III or IV, have diabetes, and be taking diuretics or anti-aldosterone agents.  They 
were less likely to be in NYHA class I or II, have had a previous MI, and be taking beta-
blockers or ACE inhibitors at randomisation. Note that these analyses also compared the 
values of each characteristic between BEAUTIFUL and SHIFT patients to some extent 
since Group 1 and Group 2 only contained BEAUTIFUL patients, and study was not 
adjusted for in the ANOVA or chi-square tests.   
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Table 8-6: Baseline characteristics of the pooled left-ventricular dysfunction placebo 
population by heart rate group. 
 Group 1 
<65bpm 
n = 1510 
Group 2 
65-69bpm 
n = 1238 
Group 3 
70-74bpm 
n = 2132 
Group 4 
75-79bpm 
n = 1436 
Group 5 
80-84bpm 
 n = 960 
Group 6 
≥85bpm 
n = 1423 
P-value 
Demographic 
Characteristics 
       
Age (years) 65.8  
(8.1) 
65.4  
(8.4) 
63.2  
(10.2) 
62.4  
(10.5) 
62.7  
(9.8) 
60.6  
(11.0) 
<0.001 
Sex (male) 1255  
(83%) 
1046  
(84%) 
1670  
(78%) 
1142  
(80%) 
777  
(81%) 
1123  
(79%) 
<0.001 
Smoking 
(current) 
181  
(12%) 
172  
(14%) 
312  
(15%) 
240  
(17%) 
186  
(19%) 
320  
(22%) 
<0.001 
BMI 28.3  
(4.1) 
28.4  
(4.3) 
28.3  
(4.7) 
28.0  
(4.8) 
28.3  
(4.6) 
28.5  
(5.4) 
<0.001 
Cardiac 
Parameters 
       
Heart rate 
(bpm) 
62.0  
(1.6) 
66.8  
(1.4) 
71.8  
(1.4) 
76.6  
(1.4) 
81.7  
(1.5) 
93.4  
(8.0) 
- 
SBP 127.1 
(15.5) 
127.3 
(14.9) 
124.8 
(15.7) 
124.7 
(16.0) 
125.9 
(16.2) 
123.5 
(16.9) 
<0.001 
DBP 76.5  
(9.2) 
76.9  
(9.2) 
76.4  
(9.2) 
76.7  
(9.2) 
77.3  
(9.3) 
77.3  
(9.9) 
<0.001 
LVEF (%) 32.8  
(5.3) 
32.6  
(5.4) 
30.8  
(5.3) 
30.4  
(5.8) 
30.4  
(5.4) 
29.4  
(5.8) 
<0.001 
NYHA Class       <0.001 
I 282  
(19%) 
185  
(15%) 
152  
(7%) 
88  
(6%) 
59  
(6%) 
75  
(5%) 
 
II 959  
(64%) 
787  
(52%) 
1221  
(57%) 
817  
(57%) 
504  
(53%) 
655  
(46%) 
 
III or IV 269  
(18%) 
266  
(18%) 
759  
(36%) 
531  
(37%) 
397  
(41%) 
693  
(49%) 
 
Medical 
History 
       
Previous MI 1345  
(89%) 
1125  
(91%) 
1542  
(72%) 
1020  
(71%) 
682  
(71%) 
939  
(66%) 
<0.001 
Hypertension 1063  
(70%) 
851  
(69%) 
1471  
(69%) 
981  
(68%) 
674  
(70%) 
949  
(67%) 
0.32 
Diabetes 449  
(30%) 
416  
(34%) 
710  
(33%) 
503  
(35%) 
359  
(37%) 
588  
(41%) 
<0.001 
Previous stroke 258  
(17%) 
210  
(17%) 
273  
(13%) 
167  
(12%) 
153  
(16%) 
203  
(14%) 
<0.001 
Treatment at 
Randomisation 
       
Beta-blocker 1371  
(91%) 
1097  
(89%) 
1926  
(90%) 
1288  
(90%) 
828  
(86%) 
1149  
(81%) 
<0.001 
ACE inhibitor 1215  
(80%) 
968  
(78%) 
1707  
(80%) 
1169  
(81%) 
732  
(76%) 
1083  
(76%) 
0.0010 
ARB 180  
(12%) 
145  
(12%) 
269  
(13%) 
170  
(12%) 
143  
(15%) 
205  
(14%) 
0.058 
Diuretics 825  
(55%) 
668  
(54%) 
1522  
(71%) 
1028  
(72%) 
727  
(76%) 
1117  
(78%) 
<0.001 
Anti-
aldosterone 
agents 
353  
(23%) 
314  
(25%) 
915  
(43%) 
633  
(44%) 
419  
(44%) 
771  
(54%) 
<0.001 
This table shows the clinical and demographic characteristics of the patients in each of the six baseline heart rate groups, 
including only patients who had their baseline resting heart rate measured.  Data are the number of patients with the 
corresponding percentage, or the mean with the standard deviation, depending on whether the variable was categorical or 
continuous, respectively.  The values of each characteristic were compared between the six baseline heart rate groups of 
patients using ANOVA and chi-square tests for continuous and categorical variables, respectively.  Note that these analyses 
also compared the values of each characteristic between BEAUTIFUL and SHIFT patients to some extent since Group 1 
and Group 2 only contained BEAUTIFUL patients, and study was not adjusted for in the tests.   
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One of the SHIFT placebo patients had an NYHA class that was “missing or Class I” and is not included in the table, while 
all of the others were NYHA Class II, III or IV; BEAUTIFUL did not include any subjects with NYHA Class IV. 
ACE = Angiotensin-Converting Enzyme; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass Index; DBP = Diastolic 
Blood Pressure; LVEF = Left Ventricular Ejection Fraction; MI = Myocardial Infarction; NYHA = New York Heart Association; 
SBP = Systolic Blood Pressure. 
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The number of events that occurred in each of the six baseline heart rate groups, as 
well as in the total pooled population, is presented by Table 8-7.  For all of the events 
with the exception of hospital admission for non-fatal MI, the percentage of patients in 
each group who experienced the event increased with increasing heart rate group.  
Accordingly, patients in the highest heart rate group experienced the highest 
percentage of each of the events, except hospital admission for non-fatal MI.  The 
percentage of patients who experienced a hospital admission for non-fatal MI event was 
similar across all six groups.   
Table 8-7: The number of first events that occurred in the pooled left-ventricular dysfunction 
placebo population and each of the baseline heart rate groups. 
  Subjects Separated by Baseline Heart Rate Group 
 Pooled 
Population 
 
n = 8699 
Group 1 
<65bpm 
 
n = 1510 
Group 2 
65-69bpm 
 
n = 1238 
Group 3 
70-74bpm 
 
n = 2132 
Group 4 
75-79bpm 
 
n = 1436 
Group 5 
80-84bpm 
 
 n = 960 
Group 6 
≥85bpm 
 
n = 1423 
Individual 
Endpoints 
       
All-cause death 1098 (13%) 120 (8%) 103 (8%) 240 (11%) 176 (12%) 155 (16%) 300 (21%) 
CV death 926 (11%) 85 (6%) 87 (7%) 206 (10%) 147 (10%) 134 (14%) 264 (19%) 
Hospital 
admission for 
HF 
1098 (13%) 78 (5%) 79 (6%) 236 (11%) 211 (15%) 149 (16%) 341 (24%) 
Hospital 
admission for 
non-fatal MI 
312 (6%) 56 (4%) 39 (3%) 75 (4%) 57 (4%) 37 (4%) 48 (3%) 
Combined 
Endpoints 
       
CV death or 
hospital 
admission for 
HF 
1659 (19%) 138 (9%) 144 (12%) 372 (17%) 285 (20%) 232 (24%) 479 (34%) 
CV death or 
hospital 
admission for 
non-fatal MI 
1143 (13%) 130 (9%) 114 (9%) 258 (12%) 184 (13%) 160 (17%) 294 (21%) 
CV death or 
hospital 
admission for 
HF or non-fatal 
MI 
1809 (21%) 170 (11%) 165 (13%) 404 (19%) 314 (22%) 252 (26%) 495 (35%) 
This table shows the total number of LV dysfunction placebo patients with available baseline resting heart rate data who 
experienced any pre-specified events of interest, as well as the number in relation to baseline heart rate group.  Data are 
number of patients who experienced each event as a first event, with the corresponding percentage.  Note that Group 1 and 
Group 2 only contained BEAUTIFUL patients.  Note that first event refers to the first event of each type: for example, a 
patient may have been admitted to hospital for a non-fatal MI, and then subsequently been admitted to hospital for HF at a 
later date. 
CV = Cardiovascular; HF = Heart Failure; LV = Left-Ventricular; MI = Myocardial Infarction.  
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The Cox models were adjusted for the variables which were significantly different 
between the heart rate groups at baseline (p<0.05): age; sex; smoking; BMI; SBP; DBP; 
LVEF; NYHA class; previous MI; diabetes; previous stroke; and intake of beta-blockers; 
ACE inhibitors; diuretics; and anti-aldosterone agents at randomisation.  Models were 
also adjusted for study.   
The linearity of effect for each continuous heart rate variable was evaluated by plotting 
the Martingale residuals (a linear transformation of Cox-Snell residuals)252,253 of each 
model against the heart rate values.  No violations of the linearity assumption were 
observed. 
For time-updated heart rate, where regression to the mean resulted in lower heart 
rates observed at follow-up, it was possible to split the lowest heart rate group 
(<65bpm) into two groups: <60bpm and 60 to 64bpm.  Comparing the risk of the 
outcomes between patients in each of the heart rate groups greater than or equal to 
60bpm (65bpm for baseline), to those in the <60bpm heart rate group (<65bpm for 
baseline), produced the HRs, 95% CIs and p-values shown by Figure 8-9 and Figure 8-10, 
and in Table A6-19 provided in Appendix 6.   
Patients in each of the baseline heart rate groups ≥70bpm were found to be at a higher 
risk of the composite of CV death or hospital admission for HF compared to those with a 
baseline heart rate <65bpm.  The risk of hospital admission for HF, and the rate of the 
combined endpoint of CV death or hospital admission for HF or non-fatal MI, was higher 
in subjects who had a baseline heart rate in the 75 to 79bpm group or above.  Patients 
in each of the baseline heart rate groups ≥80bpm were at a higher risk of all-cause 
mortality, CV mortality, and the combination of CV mortality or hospital admission for 
non-fatal MI.  Only patients with a baseline heart rate between 75 and 79bpm were 
found to be at a higher risk of hospital admission for non-fatal MI compared to those 
with a baseline heart rate <65bpm (HR 1.48, 95% CI 1.01 to 2.19, p = 0.047).   
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Patients with a time-updated heart rate ≥60bpm were found to be at a higher risk of 
hospital admission for HF, and those with a time-updated heart rate ≥65bpm were 
shown to be at a higher risk of the composites of CV death or hospital admission for HF, 
and CV death or hospital admission for HF or MI, compared to those with a time-updated 
heart rate <60bpm.  The associations with hospital admission for HF and CV death or 
hospital admission for HF remained the same after adjustment for baseline group, but 
only a time-updated heart rate group ≥70bpm was associated with an increase in the 
risk of CV death or hospital admission for HF or MI after adjustment for baseline group.  
When previous heart rate group was adjusted for, only a time-updated heart rate group 
≥70bpm was associated with an increase in risk of each of these three endpoints.   
A time-updated heart rate ≥70bpm, unadjusted or adjusted for baseline or the previous 
heart rate group, was associated with an increase in the risk of all-cause mortality, CV 
mortality, and CV mortality or hospital admission for non-fatal MI.   Finally, a time-
updated heart rate ≥75bpm was associated with an increased risk of hospital admission 
for non-fatal MI.  When the model was adjusted for baseline group only the 75 to 79bpm 
and ≥85bpm groups were associated with an increase in risk; when the model was 
adjusted for the previous time-updated group, only a heart rate ≥85bpm was associated 
with an increase in risk. 
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Figure 8-9: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the five baseline heart rate groups 
greater than or equal to 65bpm, relative to <65bpm, and each of the six time-updated heart 
rate groups greater than or equal to 60bpm, relative to <60bpm, in the pooled left-ventricular 
dysfunction placebo population. 
AC = 
All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; smoking; body mass index (BMI); systolic blood pressure (SBP); diastolic 
blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association (NYHA) class; previous 
myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-converting enzyme (ACE) 
inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study.  
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Figure 8-10: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for each of the six time-updated heart rate groups 
greater than or equal to 60bpm, relative to <60bpm, in the pooled left-ventricular 
dysfunction placebo population. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; smoking; body mass index (BMI); systolic blood pressure (SBP); diastolic 
blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association (NYHA) class; previous 
myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-converting enzyme (ACE) 
inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
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Analysing continuous heart rate measurements produced the HRs and 95% CIs shown by 
Figure 8-11 and in Table A6-20 provided in Appendix 6.   
Figure 8-11: Results of fitting Cox proportional hazards models.  Hazard ratios with 
corresponding 95% confidence intervals for a 5bpm higher heart rate in the pooled left-
ventricular dysfunction placebo population. 
 
AC = All-Cause; CV = Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; smoking; body mass index (BMI); systolic blood pressure (SBP); diastolic 
blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association (NYHA) class; previous 
myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-converting enzyme (ACE) 
inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
 
 
An elevated continuous heart rate was associated with a higher risk of all of the 
endpoints, with the exception of hospital admission for MI, in all models.  Time-updated 
heart rate strengthened the association between heart rate and risk of each of these 
endpoints compared to using baseline heart rate.  An elevated continuous baseline 
heart rate was not associated with a higher risk of hospital admission for MI, however, a 
5bpm higher time-updated heart rate was associated with a 12% (p<0.001) increase in 
risk.  The association remained significant after adjustment for baseline heart rate 
(p<0.001) and the previous heart rate measurements (p<0.001).   
The discrimination and calibration of the models were evaluated using Harrell’s C-
statistic and likelihood ratio tests, respectively.  Table A6-21 provided in Appendix 6 
shows Harrell’s C-statistics for the model excluding resting heart rate, and the model 
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including the heart rate groups variable, for each outcome.  Regardless of whether 
resting heart rate group was included, the models had the greatest predictive ability for 
hospital admission for HF, and the combined endpoint of CV mortality or hospital 
admission for HF: the C-statistics of the models both excluding and including heart rate 
ranged from 0.739 to 0.777, and 0.708 to 0.740 for each of these outcomes, 
respectively.  The C-statistics of the models for the other outcomes ranged from 0.661 
to 0.723.  The addition of resting heart rate group improved discrimination for all of the 
outcomes compared to the model excluding heart rate.  The models including time-
updated heart rate group adjusted for the previous heart rate group had the best 
discrimination for all of the outcomes (although the time-updated heart rate model 
adjusted for baseline group had the same discrimination for hospital admission for MI).  
The greatest improvement in discrimination was observed for hospital admission for HF, 
with the C-statistic increasing from 0.739 to 0.777, and the smallest was observed for 
hospital admission for MI, with the C-statistic increasing from 0.661 to 0.675.  The 
likelihood ratio test statistics and corresponding p-values for the addition of the heart 
rate group variables to the models are also presented in Table A6-21.  The addition of 
any of the heart rate group variables resulted in statistically significant improvements in 
the calibration of the models for all of the outcomes except hospital admission for MI: 
only the addition of the time-updated heart rate group variable, with or without 
adjustment for baseline or the previous heart rate group, improved the calibration of 
the models for MI.   
Harrell’s C-statistics for the model excluding resting heart rate, and the model including 
the continuous heart rate variables for each outcome are shown in Table A6-22 provided 
in Appendix 6, along with the likelihood ratio test statistics and corresponding p-values 
for the addition of the continuous heart rate variables to the models.  The results were 
very similar to those observed for the resting heart rate groups. 
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Table A6-23 and A6-24 show the p-values of the Grambsch and Therneau 1994 test for 
non-proportionality for all the models and outcomes.  Evidence of non-proportionality of 
the effect of heart rate over time was observed using a number of the different models 
for hospital admission for HF, and the combined endpoints of CV death or hospital 
admission for HF, and CV death or hospital admission for HF or MI.  Examination of the 
plots of the smoothed curve and corresponding 95% CIs of the Schoenfeld residuals for 
each model and outcome showed that the effect of elevated heart rate was highest at 
the beginning of follow-up, and then decreased over time.  Figure 8-12 shows the 
Schoenfeld residual plots for a 5bpm higher baseline heart rate, and provides an 
illustration of this finding.     
Figure 8-12: The Schoenfeld residuals plots for a 5bpm higher baseline heart rate for each 
of the outcomes where evidence of non-proportionality of the effect of heart rate over time 
was observed in the pooled left-ventricular dysfunction placebo population. 
 
The horizontal dotted lines represent the previously calculated ‘average’ hazard ratio of each outcome.  CV = 
Cardiovascular; HF = Heart Failure; MI = Myocardial Infarction. 
 
Table A6-25 provided in Appendix 6 displays the p-values for the likelihood ratio tests 
for the interaction of heart rate with study using the heart rate group variables, and the 
continuous heart rate variables, for each outcome.  There were no significant 
interactions observed between any of the heart rate variables and study for any of the 
outcomes, indicating that the results did not significantly differ between the two 
populations of patients. 
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8.5 Discussion 
In the placebo population of patients with CHD and LVSD from BEAUTIFUL, an elevated 
resting heart rate was associated with an increase in risk of all of the endpoints 
evaluated.  The addition of any of the resting heart rate variables improved 
discrimination for all of the outcomes compared to the model excluding heart rate.  In 
general, the time-updated heart rate models, unadjusted or adjusted for baseline or 
the previous heart rate measurement, yielded the highest and similar C-statistics, and 
thus had the best discriminative ability. 
Both an elevated baseline and time-updated resting heart rate, analysed categorically 
or continuously, were associated with an increase in the risk of all-cause death, CV 
death, cardiac death, admission to hospital for HF, admission to hospital for MI or 
unstable angina, revascularisation, and the combined endpoints of CV death or 
admission to hospital for HF, and CV death or admission to hospital for MI or HF. The 
addition of any of the resting heart rate variables resulted in statistically significant 
improvements in the calibration of the models for all of these outcomes excluding 
revascularisation.  For revascularisation, each of the models including a categorical 
heart rate variable had a better calibration than that of the model excluding heart rate, 
except that which included time-updated heart rate category along with the previous 
time-updated heart rate category; the addition of any of the continuous heart rate 
variables improved the calibration of the model.  Time-updated heart rate strengthened 
the associations for each of these outcomes, and remained a significant predictor for 
each, after adjustment for baseline heart rate or the previous heart rate measurement 
(with the exception of a time-updated heart rate ≥70bpm for coronary 
revascularisation, and admission to hospital for MI or unstable angina, which were 
attenuated after adjustment for either of the other heart rate variables). 
Patients with a baseline or time-updated heart rate ≥70bpm were additionally found to 
be at a higher risk of admission to hospital for MI.  Similarly, time-updated heart rate 
221 
 
strengthened the association, and remained a significant predictor after adjustment for 
baseline or the previous heart rate group.  As was previously found in the BEAUTIUFL 
baseline heart rate analysis184, an elevated continuous baseline heart rate was only 
borderline significantly associated with a higher risk of admission to hospital for MI.  
However, an elevated time-updated heart rate, unadjusted or adjusted for the baseline 
or previous heart rate measurement, was strongly associated with an elevation in risk.  
A 5bpm higher time-updated heart rate after adjustment for baseline, for example, was 
associated with a 15% (p<0.001) increase in risk.  In accordance with these results, the 
addition of any of the heart rate category variables resulted in statistically significant 
improvements in the calibration of the models for MI, while only the continuous time-
updated heart rate variable, with or without adjustment for baseline or the previous 
heart rate measurement, improved the calibration. 
In the placebo population of patients with chronic HF and LVSD from SHIFT, an elevated 
resting heart rate was associated with an increase in risk of all the endpoints evaluated.   
Both elevated baseline and time-updated resting heart rates, analysed categorically or 
continuously, were associated with an increase in the risk of all of the endpoints, 
excluding hospital admission for non-fatal MI.  Time-updated heart rate strengthened 
the associations, and remained a significant predictor for each of these outcomes after 
adjustment for baseline heart rate or the previous heart rate measurement.  The 
addition of any of the resting heart rate variables improved both discrimination and 
calibration compared to the model excluding heart rate.  In the main, the time-updated 
heart rate models adjusted for baseline or the previous heart rate measurement, 
yielded the highest and similar C-statistics, and thus had the best discriminative ability. 
No significant associations were observed between a baseline or time-updated heart 
rate ≥80bpm, unadjusted or adjusted for the baseline or previous heart rate group, and 
risk of hospital admission for non-fatal MI.  Similarly, there was no improvement in 
discrimination or calibration for hospital admission for non-fatal MI with the addition of 
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any of the heart rate category variables.  No association between an elevated 
continuous baseline heart rate and risk was observed either.  In contrast, a higher 
continuous time-updated heart rate, unadjusted or adjusted for the baseline or previous 
heart rate measurement, was associated with an increase in risk.  For example, a 5bpm 
higher time-updated heart rate adjusted for baseline was associated with a 12% (p = 
0.010) increase in risk of hospital admission for non-fatal MI.  The addition of continuous 
time-updated heart rate, with or without adjustment for baseline or the previous heart 
rate measurement, also improved discrimination for MI (but only by a maximum of 
0.003).  Furthermore, the addition of continuous time-updated heart rate, with or 
without adjustment for baseline heart rate, but not previous heart rate measurements, 
significantly improved calibration. 
Similarly, in the pooled population of placebo patients with LVSD and CHD or chronic 
HF, an elevated resting heart rate was associated with an increase in the risk of all of 
the endpoints evaluated.  The addition of any of the resting heart rate variables 
improved discrimination for all of the outcomes compared to the model excluding heart 
rate.  On the whole, the time-updated heart rate models adjusted for baseline or the 
previous heart rate measurement, yielded the highest and similar C-statistics, and thus 
had the best discriminative ability.  No significant differences between BEAUTIFUL and 
SHIFT, in relation to the effect of heart rate, were observed.  Note that a version of 
these results was published in Hamill et al. 2015277.   
Both elevated baseline and time-updated resting heart rates, analysed categorically or 
continuously, were associated with an increase in the risk of all the endpoints evaluated 
with the exception of admission to hospital for non-fatal MI.  The addition of any of the 
heart rate variables resulted in statistically significant improvements in the calibration 
of the models for these outcomes.  Again, time-updated heart rate strengthened the 
associations for each of the outcomes, and remained a significant predictor for each 
after adjustment for baseline heart rate or the previous heart rate measurement.  No 
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association between a higher continuous baseline heart rate and risk of hospital 
admission for MI was observed.  However, an elevated time-updated heart rate, 
unadjusted or adjusted for baseline or the previous heart rate measurement, was 
associated with an increase in risk.  A 5bpm higher time-updated heart rate after 
adjustment for baseline, for example, was associated with a 14% (p<0.001) increase in 
risk.  Consistent with these results, only the addition of the time-updated heart rate 
variables, with or without adjustment for baseline or the previous heart rate 
measurement, improved the calibration of the models for MI. 
Evidence of non-proportionality of the effect of an elevated heart rate was found for 
the individual outcome of hospital admission for HF, and the combined outcomes of CV 
death or admission to hospital for HF, and CV death or admission to hospital for HF or MI 
in each study.  Non-proportionality was also observed for admission to hospital for all 
causes, and CV causes, in SHIFT.  The effect of an elevated heart rate appeared to be 
highest at the beginning of follow-up, and then decreased over time.  Fox et al. 2008 
similarly found evidence of non-proportionality for admission to hospital for HF in the 
BEAUTIFUL baseline heart rate analysis184.  A baseline heart rate ≥70bpm was associated 
with an 86% (95% CI 40 to 147%, p<0.001) and a 44% (95% CI 2 to 103%, p = 0.036) 
increase in risk in the first and second nine months of follow-up, respectively.  After 18 
months of follow-up, no association between elevated heart rate and risk of hospital 
admission for HF was observed.   
The BEAUTIFUL results for all-cause death are similar to those found in the prior 
analysis of resting heart rate among the EUROPA population of CHD subjects with no HF 
presented in Chapter 5, as well as those previously found by Diaz et al. 2005148, Ho et 
al. 2010149 (in which a small percentage of the patients had HF, some of whom may have 
had LVSD), and Anselmino et al. 2010 (in the subgroup of CHD patients with diabetes)150.  
The results for CV death and hospital admission for HF are also similar to those found by 
Diaz et al. 2005148 and the EUROPA analysis.   
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In the current analysis, in accordance with Fox et al. 2008184, elevated baseline and 
time-updated resting heart rates were associated with an increase in the risk of 
revascularisation.  For example, a 5bpm higher time-updated heart rate was associated 
with a 13% (p<0.001) increase in risk.  However, as was previously discussed in Chapters 
5 and 6, elevated heart rate was associated with a decrease in the risk of 
revascularisation in the EUROPA and PROSPER populations (PROSPER included older 
individuals with, or at an increased risk of, vascular disease, some of whom had CHD).  
In the discussions of Chapters 5 and 6 (Sections 5.3 and 6.3), it was suggested that this 
may have been because revascularisation was a marker for different conditions in these 
studies, since the BEAUTIFUL trial began in 2004, around seven years after the EUROPA 
and PROSPER trials: revascularisation was mainly used to treat angina before 2000, but 
was later used more frequently to treat MI276.  However, further investigation is 
necessary to truly understand these contrasting results. 
Fox et al. 2008184 showed previously that patients with a baseline resting heart rate 
≥70bpm were at a 46% (p = 0.0066) higher risk of admission to hospital for MI, and the 
current analysis found that patients with a time-updated heart rate ≥70bpm were at a 
48% (p = 0.0084) higher risk.  In addition, a 5bpm higher time-updated heart rate 
adjusted for baseline heart rate was associated with a 15% (p<0.001) increase in risk.  
Moreover, a 5bpm higher time-updated heart rate adjusted for baseline heart rate was 
associated with a 10% (p<0.001) increase in risk of hospital admission for MI or unstable 
angina, although hospital admission for unstable angina alone was not evaluated.  
Neither the EUROPA analysis presented in Chapter 5, or the previous studies by Diaz et 
al. 2005148 and Ho et al. 2010149, observed any associations between resting heart rate 
and the risk of MI, or unstable angina  This suggests that there could be differences in 
the association between resting heart rate and risk of MI or unstable angina in CHD 
patients without HF or a reduced EF, and CHD patients with HF or reduced EF, although 
a small percentage of patients included in the Ho et al. 2010149 analysis had HF, and 
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some may have had LVSD.  Further studies would therefore be required to substantiate 
this possibility. 
None of the studies of CHD patients identified in Chapter 2, or the prior EUROPA 
analysis, evaluated the relationship between resting heart rate and risk of cardiac 
death.  The present analysis demonstrated that patients with a time-updated heart rate 
≥70bpm adjusted for baseline were at a great 225% (p<0.001) higher risk of cardiac 
death compared to those with a time-updated heart rate <70bpm.  Furthermore, a 
5bpm higher time-updated heart rate adjusted for baseline was associated with a 27% 
(p<0.001) increase in risk of cardiac death.  These were the most substantial increases 
in risk observed in the present study.  Further analyses of the risk of cardiac death in 
patients without LVSD would be interesting.   
The patients enrolled in SHIFT had LVSD and were in sinus rhythm.  Only two of the 
studies identified in the systematic review in Chapter 2 presented results regarding the 
association between baseline resting heart rate and risk of adverse CV outcomes in 
patients with chronic HF and LVSD who were in sinus rhythm174,176.  Maeder and Kaye 
2012 illustrated that such patients with a baseline heart rate >87bpm were at a 16% 
(95% CI 2 to 31%) and 31% (95% CI 15 to 50%) higher risk of all-cause death and hospital 
admission for HF, respectively174.  In the current analysis, patients with a resting heart 
rate ≥80bpm were found to be at a much higher risk of these outcomes.  For example, 
patients with a baseline heart rate ≥80bpm were shown to be at a 78% (p<0.001) and 
68% (p<0.001) higher risk of all-cause death, and hospital admission for HF, 
respectively, and those with a time-updated heart rate ≥80bpm, adjusted for baseline 
heart rate, were shown to be at an even greater 73% (p<0.001) and 120% (p<0.001) 
higher risk.  Takada et al. 2014 showed that patients with a baseline resting heart rate 
in the highest third of the distribution were at a similar 80% (95% CI 17 to 178%) higher 
risk of all-cause death.  However, no associations between baseline resting heart rate 
and the risk of CV death, HF death, or hospital admission for HF were observed176.  In 
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contrast, the current analysis established that patients with a baseline resting heart 
rate ≥80bpm were at an 81% (p<0.001) and 112% (p<0.001) higher risk of CV death and 
HF death, respectively.     
In a population of chronic HF patients with reduced or preserved EF, in sinus rhythm or 
AF, Vazir et al. 2014 recently determined that a 5bpm higher time-updated resting 
heart rate, adjusted for baseline heart rate, was associated with a 9% (p<0.001) 
increase in the risk of all-cause death, and CV death, and a 6% increase in the risk of 
hospital admission for HF, MI, and the composite of CV death or hospital admission for 
HF (p<0.001 for hospital admission for HF and the combined endpoint; p = 0.014 for 
MI)215.  The present study confirmed these results in chronic HF patients with LVSD in 
sinus rhythm, but found somewhat higher increases in risk: a 5bpm higher time-updated 
heart rate, adjusted for baseline, was associated with a 16% (p<0.001) increase in the 
risk of all-cause death and CV death, a 22% (p<0.001) increase in the risk of hospital 
admission for HF, a 12% (p = 0.010) increase in the risk of MI, and a 19% (p<0.001) 
increase in the risk of the composite of CV death or hospital admission for HF.   
8.5.1 Chapter Summary and Conclusions 
This chapter investigated the prognostic value of baseline and time-updated resting 
heart rate in the BEAUTIFUL and SHIFT placebo populations.  Both trials enrolled 
patients with LVSD who were in sinus rhythm: the BEAUTIFUL subjects had CHD, and the 
SHIFT subjects had chronic HF, although some of the BEAUTIFUL subjects also had HF.  
Analysis of each individual trial was performed, and since both studies included patients 
with LVSD in sinus rhythm, a pooled individual patient meta-analysis of the two placebo 
populations was additionally executed. 
Across all analyses, both baseline and time-updated resting heart rate, regardless of 
whether the baseline or previous heart rate measurements were adjusted for, were 
demonstrated to be directly associated with a higher risk of death and all of the other 
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adverse CV outcomes examined, excluding hospital admission for MI.  The associations 
were weaker for hospital admission for MI: for example, in each of the three analyses, 
no association between an elevated continuous baseline heart rate and risk was 
observed, while a higher continuous time-updated heart rate was associated with an 
increase in risk. 
The final and following analysis chapter, Chapter 9, presents meta-analyses of the risk 
of death from any cause and death from CV causes associated with baseline and time-
updated resting heart rate in a variety of populations, including the published 
prospective evidence identified in the systematic review of Chapter 2, as well as the 
results from this chapter and Chapters 4 to 7. 
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Chapter 9 
 
Meta-Analyses of the Associations between 
Resting Heart Rate and All-Cause and 
Cardiovascular Mortality 
9.1 Introduction 
Chapter 2 presented a systematic review of studies that focused on the prognostic value 
of resting heart rate for mortality and adverse CV outcomes.  Studies that used a single 
heart rate measurement to predict risk were distinguished from those that used 
multiple heart rate measurements.  The majority of the studies included in the review 
showed that an elevated resting heart rate measured at a single point in time is 
associated with an increase in the risk of death and adverse CV outcomes in the general 
population, as well as in patients with certain pre-existing diseases or conditions.  The 
studies by Ho et al. 2014204 and Vazir et al. 2014215 showed that time-updated heart rate 
was able to predict events where a single heart rate measurement was not.  Time-
updated heart rate may be more relevant to clinical practice, since heart rate varies 
over time, and so risk may be more closely related to newly measured levels.   
Each of the studies identified in the review included individuals from specific 
populations.  The aim of this analysis was to assess the overall association between an 
elevated resting heart rate and the risk of all-cause and CV death across different 
patient populations.  Following on from the systematic review of Chapter 2, a meta-
analysis of the published prospective evidence on the association between baseline 
resting heart rate and risk of these endpoints was carried out and is presented in 
Section 9.2.  A similar meta-analysis of time-updated resting heart rate was performed 
and is presented in Section 9.3.  The results from Chapters 4 to 8 were also included in 
the analyses.  The PRISMA guidelines94,95 were followed as extensively as possible; the 
PRISMA 2009 checklist is given in Table A7-1 provided in Appendix 7.    
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9.2 A Meta-Analysis of 28 Studies that Analysed Baseline 
Resting Heart Rate as a Prognostic Risk Marker for 
All-Cause and Cardiovascular Mortality 
9.2.1 Study Selection and Data Extraction 
The 118 studies that were reviewed in Chapter 2 were considered for inclusion in this 
meta-analysis.  Each publication was read in full to assess its eligibility.  Studies were 
accepted for inclusion if they presented a HR from a Cox model for all-cause and/or CV 
death for a change in continuous baseline heart rate, with a corresponding 95% CI.  Only 
studies published from 1990 onwards were included.  The study population had to 
include both men and women.  Studies were excluded if the study population consisted 
of only men or women, or if HRs were presented separately for men and for women.  
Studies were also excluded if they presented results only for specific subgroups of 
individuals, such as individuals who smoked and individuals who did not.  Short-term 
mortality events such as in-hospital death were not of interest, and studies which 
presented results only for such endpoints were not included.   
The HRs and 95% CIs for all-cause and/or CV death associated with a change in 
continuous baseline heart rate were obtained.  Generally, the result found using the 
most adjusted model was selected.  The following data were also extracted from each 
publication where possible: the first author’s last name; the year of publication; the 
mean or median length of follow-up; the covariates additionally adjusted for in the 
model; the number of first all-cause and/or CV death events; the number of subjects 
included in the study; and the method of heart rate measurement. 
9.2.2 Results 
As shown by Figure 9-1, 61 of the 118 publications described in Chapter 2 were 
identified as containing results associated with a continuous measurement of baseline 
resting heart rate.  A total of 52 of these publications were described in the Baseline 
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Heart Rate Studies section of Chapter 2 (Section 2.3.1), and the remaining nine were 
described in the Multiple Heart Rate Measurement Studies section (Section 2.3.2).   
Figure 9-1: Flow chart of the selection process of the studies included in the meta-analysis 
of baseline resting heart rate. 
 
 
 
Thirty-nine of these studies were excluded for the reasons outlined in Figure 9-1.  Thus, 
22 publications were eligible for inclusion in the meta-analysis, each of which were 
prospective in design.  Table A7-2 provided in Appendix 7 gives the details of these 
studies, including their quality, as appraised using the Newcastle-Ottawa scale96 (see 
Tables A1-3 and A1-15 for breakdown), along with HRs and 95% CIs for a 5bpm higher 
baseline heart rate for all-cause and/or CV death, the number of corresponding first 
events, and the other covariates adjusted for in the models.  Note that the publication 
by Fosbol et al. 2010183 is included twice in Table A7-2 since it was an analysis of two 
patient populations (DIAMOND-MI and DIAMOND-HF), and presented distinct results for 
each population.  Study quality was high, ranging from 7 to 8 stars. 
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The HRs and 95% CIs calculated for a 5bpm higher baseline heart rate presented in 
Chapters 4, 5, 6, 7 and Chapter 8 Sections 8.2 and 8.3 of this thesis were also eligible 
for inclusion in the meta-analysis.  The pooled analysis in Chapter 4 did not calculate 
results for all-cause and CV death for EPHESUS, OPTIMAAL or VALIANT individually.  
Thus, HRs and 95% CIs for a 5bpm higher heart rate for all-cause and CV death were 
calculated for each of these populations and included in the analysis.  The results for 
all-cause and CV death for these three populations and the six other populations are 
summarised in Table A7-3.   
The previously published PROSPER138, PERFORM191, and BEAUTIFUL184 studies of baseline 
resting heart rate were subsequently excluded from the analysis as they were replicated 
in the thesis.  The results presented for PROSPER, PERFORM and BEAUTIFUL are 
therefore those previously calculated in Chapters 6, 7 and 8, as opposed to those 
presented in the original baseline heart rate publications138,191,184 (note that there were 
some slight differences between these results).   
Thus, a total of 28 studies were included in this meta-analysis: 17 of which presented 
results for both all-cause and CV mortality, and 11 of which presented results for all-
cause mortality only (with Fosbol et al. 2010183 providing two separate results for all-
cause mortality).   
9.2.2.1 All-Cause Death  
A 5bpm higher baseline resting heart rate was associated with a 7.9% increase in the risk 
of all-cause death (number of studies = 29, HR = 1.079, 95% CI = 1.068 to 1.091, 
p<0.001), as shown by Figure 9-2.  There was a substantial degree of true between-
study heterogeneity (I2 = 70%), which was statistically significant (Q = 99.64, p<0.001).  
Note that these results were obtained using the 1-year results from Antoni et al. 2012169 
and Seronde et al. 2013171.  When the 4-year and 5-year results from Antoni169 and 
Seronde171, respectively, were used, the pooled risk of all-cause death associated with a 
5bpm higher resting heart rate (and the associated 95% CI) remained the same, but the 
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degree of true between-study heterogeneity was larger (I2 = 75%), as was the Q-statistic 
(Q = 101.10, p<0.001).   
The results from Jensen et al. 2013170, Antoni et al. 2012169, Parodi et al. 2010159 and 
Palatini et al. 2002147 were visually identified as outliers.  Each of these studies included 
only a small number of deaths (Jensen et al. 2013 did not state the number of deaths 
that occurred170) and reported a substantially higher increase in risk of death compared 
to the other studies.  Excluding these studies reduced the degree of heterogeneity (I2 = 
54%), although it remained significant (Q = 49.50, p = 0.002).  Among the remaining 
studies, a 5bpm higher baseline heart rate was associated with a similar 7.2% (95% CI 
6.3 to 8.1%, p<0.001) increase in the risk of all-cause death.   
To explore the heterogeneity further, summary HRs were calculated for each population 
of patients that included two or more studies.  The results are shown by Figure 9-3.  As 
can be seen, the populations that contained the most between-study heterogeneity 
were the post-MI or ACS patients, the patients with CHD and LVSD, HF or both, the 
individuals drawn from the general population, and the individuals with hypertension.  A 
5bpm higher baseline heart rate was associated with around a 6 to 9% increase in the 
risk of all-cause death in the majority of the subgroups.  In the post-MI or ACS and 
hypertensive subgroups of patients, a 5bpm higher baseline heart rate was associated 
with a 16.9% (95% CI 6.3 to 27.6%) and an 11.8% (95% CI 3.6 to 20.0%) increase in the 
risk of all-cause death, respectively.  Excluding Jensen et al. 2013170, Antoni et al. 
2012169 and Parodi et al. 2010159 from the post-MI or ACS subgroup (the studies within 
this subgroup that there visually identified as outliers) a 5bpm higher baseline heart 
rate was associated with a 6.7% (95% CI 4.0 to 9.3%).  Excluding Palatini et al. 2002147 
from the hypertensive subgroup (the other study visually identified as an outlier) left 
only the study by Julius et al. 2012, which reported that a 5bpm higher baseline heart 
rate was associated with a 9.0% (95% CI 7.0 to 10.0%) higher risk of all-cause death212. 
233 
 
9.2.2.2 Cardiovascular Death 
A 5bpm higher baseline resting heart rate was also associated with an 8.0% increase in 
the risk of CV death (number of studies = 17, HR = 1.080, 95% CI = 1.065 to 1.095, 
p<0.001), as shown by Figure 9-4.  There was a substantial degree of true between-
study heterogeneity (I2 = 63%) which was statistically significant (Q = 44.04, p<0.001).  
Note that these results were obtained using the 1-year results from Antoni et al. 
2012169.  When the 4-year result was used, the pooled risk of CV death and the 
associated 95% CI was the same; the between-study heterogeneity was slightly larger (I2 
= 64%) as was the Q-statistic (44.22, p<0.001).   
Excluding the result from Antoni et al. 2012, which was the only apparent outlier, did 
not alter the degree of heterogeneity (I2 = 63%).  Among the remaining studies, a 5bpm 
higher baseline heart rate was associated with a similar 7.8% increase in risk, and the 
width of the 95% CI was slightly reduced (95% CI 6.4 to 9.3%). 
The summary HRs for each population of patients that included two or more studies are 
shown by Figure 9-5, and were similar across all populations.  The populations of 
patients that contained the most between-study heterogeneity were those with CHD 
and LVSD, HF or both, and those who had previously experienced an MI who had LVSD, 
HF or both.    
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Figure 9-2: Forest plot representing the individual and pooled risk of all-cause death 
associated with a 5bpm higher baseline resting heart rate.   
 
Note that the results for Antoni et al. 2012169 and Seronde et al. 2013171 are the ones for 1-year all-cause mortality, as 
opposed to 4- and 5-year mortality, respectively. 
ACS = Acute Coronary Syndrome; CHD = Coronary Heart Disease; CI = Confidence Interval; HF = Heart Failure; HR = 
Hazard Ratio; LVSD = Left-Ventricular Systolic Dysfunction; MI = Myocardial Infarction.  
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Figure 9-3: Forest plot representing the individual and pooled risk of all-cause death 
associated with a 5bpm higher baseline resting heart rate, overall and by patient population. 
 
Note that the results for Antoni et al. 2012169 and Seronde et al. 2013171 are the ones for 1-year all-cause mortality, as 
opposed to 4- and 5-year mortality, respectively. 
ACS = Acute Coronary Syndrome; CHD = Coronary Heart Disease; CI = Confidence Interval; HF = Heart Failure; HR = 
Hazard Ratio; LVSD = Left-Ventricular Systolic Dysfunction; MI = Myocardial Infarction.   
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Figure 9-4: Forest plot representing the individual and pooled risk of cardiovascular death 
associated with a 5bpm higher baseline resting heart rate.   
 
Note that the result for Antoni et al. 2012169 is the one for 1-year cardiovascular mortality. 
ACS = Acute Coronary Syndrome; CHD = Coronary Heart Disease; CI = Confidence Interval; HF = Heart Failure; HR = 
Hazard Ratio; LVSD = Left-Ventricular Systolic Dysfunction; MI = Myocardial Infarction. 
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Figure 9-5: Forest plot representing the individual and pooled risk of cardiovascular death 
associated with a 5bpm higher baseline resting heart rate, overall and by patient population. 
 
Note that the result for Antoni et al. 2012169 is the one for 1-year cardiovascular mortality. 
ACS = Acute Coronary Syndrome; CHD = Coronary Heart Disease; CI = Confidence Interval; HF = Heart Failure; HR = 
Hazard Ratio; LVSD = Left-Ventricular Systolic Dysfunction; MI = Myocardial Infarction. 
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9.2.2.3 Publication Bias 
There was evidence of publication bias for all-cause death and CV death, including only 
the studies and corresponding results in Table A7-2, since the results in Table A7-3 have 
not been published (using the 1-year post-MI population results of Antoni169 and 
Seronde171) (p<0.001 for all-cause death and p = 0.017 for CV death).  Including only the 
published results, the pooled risks of all-cause and CV death associated with a 5bpm 
higher resting heart rate were 1.091 (95% CI 1.067 to 1.114, p<0.001) and 1.080 (95% CI 
1.060 to 1.101, p<0.001), respectively.   The funnel plots are shown by Figure 9-6.   
Figure 9-6: Funnel plots showing the degree of publication bias for all-cause death and 
cardiovascular death, assessed from the results in Table A7-2. 
 
The white triangular areas of the funnel plots indicate where 95% of studies would be 
expected to lie assuming that the heterogeneity within the analysis fit the assumptions 
of the random-effects model, and that no publication bias was present278.  Studies that 
lie outside of this area can be thought of as statistical outliers275.  The vertical line of 
symmetry in each triangle corresponds to the pooled risk of all-cause and CV death 
associated with a 5bpm higher baseline heart rate, including only the published results 
(1.091 and 1.080 for all-cause and CV death, respectively, as stated in the previous 
paragraph).  In theory, this line would correspond to the true risk associated with a 
5bpm higher heart rate, and studies would be symmetrically scattered around it.  
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Smaller studies represented by those with larger standard errors would be spread out at 
the bottom, and larger, more powerful studies would be gathered more tightly at the 
top as their standard errors decreased279.  In practice, the true size of the association is 
unknown, and often only published studies are represented.  If publication bias is 
present, parts of the funnel plot will be bare.  The dashed vertical line at a hazard ratio 
of one corresponds to their being no association between baseline resting heart rate and 
risk.   
As can be seen from Figure 9-6, the majority of the studies included in the analyses 
were large, with small standard errors: most of the studies are grouped quite tightly 
around the top of each triangle - more so for all-cause death.  The bottom of each 
triangle is quite bare, suggesting that smaller studies with larger standard errors are 
lacking or missing.  All of the studies lie on the right of the dashed vertical line, 
indicating that they each reported a positive association between baseline resting heart 
rate and risk of all-cause or CV death, even if it was not statistically significant (as was 
the case with the study by Ortiz et al. 2010151 in relation to all-cause death, and Palatini 
et al. 2002147 and Legeai et al. 2011206 in relation to CV death).   
Regarding all-cause death, the two results that lie outside the white triangle to its right 
are from the studies by Parodi et al. 2010 (HR 1.32, 95% CI 1.23 to 1.42)159 and Antoni et 
al. 2012 (HR 1.35, 95% CI 1.22 to 1.50 after 1 year of follow-up)169.  These studies were 
visually identified as being outliers in Section 9.2.2.1.  Three results appear to lie 
outside the triangle to its left, but in actual fact there are four, from the studies by 
Vazir et al. 2014215, Jensen et al. 2012128 and Fobsol et al. 2010 (DIAMOND-HF)183 – which 
reported the same hazard ratio and had the same standard error – and Lonn et al. 
2014216.  The hazard ratio that each of these studies reported is smaller than expected 
given their large size and small standard errors.  Similarly, in relation to CV death, the 
result lying outside of the triangle to its right is from Antoni et al. 2012 (HR 1.29, 95% CI 
1.13 to 1.46)169, which was also visually identified as being an outlier in Section 9.2.2.2.  
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The result lying outside and to the left of the triangle is again from Vazir et al. 2014215, 
which reported a hazard ratio smaller than excepted given its large size and small 
standard error. 
Using the L0 estimator of the number of missing studies, the trim and fill method 
estimated that zero and five studies were theoretically missing for all-cause and CV 
death, respectively.  Incorporating these five theoretical missing studies into the 
analysis slightly reduced the pooled HR for CV death to 1.067 (95% CI 1.047 to 1.087), 
p<0.001).  Conversely, using the R0 estimator, the trim and fill method estimated that 
three and zero studies were theoretically missing for all-cause and CV death, 
respectively.  In this case, incorporating the three theoretical missing studies into the 
analysis, the pooled HR for all-cause death was slightly reduced to 1.075 (95% CI 1.035 
to 1.115, p<0.001).   
9.3 A Meta-Analysis of 10 Studies that Analysed Time-
Updated Resting Heart Rate as a Prognostic Risk 
Marker for All-Cause and Cardiovascular Mortality 
9.3.1 Study Selection and Data Extraction 
The seven time-updated heart rate studies that were identified in Chapter 2 were 
considered for inclusion in this meta-analysis.  Each publication was read in full to 
assess its eligibility.  Studies were accepted for inclusion if they presented a HR for all-
cause and/or CV death for a change in continuous time-updated resting heart rate 
entered as a time-dependent variable in the extended Cox proportional hazards 
regression model205, with a corresponding 95% CI. 
The HRs and 95% CIs for all-cause and/or CV death associated with a change in 
continuous time-updated heart rate were obtained.  The result found using the most 
adjusted model was selected.  The following data were also extracted from each 
publication where possible: the first author’s last name; the year of publication; the 
mean or median length of follow-up; the covariates additionally adjusted for in the 
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model; the number of first all-cause and/or CV death events that occurred; the number 
of subjects included in the study; and the method of heart rate measurement.  
9.3.2 Results 
As shown by Figure 9-7, six of the seven time-updated heart rate studies identified in 
Chapter 2 were identified as containing results associated with a continuous 
measurement of resting heart rate.  Two of these were excluded for the reasons 
outlined in Figure 9-7.  Thus, four publications remained eligible for inclusion in the 
meta-analysis.  All of the studies that satisfied the inclusion criteria included both male 
and female participants and were prospective in design.  Table A7-4 gives the details of 
these four studies, including their quality, as appraised using the Newcastle-Ottawa 
scale96 (see Tables A1-3 and A1-15 for breakdown), along with HRs and 95% CIs for a 
5bpm higher time-updated resting heart rate for all-cause and/or CV mortality, the 
number of corresponding first events, and the other covariates adjusted for in the 
models.  The studies by Okin et al. 2010210 and Vazir et al. 2014215 additionally adjusted 
the time-dependent heart rate models for baseline heart rate.  Study quality was high, 
ranging from 7 to 8 stars. 
The HRs and 95% CIs calculated for a 5bpm higher time-updated heart rate presented in 
Chapter 4 Section 4.3, Chapters 5, 6, 7 and Chapter 8 Sections 8.2 and 8.3 of this thesis 
were also eligible for inclusion in the meta-analysis.  The results for all-cause and CV 
death for the six populations are summarised in Table A7-5. The result found using the 
time-updated models unadjusted and adjusted for baseline heart rate are presented 
since two of the published papers presented results additionally adjusted for baseline 
heart rate210,215, while the other two did not204,207.  The models that adjust for baseline 
heart rate are more revealing since they provide information on whether the current 
heart rate measurement contributes significant additional information about risk of 
death, despite knowing the baseline heart rate measurement. 
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Thus, a total of ten distinct studies were therefore included in this meta-analysis: nine 
of which presented results for both all-cause and CV mortality, and one of which 
presented a result for all-cause mortality only. 
Figure 9-7: Flow chart of the selection process of the studies included in the meta-analysis 
of time-updated resting heart rate. 
 
9.3.2.1 All-Cause Death 
A 5bpm higher time-updated resting heart rate was associated with a 12.8% increase in 
the risk of all-cause death (number of studies = 10, HR = 1.128, 95% CI = 1.108 to 1.147, 
p<0.001), as shown by Figure 9-8. There was a substantial degree of true between-study 
heterogeneity (I2 = 69%), which was statistically significant (Q = 32.86, p<0.001).  These 
are the results obtained using the models additionally adjusted for baseline heart rate 
from this thesis.  When the results not additionally adjusted for baseline from this thesis 
were used, the pooled risk of all-cause death associated with a 5bpm increase in time-
updated resting heart rate (and the associated 95% CI) remained the same, but the 
degree of true between-study heterogeneity was larger (I2 = 73%) as was the Q-statistic 
(Q = 34.23, p<0.001).  
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Figure 9-8: Forest plot representing the individual and pooled risk of all-cause death 
associated with a 5bpm higher time-updated resting heart rate. 
 
Note that the results from the analyses in Chapters 4 to 8 are the ones that were obtained when baseline resting heart rate 
was additionally adjusted for. 
CHD = Coronary Heart Disease; CI = Confidence Interval; HF = Heart Failure; HR = Hazard Ratio; LVSD = Left-Ventricular 
Systolic Dysfunction.; MI = Myocardial Infarction. 
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9.3.2.2 Cardiovascular Death 
A 5bpm higher time-updated resting heart rate was associated with a 10.9% increase in 
the risk of CV death (number of studies = 9, HR = 1.109, 95% CI 1.087 to 1.132, 
p<0.001), as shown by Figure 9-9.  There was a substantial degree of true between-
study heterogeneity (I2 = 57%) which was statistically significant (Q = 20.67, p = 0.008).  
These are the results obtained using the models additionally adjusted for baseline heart 
rate from this thesis.  When the results unadjusted for baseline from this thesis were 
used, the pooled risk of CV death associated with a 5bpm higher time-updated resting 
heart rate was 11.5% (95% CI 9.1 to 14.0%).  The degree of true between-study 
heterogeneity was much larger (I2 = 78%) as was the Q-statistic (Q = 33.48, p<0.001). 
9.3.2.3 Publication Bias 
It was not appropriate to assess publication bias since only the results from the four 
studies described in Table A7-4 have been published.  Tests for publication bias should 
only be applied when ten or more studies are included in the analysis275.    
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Figure 9-9: Forest plot representing the individual and pooled risk of cardiovascular death 
associated with a 5bpm higher time-updated resting heart rate. 
 
Note that the results from the analyses in Chapters 4 to 8 are the ones that were obtained when baseline resting heart rate 
was additionally adjusted for. 
CHD = Coronary Heart Disease; CI = Confidence Interval; HF = Heart Failure; HR = Hazard Ratio; LVSD = Left-Ventricular 
Systolic Dysfunction.; MI = Myocardial Infarction. 
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9.4 Discussion 
The meta-analysis presented in Section 9.2 showed that a 5bpm higher baseline heart 
rate was associated with a 7.9% and an 8.0% increase in the risk of all-cause and CV 
death, respectively, after adjustment for conventional baseline risk factors, across 
different patient populations.   
In Section 9.3, it was found that a 5bpm higher time-updated resting heart rate was 
associated with a 12.8% increase in the risk of all-cause death, and a 10.9% increase in 
the risk of CV death, after adjustment for baseline risk factors as well as baseline 
resting heart rate (only two out of the ten studies included in the meta-analyses of 
time-updated heart rate did not additionally adjust for baseline heart rate204,207). 
These findings demonstrate that measurement of resting heart rate can identify 
patients at a higher risk of death, irrespective of whether or not they have a pre-
existing CV-related condition.  Furthermore, the results of the meta-analyses of time-
updated heart rate illustrate that, despite knowing an individual’s baseline heart rate, 
updated measurements of heart rate offer additional information about their risk of all-
cause and CV death.   
There was a substantial degree of true between-study heterogeneity for all analyses.  In 
the meta-analysis of baseline heart rate and risk of all-cause death, the results from 
Palatini et al. 2002147, Parodi et al. 2010159, Antoni et al. 2012169 and Jensen et al. 
2013170 appeared to account for a considerable proportion of the heterogeneity, and 
were visually identified as outliers.  Each of these studies included only a small number 
of deaths (Jensen et al. 2013 did not state the number of deaths that occurred170) and 
reported a substantially higher increase in risk of death compared to the other studies.  
Repeating the analysis without these studies reduced the degree of heterogeneity by 
16%, but the heterogeneity that remained was still significant.  The pooled HR was 
reduced to 7.2% (95% CI 6.3 to 8.1%) from 7.9% (95% CI 6.8 to 9.1%).  In the meta-
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analysis of baseline heart rate and CV death, the result from Antoni et al. 2012169 was 
the only apparent outlier.  Neither Parodi et al. 2010159 or Jensen et al. 2013170 
evaluated the risk of CV death.  Removing Antoni et al. 2012169 from the analysis did not 
alter the degree of heterogeneity; the pooled HR for CV death was slightly reduced 
from 8.0% (95% CI 6.5 to 9.5%) to 7.8% (6.4 to 9.3%).  None of the studies of time-
updated heart rate appeared to be outliers in regards to either endpoint. 
The heterogeneity was further examined by calculating the summary HR for a 5bpm 
higher baseline heart rate and the between-study heterogeneity in each population that 
included two or more studies.  In regards to both all-cause and CV death, the subgroup 
of patients with, or at increased of, some form of vascular disease, appeared to contain 
no between-study heterogeneity (I2 = 0%).  Similarly, the subgroup of individuals from 
the general population, and the subgroup of post-MI patients with LVSD or HF, 
contained no and a very low degree of between-study heterogeneity in regards to CV 
death and all-cause death, respectively (I2 = 0% in the general population subgroup for 
CV death; I2 = 7.6% in the post-MI patients with LVSD or HF subgroup for all-cause 
death). 
The post-MI or ACS subgroup of patients, which included the studies by Parodi et al. 
2010159, Antoni et al. 2012169 and Jensen et al. 2013170, contained the greatest degree of 
between-study heterogeneity (I2 = 94%) in relation to all-cause death.  Antoni et al. 
2012169 and Jensen et al. 2013170 were the only studies within this subgroup that 
included post-PCI patients and evaluated risk associated with discharge heart rate.  
Parodi et al. 2010159, on the other hand, was more similar to Noman et al. 2013164, in 
that it included post-PCI patients but assessed the risk associated with admission heart 
rate.  Noman et al. 2013164, however, found that a 5bpm higher admission heart rate 
was associated with an 8% increase in the risk of all-cause death, while Parodi et al. 
2010159 found that it was associated with a 32% increase in the risk of death.  The other 
two studies included in this subgroup were slightly different from the others, and from 
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each other.  Seronde et al. 2013171 included post-MI patients, some of whom had 
undergone reperfusion therapy but some of whom had not,  and evaluated the risk 
associated with discharge heart rate, while Timoteo et al. 2011161 included patients 
admitted to hospital with ACS and evaluated the risk associated with admission heart 
rate. 
The subgroup of patients with CHD and LVSD, or HF, or both, also contained a large 
degree of between-study heterogeneity in regards to both all-cause (I2 = 87%) and CV 
death (I2 = 88.54%).  Although each of the four studies in this subgroup included similar 
populations of patients, each was somewhat different from the others.  Fosbol et al. 
2010 (DIAMOND-HF)183, for example, included patients with acute HF with LVSD (in sinus 
rhythm or AF), whereas the other three studies included patients with chronic HF.  The 
patients included in SHIFT182 had both ischemic and non-ischemic chronic HF with LVSD 
and were in sinus rhythm, whereas the patients included in BEAUTIFUL184 all had CHD 
with LVSD in sinus rhythm, some of whom also had chronic HF.  Vazir et al. 2014215 
included a much more heterogeneous group of patients compared to the other three 
studies.  While all patients had chronic HF, 60% had a reduced EF and 40% had a 
preserved EF, with 73% in sinus rhythm and 27% in AF.   
The summary HRs for all-cause and CV death were similar across all of the subgroups of 
patients, with the exception of the post-MI or ACS and hypertensive patients in respect 
to all-cause death.  In the post-MI or ACS subgroup, which included the studies by Parodi 
et al. 2010159, Antoni et al. 2012169 and Jensen et al. 2013170, which reported much 
higher increases in the risk of death compared to the others, a 5bpm higher baseline 
heart rate was associated with a 16.9% (95% CI 6.3 to 27.6%) increase in the risk of all-
cause death.  Similarly, in the hypertensive subgroup which included the study by 
Palatini et al. 2002147, which also reported a higher increase in the risk of death 
compared to the others, 5bpm higher baseline heart rate was associated with an 11.8% 
(95% CI 3.6 to 20.0%) increase in the risk of all-cause death. 
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In general, each study included a different population of participants, which is a 
possible reason for the heterogeneity observed.  While all of the studies were 
prospective in design, some were epidemiological studies of subjects from the general 
population; others were post-hoc studies of patients with certain diseases and 
conditions enrolled in clinical trials, some of whom were stable and some of whom were 
unstable.  Another possible contribution to the heterogeneity was the difference in the 
underlying risk of each population.  Additionally, each study followed patients up for 
different lengths of time, and those with the longest follow-up would have had lower 
event rates compared to those with the shortest follow-up which would have had much 
higher event rates.  It is also possible that some of the previously published HRs may 
have contained underlying non-proportionality, and thus would have been dependent on 
length of follow-up.  The previously published HRs calculated using time-updated heart 
rate are less likely to contain underlying non-proportionality since the updated 
measurements of heart rate pick up changes in the risk of patients at different points in 
time throughout follow-up.  However, individual patient data would be required to 
explore this possibility further.  In addition, studies most likely differed in regards to 
the events that made up the total number of all-cause and CV deaths.  Certain studies 
may have included a higher number of non-CV deaths, for example, while others may 
have included a higher number of deaths caused by CV conditions such as HF, MI and 
stroke.  Moreover, each study varied in regards to what covariates were adjusted for in 
the models.  Differences will also have existed with respect to how and when heart rate 
was measured in each study.  Furthermore, the total number of heart rate 
measurements that were entered into the time-updated heart rate models would have 
been different in each study, as would the length of time between each measurement.  
Finally, several of the studies enrolled over 10,000 subjects - when there are a number 
of large studies included in a meta-analysis, a test for heterogeneity, such as the Q 
statistic, will likely have excessive power, meaning that it may detect statistically 
significant heterogeneity that is actually of little practical importance264,267.   It is 
further reasoned that, since systematic reviews and meta-analyses always include 
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studies that differ somewhat in their methodology and clinical characteristics, 
heterogeneity is inevitable267,266.      
Although the systematic review of Chapter 2 identified a total of 118 studies that 
investigated the prognostic value of resting heart rate for adverse outcomes, the 
majority reported results for some form of categorical heart rate measurement, which 
are more difficult to combine.  In addition, deaths from more specific causes and non-
fatal outcomes such as MI and stroke were not as consistently reported on compared to 
all-cause and CV death.  Khan et al. 2015136, however, did recently perform a meta-
analysis of seven studies which reported on the association between resting heart rate 
and risk of incident HF.  The pooled RR of incident HF was 1.40 (95% CI 1.19 to 1.64) 
comparing individuals in the top quartile of resting heart rate to those in the bottom 
quartile.  Further meta-analyses of the association between resting heart rate and risk 
of other endpoints would be interesting and informative.   
9.4.1 Strengths and Limitations 
The current meta-analyses are subject to the same limitations as the systemic review in 
Chapter 2.  Namely, that the review was limited to full-text articles that were available 
in English, and did not search for, or include, studies of risk models that may have 
included heart rate, but did not highlight its inclusion in the title of the publication.  
This may have contributed to the observed publication bias for all-cause and CV death 
in relation to baseline heart rate, since studies that found a significant association 
between heart rate and risk may have been more likely to highlight its inclusion in the 
title of the publication.  However, the literature search was extensive, and the meta-
analyses did include some studies that did not observe a significant association between 
heart rate and risk, so bias should be limited.  One possible reason for the observed 
publication bias is that there is a true strong effect of baseline resting heart rate on the 
risk of all-cause and CV death.  Even after incorporating theoretical missing studies into 
the analysis using the trim and fill method, the observed association, while slightly 
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reduced, remained strongly significant.  It was not appropriate to assess publication bias 
for all-cause or CV death in relation to time-updated heart rate since few of the results 
had previously been published275.  Finally, while the post-hoc clinical trial analyses 
generally excluded treatment-group patients if the treatment directly affected heart 
rate, other treatment- and placebo-assigned patients may have been on background 
therapy that affected heart rate.  In SHIFT, for example, almost all of the placebo-
assigned patients were taking beta-blockers at baseline and throughout the trial.  
Subjects in the epidemiological studies could also have been taking heart rate-affecting 
drugs at baseline, or may have started taking such drugs during follow-up.  Use of such 
medications at baseline were usually adjusted for in the models applied, but if an 
individual began to take such medications during follow-up, this would not have been 
taken into account in the estimation of the association.  Finally, none of the sensitivity 
analyses were pre-specified.  
9.4.2 Chapter Summary and Conclusions 
Following on from the systematic review of Chapter 2, this chapter firstly presented 
meta-analyses of the associations between baseline resting heart rate and risk of death 
from any cause, and death from CV causes, including the published prospective 
evidence identified in the review as well as the results from Chapters 4 to 8.  Similar 
meta-analyses of time-updated resting heart rate were also described.   
Both an elevated baseline resting heart rate and time-updated resting heart rate, after 
adjustment for baseline, were associated with an increase in the risk of death from all-
causes and CV causes across a variety of populations.  These findings emphasise the 
potential that heart rate has for assessing future risk of death in both healthy 
individuals and disease-specific groups.   
The subsequent and final chapter, Chapter 10 discusses the thesis as a whole. 
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Chapter 10 
 
Discussion 
10.1 Background, Justification and Overview 
Heart rate is inversely correlated with life span across mammal species, with humans 
being an outlier to the general pattern, having a longer lifespan than would be expected 
given their average heart rate2.  The most likely explanation of this is that humans have 
been able to extend their lives through improvements to living standards, healthcare, 
food production and the general application of modern scientific techniques.  In the last 
100 years alone, Western man has been able to increase life expectancy by around 30 
years5.  During the 20th century, aside from access to more nutritious diets, cleaner 
drinking water, and vaccines that prevent potentially life-threatening infectious 
diseases, techniques and treatments found to effectively intervene in the process of 
heart disease were discovered.  Nevertheless, CV disease remains to be one of the 
leading causes of death in the Western world8,10,11.   
Resting heart rate has been shown to independently predict the development of 
established risk factors for CV disease such as hypertension, diabetes, and kidney 
disease.  In addition, other risk factors such as smoking, excessive consumption of 
alcohol, and leading a sedentary lifestyle, have been shown to increase heart rate.  
Furthermore, the systematic review of studies that assessed resting heart rate as a 
prognostic risk marker, described in Chapter 2, demonstrated that an elevated heart 
rate is associated with an increase in the risk of death and adverse CV events, in a 
number of different populations, independent of other risk factors.   
In view of this evidence, and the fact that it can be inexpensive and simple to measure, 
resting heart rate as a risk marker is given less consideration in clinical practice than 
perhaps it should be.   The ESC guidelines relating to CV disease prevention in clinical 
practice31, diabetes217, arterial hypertension218, stable CHD219, STEMI220, and HF221, as 
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well as the ACC/AHA guidelines for stable CHD222 and CABG surgery223, currently 
recognise elevated heart rate as an indicator of risk.  However, only the ESC guidelines 
for CV disease prevention in clinical practice, and the management of arterial 
hypertension, recommend that heart rate be measured as part of the routine physical 
examination for risk assessment31,218.  In addition, only the NICE guidelines for the 
management of ACS, and unstable angina and NSTEMI, mention that formal assessment 
of risk should include a physical examination where heart rate is measured, alongside 
blood pressure224,225.  Moreover, elevated resting heart rate does not appear to be given 
consideration in the management of post-stroke patients.  Neither the NICE guidelines 
for the management of stroke or TIA280, or the AHA/ASA guidelines for the prevention of 
stroke in post-stroke or TIA patients281, mention heart rate.  Furthermore, the ASA and 
ESO guidelines for the management of ischemic stroke and TIA282,283 only mention that 
heart rate should be measured as part of the initial examination, alongside 
measurement of other vital signs such as temperature and blood pressure.   
The majority of studies that were identified in the systematic review of Chapter 2 
evaluated the risk associated with resting heart rate measured at a single point in time 
at the beginning of follow-up using Cox proportional hazards regression.  Seven of the 
studies included in the review examined the prognostic value of multiple heart rate 
measurements gathered over the duration of follow-up, entered into the extended Cox 
proportional hazards model205 as a single time-dependent variable, often referred to as 
time-updated heart rate.  The studies by Vazir et al 2014215 and Ho et al. 2014204 showed 
that time-updated heart rate was associated with adverse events where baseline heart 
rate was not.    
One of the reasons physicians may not give much consideration to heart rate as an 
indicator of risk is because it can be influenced by a number of different factors.  Aside 
from smoking, alcohol consumption, and physical activity, heart rate can be affected by 
blood pressure60,61, gender62-64, and various conditions, such as anxiety, pain, 
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dehydration, fever, and CV diseases, such as CHD, MI and HF65.  If blood cannot travel as 
easily through the vessels because of a partial occlusion, or if the heart muscle has been 
damaged and cannot pump as effectively as it once could, the heart attempts to 
maintain adequate cardiac output by increasing the heart rate66,67.  It is reasonable to 
suppose then that a single baseline heart rate measurement may not adequately predict 
the risk of experiencing an adverse outcome many years in the future.  Taking updated 
measurements of heart rate into account could supply a more appropriate estimate of 
the risk at any given time.  The predictive value of time-updated heart rate 
measurements may therefore be more pertinent to clinical practice than that of a single 
heart rate measurement, and further studies of the relationship between time-updated 
heart rate and risk could motivate medical practitioners to give more consideration to 
regular assessment of heart rate, an approach that is not currently mentioned in the 
guidelines. 
The study by Khan et al. 2015136 recently applied meta-analysis techniques to the 
exploration of the relationship between resting heart rate and risk, and was the only 
study found in the review of Chapter 2 to use such methods.  Another reason that heart 
rate is not given much consideration in clinical practice may be because studies often 
include specific populations of subjects, and so general conclusions about its effect as a 
risk marker cannot be made.  Meta-analysis can be used can be used to calculate a 
single more powerful estimate of the effect of a risk marker by combining the results 
from different studies.  It can also be used to assess consistency of effect across 
individuals from different populations.   
In addition, the majority of studies identified in the review analysed the risk associated 
with an elevated heart rate in subjects from the general population, often with no 
evidence of existing CV disease or CHD. 
Accordingly, this thesis further examined the role of resting heart rate as a risk marker 
by performing new analyses of data from nine clinical trials, with the aim of highlighting 
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its importance as an indicator of risk.  Specifically, in Chapter 4, Section 4.3, and 
Chapters 5 to 8, both the original74 and extended Cox model205 were used to assess the 
predictive value of baseline and time-updated resting heart rate for death and other 
adverse outcomes.  In Chapter 4, Section 4.2, and Chapter 8, Section 8.4, pooled 
individual patient meta-analyses were performed.  The discrimination and calibration of 
the models applied in Chapters 4 to 8 were evaluated using Harrell’s C-statistic228,229 and 
likelihood ratio tests, respectively.  Finally, following on from the systematic review 
presented in Chapter 2, meta-analyses of the risk of death from any cause and death 
from CV causes were presented in Chapter 9 Sections 9.2 and 9.3. 
10.2 Main Findings 
10.2.1 Associations Between Resting Heart Rate and Risk 
Each of the nine trials newly analysed in this thesis recorded data on all-cause deaths, 
CV deaths and hospitalisations for HF, with the exception of PERFORM which did not 
report on hospitalisation for HF in its population of post-stroke or -TIA patients.  In 
Chapter 4, an elevated baseline heart rate was seen to be associated with an increase 
in risk of each of these endpoints in the large pooled population of patients who had 
recently experienced an MI, and had LVSD, HF or both.  In the much smaller CAPRICORN 
placebo population of post-MI patients with LVSD, no associations between baseline 
heart rate and risk of all-cause or CV death were observed.  However, an elevated time-
updated heart rate was associated with an increase in risk of both endpoints, even after 
adjustment for baseline or the previous heart rate measurement.  Both elevated 
baseline and time-updated heart rates, unadjusted or adjusted for baseline or previous 
heart rate, were associated with an increase in the risk of hospitalisation for HF.  In the 
EUROPA, PROSPER, PERFORM, BEAUTIFUL and SHIFT populations, as well as the pooled 
LV dysfunction population of BEAUTIFUL and SHIFT patients, elevated baseline and 
time-updated heart rates were also associated with an increase in the risk of all-cause 
death and CV death, regardless of whether baseline or previous heart rate 
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measurements were adjusted for.  Similar results were found for hospital admission for 
HF in the PROSPER, BEAUTIFUL, SHIFT and LV dysfunction populations, and 
incorporating time-updated heart rate strengthened each of these associations.  Thus, 
despite knowing the baseline or previous heart rate measurement, current heart rate 
measurements contribute additional information about the risk of each of these 
endpoints.  In EUROPA, no association between baseline heart rate and risk of hospital 
admission for HF was discovered, but elevated time-updated heart rate was associated 
with an increase in risk irrespective of adjustment.   
The relationship between resting heart rate and risk of a number of other causes of 
death were additionally evaluated for some studies.  In the CAPRICORN placebo 
population, the risk of sudden death was assessed, but no relationship between heart 
rate and risk was observed.  The risk of death from HF was also investigated in the 
CAPRICORN population, and in the SHIFT population of patients with chronic HF and 
LVSD.  In CAPRICORN, only an elevated continuous baseline heart rate was associated 
with a higher risk of death due to HF, whereas in SHIFT both elevated baseline and 
time-updated heart rates were associated with an increase in risk.  Similarly, in the 
PROSPER population of older individuals with, or at an increased risk of, vascular 
disease, elevated baseline and time-updated heart rates were associated with an 
increase in the risk of CHD death and non-vascular death.  On the other hand, only 
time-updated heart rate adjusted for baseline or previous heart rate was associated 
with an increase in the risk of cancer death in PROSPER.  The risk of stroke death was 
also explored, but no association with heart rate was seen.  Furthermore, the risk of 
cardiac death was assessed in the PERFORM and BEAUTIFUL populations.  No association 
between baseline heart rate and risk of cardiac death was observed in PERFORM.  
However, higher time-updated heart rate, and time-updated heart rate adjusted for 
baseline, was associated with an increase in risk.  In the BEAUTIFUL placebo population 
of patients with CHD and LVSD, some of whom also had HF, both elevated baseline and 
time-updated heart rates were associated with an increase in risk.  In SHIFT, PROSPER 
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and BEAUTIFUL, including time-updated heart rate measurements strengthened the 
associations with death due to HF, CHD death and non-vascular death, and cardiac 
death, respectively.   
Information on MI-related endpoints was common across the trials.  In the pooled acute-
MI population, an elevation in baseline heart rate was associated with an increase in risk 
of fatal or non-fatal MI.  In the PERFORM population, both elevated baseline and time-
updated heart rates were associated with an increase in risk of fatal or non-fatal MI, 
while only a higher time-updated heart rate was associated with a higher risk of non-
fatal MI.  In each instance, the association with time-updated heart rate did not retain 
its significance when baseline or previous heart rate was adjusted for.  Similarly, in the 
PROSPER population, only elevated time-updated heart rate, and time-updated heart 
rate adjusted for baseline, was associated with an increase in risk of non-fatal MI.  In 
BEAUTIFUL, SHIFT and the pooled LV dysfunction population, while no association 
between an elevated continuous baseline heart rate was observed, time-updated heart 
rates both unadjusted and adjusted for baseline or previous heart rate measurements 
were associated with an increase in risk of hospital admission for MI.  In contrast, only 
baseline as opposed to time-updated heart rate was associated with an increase in the 
risk of non-fatal MI in the CAPRICORN placebo population.  No associations between 
either baseline or time-updated heart rate and risk of fatal or non-fatal MI was observed 
in the EUROPA population. 
The risk of stroke-related endpoints was also evaluated in the pooled acute-MI, 
EUROPA, PROSPER and PERFORM populations.  In comparison to the endpoints previously 
discussed, the results for such endpoints are much less consistent.  In the pooled acute-
MI and EUROPA populations, for example, no associations between heart rate and the 
risk of fatal or non-fatal stroke were observed.  Moreover, in the PROSPER population, 
an association between time-updated heart rate adjusted for baseline and the risk of 
fatal or non-fatal stroke, non-fatal stroke, and the combined endpoint of fatal or non-
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fatal stroke or TIA, was only observed in patients taking anti-arrhythmic drugs and/or 
beta-blockers at baseline.  In addition, patients with a heart rate in the highest third of 
the distribution were found to be at a lower risk of TIA compared to those with a heart 
rate in the lowest third.  On the other hand, in the PERFORM population, while no 
significant association between baseline heart rate and risk of fatal or non-fatal stroke, 
fatal or non-fatal ischemic stroke, or non-fatal ischemic stroke was observed, higher 
time-updated heart rate was associated with a higher risk of each of these endpoints.   
Several other endpoints were investigated in certain studies.  In the EUROPA 
population, the risk of cardiac arrest and unstable angina were assessed.  No 
associations between heart rate and risk of unstable angina were observed.  Higher 
time-updated heart rate adjusted for baseline heart rate, and previous heart rate 
measurements, was associated with an increase in the risk of cardiac arrest.  The risk of 
hospitalisation due to cardiac causes was examined in the PERFORM population, and 
while it was not found to be associated with baseline heart rate, a higher time-updated 
heart rate was associated with an increase in risk, irrespective of adjustment for the 
other heart rate variables.  Finally, the risk of revascularisation was evaluated in the 
EUROPA, PROSPER and BEAUTIFUL populations.  A higher resting heart rate was 
associated with a decrease in the risk of revascularisation in EUROPA and PROSPER, and 
an increase in risk in BEAUTIFUL.  EUROPA and PROSPER occurred in the late 1990s, 
when revascularisation was mainly used to treat angina, while BEAUTIFUL occurred in 
the mid-2000s, when revascularisation was more frequently used to treat acute MI276.  
Thus it was suggested that the difference in findings may have been because 
revascularisation was more likely to be related to angina in the EUROPA and PROSPER 
trials, and emergency events such as acute MI in the BEAUTIFUL trial.  
In the discussion of Chapter 2, Section 2.4, Table 2-1 and Table 2-2 provided a 
simplified illustration of the evidence presented in the baseline and multiple heart rate 
measurement studies, respectively, in relation to each of the main adverse outcomes 
and populations of subjects.  The cells that contained one or more black shapes 
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indicated where an association between some form of resting heart rate variable and 
risk had been established, using a multivariate-adjusted model; the blank cells 
indicated where an association had yet to be established using such a model.  Each 
shape represented a different resting heart rate variable: a rectangle represented 
baseline resting heart rate; a circle represented a change in resting heart rate over 
time; a triangle represented the mean of multiple heart rate measurements gathered 
over time; and a star represented time-updated resting heart rate.  To highlight the 
contributions of the thesis to the field, Table 10-1 provides a similar summary and 
comparison of the evidence that was previously identified by the review, and the 
evidence which was presented in Chapters 4 to 8 of the thesis: the previous evidence is 
represented by the shaded shapes, and the evidence from the thesis is represented by 
the solid black shapes. 
As can be seen from Table 10-1, new associations between baseline resting heart rate 
and risk of: HF death and recurrent MI were observed in post-MI patients; cardiac death 
was observed in patients with LVSD; CHD death was observed in patients with vascular 
disease; and revascularisation was observed in patients with CHD, and vascular disease.  
Additionally, new evidence of an association between time-updated resting heart rate 
and risk of numerous outcomes was demonstrated in each of the populations examined 
in thesis, where measurements of resting heart rate had been recorded over follow-up.  
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Table 10-1: A summary and comparison of the evidence previously identified in the systematic review of Chapter 2, and the evidence presented in Chapters 
4 to 8 of the thesis, on the associations between both baseline and multiple resting heart rate measurements, and risk of each of the main adverse 
outcomes, in the populations of subjects discussed in the review and in Chapters 4 to 8. 
Outcome Category of Subjects 
General 
 
Diabetes Hypertension CHD Post-MI/ACS HF LV 
Dysfunction 
CABG Vascular 
Disease 
Post-Stroke Kidney 
Disease 
Deaths            
All-cause death 
  
      
  
 
    
  
 
 
 
CV/vascular death 
 
 
  
 
     
 
 
 
 
 
Cardiac death 
    
   
 
  
 
 
CHD death 
   
     
 
  
HF death 
 
   
  
 
    
Sudden death 
 
          
Stroke death            
Table continued and footnote provided on the following page. 
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Table 10-1 (Cont.): A summary and comparison of the evidence previously identified in the systematic review of Chapter 2, and the evidence presented in 
Chapters 4 to 8 of the thesis, on the associations between both baseline and multiple resting heart rate measurements, and risk of each of the main 
adverse outcomes, in the populations of subjects discussed in the review and in Chapters 4 to 8. 
Outcome Category of Subjects 
 General Diabetes Hypertension CHD Post-MI/ACS HF LV 
Dysfunction 
CABG Vascular 
Disease 
Post-Stroke Kidney 
Disease 
Other  
 
          
CV disease/event 
 
 
  
    
 
  
 
 
Cardiac event    
 
     
 
 
CHD 
 
 
 
        
MI 
 
   
 
  
 
  
 
Revascularisation    
 
  
 
 
 
  
HF 
 
 
 
      
 
 
 
  
Stroke 
 
   
 
 
  
  
 
The cells that contain one or more shapes indicate where an association between some form of resting heart rate variable and risk has been established, using a multivariate-adjusted model; the blank cells 
indicate where an association has yet to be established using such a model.  Each shape represents a different resting heart rate variable: a rectangle represents baseline resting heart rate; a circle represents 
a change in resting heart rate over time; a triangle represents the mean of multiple resting heart rate measurements gathered over time; and a star represents time-updated resting heart rate.  The previous 
evidence is represented by the shaded shapes, and the evidence from the thesis is represented by the solid black shapes.  The ‘Other’ events include combinations of both fatal and non-fatal events, and non-
fatal events only. 
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10.2.2 Model Discrimination and Calibration 
 In the main, models in which the resting heart rate variable was found to be 
significantly associated with risk of outcome had better discrimination and calibration 
than the model excluding resting heart rate.  This indicates that these models had a 
greater ability to differentiate between subjects who experienced the event from those 
that did not, and that the predictions from these models more accurately reflected the 
observed event rates, compared to the model not including resting heart rate.  In some 
cases, where baseline resting heart rate was not found to be associated with risk of the 
event, while an elevated time-updated resting heart rate was, the addition of the 
baseline heart rate variable did increase the C-statistic of the model, but only the 
addition of the time-updated heart rate variable resulted in statistically significant 
improvements in calibration.  Overall, the models including time-updated heart rate 
additionally adjusted for the baseline or previous heart rate measurement generally 
yielded the highest and similar C-statistics, and thus had the best discriminative ability.    
10.2.3 Evidence of Non-Proportionality of Hazards 
Non-proportionality of the effect of an elevated resting heart rate was detected for 
some of the outcomes in several of the studies.  In the pooled acute MI population, non-
proportionality of an elevated baseline heart rate was observed for all of the outcomes.  
The effect of an elevated continuous baseline heart rate was also found to be non-
proportional in relation to all-cause death in the PROSPER population.  Furthermore, in 
the BEAUTIFUL, SHIFT and pooled LV dysfunction populations, non-proportionality was 
observed in regards to hospital admission for HF, and the combinations of CV death or 
hospital admission for HF, and CV death or hospital admission for HF or MI.  A higher 
heart rate was also found to have a non-proportional association for all-cause and CV 
hospital admissions in the SHIFT population.  In each case, plots of the Schoenfeld 
residuals demonstrated that the effect of an elevated heart rate was highest at the 
beginning of follow-up, and then declined over time.  These findings could potentially 
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impact the interpretation of results from previous publications, as the proportional 
hazards assumption is not always assessed.  Thus, previous studies have may have 
reported results of the ‘average’ effect of heart rate over time, possibly containing 
some underlying non-proportionality.    
10.2.4 Meta-Analyses 
In Chapter 9, the meta-analyses of the predictive value of baseline and time-updated 
resting heart rate demonstrated that elevated resting heart rate is associated with a 
higher risk of death across individuals from the general populations and patients with 
different pre-existing conditions.  A 5bpm higher baseline heart rate was associated 
with a 7.9% and an 8.0% increase in the risk of all-cause and CV death, respectively 
(both p<0.001).  Furthermore, adjusting for baseline heart rate in eight of the ten 
studies included in the analysis, a 5bpm higher time-updated heart rate was associated 
with a 12.8% (p<0.001) and a 10.9% (p<0.001) increase in the risk of all-cause and CV 
death, respectively.   
10.3 Clinical Implications 
These findings should increase support for assessment of resting heart rate in all types 
of individuals.  Given that an elevated time-updated heart rate is in some cases 
associated with risk of events where baseline heart rate is not, and can provide 
additional information about the risk of certain events despite knowledge of baseline or 
previous heart rate measurements, regular assessment of resting heart rate should be 
considered by physicians as a method of identifying individuals at higher risk.   
The addition of resting heart rate to the models where resting heart rate was found to 
be associated with risk of outcome improved both discrimination and calibration, and in 
general, the models including time-updated heart rate along with baseline or the 
previous heart rate measurement had the highest and similar C-statistics, and thus the 
greatest discriminative ability.  The improvements in discrimination with the addition of 
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resting heart rate - even time-updated resting heart rate – however, were modest.  
While it is compelling to imagine the use of repeated measurements of resting heart 
rate in general practice, to identify individuals at higher risk of death and adverse 
cardiovascular events, prospective validation studies in different populations would very 
likely be required before clinical application would become a reality.  It is possible that 
the addition of time-updated resting heart rate would make only an incremental 
improvement to the discriminative and predictive abilities of already established risk 
scores, although further studies would have to be carried out to properly assess the 
impact of its contribution.  Nonetheless, resting heart rate can be measured simply 
using pulse palpation, and so would be easy to obtain in routine clinical practice.  
Therefore, the findings that the addition of time-updated resting heart rate does 
improve the discrimination and calibration of models for certain outcomes including 
death, even if only modestly, strengthens the case that it could be added to traditional 
risk models, and should incite medical practitioners to routinely measure patients’ 
resting heart rate in clinical practice as a means of assessing their risk of adverse 
events. 
The findings of the thesis, however, are of particular importance, and have greater 
implications for the clinical management of patients with pre-existing disease.   It has 
been shown that elevated resting heart rate measurements gathered over time are 
associated with higher risk of adverse events in post-MI and -stroke patients, and those 
with stable CHD, vascular disease, and LVSD.  Thus, in sicker patients with such 
conditions, regular assessment of resting heart rate could be used to guide medical 
decision-making.  An elevated, or increasing heart rate over time, could be used as a 
tool, potentially alongside other established risk scores, to help doctors identify patient 
deterioration or those at higher risk who might benefit from more intensive monitoring 
or treatment re-evaluation.  While a higher heart rate could simply be a sign of 
infection or dehydration (ADD REFs), for example, further investigation would no doubt 
be of some benefit and could prevent patient decline.  In addition, the re-evaluation 
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and possible alteration of a patient’s treatment regime could result in the 
implementation of more appropriate therapies, which could prevent both fatal or non-
fatal events from occurring in the future. 
10.4 The Recommended Method for Assessing Risk
 Associated with Resting Heart Rate 
The thesis explored associations between both baseline and time-updated resting heart 
rate, and risk of death and other adverse events.  Risk was compared between baseline 
and time-updated heart rate groups, and the risk associated with continuous baseline 
and time-updated heart rate was evaluated.  Additional models assessing time-updated 
resting heart rate were fitted with adjustment for (i) baseline resting heart rate group 
or baseline heart rate as appropriate, and (ii) the previous heart rate group or the 
previous measurement.  This was done to determine whether the updated heart rate 
measurements added prognostic value to the information already provided by the 
baseline or previous heart rate measurement.  Finally, in order to assess the risk 
associated with the direction of change in heart rate at each follow-up visit, models 
were fitted for ‘time-updated categorical heart rate patterns’ (see Chapter 3 Section 
3.3.3.3 for details), which accounted for the change in heart rate between visits, while 
also adjusting for the previous visit measurement (which was absorbed into the 
grouping).   
An elevated time-updated heart rate was found to be associated with risk of events 
where baseline heart rate was not, and provided additional information about the risk 
of certain events, despite knowledge of baseline or previous heart rate measurements.  
Furthermore, the models including time-updated heart rate along with baseline or the 
previous heart rate measurement generally had the highest and similar C-statistics, as 
well as significantly better calibration than the model not including any of the resting 
heart rate variables.  This suggests that these models had a greater ability to 
differentiate between subjects who experienced the event from those that did not, and 
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that the predictions from these models more accurately reflected the observed event 
rates, compared to the model not including resting heart rate. 
Currently, despite the extensive research on resting heart rate as a risk marker for 
death and adverse CV events, there is no objective cut-off level for the definition of a 
high resting heart rate, also known as tachycardia72.  Thus, in each of the different 
studies presented in the thesis, the categorical heart rate cut-off point was chosen 
somewhat arbitrarily on the basis of previously published studies (see Chapter 3 Section 
3.3.1 for details).  The textbook definition of tachycardia is a resting heart rate greater 
than 100bpm284.  However, this is not an appropriate cut-off value for a high resting 
heart rate from an epidemiological point of view - below which an individual’s heart 
rate would be considered normal – since essentially all of the observational studies and 
post-hoc clinical trial analyses reviewed in Chapter 2, in addition to the studies 
presented in the thesis, demonstrated that individuals with resting heart rates well 
below the 100bpm threshold were at a higher risk of death and adverse CV events72.   
Therefore, the models including continuous time-updated resting heart rate adjusted 
for either baseline or the previous heart rate measurements, also treated as continuous 
variables, would appear to be the best models to use for the assessment of risk 
associated with resting heart rate: since adjustment for baseline heart rate is simpler 
and possibly more intuitive, it is recommended that this method be used.    
10.5 Future Research 
In the discussion section of each analysis chapter, Chapters 4 to 9, possible future 
studies needed to clarify unresolved issues were mentioned.  Firstly, in Chapter 4, no 
associations between an elevated resting heart rate and risk of fatal or non-fatal stroke 
or sudden death were observed in post-MI patients.  Similarly, in Chapters 5 and 6 
respectively, no associations were observed between an elevated resting heart rate and 
risk of stroke in the EUROPA population of patients who had CHD without HF, or risk of 
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stroke death in the PROSPER population of elderly individuals with, or at an increased 
risk of, vascular disease.  In each case, the number of events was low, and so there may 
have been insufficient statistical power to detect associations.  In addition, none of the 
studies of subjects with ACS, or with, or at increased risk of, vascular disease, identified 
in Chapter 2, investigated the relationship between heart rate and risk stroke or sudden 
death, or stroke death, respectively.  Moreover, the studies by Diaz et al. 2005 and Ho 
et al. 2010, which enrolled patients with CHD, previously examined the relationship 
between baseline resting heart rate and stroke and observed no association.  Thus, 
further prospective studies or post-hoc analyses of clinical trials with longer follow-up 
periods and larger sample sizes of such patients, where more of these events would be 
likely to occur, are needed to elucidate whether a relationship between resting heart 
rate and risk of these events exists or not.   
Additional studies of the association between resting heart rate and risk of MI and 
unstable angina in patients with CHD both without HF or LVSD, and with HF or LVSD, are 
also required.  Neither the EUROPA analysis of CHD patients without HF presented in 
Chapter 5, or the previous studies by Diaz et al. 2005 and Ho et al. 2010, observed any 
associations between resting heart rate and the risk of MI, or unstable angina.  
Conversely, an elevated resting heart rate was associated with a higher risk of MI and 
the combined endpoint of MI or unstable angina in the BEAUTIFUL analysis of CHD 
patients with LVSD, some of whom also had HF, presented in Chapter 8.  This suggests 
that there could be differences in the association between resting heart rate and risk of 
MI or unstable angina in CHD patients without HF or a reduced EF, and CHD patients 
with HF or reduced EF, but because these seem to be the only four studies which have 
examined such associations in such patients, further similar studies are required before 
conclusions can be drawn.   
Likewise, as mentioned in Section 10.2.1, a higher resting heart rate was associated 
with a decrease in the risk of revascularisation in EUROPA and PROSPER, and an 
increase in risk in BEAUTIFUL.  It was proposed that this may have been because 
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revascularisation was more likely to be related to angina in the EUROPA and PROSPER 
trials, which took place in the late 1990s, and emergency events such as acute MI in the 
BEAUTIFUL trial which took place in the mid-2000s, when revascularisation was more 
frequently used to treat acute MI276.  It would appear that these are the only three 
analyses which have investigated this association in patients with CHD: therefore, 
further post-hoc analyses of clinical trials which enrolled patients with CHD both 
without HF or LVSD, and with HF or LVSD, recorded information on revascularisation 
events, and that took place at different times from the beginning of the 90s to the 
present day, would need to be performed to test this hypothesis. 
In general, as can be seen from Table 10-1, studies of the association between resting 
heart rate and risk of adverse events in patients with diabetes and kidney disease, and 
those who have undergone, or are about to undergo, CABG surgery, are still lacking.  In 
addition, future prospective studies should strive to measure subjects’ resting heart 
rates throughout follow-up at regular intervals, and along with post-hoc analyses of 
clinical trials that measured resting heart rate throughout follow-up, should analyse 
associations between both baseline and time-updated heart rate and risk. 
At the moment, however, the cost-effectiveness of measuring heart rate to assess 
patients’ risk is unknown.  While measurement of pulse may be relatively cheap, and 
could be done by individuals without the assistance of a healthcare professional, 
measurement using ECG would be more expensive and ECGs are not commonly recorded 
in primary care.  In addition, the optimal frequency of heart rate assessment has yet to 
be explored.  This thesis investigated the prognostic value of time-updated heart rate in 
six different trial populations.  In each trial, heart rate values were obtained at pre-
determined visits that took place at different points in time during follow-up.  
Currently, it is not known if measuring heart rate more frequently throughout follow-up 
would enhance the predictive value of resting heart rate, or whether measuring heart 
rate less frequently would be just as useful but more cost-effective.    
269 
 
Furthermore, the role of continuously recording resting heart rate, for example, when 
individuals are at home, has had little investigation.  It could contribute similarly 
valuable prognostic information to that acquired by measurement of resting heart rate 
at pre-determined visits.  In the study by Hozawa et al. 2004285, participants were 
provided with a device that allowed self-measurement of heart rate, and asked to 
measure their resting heart rate at home, in the morning and evening, over the course 
of four weeks.  Morning and evening home heart rate was then defined as the mean of 
all morning and evening measurements acquired for each individual, respectively.  A 
5bpm higher morning home heart rate was associated with a 17% (p = 0.003) and 20% (p 
= 0.01) increase in the risk of cardiovascular mortality, and cerebrovascular mortality, 
respectively.  Similar results were observed for a 5bpm higher evening home heart rate.  
The study was not able to directly compare the prognostic value of home heart rate 
with that of clinic heart rate, however, as clinic heart rate measurements were not 
obtained.  Thus, further studies comparing the predictive value of self-measured heart 
rate at home with that of heart rate measured in a clinical setting would provide 
further insight into the usefulness of home heart rate for assessing cardiovascular risk. 
The potential benefit of measuring a risk marker for CV disease, apart from the general 
information this provides on an individual patient, is to identify patients who would 
have a high enough risk to justify the cost of implementing a pharmacological or other 
risk reduction treatment, or to identify those in whom modification of that particular 
risk marker would confer benefit.  Although there is a clear association between an 
elevation in heart rate and an increase in risk, lowering heart rate, unlike lowering 
other risk markers such as cholesterol and blood pressure, has only been shown 
definitively to reduce the risk of adverse outcomes in patients with a resting heart rate 
greater than or equal to 70bpm, in sinus rhythm, with LVSD and chronic HF32.  In the 
SHIFT trial, treatment with ivabradine, the first of a new class of drugs that lowers 
heart rate without any other direct effects on the CV system, reduced risk of the 
primary outcome of CV death or hospital admission for worsening HF by 18% (95% CI 10 
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to 25%, p<0.0001)32.  Treatment with ivabradine also reduced risk of admission to 
hospital for MI, admission to hospital for MI or unstable angina, and coronary 
revascularisation by 36%, 22% and 30%, respectively, in a subgroup of patients with a 
heart rate greater than or equal to 70bpm in the BEAUTIFUL trial248.  However, as there 
was no impact on the primary endpoint in the total trial population, the finding is not 
considered as definitive.  On the other hand, in the recent SIGNIFY trial of patients with 
CHD without HF, treatment with ivabradine was not associated with a reduction in risk 
of any of the outcomes evaluated, and there was a suggestion of a possible increase in 
risk in the subgroup of participants with angina286.   Further assessment of heart rate 
reduction with ivabradine in relation to risk of adverse outcomes in individuals with 
other conditions would be informative.  However, given the results of SIGNIFY this is 
unlikely to happen.  Other drugs, such as beta-blockers, diltiazem and verapamil, lower 
heart rate, as does smoking cessation and increased exercise.  However, as they have 
other effects on the CV system it is not possible to identify the specific impact on 
outcomes of their heart rate lowering effects. 
Finally, at this moment in time, one of the most important questions for future research 
to address is what defines a high heart rate.  As discussed in Section 10.4, there is 
currently no objective cut-off value for the definition of a high resting heart rate: the 
textbook definition of tachycardia – a resting heart rate greater than 100bpm – is not 
appropriate for epidemiological purposes since virtually all of the research on the 
association between resting heart rate and risk has shown that risk of adverse outcomes 
increases at resting heart rates much lower than 100bpm.  The optimal method for 
defining the upper normal limit of a clinical variable is to establish the value at which 
the benefits of treatment outweigh the risks72.  However, ivabradine is presently the 
only drug which lowers heart rate without affecting any other part of the CV system, 
and as discussed in the previous paragraph, it is unlikely that further assessment of 
heart rate reduction with ivabradine will take place in the foreseeable future.  The 
evidence from the BEAUTIFUL and SHIFT trials, although somewhat inconclusive, 
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indicated that patients with a baseline resting heart rate greater than or equal to 
70bpm benefited from treatment with ivabradine32,248,287.  However, approximately 87% 
and 90% of the patients enrolled in BEAUTIFUL and SHIFT, respectively, were taking 
beta-blockers at randomisation, and thus their natural resting heart rate would probably 
have been much higher than their heart rate recorded at baseline.  The only other 
available data on the effect of heart rate reduction in humans can be derived from 
retrospective analyses of post-MI patients or those with congestive HF288,289.  Carvedilol 
has demonstrated favourable effects in individuals with congestive HF but the mortality 
benefit was only clear in patients with a resting heart rate greater than 82bpm290.  
Nonetheless, these results cannot be transferred to individuals from the general 
population or those with other forms of pre-existing disease.  If researchers were 
somehow able to overcome these issues in the future, and specify a new definition of 
tachycardia applicable to all individuals, the public could be informed of the risks 
associated with a resting heart rate greater than this level.  Individuals could then 
choose to monitor their own resting heart rate, and possibly implement lifestyle 
changes with the aim of lowering their resting heart rate, or seek medical advice, if 
they identified that it was consistently above the threshold.  As a result, they could 
potentially lower their risk of developing CV disease, or delay any existing CV disease 
from progressing to a more dangerous stage.   
10.6 Limitations 
A limitation of the analyses presented in this thesis was that the data analysed in 
Chapters 4 to 8 were taken from previous clinical trials, and so the findings may not be 
generalisable to other populations of patients.  However, the trial designs ensured 
independent endpoint adjudication with well-defined criteria, and standardised 
measurement of resting heart rate.   
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10.7 Summary 
Using meta-analyses techniques and the extended Cox model that allows for assessment 
of time-dependent covariates, it has been demonstrated that both elevated baseline 
and time-updated resting heart rates are associated with an increase in the risk of 
adverse CV events in patients with varying pre-existing diseases and conditions.  In some 
instances, elevated time-updated heart rate predicts risk of events where baseline 
heart rate does not.  Time-updated heart rate also contributes additional information 
about the risk of certain events despite knowledge of baseline heart rate or previous 
heart rate measurements.  These findings could encourage medical practitioners to use 
routine assessment of resting heart rate as a means of identifying individuals at higher 
risk of adverse events.   
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Appendix 1 
Supplementary Tables for Chapter 2 
Table A1-1: PRISMA 2009 checklist94 for the systematic review of heart rate as a prognostic risk marker for mortality and adverse cardiovascular outcomes. 
Section/Topic Item 
No. 
Checklist Item Reported On Page No. 
Title    
Title 1 Identify the report as a systematic review, meta-analysis, or both. 21 
Abstract    
Structured 
summary 
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number. 
N/A as thesis chapter as 
opposed to journal article 
Introduction    
Rationale 3 Describe the rationale for the review in the context of what is already known. 21 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study 
design (PICOS).   
21 
Methods    
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as Web address), and, if available, provide registration 
information including registration number. 
No review protocol, noted 
as limitation in discussion  
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication 
status) used as criteria of eligibility, giving rationale. 
23-4 
Information 
sources 
7 Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched. 
22-3 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 22-3, and Table A1-2 
provided in Appendix 1 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis). 
23 
Data collection 
process 
10 Describe the method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators. 
24 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made. 24 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias in individual studies (including specification of whether this was done at study or outcome 
level), and how this information is to be used in any data synthesis 
25 
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Summary 
measures 
13 State the principal summary measures (such as risk ratio, difference in means). N/A 
Synthesis of 
results 
14 Describe the method of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistics) for 
each meta-analysis. 
N/A 
 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selecting reporting within studies). N/A 
Additional 
analyses 
16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-
specified. 
N/A 
Results    
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with 
a flow diagram. 
25-6, Figure 2-1 
 
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the 
citations. 
26-55, Tables A1-4 to A1-14 
and Tables A1-16 and A1-17 
Risk of bias 
within studies 
19 Present data on risk bias of each study and, if available, any outcome-level assessment (see item 12). 26 and 49, Tables A1-3 and 
A1-15 
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study: (a) simple summary data for each intervention group and (b) effect 
estimates and confidence intervals, ideally with a forest plot. 
N/A 
Synthesis of 
results 
21 Present the main results of the review.  If meta-analyses are done, include for each, confidence intervals and measures of inconsistency. 26-55 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15). N/A 
Additional 
analysis 
23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16). N/A 
Discussion    
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as 
health care providers, uses, and policy makers). 
55-61 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, 
reporting bias). 
61-2 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 63 
Funding    
Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic 
review 
PhD funded by Servier; 
systematic review not 
specifically funded 
  
276 
 
Table A1-2: Search strategy applied using Ovid to simultaneously search MEDLINE (1946-April 2015) and Embase (1947-April 2015) for studies that focused 
on the prognostic value resting heart rate for mortality and adverse cardiovascular outcomes.  
Search Search Term(s) Result 
#1 “heart rate” OR “pulse rate” OR “pulse” 32,607 
#2 “risk” OR “hazard” OR “prognos**” OR “predict**” OR “event**” OR “outcome**” OR “adverse” OR “death” OR “mortality” OR “survival” 1,023,274 
#3 #1 AND #2 3,330 
#4 #3 de-duplicated with Field Preference “has abstract” with Database Preferences 1. Embase and 2. MEDLINE 1,977 
#5 #4 NOT (“paediatric” OR “pediatric” OR “fetal” OR “foetal” OR “fetus” OR “foetus” OR “infant” OR “child” OR “newborn” OR “baby” OR “babies”) 1,762 
#6 #5 NOT (“pulse pressure” OR “wave**” OR “oxi**” OR “oxy**” OR “energy”) 1,201 
#7 #6 NOT (“react**” OR “respons**” OR “dynamic**” OR “turbul**”) 1,047 
#8 #7 NOT (“heart rate varia**” OR “heart rate recovery” OR “maxim**”) 569 
#9 #8 NOT “ST segment” 556 
All searches were Title searches, and specified the following limits: English Language; Full Text; Human; and Humans.  
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Table A1-3: The quality of each of the ‘baseline heart rate’ studies, according to the Newcastle Ottawa Scale96.  
Study Population Selection Comparability Outcome Total 
Dyer et al. 1980101 General *** ** ** ******* 7 
Kannel et al. 1987108 General **** ** ** ******** 8 
Gillum et al. 1991109 General *** ** *** ******** 8 
Filipovsky et al. 1992102 General *** ** ** ******* 7 
Shaper et al. 1993107  General **** ** ** ******** 8 
Greenland et al. 1999110  General **** ** *** ********* 9 
Palatini et al. 1999111  General *** ** ** ******* 7 
Benetos et al. 1999112 General *** ** ** ******* 7 
Reunanen et al. 2000113 General **** ** ** ******** 8 
Kristal-Boneh et al. 2000103 General *** ** *** ******** 8 
Seccareccia et al. 2001104 General *** ** *** ******** 8 
Fujiura et al.2001105 General *** ** ** ******* 7 
Kado et al. 2002123 General *** ** ** ******* 7 
Chang et al. 200397 General *** ** * ****** 6 
Perk et al. 2003114 General **** ** ** ******** 8 
Okamura et al. 2004115 General **** ** *** ********* 9 
Theobald and Wandell 2007116 General *** ** ** ******* 7 
Cacciatore et al. 2007125 General *** ** *** ******** 8 
Kizilbash et al. 2008117 General *** ** *** ******** 8 
Tverdal et al. 2008100 General ***** ** *** ********* 9 
Hsia et al. 2009124 General **** ** ** ******** 8 
Fagundes and Castro 2010126 General ** ** *** ******* 7 
Nauman et al. 2010118 General **** ** ** ******** 8 
Cooney et al. 2010119  General **** ** ** ******** 8 
Batty et al. 201098 General *** ** ** ******* 7 
Mao et al. 2010120  General **** ** *** ********* 9 
Jensen et al. 2011127 General **** ** ** ******** 8 
Jensen et al. 2012128 General **** ** ** ******** 8 
Pfister et al. 2012129 General *** ** ** ******* 7 
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O’Hartaigh et al. 2012130 General *** ** ** ******* 7 
Teodorescu et al.2013137  General **** ** *** ********* 9 
Pittaras et al. 2013131 General *** ** ** ******* 7 
Johansen et al. 2013132  General *** ** ** ******* 7 
Jensen et al. 2013106 General *** ** ** ******* 7 
Opdahl et al. 201466 General **** ** ** ******** 8 
Aladin et al. 2014133 General *** ** ** ******* 7 
Wang et al. 2014134 General **** ** * ******* 7 
Carlson et al. 201499 General *** ** *** ******** 8 
Makita et al. 2014121 General *** ** ** ******* 7 
Woodward et al. 2014135 General **** ** ** ******** 8 
Vassalle et al. 2014122 General *** ** ** ******* 7 
Khan et al. 2015136 General *** ** ** ******* 7 
Stettler et al. 2007140 Diabetic *** ** *** ******** 8 
Hillis et al. 2012141 Diabetic *** ** ** ******* 7 
Miot et al. 2012142 Diabetic *** ** ** ******* 7 
Gillman et al. 1993144 Hypertensive **** ** ** ******** 8 
Palatini et al. 2002147  Hypertensive *** ** ** ******* 7 
King et al. 2006145 Hypertensive *** ** ** ******* 7 
Salles et al. 2013146  Hypertensive *** ** ** ******* 7 
Diaz et al. 2005148 CHD *** ** ** ******* 7 
Ho et al. 2010149 CHD *** ** ** ******* 7 
Anselmino et al. 2010150 CHD **** ** * ******* 7 
Ortiz et al. 2010151 CHD **** ** ** ******** 8 
Hjalmarson et al. 1990152 Post-MI/ACS **** ** * ******* 7 
Disegni et al. 1995153 Post-MI/ACS *** ** ** ******* 7 
Zuanetti et al. 1998154 Post-MI/ACS *** ** ** ******* 7 
Kovar et al. 2004155 Post-MI/ACS *** ** ** ******* 7 
Mauss et al. 2005156 Post-MI/ACS **** ** * ******* 7 
Honda et al. 2010157 Post-MI/ACS *** ** *** ******** 8 
Parodi et al. 2010159 Post-MI/ACS **** ** * ******* 7 
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Bangalore et al. 2010160 Post-MI/ACS **** ** ** ******** 8 
Timoteo et al. 2011161 Post-MI/ACS **** ** * ******* 7 
Han et al. 2012162 Post-MI/ACS **** ** ** ******** 8 
Facila et al. 2012163 Post-MI/ACS **** ** *** ********* 9 
Antoni et al. 2012169 Post-MI/ACS **** ** ** ******** 8 
Noman et al. 2013164 Post-MI/ACS **** ** ** ******** 8 
Jensen et al. 2013170 Post-MI/ACS *** ** ** ******* 7 
Davidovic et al. 2013165 Post-MI/ACS *** * * ***** 5 
Li et al. 2013166 Post-MI/ACS *** ** ** ******* 7 
Seronde et al. 2014171 Post-MI/ACS **** ** ** ******** 8 
Asaad et al. 2014167  Post-MI/ACS **** ** * ******* 7 
Salwa et al. 2015168 Post-MI/ACS *** ** ** ******* 7 
Kapoor and Heidenreich 2010172 Heart Failure *** ** ** ******* 7 
Castagno et al. 2012173 Heart Failure *** ** ** ******* 7 
Maeder and Kaye 2012174 Heart Failure *** ** ** ******* 7 
Bui et al. 2013177 Heart Failure **** ** ** ******** 8 
Habal et al. 2014178  Heart Failure **** ** ** ******** 8 
Bohm et al. 2014175 Heart Failure *** ** ** ******* 7 
Kaplon-Cieslicka et al. 2014179  Heart Failure **** ** * ******* 7 
Takada et al. 2014176 Heart Failure **** ** * ******* 7 
Lancellotti et al. 2015180 Heart Failure *** ** ** ******* 7 
Laskey et al. 2015181 Heart Failure **** ** * ******* 7 
Fox et al. 2008184 LV Dysfunction *** ** ** ******* 7 
Bohm et al. 2010182 LV Dysfunction *** ** ** ******* 7 
Fosbol et al. 2010183 LV Dysfunction *** ** ** ******* 7 
Fillinger et al. 2002185 Pre- or Post-CABG **** ** ** ******** 8 
Aboyans et al. 2008186 Pre- or Post-CABG *** ** ** ******* 7 
Frank et al. 2010187 Pre- or Post-CABG **** ** ** ******** 8 
Bemelmans et al. 2013188 Vascular Disease *** ** *** ******** 8 
Nanchen et al. 2013138 Vascular Disease *** ** ** ******* 7 
van Kruijsdijk et al. 2014189 Vascular Disease *** ** *** ******** 8 
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Bohm et al. 2012190 Post-Stroke *** ** ** ******* 7 
Fox et al. 2013191 Post-Stroke *** ** ** ******* 7 
Sandset et al. 2014192 Post-Stroke *** ** ** ******* 7 
Erdur et al. 2014193 Post-Stroke *** ** ** ******* 7 
Beddhu et al. 2009194 Kidney Disease *** ** * ****** 6 
Iseki et al. 2011195  Kidney Disease **** ** ** ******** 8 
Inoue et al. 2012196 Kidney Disease *** ** ** ******* 7 
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Table A1-4: An overview of studies which have investigated baseline resting heart rate as a risk marker in a general population of subjects. 
Authors Year Study Name Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Dyer et al.101 1980 The Chicago People Gas 
Company study; the 
Chicago Western Electric 
Company study; and the 
Chicago Heart Association 
Detection Project in 
Industry 
Three groups of middle-aged 
white men (between 40 and 64 
years) free of definite CHD 
1233, 1899 and 
5784, respectively 
15, 17 and 5 
years, 
respectively 
Baseline resting heart 
rate measured by 
ECG, pulse, and ECG, 
respectively for the 
three different study 
groups 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD death 
 
Sudden death 
Kannel et 
al.108 
1987 The Framingham Study White men and women free of CV 
disease 
5070 30 years Baseline resting heart 
rate measured by ECG 
Logistic 
regression 
All-cause death 
 
CV death 
 
CHD death 
 
Sudden death 
Gillum et 
al.109 
1991 NHEFS Black and white men and women 
without known CV disease  
5995 9.9 years for 
white, and 10.3 
years for black 
subjects 
Baseline resting heart 
rate measured by 
pulse  
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD death (white 
subjects only) 
 
Incidence of CHD (white 
subjects only) 
Filipovsky et 
al.102 
1992 The Paris Prospective 
Study I 
Native-born Frenchmen aged 42 
to 53 years employed by the Paris 
Civil Service without known CV 
disease 
4907 17 years Baseline resting heart 
rate and difference 
between baseline and 
exercise test heart 
rate 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
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Shaper et 
al.107  
1993 British Regional Heart 
Study 
Men aged 40 to 59 years selected 
from GP age-sex registers in 24 
towns across Britain 
7735 (7683 with 
heart rate 
measurements) 
 8 years Baseline resting heart 
rate measured by ECG 
Logistic 
regression 
Major CHD event 
 
CHD death 
 
Sudden death 
Greenland 
et al.110  
1999 Chicago Heart Association 
Detection Project 
Men and women aged 18 to 74 
years from Chicago, with no 
evidence of a prior MI  
33781 22 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD death 
Palatini et 
al.111  
1999 CASTEL Men and women from northeast 
Italy, aged ≥65 years in sinus 
rhythm 
1938 12 years Baseline resting heart 
rate measured by 
palpation of the radial 
pulse 
Logistic 
regression 
All-cause death 
 
CV death 
 
Sudden death 
Benetos et 
al.112 
1999 - Men and women from Paris, aged 
40 to 69 years 
19386 18.2 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD death 
 
Stroke death 
Reunanen et 
al.113 
2000 - Finnish men and women aged 30 
to 59 years 
10717 23 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD death 
 
Stroke death 
Kristal-
Boneh et 
al.103 
2000 The CORDIS Study Jewish male Israeli industrial 
employees at least 25 years old 
without CV disease or on heart 
medication, with a mean age of 
43 years 
3527 8 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
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Seccareccia 
et al.104 
2001 MATISS Middle-aged men (40 to 69 years) 
residing in Central Italy 
2533 - Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
Fujiura et 
al.105 
2001 - Men aged 40 to 64 years from the 
rural farming community 
Tanushimaru in Japan 
573 18 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
Kado et 
al.123 
2002 Study of Osteoporotic 
Fractures 
Elderly white women (≥65 years 
old) from America  
9702 6 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression and 
logistic 
regression 
All-cause death 
 
CHD death 
 
Stroke death 
Chang et 
al.97 
2003 WHAS I American community-dwelling 
older women (≥65 years old) with 
a moderate to severe disability 
953 3 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
Perk et al.114 2003 Jerusalem 70-year-old 
Longitudinal Survey 
Elderly men and women (aged 70 
years at entry) living in Jerusalem  
422 6 years Baseline resting heart 
rate measured by 
pulse and ECG 
Logistic 
regression 
All-cause death 
Okamura et 
al.115 
2004 National Survey on 
Circulatory Disorders 
Men and women from Japan who 
were community dwellers aged 30 
years or older, with no history of 
CHD or stroke, any arrhythmias or 
AF 
8088 16.5 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD and HF death 
Theobald 
and 
Wandell116 
2007 - Men and women from Stockholm 
county aged 18 to 64 years  
989 26 years Resting baseline heart 
rate measured from 
pulse 
Cox proportional 
hazards 
regression 
All-cause death 
Cacciatore 
et al.125 
2007 Osservatorio Geriatrico 
Regione Campania 
Elderly Italian men and women 
(>65 years old) 
1163 12 years Baseline resting heart 
rate measured by 
cardiac auscultation 
Cox proportional 
hazards 
regression 
All-cause death 
284 
 
Kizilbash et 
al.117 
2008 Chicago Heart Association 
Detection Project in 
Industry 
Normal-weight men and women 
aged 18 to 59 years with no 
history or evidence of MI 
14653 32 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
CV death 
Tverdal et 
al.100 
2008 - Middle-aged (40 to 45 years) 
Norwegian men and women with 
no history of CV disease or 
diabetes 
379843 12.6 years Baseline resting heart 
rate measured using 
an automatic device 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CHD death 
 
Stroke death 
 
Sudden death 
Hsia et al.124 2009 The Women’s Health 
Initiative 
Post-menopausal women from the 
United States with a mean age of 
approximately 62 years, without a 
prior MI, stroke or 
revascularisation, or on heart rate 
medication 
129135 7.8 years Baseline resting heart 
rate measured by 
palpation of the radial 
pulse 
Cox proportional 
hazards 
regression 
MI or coronary death 
 
Stroke 
Fagundes 
and Castro126 
2010 - Men and women from Brazil who 
were dead (case) or alive 
(control) who had undergone 
exercise stress testing, with a 
mean age of 55.43 years 
7055 12 years Seated resting heart 
rate measured 
manually before 
exercise stress testing 
by a heart monitor   
Logistic 
regression 
AC death 
 
CV death 
Nauman et 
al.118 
2010 HUNT Men and women from Norway, 
aged 20 years or older, with no 
signs of CV disease 
50088 18.2 years Baseline resting heart 
rate measured by 
radial pulse palpation 
Cox proportional 
hazards 
regression 
CHD death 
Cooney et 
al.119  
2010 FINRISK Finnish men and women aged 25 
to 74 years drawn from the 
general population with no history 
of MI, angina or HF, not on 
hypertensive medications 
28047 12 years Baseline resting heart 
rate measured by 
palpation of the radial 
artery 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV disease death 
 
CHD death 
 
Fatal and non-fatal CHD 
events 
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Batty et al.98 2010 The Whitehall Study Non-industrial, government 
employed men aged 40 to 69 
years from London 
1183 40 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression  
All-cause death 
 
CHD death 
 
Stroke death 
Mao et al.120  2010 China National 
Hypertension Survey 
Epidemiology Follow-Up 
Study 
Chinese men and women aged 40 
years or older without prevalent 
CV disease or hypertension 
108534 8.3 years Baseline resting heart 
rate obtained 
manually 
Cox proportional 
hazards 
regression 
CV disease 
 
Heart disease 
 
CHD 
 
Stroke 
 
Ischemic stroke  
 
Haemorrhagic stroke 
Jensen et 
al.127 
2011 CCHS Men and women aged 20 years 
and older sampled from the 
Copenhagen Population Register, 
without CHD, diabetes or AF, who 
had never had an MI or stroke, 
not taking any heart medications 
16516 21.2 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death  
 
CV death 
Jensen et 
al.128 
2012 CCHS Danish men and women with a 
mean age of 56.2 years without 
CHD, diabetes or AF, who had 
never had an MI or stroke, not 
taking any heart medications 
6518 14 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
Pfister et 
al.129 
2012 EPIC-Norfolk Men and women aged 39 to 79 
years from Norfolk in the United 
Kingdom 
22126 12.9 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression 
Incident HF 
O’Hartaigh 
et al.130 
2012 LURIC German Caucasian men and 
women aged 18 to 95 years who 
were referred for coronary 
angiography, with stable clinical 
disease 
3316 9.9 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death  
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Teodorescu 
et al.137  
2013 Oregon Sudden Unexpected 
Death Study 
Men and women from Portland, 
Oregon, who had died of sudden 
cardiac death (case) or who were 
alive with or without CHD 
(control) aged ≥35 years with a 
mean age of 67.7 years 
756 - Resting heart rate 
measured by ECG – 
the most prior but 
unrelated to the 
sudden cardiac death 
for cases  
Logistic 
regression 
Sudden cardiac death 
Pittaras et 
al.131 
2013 - Male and female veterans with a 
mean age of 58 years  
18462 10 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression 
All-cause death 
Johansen et 
al.132  
2013 The Copenhagen Holter 
Study 
Middle-aged and elderly men and 
women (55 to 75 years) from 
Copenhagen with no known heart 
disease 
653 6.3 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV event (CV death, 
acute MI, or 
revascularisation) 
Jensen et 
al.106 
2013 The Copenhagen Male 
Study 
Healthy Caucasian middle-aged 
men employed at 14 large 
workplaces in Copenhagen in 1970 
to 1971 
2798 16 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
Opdahl et 
al.66 
2014 The MESA Study Men and women from America 
aged 45 to 84 years without 
known CV disease 
- 7 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
Incident HF 
Aladin et 
al.133 
2014 The FIT Project Men and women ≥18 years 
without known CHD or AF who 
underwent a clinically indicated 
exercise stress test 
56634 11.1 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression 
All-cause death 
 
MI 
 
Revascularisation 
 
Major adverse cardiac 
event (a combination of 
the three above) 
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Wang et 
al.134 
2014 The Kailuan Study Men and women aged 18 to 98 
years from the Kailuan community 
in Tangshan of China 
92562 4 years Baseline resting heart 
rat measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV disease 
 
MI 
 
Any stroke 
 
Ischemic stroke 
 
Hemorrhagic stroke 
Carlson et 
al.99 
2014 CCHS Men and women from Copenhagen 
>20 years with no known CV 
disease 
131 13.6 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
Composite of non-fatal 
HF, acute MI, CHD and 
CV death 
Makita et 
al.121 
2014 Iwate-Kenpoku Cohort 
Study 
Community-dwelling 40 to 79 
year-old men and women from 
northern Japan without known CV 
disease or AF 
17766 5.6 years Baseline resting pulse 
rate  
Cox proportional 
hazards 
regression 
Any CV disease event 
including CV death 
Woodward 
et al.135 
2014 APCSC Men and women within the Asian-
Pacific region at least 20 years 
old, drawn from the general 
population 
112680 7.4 years Baseline resting heart 
rate 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV disease death 
 
HF death 
 
Fatal and non-fatal: 
CV disease 
CHD 
All stroke 
Haemorrhagic stroke 
Ischemic stroke 
Unclassified stroke 
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Vassalle et 
al.122 
2014 - Men and women admitted to the 
Coronary Care Unit of the CNR-
Clinical Physiology Institute in 
Pisa to undergo a coronary 
angiography, with a mean age of 
66 years 
3559 2.9 years Resting heart rate 
obtained at admission 
Cox proportional 
hazards 
regression 
All-cause death 
 
Cardiac death  
Khan et 
al.136 
2015 Health ABC; CHD; KIHD American men and women aged 
65 to 100 years, and men from 
Eastern Finland aged 42 to 61 
years, without prevalent HF or 
major ECG abnormalities; mean 
age 67 years 
7073 
 
Meta-analysis 
n = 43051 
- Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
 
Meta-analysis 
Incident HF (non-fatal 
hospital admission for 
HF) 
If no study name is given it is because the study was not explicitly named in the publication or was not given a name. Follow-up duration for each study is either total, median or mean follow-up depending on 
what was stated in the publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was 
not stated in the publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
NHEFS stands for the first National Health and Nutrition Examination Survey (NHANES I) Epidemiologic Follow-Up Study (NHEFS).   
CASTEL stands for the CArdiovasuclar STudy of the ELderly.   
CORDIS stands for Cardiovascular Occupational Risk Factors Determination in Israel. 
MATISS stands for the Malattie Cardiovasculari Aterosclerotiche, Istituto Superiore di Sanita (MATISS) Project.  Seccareccia et al. 2001104 do not explicitly state the follow-up period.   
WHAS I stands for the Women’s Health and Aging Study I. 
HUNT stands for the Nord-Trondelag Health (HUNT) Study. 
FINRISK stands for the Finland Cardiovascular Risk Study. 
CCHS stands for the Copenhagen City Heart Study. 
EPIC-Norfolk stands for the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. 
LURIC stands for the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study.  
MESA stands for the Multi-Ethnic Study of Atherosclerosis (MESA).  In the Opdahl et al. 201466 publication it is not completely clear how many patients were included in the different analyses.   
FIT stands for Henry Ford Exercise Testing (FIT). 
APCSC stands for the Asia Pacific Cohort Studies Collaboration.   
ABC stands for Aging and Body Composition; CHD stands for Cardiovascular Health Study; and KIHD stands for Kuopio Ischemic Heart Disease.  Khan et al. 2015136 only stated follow-up in person-years. 
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AF = Atrial Fibrillation; CV = Cardiovascular; CHD = Coronary Heart Disease; ECG = Electrocardiography; GP = General Practitioner; HF = Heart Failure; MI = Myocardial Infarction.   
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Table A1-5: An overview of studies which have investigated baseline resting heart rate as a risk marker in subjects with diabetes. 
Authors Year Study Name Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Stettler 
et al.140 
2007 The WHO Multinational 
Study of Vascular Disease 
in Diabetes 
Swiss men and women aged 
between 35 and 54 years 
with type 1 or 2 diabetes 
523 22.6 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
Cardiac death 
 
CHD death 
Hillis et 
al.141 
2012 ADVANCE Men and women at least 55 
years old with type 2 
diabetes, with a mean age 
of 66 years 
11138 4.4 years Baseline resting heart 
rate measured using a 
digital monitor 
Cox proportional 
hazards regression 
 
Proportional sub-
distributions hazards 
regression 
All-cause death 
 
CV death 
 
Major CV event (CV death, non-
fatal MI, or stroke) 
Miot et 
al.142 
2012 SURDIAGENE Men and women from 
France, with type 2 
diabetes, with a mean age 
of approximately 65 years 
1088 4.2 years Baseline resting heart 
rate measured by ECG 
Fine and Gray143 Primary outcome: CV death, non-
fatal MI, non-fatal stroke, 
hospitalisation from HF, or onset 
of end-stage renal disease 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
WHO stands for the World Health Association (WHO). 
ADVANCE stands for the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Study. 
SURDIAGENE stands for Survie Diabete de type 2 et Genetique (SURDIAGENE) study. 
CV = Cardiovascular; CHD = Coronary Heart Disease; ECG = Electrocardiography; HF = Heart Failure; MI = Myocardial Infarction.  
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Table A1-6: An overview of studies which have investigated baseline resting heart rate as a risk marker in subjects with hypertension. 
Authors Year Study Name Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Gillman 
et al.144 
1993 The 
Framingham 
Study 
Men and women with hypertension 
(SBP >140mmHg or DBP >90mmHg) 
not taking anti-hypertensive 
medication, with a mean age of 
around 55 years 
4530 36 years Baseline resting heart rate 
measured by ECG 
Logistic regression All-cause death 
 
CV death 
 
CHD death 
 
Sudden death 
 
CV disease (fatal and 
non-fatal) 
 
CHD (fatal and non-fatal) 
 
Palatini 
et al.147  
2002 Syst-Eur Men and women ≥60 years with a 
baseline blood pressure 
measurement between 160 and 
219mmHg systolic, and <95mmHg 
diastolic, who were randomised to 
the placebo group 
2293 2 years Baseline resting heart rate, referred 
to as clinical/conventional heart 
rate in the paper (the mean of six 
readings during three visits in the 
placebo run-in period) 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
 
King et 
al.145 
2006 ARIC Men and women aged between 45 
and 64 years, with pre-hypertension, 
free of CHD  
3275 10.1 years Baseline resting heart rate 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death 
 
Incident CHD 
Salles et 
al.146  
2013 - Men and women from Brazil, with 
resistant hypertension and a mean 
age of 60 to 70 years, who were in 
sinus rhythm 
528 4.8 years Baseline resting heart rate 
measured by radial artery palpation 
(clinic heart rate) 
 
Baseline resting heart rate 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
Composite endpoint: all 
fatal or non-fatal CV 
events 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
Sys-Eur stands for the Systolic Hypertension in Europe (Sys-Eur) trial.   
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ARIC stands for the Atherosclerosis Risk in communities (ARIC) study. 
CV = Cardiovascular; CHD = Coronary Heart Disease; DBP = Diastolic Blood Pressure; ECG = Electrocardiography; SBP = Systolic Blood Pressure.  
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Table A1-7: An overview of studies which have investigated baseline heart rate as a risk marker in subjects with coronary heart disease. 
Authors Year Study 
Name 
Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Diaz et 
al.148 
2005 CASS Men and women who underwent a coronary 
angiography for suspected or proven CHD, who 
were shown to have stable CHD if suspected, with 
a mean age of 53 years 
24913 14.7 years Baseline resting 
heart rate measured 
by pulse 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV death 
 
CV rehospitalisation 
(hospitalisation for MI, angina, 
stroke, revascularisation or 
rhythm disturbance) 
 
Rehospitalisation due to acute MI 
 
Rehospitalisation due to angina 
 
Rehospitalisation due to stroke 
 
Rehospitalisation due to 
congestive HF 
Ho et al.149 2010 TNT Men and women aged 35 to 75 years with clinically 
evident CHD, defined by one or more of the 
following: previous MI, previous or current angina 
with evidence of atherosclerotic CHD, or a history 
of coronary revascularisation 
9580 4.9 years Baseline resting 
heart rate measured 
by ECG 
Cox proportional 
hazards 
regression 
A major CV event defined as CHD 
death, non-fatal MI, stroke or a 
resuscitated cardiac arrest 
 
All-cause death 
 
Non-fatal MI 
 
Fatal or non-fatal stroke 
 
HF hospitalisation 
Anselmino 
et al.150 
2010 Euro 
Heart 
Survey 
Men and women with CHD, with a mean age in the 
region of 65 to 70 years 
2507 1 year Baseline resting 
heart rate (the 
average of two 
measurements 
taken) 
Cox proportional 
hazards 
regression 
All-cause death 
 
CV event (all-cause death, non-
fatal MI or stroke) 
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Ortiz et 
al.151 
2010 - Men and women with stable CHD with a mean age 
of 68 years 
1264 2.1 years Baseline resting 
heart rate measured 
by ECG 
Cox proportional 
hazards 
regression 
A major CV event (death, ACS, 
revascularisation, stroke or 
hospitalisation for HF) 
 
A coronary event (ACS or 
revascularisation) 
 
All-cause death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
CASS stands for the Coronary Artery Surgery Study (CASS).   
TNT stands for the Treating to New Targets (TNT) study.   
ACS = Acute Coronary Syndrome; CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; MI = Myocardial Infarction.  
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Table A1-8: An overview of studies which have investigated heart rate as a risk marker in patients with acute coronary syndromes, myocardial infarction 
and unstable angina. 
Authors Year Study Name Study Population No. of Subjects Follow-up Type of Heart ate Type of Analysis Outcomes 
Hjalmarson 
et al.152 
1990 - Men and women with acute-MI 
admitted to the hospital within 24-
hours of onset of symptoms, with a 
mean age of around 63 years 
1807 (1585 
discharged from 
hospital) 
1 year Admission heart rate Cox proportional 
hazards regression 
In-hospital mortality 
 
1-year post-discharge mortality 
Disegni et 
al.153 
1995 SPRINT 2 Men and women hospitalised with 
proven acute MI in Israel, with a 
mean age of around 64 years 
1044 1 year Admission heart rate Logistic regression In-hospital mortality 
 
1-year post-discharge mortality 
Zuanetti et 
al.154 
1998 GISSI-2 Men and women hospitalised for 
acute MI, treated with thrombolytic 
agents within 12-hours of onset of 
symptoms 
8915 0.5 years Admission heart rate 
measured by ECG 
 
Discharge heart rate 
measured by ECG 
Logistic regression 
 
Cox proportional 
hazards regression 
In-hospital mortality 
 
6-month post-discharge 
mortality 
Kovar et 
al.155 
2004 OPUS-TIMI-16 Men and women with ACS, with a 
mean age of around 61 years 
10267 0.83 years Admission heart rate 
measured by physical 
exam or ECG 
Cox proportional 
hazards regression 
30-day mortality 
 
10-month mortality 
Mauss et 
al.156 
2005 - Men and women presenting with 
acute MI in Germany, with a mean 
age of 58 years 
432 3.42 years Discharge heart rate 
measured by ECG 
Logistic regression The combined endpoint of all-
cause death and arrhythmic 
events (i.e. sudden death, 
resuscitated ventricular 
fibrillation, sustained ventricular 
tachycardia) 
Honda et 
al.157 
2010 - Men and women admitted to the 
Department of Cardiology at 
Kumamoto Medical Center in Japan, 
within 24 hours of acute MI, who 
underwent coronary angiography, 
with a mean age in the region of 67 
to 71 years 
200 - Heart rate measured at 
the time of arrival at 
the emergent unit of 
the Center 
Logistic regression  Poor LV function (LVEF before 
discharge <50%) 
 
In-hospital death 
296 
 
Parodi et 
al.159 
2010 - Men and women with STEMI 
undergoing primary PCI in sinus 
rhythm with a mean age of around 
65 years 
2477 0.5 years Presenting/baseline 
heart rate assessed by a 
calliper in the patient 
diagnostic ECG 
Cox proportional 
hazards regression 
6-month mortality 
Bangalore 
et al.160 
2010 CRUSADE Men and women with NSTE-ACS 
admitted to an American hospital, 
with a mean age of around 67 years 
135164 - Admission heart rate Generalised 
estimating 
equations 
Primary: the composite of in-
hospital all-cause death, non-
fatal re-infarction, and stroke 
 
All-cause death 
 
Non-fatal re-infarction 
 
Stroke 
Timoteo et 
al.161 
2011 - Men and women admitted to ICU in 
Portugal, with ACS, with a mean 
age of 64 years 
1126 1 year Admission heart rate Cox proportional 
hazards regression 
1-year post-discharge mortality 
Han et al.162 2012 - Men and women with STEMI 
admitted to a hospital in China 
within 12 hours of onset of 
symptoms, with a mean age in the 
region of 60 to 65 years 
7294 30 days Admission heart rate 
measured by ECG 
Cox proportional 
hazards regression 
30-day all-cause mortality 
 
30-day CV events (all-cause 
death, re-infarction, or stroke) 
Facila et 
al.163 
2012 PAMISCA Men and women admitted to a 
Spanish hospital with ACS, with a 
mean age of 67 years 
1054 1 year Admission heart rate 
measured between day 
3 and 7 of the ACS 
event once the patient 
was stable 
Cox proportional 
hazards regression 
1-year post-discharge mortality 
Antoni et 
al.169 
2012 - Men and women admitted with 
STEMI treated with PCI in sinus 
rhythm, with a mean age of 61 
years from the Netherlands 
1492 3.3 years Discharge heart rate 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death at 1- and 4-years 
post-discharge 
 
CV death at 1- and 4-years post-
discharge 
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Noman et 
al.164 
2013 - Men and women who underwent 
primary PCI for STEMI at Freeman 
Hospital in Newcastle, United 
Kingdom with a mean age of around 
62 years 
2310 1.6 years Admission heart rate 
measured by ECG 
Logistic regression 
 
Cox proportional 
hazards regression 
Long-term post-discharge 
mortality 
 
In-hospital mortality 
Jensen et 
al.170 
2013 BASKET-PROVE Men and women with stable or 
unstable ACS treated with PCI and 
in need of stenting, from 
Switzerland, Denmark, Austria and 
Italy, with a mean age of around 63 
years 
2029 2 years Discharge heart rate 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death 
 
CV death or non-fatal MI 
Davidovic et 
al.165 
2013 - Men and women with anterior wall 
STEMI treated in the Coronary Unit 
at the Clinical Center Kragujevac in 
Serbia, ≥30 years with no history of 
diabetes 
140 - Admission heart rate 
measured by ECG 
Logistic regression In-hospital mortality 
Li et al.166 2013 OMEGA Post-MI men and women presenting 
with AF, with a mean age of 72 
years 
211 1 year Admission heart rate Logistic regression 1-year mortality 
Seronde et 
al.171 
2014 FAST-MI Male and female patients admitted 
to coronary care units in France for 
MI, who survived, with a mean age 
of around 66 years 
3079 5 years Discharge heart rate Cox proportional 
hazards regression 
1-year post-discharge mortality 
 
5-year post-discharge mortality 
 
5-year post-discharge mortality 
excluding patients who died 
within the first year 
Asaad et 
al.167  
2014 Gulf RACE-2 Male and female ACS patients 
(diagnosed with unstable angina 
and NSTEMI or STEMI/LBBB) from 
Middle Eastern Gulf countries, with 
a mean age of 56 years 
7939 1 year Admission heart rate Logistic regression In-hospital HF 
 
1-month mortality 
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Salwa et 
al.168 
2015 - Men and women with STEMI 
hospitalised in the Clinical 
Department of Cardiology in 
Poland, with a mean age of 65 years 
927 - Admission heart rate 
measured by ECG 
Logistic regression In-hospital CV death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
Honda et al. 2010157, Bangalore et al. 2010160, Davidovic et al. 2013165 and Salwa et al. 2015168 only analysed in-hospital events hence why no follow-up period is stated.   
SPRINT 2 stands for the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT 2).   
GISSI-2 stands for the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) 2 trial.  GISSI an influence Italian cardiology research group for the study of the survival of MI. 
OPUS-TIMI stands for the Orofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI)-16 trial.   
CRUSADE stands for the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the American College of Cardiology/American Heart Association 
Guidelines (CRUSADE) National Quality Improvement Initiative database. 
PAMISCA stands for the Prevalence of Peripheral Arterial Disease in Patients with Acute Coronary Syndrome (PAMISCA) registry study.  The heart rate measurement in Facila et al. 2012163 was determined 
between day 3 and 7 of a subject experiencing an ACS event once they were stable. 
BASKET-PROVE stands for the BAsel Stent Kosten Effektivitats Trial PROspective Validation Examination. 
OMEGA was a randomised trial investigating the effect of omega-3 fatty acid supplementation on the rate of sudden cardiac death in survivors of acute MI. 
FAST-MI stands for the French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarction (FAST-MI) 2005 registry.   
Gulf RACE-2 stands for the Gulf Registry of Acute Coronary Events. 
AF = Atrial Fibrillation; ACS = Acute Coronary Syndrome; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; ICU = Intensive Care Unit; LBBB = Left Bundle Branch Block; LV = Left-
Ventricular; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction; NSTE-ACS = Non-ST Segment Elevation Acute Coronary Syndrome; NSTEMI = Non-ST Segment Elevation Myocardial 
Infarction; PCI = Percutaneous Coronary Intervention; STEMI = ST Segment Elevation Myocardial Infarction. 
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Table A1-9: An overview of studies which have investigated baseline, admission or, in-hospital or discharge heart rate as a risk marker in subjects with 
heart failure.  
Authors Year Study Name Study Population No. of 
Subjects 
Follow-up Type of Heart Rate Type of Analysis Outcomes 
Kapoor and 
Heidenreich172 
2010 - Men and women with HF and LVEF 
≥50%, with a mean age of 70 years, 
in sinus rhythm 
685 2.9 years Baseline resting heart rate 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death at 1-year 
post-discharge 
Castagno et 
al.173 
2012 CHARM Men and women with chronic HF 
with a mean age in the region of 
65 to 70 years 
7597 3.14 years Baseline resting heart rate 
measured by ECG, 
palpation, or auscultation 
Cox proportional 
hazards regression 
All-cause death 
 
CV death or hospital stay 
for worsening HF 
Maeder and 
Kaye174 
2012 DIG (main and 
ancillary) 
Men and women with HF and 
reduced or preserved ejection 
fraction, with a mean age of 63 
years and 67 years, respectively, in 
sinus rhythm  
7780 Around 3 years 
(median of 3.15 
years in the main 
trial and 3.21 
years in the 
ancillary trial) 
Baseline resting heart rate Cox proportional 
hazards regression 
All-cause death 
 
HF hospitalisation 
Bui et al.177 2013 GWTG-HF Men and women hospitalised for HF 
with a mean age in the region of 
70 to 80 years 
145221 - Admission heart rate 
defined as the first 
measurement obtained 
after presentation to the 
emergency department or 
admission to the hospital 
ward 
Logistic regression  In-hospital mortality 
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Habal et al.178  2014 EFFECT-HF Men and women hospitalised for HF 
in sinus rhythm with a mean age of 
around 80 years 
9097 1 year Discharge heart rate 
defined as the last 
recorded heart rate 
obtained within 24 hours 
before or at discharge 
Logistic regression  
 
Cox proportional 
hazards regression 
All-cause death at 30 days 
and 1- year post-discharge 
 
CV death at 30 days and  
1-year post-discharge 
 
Re-admission for HF at 30 
days and 1-year  
post-discharge 
 
Re-admission for CHD at 
30 days and 1-year  
post-discharge 
 
Re-admission for CV 
disease at 30 days and  
1-year post-discharge 
Bohm et al.175 2014 I-PRESERVE Men and women >60 years old on 
irbesartan with HF and preserved 
ejection fraction (>45%) in sinus 
rhythm or AF 
3967 (3271 in 
sinus rhythm 
and 696 in AF) 
4.13 years Baseline resting heart rate 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death or CV 
hospitalisation 
(hospitalisation due to HF, 
MI, unstable angina, 
arrhythmia or stroke) 
 
All-cause death 
 
CV death or HF 
hospitalisation 
 
CV death 
 
HF hospitalisation 
Kaplon-
Cieslicka et 
al.179  
2014 Heart Failure 
Pilot Survey of 
the European 
Society of 
Cardiology 
Polish men and women admitted to 
hospital due to HF with a median 
age of 69 years 
598 - Admission heart rate Logistic regression In-hospital mortality 
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Takada et al.176 2014 CHART-2 Japanese men and women with HF 
in sinus rhythm, with a mean age 
of 67.5 years 
10219 3.13 years Baseline resting heart rate Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
HF death 
 
HF hospital admission 
Lancellotti et 
al.180 
2015 - Men and women presenting with 
acute HF at Centre Hospitalier 
Universitaire of Liege, Belgium, in 
sinus rhythm, who were alive 24 to 
36 hours after admission, with a 
mean age of 72 years 
712 - Resting heart rate at 24-36 
hours after admission 
obtained by ECG or cardiac 
monitoring  
Logistic regression In-hospital mortality 
Laskey et al.181 2015 GWTG-HF Men and women hospitalised for HF 
with a median age of 80 years 
46127 (26020 
in sinus 
rhythm and 
20197 in AF) 
1 year Discharge heart rate 
measured by palpation or 
telemetry for subjects in 
sinus rhythm, or by ECG or 
telemetry for subjects in 
AF 
Cox proportional 
hazards regression 
All-cause death  
 
All-cause readmission 
 
All-cause readmission or 
death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
Bui et al. 2013177, Kaplon-Cieslicka et al. 2014179, and Lancellotti et al. 2015180 only analysed in-hospital events hence why no follow-up period is stated.   
CHARM stands for the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. 
DIG stands for the Digitalis Investigations Group (DIG) trial.   
GWTG-HF stands for the American Heart Failure Associations’ Get With the Guidelines-Heart Failure (GWTG-HF) program.   
EFFECT-HF stands for the Enhanced Feedback for Effective Cardiac Treatment (EFFECT-HF) cohort. 
I-PRESERVE stands for the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) study.   
CHART-2 stands for the Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2) Study. 
AF = Atrial Fibrillation; CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction.  
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Table A1-10: An overview of studies which have investigated baseline resting heart rate as a risk marker in subjects with left-ventricular dysfunction. 
Authors Year Study Name Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Fox et 
al.184 
2008 BEAUTIFUL Men and women ≥55 years old with CHD, 
LVEF <40% and end-diastolic short-axis 
internal dimension larger than 56mm, in 
sinus rhythm with baseline heart rate 
≥60bpm 
5438 1.58 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
CV death 
 
HF hospitalisation (fatal and 
non-fatal) 
 
MI hospitalisation (fatal and 
non-fatal) 
 
Coronary revascularisation 
Bohm et 
al.182 
2010 SHIFT Men and women with symptomatic 
chronic HF with baseline heart rate 
≥70bpm and LVEF ≤35% in sinus rhythm, 
with a mean age of 60.4 years 
3264 1.91 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
CV death or hospital 
admission for worsening HF 
 
All-cause death 
 
CV death 
 
Death from HF 
 
All-cause hospital admission 
 
Hospital admission for 
worsening HF 
 
Any CV hospital admission 
 
CV death, or hospital 
admission for worsening HF 
or non-fatal MI 
Fosbol et 
al.183 
2010 DIAMOND Men and women with a mean age of 
around 70 years who were hospitalised 
with LVEF ≤35% with either HF or who 
were post-MI 
3013 (1518 with HF 
and 1510 who were 
post-MI) 
10 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards 
regression 
All-cause death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
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BEAUTIFUL stands for the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.  Fox et al. 2008184 did not 
explicitly state the follow-up period of the placebo group. 
SHIFT stands for the Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial (SHIFT).  Bohm et al. 2010182 also evaluated heart rate achieved at 28 days in the ivabradine group, but since 
ivabradine can affect heart rate, only the number of patients in the placebo group is stated.   
DIAMOND stands for the Danish Investigations and Arrhythmia ON Dofetilide (DIAMOND) study. 
CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction.  
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Table A1-11: An overview of studies which have investigated pre-induction, admission, or post-operative heart rate as a risk marker in CABG patient 
populations. 
Authors Year Study 
Name 
Study Population No. of 
Subjects 
Follow-up Type of Heart Rate Type of Analysis Outcomes 
Fillinger 
et al.185 
2002 NNECDSG Men and women having 
isolated CABG procedures, 
with a mean age of around 
65 years 
5934 - Pre-induction heart rate 
measured by ECG upon 
arrival to the operating 
room 
Logistic regression used to 
calculate predicted risk of 
adverse outcomes for each 
patient 
 
Cuzik extension of the 
Wilcoxon’s ranked sum non-
parametric test for trend 
In-hospital mortality 
 
Intra- or post-operative stroke 
 
 
Aboyans 
et al.186 
2008 - Men and women with a mean 
age of 67 years referred for 
non-urgent CABG 
1022 30 days 
post-CABG 
Pre-operative admission 
heart rate measured by 
ECG 
Logistic regression Primary: All-cause death, non-fatal MI or 
non-fatal stroke or TIA 
 
Secondary: All-cause death or stroke or 
TIA 
Frank et 
al.187 
2010 - Men and women with a mean 
age of 66 years referred for 
non-urgent CABG 
794 3.2 years Post-operative heart 
rate measured by ECG at 
the first outpatient visit  
Cox proportional hazards 
regression 
Primary: All-cause death 
 
Secondary: All-cause death, secondary 
coronary revascularisation, non-fatal ACS, 
non-fatal stroke or TIA, or vascular 
surgery 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
NNECDSG stands for the Northern New England Cardiovascular Disease Study Group.  Follow-up is not stated for Fillinger et al. 2002185 since only in-hospital outcomes were evaluated. 
Note that Aboyans et al. 2008186 and Frank et al. 2010187 analysed the same population of patients. 
ACS = Acute Coronary Syndrome; CABG = Coronary Artery Bypass Graft; ECG = Electrocardiography; MI = Myocardial Infarction; TIA = Transient Ischemic Attack.  
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Table A1-12: An overview of studies which have investigated baseline resting heart rate as a risk marker in mixed groups of subjects with some form of 
vascular disease. 
Authors Year Study 
Name 
Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Bemelmans 
et al.188 
2013 SMART Men and women aged 18 to 80 years from the 
Netherlands with manifest atherosclerotic 
vascular disease: CHD; cerebrovascular disease; 
PAD; or abdominal aortic aneurysm 
4272 4.4 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards regression 
MI 
 
Ischemic stroke 
 
All vascular events 
 
Vascular death 
 
All-cause death 
Nanchen et 
al.138 
2013 PROSPER Men and women aged 70 to 82 years from the 
Netherlands, Scotland and Ireland, with a 
history of vascular disease defined as coronary, 
cerebral or PAD, or those with known CV risk 
factors, such as smoking, hypertension, or 
diabetes, in sinus rhythm, with a mean age of 75 
years 
4084 3.2 years Baseline resting heart 
rate measured by ECG 
Cox proportional 
hazards regression 
HF hospitalisation 
 
CV mortality 
van 
Kruijsdijk et 
al.189 
2014 SMART Men and women aged 18 to 80 years from the 
Netherlands with manifest atherosclerotic 
vascular disease: CHD; cerebrovascular disease; 
PAD; or abdominal aortic aneurysm 
6007 6 years Baseline resting heart 
rate measured by ECG 
Fine and Gray143 All-cause death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
SMART stands for the Second Manifestations of ARTerial disease study. 
PROSPER stands for the PROspective study of pravastatin in the elderly at risk (PROSPER) study. 
CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; MI = Myocardial Infarction; PAD = Peripheral Artery Disease.  
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Table A1-13: An overview of studies which have investigated baseline resting heart rate as a risk marker in post-stroke subjects. 
Authors Year Study 
Name 
Study Population No. of Subjects Follow-up Type of Heart Rate Type of analysis Outcomes 
Bohm et 
al.190 
2012 PRoFESS Post-ischemic stroke patients (male and 
female) aged 55 years or older, or aged 50 to 
54 years with two additional CV risk factors, 
with a mean age of 66 years 
20165 2.4 years Baseline resting heart rate Cox proportional 
hazards regression 
Recurrent stroke of any 
type 
 
MI 
 
Chronic HF 
 
All-cause death 
 
Vascular death 
Fox et 
al.191 
2013 PERFORM Post ischemic stroke or TIA men and women 
aged 55 years or older 
18980 2.4 yeas Baseline resting heart rate 
measured by palpitation, 
auscultation, or 12-lead ECG 
Cox proportional 
hazards regression 
All fatal or non-fatal MI 
 
Non-fatal MI 
 
All fatal or non-fatal 
ischemic stroke 
 
Non-fatal ischemic stroke 
 
All fatal or non-fatal 
stroke 
 
Vascular death 
 
All-cause death 
 
Fatal or non-fatal 
ischemic stroke, MI, and 
other vascular death 
Sandset 
et al.192 
2014 VALUE Male and female post-stroke or TIA patients 
with hypertension aged 50 years or older, 
with a mean age of 67.3 years 
3014 4.5 years Baseline resting heart rate 
measured by ECG 
Cox proportional 
hazards regression 
Recurrent stroke 
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Erdur et 
al.193 
2014 - Acute ischemic stroke patients admitted to 
hospital within 72 hours after onset of 
symptoms with a median age of 73 years, in 
sinus rhythm 
1335 - Admission to the emergency 
department heart rate measured 
by ECG 
Logistic regression In-hospital mortality 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
Erdur et al. 2014193 only analysed in-hospital events hence why no follow-up period is stated.   
PRoFESS stands for the Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS) trial.   
PERFORM stands for the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic stroke or tRansientischemic attack (PERFORM) trial. 
VALUE stands for the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial.  
CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; MI = Myocardial Infarction; TIA = Transient Ischemic Attack.  
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Table A1-14: An overview of studies which have investigated baseline resting heart rate as a risk marker in subjects with kidney disease. 
Authors Year Study 
Name 
Study Population No. of 
Subjects 
Follow-up Type of Heart Rate Type of 
Analysis 
Outcomes 
Beddhu 
et al.194 
2009 ARIC American men and women aged 45 to 64 
years with chronic kidney disease, with a 
mean age of 57 years 
460 From 1987-1989 until 
1998 (approximately 9 
to 11 years) 
Resting heart rate measured by 
ECG after a 12-hour fast followed 
by a light snack and ≥1 hour after 
smoking or caffeine intake 
Cox proportional 
hazards 
regression 
CV event (MI, fatal CHD 
event, incident stroke or 
coronary revascularisation) 
 
All-cause death 
Iseki et 
al.195  
2011 JSDT Japanese men and women with a mean age 
of 64 years receiving haemodialysis three 
times a week from the database of the 
Committee of Renal Data Registry for the 
JSDT 
147702 1 year Pre-haemodialysis resting heart 
rate measured by pulse, generally 
in the supine position 
Logistic 
regression 
All-cause death 
Inoue et 
al.196 
2012 - Japanese men and women with a mean age 
of 62 years receiving haemodialysis three 
times a week, recruited from two clinics in 
Okinawa, Japan 
229 1.4 years Baseline resting heart rate 
measured by ECG 
Cox proportional 
hazards 
regression 
Primary: All-cause death, 
ACS, or stroke 
 
Secondary: the primary 
outcome or any other CV 
event 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
ARIC stands for the Atherosclerosis Risk in Communities (ARIC) study.  Beddhu et al. 2009194 did not explicitly state the period of follow-up. 
JSDT stands for the Japanese Society for Dialysis Therapy.   
ACS = Acute Coronary Syndrome; CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; MI = Myocardial Infarction.    
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Table A1-15: The quality of each of the ‘multiple heart rate measurement’ studies according to the Newcastle-Ottawa scale96. 
Study Population Selection Comparability Outcome Total 
Mensink and Hoffmeister 1999197 General ** ** *** ******* 7 
Jouven et al. 2001202  General *** ** *** ******** 8 
Jouven et al. 2009198 General *** ** *** ******** 8 
Nauman et al. 2011199 General **** ** *** ********* 9 
Legeai et al. 2011206 General *** ** ** ******* 7 
Leistner et al. 2012200 General **** ** ** ******** 8 
Nanchen et al. 2013139 General **** ** ** ******** 8 
Ho et al. 2014204 General **** ** ** ******** 8 
O’Hartaigh et al. 2014201  General *** ** ** ******* 7 
O’Hartaigh et al. 2015207  General *** ** *** ******** 8 
Floyd et al. 2015203 General *** ** ** ******* 7 
Paul et al. 2010209 Hypertensive **** ** ** ******** 8 
Okin et al. 2010210 Hypertensive *** ** ** ******* 7 
Okin et al. 2012211 Hypertensive *** ** ** ******* 7 
Julius et al. 2012212 Hypertensive *** ** ** ******* 7 
Kolloch et al. 2008208 Stable CHD and Hypertensive *** ** *** ******** 8 
Jabre et al. 2014213 Post-MI **** ** *** ********* 9 
Greene et al. 2013214  Heart Failure *** ** ** ******* 7 
Vazir et al. 2014215 Heart Failure *** ** ** ******* 7 
Lonn et al. 2014216 Vascular Disease *** ** ** ******* 7 
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Table A1-16: An overview of studies which have investigated one or more heart rate measurements updated post-baseline as a risk marker in subjects from 
the general population. 
Authors Year Study Name Study Population No. of Subjects Follow-up Type of Heart Rate Type of Analysis Outcomes 
Mensink and 
Hoffmeister197 
1997 Spandau 
Health Test 
Men and women who were citizens 
of Berlin-Spandau aged 40 to 80 
years 
4756 12 years Baseline and change in resting 
heart over the following 2 years 
Cox proportional 
hazards regression 
All-cause death 
 
CV disease death 
Jouven et al.202  2001 Paris 
Prospective 
Study 1 
Native French men employed by 
the Paris Civil Service aged 42 to 
53 years who were free of clinically 
detectable CV disease 
7079 23 years Baseline and average of resting 
heart rate over the first 5 years of 
follow-up measured by radial 
pulse (although the paper states 
that subjects underwent an ECG 
also) 
Cox proportional 
hazards regression 
Sudden death 
 
Fatal MI 
Jouven et al.198 2009 Paris 
Prospective 
Study 1 
Native French men employed by 
the Paris Civil Service aged 42 to 
53 years who were free of clinically 
detectable CV disease 
5139 23 years Baseline and change in resting 
heart rate over the following 5 
years, measured by radial pulse 
(although the paper states that 
subjects underwent an ECG also) 
Cox proportional 
hazards regression 
All-cause death 
 
Nauman et 
al.199 
2011 HUNT-1 and 
HUNT-2 
Men and women from Norway aged 
20 years or older without known CV 
disease 
29325 12 years Change in resting heart rate from 
HUNT-1 to HUNT-2, measured by 
palpation of the radial pulse in 
HUNT-1, and by Dinamap in HUNT-
2 
Cox proportional 
hazards regression 
CHD death 
 
All-cause death 
Legeai et al.206 2011 Three-City 
Study 
Men and women aged 65 years or 
older, who were French community 
dwellers, selected from the 
electoral roll of three large cities 
7147 6 years Baseline resting heart rate, as 
well as heart rate updated at each 
examination, measured using a 
validated digital electronic 
tensiometer 
Time-fixed and 
time-dependent 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
CHD 
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Leistner et 
al.200 
2012 DETECT  Unselected male and female 
primary care subjects from 
Germany, free from any known CV 
disease, with a mean age of 55.9 
years 
5320 (4472 with  
1-year heart rate 
measurements) 
5 years Baseline resting heart rate 
measured in the standard way the 
primary care physician measured 
it in their daily routine 
 
Change in heart rate from baseline 
to the 1-year follow-up 
assessment 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
Major CV event (MI, 
revascularisation or 
CV death) 
 
CV event (non-fatal 
MI or 
revascularisation) 
Nanchen et 
al.139 
2013 Rotterdam 
Study 
Men and women from Rotterdam in 
the Netherlands, aged 55 years or 
older, not using beta-blockers or 
CCBs, free of heart disease and in 
sinus rhythm 
4768 14.6 years Baseline rate and time-updated 
resting heart rate measured at 3 
follow-up visits post-baseline, 
measured by radial artery 
palpation, as well as by ECG 
Time-fixed and 
time-dependent 
Cox proportional 
hazards regression 
The development of 
HF 
Ho et al.204 2014 Framingham 
Heart Study 
Men and women with a mean age 
of 55 years, from Framingham, 
Massachusetts, United States, with 
no evidence of a prior MI, HF or AF, 
not taking any heart rate-affecting 
medications 
4058 19 years Baseline resting heart rate, and 
time-updated heart rate updated 
over 8 years post-baseline 
measured using an ECG, analysed 
as an average of the 
measurements, and as a time-
dependent variable  
Time-fixed and 
time-dependent 
Cox proportional 
hazards regression 
CV disease 
 
HF 
 
CHD 
 
Stroke 
 
All-cause death 
 
CV death 
O’Hartaigh et 
al.201  
2014 The MRC 
NSHD 
Men and women born in Britain 
during one week in 1946, still alive 
and living in Britain in 1971 
4638 - Resting heart rate at age 6, 7, 11, 
36 and 43, and change in resting 
heart rate from age 36 to 43, 
measured using the radial artery 
Cox proportional 
hazards regression 
All-cause death 
O’Hartaigh et 
al.207  
2015 CHS Men and women from America ≥65 
years old, identified from the 
Medicare eligibility lists of the 
Health Care Financing 
Administration 
5691 7.9 years Time-updated resting heart rate 
measured at 6 annual assessments 
post-baseline 
Time-dependent 
Cox proportional 
hazards regression 
All-cause death 
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Floyd et al.203 2015 CHS Men and women from the United 
States, aged over 65 years, with no 
prevalent CV disease, not using any 
medications that directly affect 
heart rate 
1991 12.4 years Mean, trend and variation of five 
annual resting heart rate 
measurements, estimated using 
linear regression, measured by 
ECG 
Cox proportional 
hazards regression 
Incident MI 
 
All-cause death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
HUNT stands for the Nord-Trondelag Health (HUNT) Study.  
DETECT stands for the Diabetes Cardiovascular Risk Evaluation Targets and Essential Data for Commitment of Treatment (DETECT) trial. 
MRC NSHD stands for the Medical Research Council (MRC) National Survey of Health and Development (NSHD).  In the O’Hartaigh et al. 2014 study, subjects were followed-up until the age of 66. 
CHS stands for the Cardiovascular Health Study.   
AF = Atrial Fibrillation; CCB = Calcium Channel Blocker; CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; MI = Myocardial Infarction.  
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Table A1-17: An overview of studies which have investigated heart rate updated over time in disease-specific populations. 
Type of 
Population 
Authors Year Study Name Study Population No. of 
Subjects 
Follow-up Type of Heart Rate Type of Analysis Outcomes 
Hypertensive Paul et 
al.209 
2010 Glasgow 
Blood 
Pressure 
Clinic 
Men and women from the west 
of Scotland, with 
hypertension, with a mean age 
of around 50 to 55 years, in 
sinus rhythm 
4065 2.5 yeas Baseline, final and change in 
resting heart rate from baseline to 
final, analysed in a number of 
different ways 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 
CHD death 
 Okin et 
al.210 
2010 LIFE Men and women with 
hypertension and ECG LV 
hypertrophy, with a mean age 
of around 67 years 
9190 4.8 years Baseline and time-updated heart 
rate measured throughout follow-
up, measured by ECG 
Time-dependent 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
 Okin et 
al.211 
2012 LIFE Men and women with 
hypertension and ECG LV 
hypertrophy, without HF, with 
a mean age of around 67 years 
9024  4.7 years Baseline and time-updated resting 
heart rate measured throughout 
follow-up, measured by ECG 
Time-dependent 
Cox proportional 
hazards regression 
The development of 
HF 
 Julius et 
al.212 
2012 VALUE Men and women with 
hypertension at high CV risk, 
with a mean age of around 67 
years 
15193 5 years Baseline and 1-year post-baseline 
resting heart rate measured by ECG 
Cox proportional 
hazards regression 
Cardiac event 
(primary endpoint) 
 
HF 
 
Sudden cardiac death 
 
MI 
 
Stroke 
 
All-cause death 
Stable CHD 
and 
Hypertensive 
Kolloch 
et al.208 
2008 INVEST Men and women with stable 
CHD and hypertension, with a 
mean age of 67 years 
22192 2.7 years Baseline and average of resting 
heart rate updated throughout 
follow-up 
Cox proportional 
hazards regression 
All-cause death, non-
fatal MI, or non-fatal 
stroke 
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Post-MI Jabre et 
al.213 
2014 - Men and women ≥18 years 
hospitalised for an incident MI 
in Olmsted County (Minnesota, 
United States) 
1571 7 years Admission heart rate and heart rate 
obtained around 6 months post-MI, 
measured by ECG 
Cox proportional 
hazards regression 
All-cause death 
 
CV death 
Heart Failure Greene 
et al.214  
2013 EVEREST Men and women ≥18 years who 
were hospitalised with 
worsening HF, with LVEF ≤40%, 
and signs of fluid overload, in 
sinus rhythm 
1947 0.83 years Resting heart rate measured at 
baseline, discharge (or day 7),  
1-week post-discharge and 4-weeks 
post-discharge 
 
The change between heart rate 
measured at baseline and measured 
at discharge (or day 7) 
Cox proportional 
hazards regression 
All-cause death 
 Vazir et 
al.215 
2014 CHARM Men and women with 
symptomatic chronic HF in 
sinus rhythm or in AF, on 
standard therapy, with a mean 
age of 65 years 
7599 3.17 years Baseline, time-updated heart rate 
measured throughout follow-up, 
and changes in time-updated heart 
rate between measurements 
recorded by palpation, or from 
auscultation of the heart, or from 
ECG 
Time-fixed and 
time-dependent 
Cox proportional 
hazards regression 
All-cause death 
 
CV death or 
hospitalisation for HF 
 
CV death 
 
Hospitalisation for HF 
 
Fatal and non-fatal MI 
 
Fatal and non-fatal 
stroke 
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Vascular 
Disease 
Lonn et 
al.216 
2014 ONTARGET 
and 
TRANSCEND 
Men and women aged 55 years 
or older with coronary, 
peripheral or cerebrovascular 
disease, or diabetes with end 
organ damage 
31531 4.7 years Baseline and average of resting 
heart rate at baseline, and updated 
throughout follow-up, measured 
using an automated validated 
device 
Cox proportional 
hazards regression 
Major vascular event 
(CV death, MI, stroke 
or hospitalisation for 
HF) 
 
CV death 
 
MI 
 
Stroke 
 
Hospitalisation for HF 
 
All-cause death 
If no study name is given it is because the study was not explicitly named in the publication. Follow-up duration for each study is either total, median or mean follow-up depending on what was stated in the 
publication; if follow-up was given in months or days it was converted to the approximate time in years if appropriate.  If no method of heart rate measurement is stated it is because it was not stated in the 
publication.  Note that some studies presented results for other adverse non-CV outcomes, such as cancer, but they are not mentioned in the table since they were not relevant to the review. 
LIFE stands for the Losartan Intervention for Endpoint (LIFE) in hypertension study.   
VALUE stands for the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. 
INVEST stands for the International Verapamil-SR/trandolapril Study (INVEST).   
EVEREST stands for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (VEREST) study. 
CHARM stands for the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program.  
ONTARGET stands for the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).  TRANSCEND stands for the Telmisartan Randomised Assessment Study in ACE 
Intolerant Subjects with Cardiovascular Disease (TRANSCEND) trials. 
AF = Atrial Fibrillation; CHD = Coronary Heart Disease; CV = Cardiovascular; ECG = Electrocardiography; HF = Heart Failure; LV = Left-Ventricular; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial 
Infarction. 
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Appendix 2 
Supplementary Tables for Chapter 4 
Table A2-1: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for each of the five baseline heart rate groups greater 
than or equal to 65bpm, relative to a baseline heart rate <65bpm, in the pooled population of 
patients included in the High Risk MI Database.   
 Group 2 
65-69bpm 
 
Group 3 
70-74bpm 
 
Group 4 
75-79bpm 
 
Group 5 
80-84bpm 
 
Group 6 
≥85bpm 
 
P-value for 
Interaction* 
 Hazard Ratio (95% Confidence Interval), p-value  
Mortality-Related 
Endpoints 
      
All-cause death,  
n = 5108 
1.12 (1.15 
to 1.25) 
0.061 
1.15 (1.04-
1.27), 
0.0073 
1.28 (1.15 
to 1.42), 
<0.001 
1.35 (1.22 
to 1.49), 
<0.001 
1.67 (1.52 
to 1.83), 
<0.001 
0.076 
Cardiovascular 
death, n = 4387 
1.13 (1.00 
to 1.28), 
0.052 
1.13 (1.01 
to 1.26), 
0.027 
1.30 (1.16 
to 1.46), 
<0.001 
1.37 (1.24 
to 1.54), 
<0.001 
1.71 (1.55 
to 1.89), 
<0.001 
0.040 
Hospitalisation-
related endpoints 
      
Cardiovascular 
hospitalisation,  
n = 13111 
1.01 (0.95 
to 1.08), 
0.75 
0.98 (0.92 
to 1.03), 
0.39 
1.02 (0.96 
to 1.08), 
0.55 
0.99 (0.94 
to 1.05), 
0.83 
1.09 (1.03 
to 1.15), 
0.0016 
0.0025 
Heart failure 
hospitalisation,  
n = 3375 
1.24 (1.08 
to 1.43), 
0.0025 
1.23 (1.08 
to 1.39), 
0.0013 
1.37 (1.20 
to 1.57), 
<0.001 
1.49 (1.32 
to 1.69), 
<0.001 
1.82 (1.62 
to 2.04), 
<0.001 
0.071 
Other Individual 
Endpoints 
      
Subsequent MI 
(fatal or non-fatal),  
n = 3116 
1.06 (0.93 
to 1.21), 
0.36 
0.95 (0.84 
to 1.07), 
0.38 
0.98 (0.86 
to 1.11), 
0.71 
1.00 (0.88 
to 1.13), 
0.99 
1.17 (1.04 
to 1.31), 
0.0069 
0.35 
Stroke (fatal or 
non-fatal), n = 937 
0.99 (0.77 
to 1.27), 
0.94 
1.03 (0.83 
to 1.28), 
0.77 
1.19 (0.94 
to 1.50), 
0.14 
1.02 (0.82 
to 1.28), 
0.84 
1.13 (0.92 
to 1.39), 
0.24 
0.44 
Composite 
Endpoints 
      
Cardiovascular 
death or non-fatal 
MI,  
n = 6104 
1.07 (0.97 
to 1.18), 
0.20 
1.05 (0.96 
to 1.14), 
0.30 
1.10 (1.00 
to 1.21), 
0.044 
1.18 (1.08 
to 1.29), 
<0.001 
1.39 (1.28 
to 1.51), 
<0.001 
0.57 
Cardiovascular 
death or non-fatal 
stroke, 
n = 4939 
1.14 (1.01 
to 1.28), 
0.031 
1.12 (1.01 
to 1.24), 
0.036 
1.31 (1.18 
to 1.46), 
<0.001 
1.31 (1.18 
to 1.45), 
<0.001 
1.64 (1.50 
to 1.80), 
<0.001 
0.12 
Cardiovascular 
death or heart 
failure 
hospitalisation,  
n = 6646 
1.16 (1.05 
to 1.29), 
0.0037 
1.18 (1.08 
to 1.29), 
<0.001 
1.31 (1.19 
to 1.44), 
<0.001 
1.41 (1.29 
to 1.54), 
<0.001 
1.76 (1.62 
to 1.90), 
<0.001 
0.027 
Cardiovascular 
death, non-fatal MI, 
or non-fatal stroke,  
n = 6597 
1.07 (0.97 
to 1.18), 
0.15 
1.04 (0.96 
to 1.13), 
0.34 
1.13 (1.03 
to 1.23), 
0.011 
1.15 (1.06 
to 1.26), 
0.0012 
1.37 (1.27 
to 1.49), 
<0.001 
0.54 
Cardiovascular 
death, non-fatal MI, 
non-fatal stroke or 
heart failure 
hospitalisation,  
n = 8457 
1.10 (1.01 
to 1.20), 
0.023 
1.10 (1.02 
to 1.19), 
0.012 
1.17 (1.08 
to 1.27), 
<0.001 
1.24 (1.15 
to 1.34), 
<0.001 
1.48 (1.38 
to 1.59), 
<0.001 
0.12 
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Cardiovascular 
death or 
cardiovascular 
hospitalisation,  
n = 15017 
1.01 (0.95 
to 1.08), 
0.66 
1.00 (0.94 
to 1.05), 
0.88 
1.05 (0.99 
to 1.11), 
0.099 
1.04 (0.98 
to 1.10), 
0.21 
1.18 (1.12 
to 1.24), 
<0.001 
0.034 
*P-values for the likelihood ratio test comparing the model containing the interaction heart rate group x study, and the model 
containing only heart rate group and study additively.  MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; intake of certain drugs at randomisation which were aspirin, 
statins, vitamin K antagonists, diuretics and cardiac glycosides; and study. 
 
Table A2-2: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher baseline heart rate, in the pooled 
population of patients included in the High Risk MI Database. 
 Hazard Ratio (95% Confidence 
Interval), p-value 
P-value for 
Interaction* 
Mortality-Related Endpoints   
All-cause death, n = 5108 1.07 (1.06 to 1.09), <0.001 0.082 
Cardiovascular death, n = 4387 1.08 (1.07 to 1.09), <0.001 0.099 
Hospitalisation-Related Endpoints   
Cardiovascular hospitalisation, n = 13111 1.01 (1.00 to 1.02), 0.0059 <0.001 
Heart failure hospitalisation, n = 3375 1.08 (1.07 to 1.10), <0.001 0.059 
Other Individual Endpoints   
Subsequent MI (fatal or non-fatal), n = 3116 1.02 (1.00 to 1.03), 0.0086 0.0045 
Stroke (fatal or non-fatal), n = 937 1.02 (1.00 to 1.05), 0.062 0.36 
Composite Endpoints   
Cardiovascular death or non-fatal MI, n = 6104 1.05 (1.04 to 1.06), <0.001 0.65 
Cardiovascular death or non-fatal stroke, n = 4939 1.07 (1.06 to 1.09), <0.001 0.43 
Cardiovascular death or heart failure hospitalisation,  
n = 6646 
1.08 (1.07 to 1.09), <0.001 0.068 
Cardiovascular death, non-fatal MI, or non-fatal 
stroke, n = 6597 
1.05 (1.04 to 1.06), <0.001 0.42 
Cardiovascular death, non-fatal MI, non-fatal stroke or 
heart failure hospitalisation, n = 8457 
1.06 (1.05 to 1.07), <0.001 0.079 
Cardiovascular death or cardiovascular 
hospitalisation, n = 15017 
1.022 (1.015 to 1.03), <0.001 0.0027 
*P-values for the likelihood ratio test comparing the model containing the interaction heart rate x study, and the model 
containing only heart rate and study additively.  MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; intake of certain drugs at randomisation which were aspirin, 
statins, vitamin K antagonists, diuretics and cardiac glycosides; and study.  
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Table A2-3: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the model including the baseline heart rate groups variable, which produced the results 
shown in Table A2-1 in the pooled population of patients included in the High Risk MI 
Database. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Mortality-Related Endpoints    
All-cause death, n = 5108 Model 0.712  
 Model + Baseline 0.719 151.83, <0.001 
Cardiovascular death, n = 4387 Model 0.715  
 Model + Baseline 0.723 147.40, <0.001 
Hospitalisation-Related Endpoints    
Cardiovascular hospitalisation, n = 13111 Model 0.581  
 Model + Baseline 0.582 19.57, 0.0015 
Heart failure hospitalisation, n = 3375 Model 0.727  
 Model + Baseline 0.735 126.81, <0.001 
Other Individual Endpoints    
Subsequent MI (fatal or non-fatal), n = 3116 Model 0.650  
 Model + Baseline 0.652 16.30, 0.0060 
Stroke (fatal or non-fatal), n = 937 Model 0.675  
 Model + Baseline 0.679 3.78, 0.58 
Composite Endpoints    
Cardiovascular death or non-fatal MI, n = 6104 Model 0.675  
 Model + Baseline 0.679 82.07, <0.001 
Cardiovascular death or non-fatal stroke,  
n = 4939 
Model 0.703  
 Model + Baseline 0.709 140.14, <0.001 
Cardiovascular death or heart failure 
hospitalisation, n = 6646 
Model 0.710  
 Model + Baseline 0.717 231.82, <0.001 
Cardiovascular death, non-fatal MI, or non-fatal 
stroke, n = 6597 
Model 0.670  
 Model + Baseline 0.674 80.71, <0.001 
Cardiovascular death, non-fatal MI, non-fatal 
stroke or heart failure hospitalisation, n = 8457 
Model 0.677  
 Model + Baseline 0.682 145.71, <0.001 
Cardiovasuclar death or cardiovascular 
hospitalisation, n = 15017 
Model 0.588  
 Model + Baseline 0.591 55.68, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; race; body mass index (BMI); smoking 
history; diabetes; hypertension; angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure 
(HF); chronic obstructive pulmonary disease; diastolic blood pressure (DBP); Killip class; intake of certain drugs at 
randomisation which were aspirin, statins, vitamin K antagonists, diuretics and cardiac glycosides; and study. 
‘Model + Baseline’ is the multivariate model described above including the baseline resting heart rate group variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
baseline resting heart rate to the multivariate model excluding resting heart rate.     
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Table A2-4: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the model including the continuous baseline heart rate variable, which produced the 
results shown in Table A2-2 in the pooled population of patients included in the High Risk 
MI Database.  
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Mortality-Related Endpoints    
All-cause death, n = 5108 Model 0.712  
 Model + Baseline 0.720 173.85, <0.001 
Cardiovascular death, n = 4387 Model 0.715  
 Model + Baseline 0.724 174.72, <0.001 
Hospitalisation-Related Endpoints    
Cardiovascular hospitalisation, n = 13111 Model 0.581  
 Model + Baseline 0.582 7.53, 0.0060 
Heart failure hospitalisation, n = 3375 Model 0.727  
 Model + Baseline 0.736 139.77, <0.001 
Other Individual Endpoints    
Subsequent MI (fatal or non-fatal), n = 3116 Model 0.650  
 Model + Baseline 0.651 6.83, 0.0089 
Stroke (fatal or non-fatal), n = 937 Model 0.675  
 Model + Baseline 0.676 3.44, 0.064 
Composite Endpoints    
Cardiovascular death or non-fatal MI, n = 6104 Model 0.675  
 Model + Baseline 0.679 89.39, <0.001 
Cardiovascular death or non-fatal stroke,  
n = 4939 
Model 0.703  
 Model + Baseline 0.710 166.24, <0.001 
Cardiovascular death or heart failure 
hospitalisation, n = 6646 
Model 0.710  
 Model + Baseline 0.719 271.61, <0.001 
Cardiovascular death, non-fatal MI, or non-fatal 
stroke, n = 6597 
Model 0.670  
 Model + Baseline 0.674 88.79, <0.001 
Cardiovascular death, non-fatal MI, non-fatal 
stroke or heart failure hospitalisation, n = 8457 
Model 0.677  
 Model + Baseline 0.683 162.43, <0.001 
Cardiovasuclar death or cardiovascular 
hospitalisation, n = 15017 
Model 0.588  
 Model + Baseline 0.591 44.93, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; race; body mass index (BMI); smoking 
history; diabetes; hypertension; angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure 
(HF); chronic obstructive pulmonary disease; diastolic blood pressure (DBP); Killip class; intake of certain drugs at 
randomisation which were aspirin, statins, vitamin K antagonists, diuretics and cardiac glycosides; and study. 
‘Model + Baseline’ is the multivariate model described above including the continuous baseline resting heart rate variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
baseline resting heart rate to the multivariate model excluding resting heart rate.     
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Table A2-5: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for each of the five baseline heart rate groups greater than or equal to 65bpm, 
relative to a baseline heart rate <65bpm, in the pooled population of patients included in the 
High Risk MI Database. 
 Group 2 
65-69bpm 
 
n = 3278 
Group 3 
70-74bpm 
 
n = 5250 
Group 4 
75-79bpm 
 
n = 3740 
Group 5 
80-84bpm 
 
n = 4558 
Group 6 
≥85bpm 
 
n = 6141 
 P-value     
Mortality-Related Endpoints      
All-cause death, n = 5108 0.82 0.94 0.018 <0.001 <0.001 
Cardiovascular death, n = 4387 0.89 0.62 0.044 <0.001 <0.001 
Hospitalisation-related endpoints      
Cardiovascular hospitalisation, n = 13111 0.69 0.47 0.70 0.30 0.0078 
Heart failure hospitalisation, n = 3375 0.35 0.38 0.32 0.043 0.012 
Other Individual Endpoints      
Subsequent MI (fatal or non-fatal),  
n = 3116 
0.92 0.61 0.83 0.067 <0.001 
Stroke (fatal or non-fatal), n = 937 0.72 0.94 0.44 0.054 0.17 
Composite Endpoints      
Cardiovascular death or non-fatal MI,  
n = 6104 
0.58 0.16 0.78 0.014 <0.001 
Cardiovascular death or non-fatal stroke, 
n = 4939 
0.94 0.71 0.083 <0.001 <0.001 
Cardiovascular death or heart failure 
hospitalisation, n = 6646 
0.64 0.50 0.061 <0.001 <0.001 
Cardiovascular death, non-fatal MI, or non-
fatal stroke, n = 6597 
0.85 0.30 0.64 0.0040 <0.001 
Cardiovascular death, non-fatal MI, non-
fatal stroke or heart failure hospitalisation,  
n = 8457 
0.66 0.75 0.22 <0.001 <0.001 
Cardiovascular death or cardiovascular 
hospitalisation, n = 15017 
0.75 0.44 0.73 0.038 <0.001 
MI = Myocardial Infarction. 
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Table A2-6: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for an elevated continuous baseline heart rate, in the pooled population of patients 
included in the High Risk MI Database. 
Mortality-Related Endpoints P-value 
All-cause death, n = 5108 <0.001 
Cardiovascular death, n = 4387 <0.001 
Hospitalisation-Related Endpoints  
Cardiovascular hospitalisation, n = 13111 <0.001 
Heart failure hospitalisation, n = 3375 <0.001 
Other Individual Endpoints  
Subsequent MI (fatal or non-fatal), n = 3116 <0.001 
Stroke (fatal or non-fatal), n = 937 0.045 
Composite Endpoints  
Cardiovascular death or non-fatal MI, n = 6104 <0.001 
Cardiovascular death or non-fatal stroke, n = 4939 <0.001 
Cardiovascular death or heart failure hospitalisation, n = 6646 <0.001 
Cardiovascular death, non-fatal MI, or non-fatal stroke, n = 6597 <0.001 
Cardiovascular death, non-fatal MI, non-fatal stroke or heart failure 
hospitalisation, n = 8457 
<0.001 
Cardiovascular death or cardiovascular hospitalisation, n = 15017 <0.001 
MI = Myocardial Infarction. 
 
 
  
322 
 
Table A2-7: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for each of the five baseline heart rate groups greater 
than or equal to 65bpm, relative to a baseline heart rate <65bpm, in the CAPRICORN, 
EPHESUS, OPTIMAAL and VALIANT populations, for the outcomes that showed a 
significant interaction between heart rate and study. 
  Group 2 
65-69bpm 
 
Group 3 
70-74bpm 
 
Group 4 
75-79bpm 
 
Group 5 
80-84bpm 
 
Group 6 
≥85bpm 
 
  Hazard Ratio (95% Confidence Interval), p-value 
Mortality-
Related 
Endpoints 
      
Cardiovascular 
death, n = 4387 
CAPRICORN 1.09 (0.57 to 
2.11), 0.79 
1.67 (0.98 to 
2.85), 0.60 
2.01 (1.17 to 
3.44), 0.011 
1.52 (0.87 to 
2.66), 0.14 
1.65 (0.98 to 
2.79), 0.59 
 EPHESUS 1.28 (0.99 to 
1.66), 0.60 
1.20 (0.95 to 
1.51), 0.13 
1.30 (1.01 to 
1.68), 0.040 
1.36 (1.07 to 
1.73), 0.011 
1.83 (1.46 to 
2.29), <0.001 
 OPTIMAAL 1.25 (0.93 to 
1.69), 0.14 
1.40 (1.08 to 
1.83), 0.013 
1.30 (0.96 to 
1.76), 0.092 
1.80 (1.40 to 
2.32), <0.001 
2.06 (1.64 to 
2.59), <0.001 
 VALIANT 1.02 (0.86 to 
1.21), 0.78 
0.98 (0.85 to 
1.14), 0.82 
1.22 (1.05 to 
1.42), 0.0099 
1.21 (1.05 to 
1.40), 0.0088 
1.54 (1.35 to 
1.75), <0.001 
Hospitalisation-
Related 
Endpoints 
      
Cardiovascular 
hospitalisation,  
n = 13111 
CAPRICORN 1.04 (0.72 to 
1.50), 0.84 
1.12 (0.82 to 
1.55), 0.47 
1.42 (1.03 to 
1.96), 0.032 
1.07 (0.77 to 
1.49), 0.68 
1.40 (1.03 to 
1.89), 0.032 
 EPHESUS 0.95 (0.83 to 
1.09), 0.49 
1.01 (0.90 to 
1.14), 0.83 
1.05 (0.92 to 
1.19), 0.50 
1.11 (0.98 to 
1.25), 0.11 
1.25 (1.11 to 
1.41), <0.001 
 OPTIMAAL 1.04 (0.91 to 
1.19), 0.53 
1.02 (0.91 to 
1.15), 0.70 
1.04 (0.91 to 
1.19), 0.54 
0.94 (0.83 to 
1.06), 0.31 
0.98 (0.88 to 
1.10), 0.73 
 VALIANT 1.02 (0.93 to 
1.11), 0.74 
0.93 (0.86 to 
1.01), 0.071 
0.97 (0.88 to 
1.05), 0.44 
0.96 (0.88 to 
1.04), 0.30 
1.06 (0.98 to 
1.14), 0.14 
Composite 
Endpoints 
      
Cardiovascular 
death or heart 
failure 
hospitalisation,  
n = 6646 
CAPRICORN 1.27 (0.79 to 
2.03), 0.33 
1.57 (1.05 to 
2.35), 0.029 
1.96 (1.30 to 
2.94), 0.0012 
1.38 (0.91 to 
2.11), 0.13 
1.81 (1.23 to 
2.67), 0.0028 
 EPHESUS 1.21 (0.99 to 
1.49), 0.065 
1.22 (1.02 to 
1.47), 0.028 
1.31 (1.07 to 
1.59), 0.0075 
1.44 (1.20 to 
1.73), <0.001 
1.89 (1.59 to 
2.25), <0.001 
 OPTIMAAL 1.23 (0.96 to 
1.56), 0.10 
1.46 (1.18 to 
1.81), <0.001 
1.34 (1.05 to 
1.71), 0.018 
1.76 (1.43 to 
2.17), <0.001 
1.97 (1.63 to 
2.38), <0.001 
 VALIANT 1.10 (0.96 to 
1.26), 0.19 
1.04 (0.92 to 
1.17), 0.56 
1.22 (1.07 to 
1.38), 0.0025 
1.26 (1.12 to 
1.42), <0.001 
1.59 (1.43 to 
1.77), <0.001 
Cardiovascular 
death or 
cardiovascular 
hospitalisation,  
n = 15017 
CAPRICORN 1.10 (0.79 to 
1.55), 0.57 
1.21 (0.90 to 
1.63), 0.20 
1.50 (1.11 to 
2.02), 0.0078 
1.19 (0.87 to 
1.61), 0.27 
1.48 (1.11 to 
1.96), 0.0067 
 EPHESUS 0.99 (0.86 to 
1.12), 0.82 
1.05 (0.93 to 
1.18), 0.42 
1.07 (0.95 to 
1.22), 0.27 
1.13 (1.00 to 
1.27), 0.049 
1.29 (1.15 to 
1.45), <0.001 
 OPTIMAAL 1.05 (0.93 to 
1.20), 0.43 
1.04 (0.93 to 
1.17), 0.51 
1.07 (0.94 to 
1.22), 0.31 
1.01 (0.89 to 
1.13), 0.91 
1.08 (0.97 to 
1.20), 0.18 
 VALIANT 1.00 (0.92 to 
1.09), 0.96 
0.94 (0.87 to 
1.02), 0.12 
1.00 (0.92 to 
1.09), 0.997 
0.99 (0.92 to 
1.09), 0.88 
1.15 (1.07 to 
1.24), <0.001 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; and intake of certain drugs at randomisation which were 
aspirin, statins, vitamin K antagonists, diuretics and cardiac glycosides.  
323 
 
Table A2-8: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher baseline heart rate, in CAPRICORN, 
EPHESUS, OPTIMAAL and VALIANT populations, for the outcomes that showed a 
significant interaction between heart rate and study. 
 CAPRICORN EPHESUS OPTIMAAL VALIANT 
 Hazard Ratio (95% Confidence Interval), p-value 
Hospitalisation-Related 
Endpoints 
    
Cardiovascular hospitalisation,  
n = 13111 
1.05 (1.01 to 
1.09), 0.0086 
 
1.03 (1.02 to 
1.05), <0.001 
 
0.99 (0.98 to 
1.01), 0.28 
1.01 (1.00 to 
1.02), 0.18 
 
Other Individual Endpoints     
Subsequent MI (fatal or non-
fatal), n = 3116 
1.06 (0.98 to 
1.15), 0.14 
1.04 (1.00 to 
1.07), 0.039 
0.97 (0.95 to 
1.00), 0.077 
 
1.03 (1.01 to 
1.05), <0.001 
Composite Endpoints     
Cardiovascular death or 
cardiovascular hospitalisation,  
n = 15017 
1.05 (1.02 to 
1.09), 0.0022 
 
1.04 (1.02 to 
1.05), <0.001 
 
1.01 (0.99 to 
1.02), 0.30 
 
1.02 (1.01 to 
1.03), <0.001 
 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; race; body mass index (BMI); smoking history; diabetes; hypertension; 
angina; prior myocardial infarction (MI); atrial fibrillation (AF); dyslipidaemia; heart failure (HF); chronic obstructive 
pulmonary disease; diastolic blood pressure (DBP); Killip class; and intake of certain drugs at randomisation which were 
aspirin, statins, vitamin K antagonists, diuretics and cardiac glycosides.  
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Table A2-9: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a heart rate ≥75bpm compared to a heart rate <75bpm 
in the CAPRICORN placebo population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 HR (95% CI), p-value 
Primary Endpoints     
All-cause mortality, n = 150 1.24 (0.88 to 
1.75), 0.21 
1.62 (1.15 to 
2.28), 0.0058 
1.58 (1.11 to 
2.25), 0.012 
1.54 (1.06 to 
2.22), 0.023 
All-cause mortality or 
cardiovascular cause hospital 
admission, n = 366 
1.30 (1.05 to 
1.61), 0.017 
1.30 (1.06 to 
1.61), 0.014 
1.23 (0.99 to 
1.53), 0.067 
1.27 (1.01 to 
1.60), 0.043 
Secondary Endpoints     
Sudden death, n = 68 1.28 (0.77 to 
2.12), 0.34 
1.44 (0.87 to 
2.36), 0.15 
1.37 (0.82 to 
2.31), 0.23 
1.27 (0.74 to 
2.18), 0.38 
Hospital admission for heart 
failure,  
n = 138 
1.65 (1.14 to 
2.38), 0.0075 
1.91 (1.33 to 
2.74), <0.001 
1.74 (1.20 to 
2.53), 0.0037 
1.78 (1.20 to 
2.62), 0.0039 
Other Endpoints     
Cardiovascular-cause 
mortality, n = 138 
1.20 (0.84 to 
1.70), 0.32 
1.57 (1.10 to 
2.23), 0.013 
1.54 (1.07 to 
2.23), 0.021 
1.51 (1.03 to 
2.21), 0.036 
Death due to heart failure,  
n = 30 
1.88 (0.79 to 
4.45), 0.15 
1.76 (0.80 to 
3.89), 0.16 
1.59 (0.71 to 
3.56), 0.26 
1.68 (0.72 to 
3.93), 0.23 
Non-fatal myocardial 
infarction, n = 57 
1.78 (1.02 to 
3.11), 0.042 
1.19 (0.70 to 
2.00), 0.52 
1.01 (0.58 to 
1.73), 0.98 
1.10 (0.62 to 
1.94), 0.76 
All-cause mortality or non-
fatal myocardial infarction,  
n = 191 
1.34 (0.93 to 
1.81), 0.056 
1.43 (1.06 to 
1.92), 0.019 
1.35 (0.99 to 
1.83), 0.058 
1.33 (0.96 to 
1.84), 0.082 
Models were additionally adjusted for: sex; previous diabetes; left-ventricular ejection fraction (LVEF); site of MI; and in-
hospital treatment with intravenous diuretics. 
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Table A2-10: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the CAPRICORN placebo 
population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Endpoints     
All-cause mortality,  
n = 150 
1.05 (0.98 to 
1.12), 0.15 
1.12 (1.06 to 
1.18), 0.012 
1.12 (1.06 to 
1.18), <0.001 
1.11 (1.04 to 
1.18), 0.0014 
All-cause mortality or 
cardiovascular cause 
hospital admission, n = 366 
1.05 (1.01 to 
1.10), 0.020 
1.08 (1.04 o 
1.13), <0.001 
1.08 (1.03 to 
1.12), <0.001 
1.08 (1.03 to 
1.13), 0.0010 
Secondary Endpoints     
Sudden death, n = 68 1.02 (0.92 to 
1.13), 0.68 
1.08 (0.99 to 
1.19), 0.087 
1.09 (0.99 to 
1.20), 0.094 
1.04 (0.93 to 
1.16), 0.47 
Hospital admission for 
heart failure, n = 138 
1.09 (1.02 to 
1.17), 0.012 
1.12 (1.06 to 
1.18), <0.001 
1.11 (1.05 to 
1.17), <0.001 
1.10 (1.04 to 
1.17), 0.0018 
Other Endpoints     
Cardiovascular-cause 
mortality, n = 138 
1.05 (0.98 to 
1.12), 0.19 
1.10 (1.04 to 
1.17), <0.001 
1.10 (1.03 to 
1.17), 0.0031 
1.09 (1.02 to 
1.17), 0.015 
Death due to heart failure, 
n = 30 
1.17 (1.03 to 
1.33), 0.018 
1.12 (1.00 to 
1.25), 0.060 
1.07 (0.95 to 
1.22), 0.27 
1.12 (0.97 to 
1.28), 0.11 
Non-fatal myocardial 
infarction, n = 57 
1.08 (0.96 to 
1.20), 0.19 
1.09 (0.99 to 
1.20), 0.089 
1.07 (0.96 to 
1.19), 0.20 
1.08 (0.96 to 
1.21), 0.20 
All-cause mortality or non-
fatal myocardial 
infarction, n = 191 
1.06 (1.00 to 
1.12), 0.060 
1.10 (1.05 to 
1.16), <0.001 
1.09 (1.04 to 
1.15), <0.001 
1.09 (1.02 to 
1.15), 0.0057 
Models were additionally adjusted for: sex; previous diabetes; left-ventricular ejection fraction (LVEF); site of MI; and in-
hospital treatment with intravenous diuretics. 
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Table A2-11: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals and p-values for the time-updated categorical heart rate patterns ‘high-
low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the CAPRICORN placebo 
population. 
 Heart Rate 
Category 
Hazard Ratio (95% 
Confidence Interval), 
p-value 
Primary Endpoints   
All-cause mortality, n = 150 high-low 0.85 (0.47 to 1.55), 
0.60 
 low-high 1.20 (0.69 to 2.07), 
0.52 
 high-high 1.67 (1.12 to 2.49), 
0.012 
All-cause mortality or cardiovascular-cause hospital admission,  
n = 366 
high-low 1.14 (0.81 to 1.59), 
0.46 
 low-high 1.34 (0.97 to 1.86), 
0.075 
 high-high 1.36 (1.06 to 1.76), 
0.017 
Secondary Endpoints   
Sudden death, n = 68 high-low 1.17 (0.52 to 2.63), 
0.71 
 low-high 1.08 (0.46 to 2.50), 
0.87 
 high-high 1.69 (0.93 to 3.06), 
0.086 
Hospital admission for heart failure, n = 138 high-low 1.22 (0.66 to 2.26), 
0.52 
 low-high 1.80 (1.03 to 3.13), 
0.038 
 high-high 2.14 (1.38 to 3.33), 
<0.001 
Other Endpoints   
Cardiovascular-cause mortality, n = 138 high-low 0.85 (0.45 to 1.58), 
0.60 
 low-high 1.21 (0.69 to 2.13), 
0.50 
 high-high 1.59 (1.05 to 2.42), 
0.028 
Death due to heart failure, n = 30 high-low 0.87 (0.22 to 3.50), 
0.84 
 low-high 1.34 (0.38 to 4.77), 
0.65 
 high-high 1.79 (0.69 to 4.64), 
0.23 
Non-fatal myocardial infarction, n = 57 high-low 1.24 (0.55 to 2.80), 
0.60 
 low-high 1.12 (0.48 to 2.61), 
0.79 
 high-high 1.33 (0.71 to 2.50), 
0.37 
All-cause mortality or non-fatal myocardial infarction, n = 191 high-low 1.01 (0.61 to 1.65), 
0.61 
 low-high 1.13 (0.70 to 1.84), 
0.61 
 high-high 1.54 (1.09 to 2.19), 
0.015 
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Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 75bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 75bpm, and so on.  
Models were additionally adjusted for: sex; previous diabetes; left-ventricular ejection fraction (LVEF); site of MI; and in-
hospital treatment with intravenous diuretics. 
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Table A2-12: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the heart rate variables that categorised subjects according to 
whether they had a heart rate less than, or greater than or equal to, 75bpm, which produced 
the results shown in Table A2-9 in the CAPRICORN placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Endpoints    
All-cause mortality, n = 150 Model 0.632  
 Model + Baseline 0.640 1.60, 0.021 
 Model + Time-Updated 0.645 7.90, 0.0049 
 Model + Time-Updated 
+ Baseline 
0.646 8.17, 0.017 
 Model + Time-Updated 
+ Previous 
0.644 8.42, 0.015 
All-cause mortality or cardiovascular-
cause hospital admission,  
n = 366 
Model 0.604  
 Model + Baseline 0.609 5.82, 0.016 
 Model + Time-Updated 0.609 6.14, 0.013 
 Model + Time-Updated 
+ Baseline 
0.613 9.22, 0.010 
 Model + Time-Updated 
+ Previous 
0.610 6.45, 0.040 
Secondary Endpoints    
Sudden death, n = 68 Model 0.622  
 Model + Baseline 0.636 0.94, 0.33 
 Model + Time-Updated 0.630 2.07, 0.15 
 Model + Time-Updated 
+ Baseline 
0.638 2.38, 0.30 
 Model + Time-Updated 
+ Previous 
0.640 3.33, 0.19 
Hospital admission for heart failure,  
n = 138 
Model 0.682  
 Model + Baseline 0.692 7.53, 0.0061 
 Model + Time-Updated 0.699 13.09, <0.001 
 Model + Time-Updated 
+ Baseline 
0.703 16.41, <0.001 
 Model + Time-Updated 
+ Previous 
0.699 14.02, <0.001 
Other Endpoints    
Cardiovascular-cause mortality, n = 138 Model 0.630  
 Model + Baseline 0.636 0.99, 0.32 
 Model + Time-Updated 0.641 6.38, 0.012 
 Model + Time-Updated 
+ Baseline 
0.642 6.48, 0.039 
 Model + Time-Updated 
+ Previous 
0.642 6.63, 0.0036 
Death due to heart failure, n = 30 Model 0.733  
 Model + Baseline 0.759 2.23, 0.14 
 Model + Time-Updated 0.752 2.08, 0.15 
 Model + Time-Updated 
+ Baseline 
0.768 3.55, 0.17 
 Model + Time-Updated 
+ Previous 
0.756 2.17, 0.34 
Non-fatal myocardial infarction, n = 57 Model 0.632  
 Model + Baseline 0.657 4.35, 0.037 
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 Model + Time-Updated 0.636 0.409, 0.52 
 Model + Time-Updated 
+ Baseline 
0.656 4.35, 0.11 
 Model + Time-Updated 
+ Previous 
0.638 0.86, 0.65 
All-cause mortality or non-fatal myocardial 
infarction, n = 191 
Model 0.607  
 Model + Baseline 0.618 3.74, 0.053 
 Model + Time-Updated 0.614 5.67, 0.017 
 Model + Time-Updated 
+ Baseline 
0.619 7.38, 0.025 
 Model + Time-Updated 
+ Previous 
0.616 6.80, 0.035 
‘Model’ is the multivariate model excluding heart rate which included: sex; previous diabetes; left-ventricular ejection fraction 
(LVEF); site of MI; and in-hospital treatment with intravenous diuretics. 
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate group variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate group variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate group variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
group variable and the previous time-updated heart rate group variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A2-13: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A2-10 in the CAPRICORN placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Endpoints    
All-cause mortality, n = 150 Model 0.632  
 Model + Baseline 0.638 2.01, 0.157 
 Model + Time-Updated 0.657 14.80, <0.001 
 Model + Time-Updated 
+ Baseline 
0.657 14.80, <0.001 
 Model + Time-Updated 
+ Previous 
0.658 15.12, <0.001 
All-cause mortality or cardiovascular-
cause hospital admission,  
n = 366 
Model 0.604  
 Model + Baseline 0.610 5.24, 0.022 
 Model + Time-Updated 0.622 15.58, <0.001 
 Model + Time-Updated 
+ Baseline 
0.622 16.38, <0.001 
 Model + Time-Updated 
+ Previous 
0.622 15.68, <0.001 
Secondary Endpoints    
Sudden death, n = 68 Model 0.622  
 Model + Baseline 0.625 0.17, 0.68 
 Model + Time-Updated 0.632 2.64, 0.10 
 Model + Time-Updated 
+ Baseline 
0.631 2.69, 0.26 
 Model + Time-Updated 
+ Previous 
0.640 4.21, 0.12 
Hospital admission for heart failure,  
n = 138 
Model 0.682  
 Model + Baseline 0.691 6.02, 0.014 
 Model + Time-Updated 0.711 14.94, <0.001 
 Model + Time-Updated 
+ Baseline 
0.711 16.33, <0.001 
 Model + Time-Updated 
+ Previous 
0.710 15.58, <0.001 
Other Endpoints    
Cardiovascular-cause mortality, n = 138 Model 0.630  
 Model + Baseline 0.635 1.65, 0.20 
 Model + Time-Updated 0.647 9.15, 0.0025 
 Model + Time-Updated 
+ Baseline 
0.647 9.19, 0.010 
 Model + Time-Updated 
+ Previous 
0.647 9.37, 0.0092 
Death due to heart failure, n = 30 Model 0.733  
 Model + Baseline 0.773 4.97, 0.026 
 Model + Time-Updated 0.758 2.89, 0.089 
 Model + Time-Updated 
+ Baseline 
0.775 6.07, 0.048 
 Model + Time-Updated 
+ Previous 
0.758 2.90, 0.24 
Non-fatal myocardial infarction, n = 57 Model 0.632  
 Model + Baseline 0.651 1.66, 0.20 
 Model + Time-Updated 0.648 2.56, 0.11 
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 Model + Time-Updated 
+ Baseline 
0.652 3.13, 0.21 
 Model + Time-Updated 
+ Previous 
0.649 2.60, 0.27 
All-cause mortality or non-fatal myocardial 
infarction, n = 191 
Model 0.607  
 Model + Baseline 0.618 3.42, 0.064 
 Model + Time-Updated 0.629 12.68, <0.001 
 Model + Time-Updated 
+ Baseline 
0.631 13.04, 0.0015 
 Model + Time-Updated 
+ Previous 
0.630 13.24, 0.0013 
‘Model’ is the multivariate model excluding heart rate which included: sex; previous diabetes; left-ventricular ejection fraction 
(LVEF); site of MI; and in-hospital treatment with intravenous diuretics. 
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A2-14: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the time-updated categorical heart rate patterns variable, which 
produced the results shown in Table A2-11 in the CAPRICORN placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Endpoints    
All-cause mortality, n = 150 Model 0.632  
 Model + Pattern 0.646 10.03, 0.018 
All-cause mortality or cardiovascular-cause 
hospital admission,  
n = 366 
Model 0.604  
 Model + Pattern 0.611 6.69, 0.083 
Secondary Endpoints    
Sudden death, n = 68 Model 0.622  
 Model + Pattern 0.640 3.60, 0.31 
Hospital admission for heart failure, n = 
138 
Model 0.682  
 Model + Pattern 0.699 14.02, 0.0029 
Other Endpoints    
Cardiovascular-cause mortality, n = 138 Model 0.630  
 Model + Pattern 0.642 7.80, 0.050 
Death due to heart failure, n = 30 Model 0.733  
 Model + Pattern 0.752 2.40, 0.49 
Non-fatal myocardial infarction, n = 57 Model 0.632  
 Model + Pattern 0.638 0.86, 0.83 
All-cause mortality or non-fatal myocardial 
infarction, n = 191 
Model 0.607  
 Model + Pattern 0.617 7.61, 0.055 
‘Model’ is the multivariate model excluding heart rate which included: sex; previous diabetes; left-ventricular ejection fraction 
(LVEF); site of MI; and in-hospital treatment with intravenous diuretics. 
‘Model + Pattern’ is the multivariate model described above including the time-updated categorical heart rate patterns 
variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
the time-updated categorical heart rate patterns variable to the multivariate model excluding resting heart rate.     
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Table A2-15: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a heart rate ≥75bpm compared to a heart rate <75bpm in the CAPRICORN 
placebo population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Endpoints     
All-cause mortality, n = 150 0.50 0.13 0.076 0.063 
All-cause mortality or 
cardiovascular cause hospital 
admission, n = 366 
0.16 0.27 0.41 0.080 
Secondary Endpoints     
Sudden death, n = 68 0.25 0.48 0.26 0.37 
Hospital admission for heart 
failure, n = 138 
0.49 0.74 0.65 0.68 
Other Endpoints     
Cardiovascular-cause mortality, 
n = 138 
0.28 0.19 0.097 0.11 
Death due to heart failure,  
n = 30 
0.84 0.077 0.071 0.036 
Non-fatal myocardial 
infarction, n = 57 
0.87 0.18 0.11 0.17 
All-cause mortality or non-fatal 
myocardial infarction, n = 191 
0.37 0.41 0.014 0.032 
 
Table A2-16: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for an elevated continuous heart rate in the CAPRICORN placebo population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Endpoints     
All-cause mortality, n = 150 0.70 0.18 0.15 0.17 
All-cause mortality or 
cardiovascular cause hospital 
admission, n = 366 
0.41 0.85 0.65 0.55 
Secondary Endpoints     
Sudden death, n = 68 0.55 0.997 0.89 0.87 
Hospital admission for heart 
failure, n = 138 
0.25 0.45 0.68 0.90 
Other Endpoints     
Cardiovascular-cause mortality, 
n = 138 
0.58 0.38 0.28 0.38 
Death due to heart failure,  
n = 30 
0.97 0.055 0.029 0.018 
Non-fatal myocardial 
infarction, n = 57 
0.20 0.52 0.21 0.27 
All-cause mortality or non-fatal 
myocardial infarction, n = 191 
0.46 0.14 0.069 0.20 
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Table A2-17: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for the time-updated categorical heart rate patterns ‘high-low’, ‘low-high’ and ‘high-
high’ relative to the category ‘low-low’ in the CAPRICORN placebo population. 
 Heart Rate 
Category 
P-value 
Primary Endpoints   
All-cause mortality, n = 150 high-low 0.64 
 low-high 0.076 
 high-high 0.42 
All-cause mortality or cardiovascular-cause hospital admission, n = 366 high-low 0.28 
 low-high 0.22 
 high-high 0.99 
Secondary Endpoints   
Sudden death, n = 68 high-low 0.57 
 low-high 0.12 
 high-high 0.55 
Hospital admission for heart failure, n = 138 high-low 0.081 
 low-high 0.76 
 high-high 0.17 
Other Endpoints   
Cardiovascular-cause mortality, n = 138 high-low 0.52 
 low-high 0.20 
 high-high 0.52 
Death due to heart failure, n = 30 high-low 0.060 
 low-high 0.50 
 high-high 0.64 
Non-fatal myocardial infarction, n = 57 high-low 0.72 
 low-high 0.47 
 high-high 0.31 
All-cause mortality or non-fatal myocardial infarction, n = 191 high-low 0.69 
 low-high 0.11 
 high-high 0.15 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 75bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 75bpm, and so on.  
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Appendix 3 
Supplementary Tables for Chapter 5 
Table A3-1: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a heart rate ≥70bpm compared to a heart rate <70bpm 
in the EUROPA population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Composite Endpoint     
Cardiovascular mortality, MI or 
cardiac arrest, n = 1091 
1.02 (0.90 to 
1.16), 0.71 
1.07 (0.95 to 
1.21), 0.25 
1.07 (0.94 to 
1.23), 0.28 
1.05 (0.92 to 
1.21), 0.49 
Individual Components of the 
Primary Composite Endpoint 
    
Cardiovascular mortality,  
n = 464 
1.15 (0.95 to 
1.39), 0.16 
1.30 (1.08 to 
1.57), 0.0059 
1.28 (1.05 to 
1.56), 0.015 
1.24 (1.01 to 
1.53), 0.042 
Fatal or non-fatal MI, n = 738 0.95 (0.81 to 
1.11), 0.53 
0.99 (0.85 to 
1.15), 0.85 
1.00 (0.85 to 
1.18), 0.97 
0.99 (0.84 to 
1.17), 0.90 
Cardiac arrest, n = 17 0.98 (0.35 to 
2.69), 0.96 
2.56 (0.92 to 
7.12), 0.071 
3.20 (1.05 to 
9.78), 0.041 
4.19 (1.35 to 
13.04), 0.013 
Other Composite Endpoints     
Total mortality, MI, unstable 
angina or cardiac arrest,  
n = 1946 
1.03 (0.93 to 
1.13), 0.57 
1.16 (1.06 to 
1.27), 0.0017 
1.17 (1.06 to 
1.29), 0.0016 
1.13 (1.02 to 
1.26), 0.017 
Other Mortality Endpoints     
Total mortality, n = 795 1.23 (1.06 to 
1.42), 0.0061 
1.62 (1.40 to 
1.86), <0.001 
1.59 (1.37 to 
1.85), <0.001 
1.52 (1.30 to 
1.78), <0.001 
Other Individual Endpoints     
Unstable angina, n = 708 0.91 (0.78 to 
1.07), 0.27 
0.92 (0.79 to 
1.07), 0.29 
0.94 (0.80 to 
1.12), 0.49 
0.92 (0.77 to 
1.09), 0.33 
Stroke, n = 199 0.90 (0.66 to 
1.21), 0.47 
1.18 (0.89 to 
1.57), 0.25 
1.26 (0.93 to 
1.71), 0.13 
1.17 (0.85 to 
1.61), 0.35 
Revascularisation, n = 1177 0.86 (0.76 to 
0.98), 0.020 
0.89 (0.79 to 
1.00), 0.052 
0.92 (0.81 to 
1.05), 0.22 
0.96 (0.84 to 
1.10), 0.59 
Heart failure requiring hospital 
admission, n = 166 
1.28 (0.93 to 
1.76), 0.14 
1.47 (1.08 to 
2.02), 0.015 
1.41 (1.01 to 
1.97), 0.042 
1.14 (0.81 to 
1.62), 0.46 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; history of percutaneous coronary intervention (PCI); history of coronary 
artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; hypercholesterolemia; treatment with 
platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers (CCBs); and diuretics (potassium 
sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
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Table A3-2: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the EUROPA population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Composite 
Endpoint 
    
Cardiovascular mortality, MI 
or cardiac arrest, n = 1091 
1.03 (1.00 to 
1.06), 0.098 
1.03 (1.01 to 
1.06), 0.019 
1.03 (1.00 to 
1.06), 0.076 
1.03 (1.00 to 
1.06), 0.16 
Individual Components of 
the Primary Composite 
Endpoint 
    
Cardiovascular mortality,  
n = 464 
1.06 (1.02 to 
1.11), 00058 
1.11 (1.07 to 
1.16), <0.001 
1.10 (1.06 to 
1.15), <0.001 
1.10 (1.05 to 
1.15), <0.001 
Fatal or non-fatal MI, n = 738 1.00 (0.96 to 
1.04), 0.999 
1.02 (0.98 to 
1.05), 0.38 
1.02 (0.98 to 
1.06), 0.32 
1.02 (0.98 to 
1.06), 0.41 
Cardiac arrest, n = 17 0.95 (0.75 to 
1.21), 0.67 
1.15 (0.94 to 
1.41), 0.17 
1.25 (1.01 to 
1.56), 0.045 
1.27 (1.02 to 
1.59), 0.035 
Other Composite Endpoints     
Total mortality, MI, unstable 
angina or cardiac arrest,  
n = 1946 
1.03 (1.01 to 
1.05), 0.0072 
1.06 (1.04 to 
1.09), <0.001 
1.06 (1.04 to 
1.09), <0.001 
1.06 (1.04 to 
1.09), <0.001 
Other Mortality Endpoints     
Total mortality, n = 795 1.09 (1.05 to 
1.13), <0.001 
1.17 (1.13 to 
1.20), <0.001 
1.16 (1.13 to 
1.20), <0.001 
1.16 (1.12 to 
1.20), <0.001 
Other Individual Endpoints     
Unstable angina, n = 708 0.99 (0.95 to 
1.02), 0.45 
1.00 (0.96 to 
1.03), 0.84 
1.00 (0.96 to 
1.05), 0.87 
1.00 (0.96 to 
1.05), 0.92 
Stroke, n = 199 0.99 (0.92 to 
1.06), 0.72 
1.05 (0.99 to 
1.12), 0.12 
1.07 (1.00 to 
1.16), 0.051 
1.07 (0.99 to 
1.15), 0.10 
Revascularisation, n = 1177 0.96 (0.93 to 
0.99), 0.0070 
0.96 (0.94 to 
0.99), 0.011 
0.98 (0.94 to 
1.10), 0.15 
0.98 (0.95 to 
1.02), 0.29 
Heart failure requiring 
hospital admission, n = 166 
1.08 (1.00 to 
1.16), 0.052 
1.17 (1.10 to 
1.25), <0.001 
1.18 (1.10 to 
1.26), <0.001 
1.10 (1.01 to 
1.19), 0.021 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; history of percutaneous coronary intervention (PCI); history of coronary 
artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; hypercholesterolemia; treatment with 
platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers (CCBs); and diuretics (potassium 
sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
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Table A3-3: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for the time-updated categorical heart rate patterns ‘high-
low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the EUROPA population.   
 Heart Rate 
Category 
Hazard Ratio (95% Confidence 
Interval), p-value 
Primary Composite Endpoint   
Cardiovascular mortality, MI or cardiac arrest, n = 1091 high-low 1.05 (0.86 to 1.27), 0.64 
 low-high 1.04 (0.86 to 1.26), 0.65 
 high-high 1.11 (0.96 to 1.28), 0.18 
Individual Components of the Primary Composite 
Endpoint 
  
Cardiovascular mortality, n = 464 high-low 1.08 (0.79 to 1.45), 0.64 
 low-high 1.20 (0.90 to 1.61), 0.21 
 high-high 1.38 (1.11 to 1.72), 0.0040 
Fatal or non-fatal MI, n = 738 high-low 1.00 (0.80 to 1.26), 0.98 
 low-high 1.00 (0.79 to 1.26), 0.99 
 high-high 0.98 (0.82 to 1.17), 0.83 
Cardiac Arrest, n = 17 high-low - 
 low-high - 
 high-high - 
Other Composite Endpoints   
Total mortality, MI, unstable angina or cardiac arrest, n = 
1946 
high-low 1.08 (0.93 to 1.24), 0.31 
 low-high 1.16 (1.01 to 1.34), 0.035 
 high-high 1.19 (1.07 to 1.32), 0.0020 
Other Mortality Endpoints   
Total mortality, n = 795 high-low 1.12 (0.88 to 1.42), 0.35 
 low-high 1.48 (1.19 to 1.84), <0.001 
 high-high 1.75 (1.48 to 2.07), <0.001 
Other Individual Endpoints 
 
 
Unstable Angina, n = 708 high-low 1.16 (0.92 to 1.45), 0.21 
 low-high 1.06 (0.84 to 1.34), 0.62 
 high-high 0.90 (0.75 to 1.09), 0.27 
Stroke, n = 199 high-low 1.15 (0.73 to 1.79), 0.55 
 low-high 1.29 (0.84 to 1.98), 0.24 
 high-high 1.19 (0.85 to 1.67), 0.32 
Revascularisation, n = 1177 high-low 0.88 (0.73 to 1.05), 0.16 
 low-high 1.02 (0.86 to 1.21), 0.81 
 high-high 0.78 (0.67 to 0.90), 0.0010 
Heart failure requiring hospital admission, n = 166 high-low 1.32 (0.80 to 2.17), 0.28 
 low-high 0.74 (0.39 to 1.38), 0.34 
 high-high 1.98 (1.38 to 2.84), <0.001 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.  
There were not enough Cardiac Arrest events to allow analysis to be done in this case.  MI = Myocardial Infarction. 
Models were additionally adjusted for: age; sex; history of percutaneous coronary intervention (PCI); history of coronary 
artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; hypercholesterolemia; treatment with 
platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers (CCBs); and diuretics (potassium 
sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
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Table A3-4: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the heart rate variables that categorised subjects according to 
whether they had a heart rate less than, or greater than or equal to, 70bpm, which produced 
the results shown in Table A3-1 in the EUROPA population. 
  C-statistic Likelihood Ratio Test 
Statistics, p-value 
Primary Composite Endpoint    
Cardiovascular mortality, MI or cardiac 
arrest, n = 1091 
Model 0.631  
 Model + Baseline 0.631 0.14, 0.71 
 Model + Time-Updated 0.632 1.29, 0.26 
 Model + Time-Updated  
+ Baseline 
0.632 1.29, 0.052 
 Model + Time-Updated  
+ Previous  
0.632 1.82, 0.40 
Individual Components of the Primary 
Composite Endpoint 
   
Cardiovascular mortality, n = 464 Model 0.716  
 Model + Baseline 0.717 1.98, 0.16 
 Model + Time-Updated 0.720 7.56, 0.0060 
 Model + Time-Updated  
+ Baseline 
0.720 7.82, 0.020 
 Model + Time-Updated  
+ Previous 
0.721 8.52, 0.014 
Fatal or non-fatal MI, n = 738 Model 0.602  
 Model + Baseline 0.602 0.40, 0.53 
 Model + Time-Updated 0.602 0.035, 0.85 
 Model + Time-Updated  
+ Baseline 
0.602 0.40, 0.82 
 Model + Time-Updated  
+ Previous 
0.602 0.042, 0.98 
Cardiac Arrest, n = 17 Model 0.808  
 Model + Baseline 0.808 0.0023, 0.96 
 Model + Time-Updated 0.835 3.44, 0.064 
 Model + Time-Updated  
+ Baseline 
0.837 4.34, 0.11 
 Model + Time-Updated  
+ Previous  
0.850 6.88, 0.032 
Other Composite Endpoints    
Total mortality, MI, unstable angina or 
cardiac arrest, n = 1946 
Model 0.605  
 Model + Baseline 0.605 0.329, 0.57 
 Model + Time-Updated 0.607 9.85, 0.0017 
 Model + Time-Updated  
+ Baseline 
0.607 10.21, 0.0061 
 Model + Time-Updated  
+ Previous  
0.607 10.68, 0.0048 
Other Mortality Endpoints    
Total mortality, n = 795 Model 0.690  
 Model + Baseline 0.692 7.44, 0.0064 
 Model + Time-Updated 0.701 43.38, <0.001 
 Model + Time-Updated  
+ Baseline 
0.702 43.75, <0.001 
 Model + Time-Updated  
+ Previous  
0.703 46.50, <0.001 
Other Individual Endpoints    
Unstable Angina, n = 708 Model 0.585  
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 Model + Baseline 0.587 1.25, 0.26 
 Model + Time-Updated 0.587 1.13, 0.29 
 Model + Time-Updated  
+ Baseline 
0.587 1.72, 0.42 
 Model + Time-Updated  
+ Previous 
0.587 1.14, 0.57 
Stroke, n = 199 Model 0.705  
 Model + Baseline 0.705 0.52, 0.47 
 Model + Time-Updated 0.706 1.29, 0.26 
 Model + Time-Updated  
+ Baseline 
0.706 2.76, 0.25 
 Model + Time-Updated  
+ Previous 
0.706 1.32, 0.52 
Revascularisation, n = 1177 Model 0.615  
 Model + Baseline 0.617 5.53, 0.0019 
 Model + Time-Updated 0.616 3.82, 0.051 
 Model + Time-Updated  
+ Baseline 
0.617 7.02, 0.030 
 Model + Time-Updated  
+ Previous 
0.617 12.08, 0.0024 
Heart failure requiring hospital 
admission, n = 166 
Model 0.754  
 Model + Baseline 0.757 2.22, 0.14 
 Model + Time-Updated 0.756 5.88, 0.015 
 Model + Time-Updated  
+ Baseline 
0.757 6.37, 0.041 
 Model + Time-Updated  
+ Previous  
0.768 16.11, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; history of percutaneous coronary 
intervention (PCI); history of coronary artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; 
hypercholesterolemia; treatment with platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers 
(CCBs); and diuretics (potassium sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate group variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate group variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate group variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
group variable and the previous time-updated heart rate group variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A3-5: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A3-2 in the EUROPA population. 
  C-statistic Likelihood Ratio Test 
Statistics, p-value 
Primary Composite Endpoint    
Cardiovascular mortality, MI or cardiac 
arrest, n = 1091 
Model 0.631  
 Model + Baseline 0.632 2.72, 0.099 
 Model + Time-Updated 0.633 5.44, 0.020 
 Model + Time-Updated  
+ Baseline 
0.633 5.83, 0.054 
 Model + Time-Updated  
+ Previous  
0.633 6.31, 0.043 
Individual Components of the Primary 
Composite Endpoint 
   
Cardiovascular mortality, n = 464 Model 0.716  
 Model + Baseline 0.719 7.43, 0.0064 
 Model + Time-Updated 0.724 24.33, <0.001 
 Model + Time-Updated  
+ Baseline 
0.724 24.71, <0.001 
 Model + Time-Updated  
+ Previous 
0.724 25.05, <0.001 
Fatal or non-fatal MI, n = 738 Model 0.602  
 Model + Baseline 0.602 0.0000034, 0.999 
 Model + Time-Updated 0.603 0.75, 0.39 
 Model + Time-Updated  
+ Baseline 
0.603 0.97, 0.61 
 Model + Time-Updated  
+ Previous 
0.603 0.79, 0.68 
Cardiac Arrest, n = 17 Model 0.808  
 Model + Baseline 0.806 0.19, 0.66 
 Model + Time-Updated 0.821 1.68, 0.19 
 Model + Time-Updated  
+ Baseline 
0.820 3.46, 0.18 
 Model + Time-Updated  
+ Previous  
0.823 3.67, 0.16 
Other Composite Endpoints    
Total mortality, MI, unstable angina or 
cardiac arrest, n = 1946 
Model 0.605  
 Model + Baseline 0.607 7.14, 0.0075 
 Model + Time-Updated 0.611 32.68, <0.001 
 Model + Time-Updated  
+ Baseline 
0.611 32.68, <0.001 
 Model + Time-Updated  
+ Previous  
0.611 32.76, <0.001 
Other Mortality Endpoints    
Total mortality, n = 795 Model 0.690  
 Model + Baseline 0.695 24.46, <0.001 
 Model + Time-Updated 0.712 99.35, <0.001 
 Model + Time-Updated  
+ Baseline 
0.712 100.04, <0.001 
 Model + Time-Updated  
+ Previous  
0.712 100.34, <0.001 
Other Individual Endpoints    
Unstable Angina, n = 708 Model 0.585  
 Model + Baseline 0.586 0.48, 0.49 
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 Model + Time-Updated 0.586 0.042, 0.84 
 Model + Time-Updated  
+ Baseline 
0.586 0.51, 0.78 
 Model + Time-Updated  
+ Previous 
0.586 0.25, 0.88 
Stroke, n = 199 Model 0.705  
 Model + Baseline 0.705 0.13, 0.72 
 Model + Time-Updated 0.705 2.29, 0.13 
 Model + Time-Updated  
+ Baseline 
0.704 3.76, 0.15 
 Model + Time-Updated  
+ Previous 
0.706 2.71, 0.26 
Revascularisation, n = 1177 Model 0.615  
 Model + Baseline 0.617 7.36, 0.0067 
 Model + Time-Updated 0.617 6.52, 0.011 
 Model + Time-Updated  
+ Baseline 
0.617 9.41, 0.0091 
 Model + Time-Updated  
+ Previous 
0.618 10.12, 0.0063 
Heart failure requiring hospital 
admission, n = 166 
Model 0.754  
 Model + Baseline 0.759 3.68, 0.055 
 Model + Time-Updated 0.766 22.25, <0.001 
 Model + Time-Updated  
+ Baseline 
0.766 22.28, <0.001 
 Model + Time-Updated  
+ Previous  
0.777 31.35, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; history of percutaneous coronary 
intervention (PCI); history of coronary artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; 
hypercholesterolemia; treatment with platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers 
(CCBs); and diuretics (potassium sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A3-6: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the time-updated categorical heart rate patterns variable, which 
produced the results shown in Table A3-3 in the EUROPA population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Cardiovascular mortality, MI or cardiac arrest, n 
= 1091 
Model 0.631  
 Model + Pattern 0.632 1.82, 0.61 
Individual Components of the Primary 
Composite Endpoint 
   
Cardiovascular mortality, n = 464 Model 0.716  
 Model + Pattern 0.721 8.61, 0.035 
Fatal or non-fatal MI, n = 738 Model 0.602  
 Model + Pattern 0.602 0.055, 0.997 
Cardiac Arrest, n = 17 Model - - 
 Model + Pattern - - 
Other Composite Endpoints    
Total mortality, MI, unstable angina or cardiac 
arrest, n = 1946 
Model 0.605  
 Model + Pattern 0.607 10.94, 0.012 
Other Mortality Endpoints    
Total mortality, n = 795 Model 0.690  
 Model + Pattern 0.703 46.61, <0.001 
Other Individual Endpoints    
Unstable Angina, n = 708 Model 0.585  
 Model + Pattern 0.587 4.21, 0.24 
Stroke, n = 199 Model 0.705  
 Model + Pattern 0.706 1.77, 0.62 
Revascularisation, n = 1177 Model 0.615  
 Model + Pattern 0.617 13.09, 0.0044 
Heart failure requiring hospital admission, n = 
166 
Model 0.754  
 Model + Pattern 0.772 19.51, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; history of percutaneous coronary 
intervention (PCI); history of coronary artery bypass graft (CABG); peripheral artery disease (PAD); diabetes mellitus; 
hypercholesterolemia; treatment with platelet inhibitors; lipid-lowering therapies; beta-blockers; calcium channel blockers 
(CCBs); and diuretics (potassium sparing and other); and systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
‘Model + Pattern’ is the multivariate model described above including the time-updated categorical heart rate patterns 
variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
the time-updated categorical heart rate patterns variable to the multivariate model excluding resting heart rate.     
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Table A3-7: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a heart rate ≥70bpm compared to a heart rate <70bpm in the EUROPA 
population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Composite Endpoint     
Cardiovascular mortality, MI or 
cardiac arrest, n = 1091 
0.72 0.49 0.36 0.82 
Individual Components of the 
Primary Composite Endpoint 
    
Cardiovascular mortality,  
n = 464 
0.53 0.82 0.99 0.44 
Fatal or non-fatal MI, n = 738 0.58 0.48 0.30 0.51 
Cardiac arrest, n = 17 0.98 0.33 0.49 0.32 
Other Composite Endpoints     
Total mortality, MI, unstable 
angina or cardiac arrest,  
n = 1946 
0.77 0.68 0.89 0.35 
Other Mortality Endpoints     
Total mortality, n = 795 0.72 0.73 0.88 0.30 
Other Individual Endpoints     
Unstable angina, n = 708 0.91 0.56 0.51 0.62 
Stroke, n = 199 0.68 0.066 0.055 0.077 
Revascularisation, n = 1177 0.89 0.14 0.079 0.34 
Heart failure requiring hospital 
admission, n = 166 
0.13 0.14 0.30 0.47 
MI = Myocardial Infarction. 
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Table A3-8: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for an elevated continuous heart rate in the EUROPA population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Change in Heart 
Rate Adjusted 
for Previous 
 P-value    
Primary Composite Endpoint     
Cardiovascular mortality, MI 
or cardiac arrest, n = 1091 
0.72 0.81 0.63 0.89 
Individual Components of 
the Primary Composite 
Endpoint 
    
Cardiovascular mortality,  
n = 464 
0.95 0.068 0.051 0.088 
Fatal or non-fatal MI, n = 738 0.62 0.48 0.52 0.52 
Cardiac arrest, n = 17 0.40 0.27 0.84 0.14 
Other Composite Endpoints     
Total mortality, MI, unstable 
angina or cardiac arrest,  
n = 1946 
0.90 0.39 0.43 0.36 
Other Mortality Endpoints     
Total mortality, n = 795 0.63 0.29 0.20 0.13 
Other Individual Endpoints     
Unstable angina, n = 708 0.97 0.38 0.27 0.40 
Stroke, n = 199 0.39 0.48 0.34 0.51 
Revascularisation, n = 1177 0.34 0.10 0.15 0.56 
Heart failure requiring 
hospital admission, n = 166 
0.057 0.24 0.57 0.93 
MI = Myocardial Infarction. 
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Table A3-9: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for the time-updated categorical heart rate patterns ‘high-low’, ‘low-high’ and ‘high-
high’ relative to the category ‘low-low’ in the EUROPA population.   
 Heart Rate Category P-value 
Primary Composite Endpoint   
Cardiovascular mortality, MI or cardiac arrest, n = 1091 high-low 0.96 
 low-high 0.71 
 high-high 0.30 
Individual Components of the Primary Composite Endpoint   
Cardiovascular mortality, n = 464 high-low 0.49 
 low-high 0.47 
 high-high 0.67 
Fatal or non-fatal MI, n = 738 high-low 0.80 
 low-high 0.78 
 high-high 0.54 
Cardiac Arrest, n = 17 high-low - 
 low-high - 
 high-high - 
Other Composite Endpoints   
Total mortality, MI, unstable angina or cardiac arrest, n = 1946 high-low 0.88 
 low-high 0.10 
 high-high 0.73 
Other Mortality Endpoints   
Total mortality, n = 795 high-low 0.39 
 low-high 0.33 
 high-high 0.61 
Other Individual Endpoints 
 
 
Unstable Angina, n = 708 high-low 0.52 
 low-high 0.70 
 high-high 0.41 
Stroke, n = 199 high-low 0.61 
 low-high 0.056 
 high-high 0.17 
Revascularisation, n = 1177 high-low 0.66 
 low-high 0.72 
 high-high 0.39 
Heart failure requiring hospital admission, n = 166 high-low 0.53 
 low-high 0.93 
 high-high 0.083 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.  
There were not enough Cardiac Arrest events to allow analysis to be done in this case.  MI = Myocardial Infarction.
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Appendix 4 
Supplementary Tables for Chapter 6 
Table A4-1: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for gender-specific heart rate thirds, relative to the low 
heart rate third in the PROSPER population. 
  Baseline 
Heart Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Heart 
Rate 
Third 
Hazard Ratio (95% Confidence Interval), p-value 
Primary Endpoint      
CHD death, non-fatal MI or 
fatal or non-fatal stroke,  
n = 868 
Middle 0.92 (0.78 to 
1.09), 0.32 
1.00 (0.84 to 
1.19), 0.99 
1.12 (0.92 to 
1.37), 0.26 
1.13 (0.92 to 
1.39), 0.24 
 
High 1.09 (0.92 to 
1.28), 0.31 
1.36 (1.16 to 
1.60), <0.001 
1.61 (1.29 to 
2.01), <0.001 
1.54 (1.22 to 
1.95), <0.001 
Secondary Endpoints      
CHD death or non-fatal MI,  
n = 639 
Middle 0.94 (0.78 to 
1.14), 0.55 
0.94 (0.77 to 
1.15), 0.58 
1.04 (0.82 to 
1.32), 0.74 
1.05 (0.82 to 
1.33), 0.72 
 High 1.10 (0.91 to 
1.33), 0.33 
1.42 (1.18 to 
1.71), <0.001 
1.72 (1.33 to 
2.22), <0.001 
1.62 (1.24 to 
2.12), <0.001 
Fatal or non-fatal stroke,  
n = 261 
Middle 0.78 (0.58 to 
1.07), 0.12 
0.98 (0.73 to 
1.34), 0.92 
1.13 (0.71 to 
1.62), 0.49 
1.16 (0.80 to 
1.67), 0.44 
 High 1.02 (0.76 to 
1.37), 0.90 
1.06 (0.79 to 
1.44), 0.68 
1.09 (0.72 to 
1.65), 0.67 
1.20 (0.78 to 
1.85), 0.41 
Other Outcomes      
Non-fatal MI, n = 471 Middle 0.92 (0.73 to 
1.15), 0.46 
0.98 (0.78 to 
1.24), 0.88 
1.10 (0.84 to 
1.45), 0.47 
1.12 (0.85 to 
1.48), 0.43 
 
High 1.04 (0.83to 
1.30), 0.72 
1.31 (1.05 to 
1.64), 0.015 
1.59 (1.17 to 
2.16), 0.0027 
1.53 (1.11 to 
2.10), 0.0095 
Non-fatal stroke, n = 231 Middle 0.78 (0.56 to 
1.08), 0.14 
0.98 (0.71 to 
1.35), 0.89 
1.14 (0.78 to 
1.66), 0.51 
1.19 (0.81 to 
1.75), 0.38 
 
High 1.00 (0.73 to 
1.37), 0.997 
1.07 (0.78 to 
1.48), 0.66 
1.14 (0.74 to 
1.77), 0.55 
1.30 (0.82 to 
2.05), 0.26 
TIA, n = 177 Middle 0.69 (0.48 to 
1.00), 0.051 
0.70 (0.49 to 
1.00), 0.050 
0.75 (0.49 to 
1.13), 0.17 
0.59 (0.38 to 
0.90), 0.015 
 
High 0.82 (0.57 to 
1.17), 0.26 
0.68 (0.47 to 
0.98), 0.038 
0.63 (0.38 to 
1.03), 0.066 
0.57 (0.34 to 
0.95), 0.031 
PTCA or CABG, n = 87 Middle 0.85 (0.53 to 
1.38), 0.52 
0.73 (0.44 to 
1.19), 0.20 
0.75 (0.41 to 
1.34), 0.33 
0.65 (0.35 to 
1.20), 0.17 
 
High 0.56 (0.31 to 
1.01), 0.055 
0.58 (0.33 to 
1.02), 0.060 
0.73 (0.35 to 
1.55), 0.41 
0.60 (0.28 to 
1.32), 0.21 
Peripheral arterial 
surgery/angioplasty, n = 79 
Middle 0.77 (0.45 to 
1.34), 0.36 
0.74 (0.42 to 
1.29), 0.29 
0.81 (0.42 to 
1.58), 0.54 
0.70 (0.35 to 
1.39), 0.30 
 
High 0.91 (0.53 to 
1.57), 0.74 
0.98 (0.58 to 
1.69), 0.95 
1.09 (0.52 to 
2.30), 0.82 
0.85 (0.39 to 
1.86), 0.68 
All cardiovascular events,  
n = 963 
Middle 0.91 (0.78 to 
1.07), 0.24 
0.96 (0.82 to 
1.13), 0.64 
1.07 (0.89 to 
1.30), 0.48 
1.07 (0.88 to 
1.30), 0.50 
 
High 1.05 (0.90 to 
1.22), 0.57 
1.28 (1.10 to 
1.49), 0.0018 
1.51 (1.22 to 
1.87), <0.001 
1.42 (1.13 to 
1.78), 0.0023 
Fatal or non-fatal stroke or 
TIA, n = 409 
Middle 0.73 (0.57 to 
0.93), 0.011 
0.85 (0.67 to 
1.08), 0.19 
0.96 (0.73 to 
1.28), 0.80 
0.87 (0.65 to 
1.16), 0.35 
 High 0.93 (0.73 to 
1.17), 0.52 
0.88 (0.69 to 
1.12), 0.30 
0.87 (0.62 to 
1.20), 0.39 
0.87 (0.62 to 
1.23), 0.43 
HF hospitalisation, n = 232 Middle 1.49 (1.06 to 
2.09), 0.020 
1.26 (0.90 to 
1.79), 0.19 
1.10 (0.73 to 
1.66), 0.65 
1.08 (0.71 to 
1.66), 0.72 
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 High 1.77 (1.27 to 
2.46), <0.001 
2.10 (1.52 to 
2.92, <0.001 
1.94 (1.27 to 
2.98), 0.0024 
1.78 (1.14 to 
2.80), 0.011 
Deaths      
CHD, n = 212 Middle 1.10 (0.78 to 
1.56), 0.58 
0.89 (0.61 to 
1.29), 0.54 
0.89 (0.58 to 
1.36), 0.58 
0.4 (0.54 to 
1.31), 0.45 
 High 1.43 (1.03 to 
1.99), 0.035 
1.84 (1.33 to 
2.54), <0.001 
1.97 (1.28 to 
3.02), 0.0020 
1.90 (1.21 to 
2.97), 0.0051 
Stroke, n = 35 Middle 0.73 (0.30 to 
1.76), 0.49 
0.97 (0.43 to 
2.19), 0.94 
1.06 (0.39 to 
2.89), 0.91 
0.87 (0.31 to 
2.44), 0.79 
 High 1.04 (0.47 to 
2.32), 0.92 
0.82 (0.35 to 
1.92), 0.65 
0.62 (0.19 to 
2.07), 0.44 
0.50 (0.14 to 
1.71), 0.27 
Vascular, n = 287 Middle 1.03 (0.76 to 
1.39), 0.87 
0.90 (0.66 to 
1.23), 0.51 
0.90 (0.62 to 
1.29), 0.55 
0.84 (0.58 to 
1.22), 0.35 
 High 1.45 (1.09 to 
1.93), 0.0099 
1.68 (1.27 to 
2.22), <0.001 
1.64 (1.13 to 
2.39), 0.0095 
1.59 (1.08 to 
2.36), 0.020 
Non-vascular, n = 303 Middle 0.95 (0.70 to 
1.28), 0.73 
0.87 (0.64 to 
1.20), 0.40 
0.90 (0.63 to 
1.29), 0.57 
0.86 (0.60 to 
1.23), 0.41 
 High 1.46 (1.10 to 
1.92), 0.0080 
1.71 (1.30 to 
2.25), <0.001 
1.69 (1.17 to 
2.42), 0.0046 
1.67 (1.14 to 
2.43), 0.0079 
Cancer, n = 199 Middle 1.04 (0.73 to 
1.49), 0.82 
0.83 (0.56 to 
1.22), 0.33 
0.83 (0.54 to 
1.28), 0.41 
0.81 (0.52 to 
1.25), 0.34 
 High 1.28 (0.91 to 
1.81), 0.16 
1.60 (1.15 to 
2.23), 0.0057 
1.71 (1.11 to 
2.62), 0.015 
1.75 (1.12 to 
2.73), 0.014 
All-causes, n = 590 Middle 0.99 (0.80 to 
1.22), 0.91 
0.89 (0.71 to 
1.11), 0.28 
0.90 (0.70 to 
1.16), 0.41 
0.85 (0.65 to 
1.11), 0.22 
 High 1.46 (1.20 to 
1.78), <0.001 
1.70 (1.40 to 
2.07), <0.001 
1.67 (1.29 to 
2.16), <0.001 
1.64 (1.25 to 
2.15), <0.001 
Male participants with a baseline heart rate less than or equal to 59bpm, between 60 and 68bpm, and greater than 68bpm, 
were classed as being in the ‘low’, ‘medium’ and ‘high’ heart rate thirds, respectively.  Similarly, female participants with a 
baseline heart rate less than or equal to 62bpm, between 63 and 72bpm, and greater than 72bpm were classed as being in 
the ‘low’, ‘medium’ and ‘high’ heart rate thirds. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs). 
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Table A4-2: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the PROSPER population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
  
Hazard Ratio (95% Confidence Interval), p-value 
Primary Endpoint     
CHD death, non-fatal MI or 
fatal or non-fatal stroke,  
n = 868 
1.00 (0.97 to 
1.03), 0.92 
1.05 (1.02 to 
1.08), <0.001 
1.10 (1.06 to 
1.14), <0.001 
1.09 (1.04 to 
1.13), <0.001 
Secondary Endpoints     
CHD death or non-fatal MI,  
n = 639 
1.01 (0.98 to 
1.04), 0.57 
1.06 (1.03 to 
1.10), <0.001 
1.11 (1.07 to 
1.16), <0.001 
1.10 (1.05 to 
1.15), <0.001 
Fatal or non-fatal stroke,  
n = 261 
0.97 (0.92 to 
1.03), 0.29 
1.01 (0.95 to 
1.06), 0.85 
1.05 (0.98 to 
1.13), 0.16 
1.04 (0.97 to 
1.13), 0.27 
Other Outcomes     
Non-fatal MI, n = 471 0.99 (0.95 to 
1.03), 0.55 
1.04 (1.00 to 
1.08), 0.050 
1.09 (1.04 to 
1.15), <0.001 
1.07 (1.02 to 
1.13), 0.0097 
Non-fatal stroke, n = 231 0.97 (0.92 to 
1.03), 0.39 
1.01 (0.95 to 
1.06), 0.81 
1.05 (0.97 to 
1.13), 0.22 
1.04 (0.96 to 
1.13), 0.30 
TIA, n = 177 0.97 (0.90 to 
1.03), 0.32 
0.96 (0.90 to 
1.02), 0.19 
0.96 (0.87 to 
1.05), 0.39 
0.94 (0.85 to 
1.04), 0.23 
PTCA or CABG, n = 87 0.86 (0.78 to 
0.96), 0.0052 
0.86 (0.78 to 
0.96), 0.0054 
0.92 (0.79 to 
1.07), 0.30 
0.87 (0.74 to 
1.02), 0.088 
Peripheral arterial 
surgery/angioplasty, n = 79 
1.00 (0.90 to 
1.10) 0.97 
1.03 (0.94 to 
1.13), 0.57 
1.06 (0.93 to 
1.21), 0.38 
1.02 (0.89 to 
1.18), 0.75 
All CV events, n = 963 1.00 (0.97 to 
1.02), 0.79 
1.04 (1.01 to 
1.07), 0.0024 
1.09 (1.05 to 
1.13), <0.001 
1.07 (1.03 to 
1.11), <0.001 
Fatal or non-fatal stroke or 
TIA, n = 409 
0.97 (0.92 to 
1.01), 0.13 
0.98 (0.94 to 
1.02), 0.38 
1.01 (0.95 to 
1.07), 0.75 
0.99 (0.93 to 
1.06), 0.81 
HF hospitalisation, n = 232 1.10 (1.05 to 
1.16), <0.001 
1.17 (1.12 to 
1.22), <0.001 
1.18 (1.12 to 
1.25), <0.001 
1.17 (1.11 to 
1.24), <0.001 
Deaths     
CHD, n = 212 1.08 (1.02 to 
1.14), 0.0046 
1.13 (1.07 to 
1.21), <0.001 
1.13 (1.06 to 
1.20), <0.001 
1.14 (1.07 to 
1.22), <0.001 
Stroke, n = 35 0.92 (0.79 to 
1.07), 0.29 
0.95 (0.82 to 
1.10), 0.52 
1.02 (0.83 to 
1.26), 0.82 
1.00 (0.79 to 
1.25), 0.97 
Vascular, n = 287 1.07 (1.02 to 
1.13), 0.0046 
1.11 (1.06 to 
1.16), <0.001 
1.11 (1.05 to 
1.18), <0.001 
1.12 (1.06 to 
1.19), <0.001 
Non-vascular, n = 303 1.09 (1.04 to 
1.15), <0.001 
1.13 (1.08 to 
1.18), <0.001 
1.13 (1.07 to 
1.19), <0.001 
1.14 (1.08 to 
1.20), <0.001 
Cancer, n = 199 1.05 (0.99 to 
1.12), 0.087 
1.12 (1.06 to 
1.18), <0.001 
1.14 (1.07 to 
1.22), <0.001 
1.15 (1.08 to 
1.23), <0.001 
All-causes, n = 590 1.08 (1.05 to 
1.12), <0.001 
1.12 (1.09 to 
1.15), <0.001 
1.12 (1.08 to 
1.17), <0.001 
1.13 (1.09 to 
1.18), <0.001 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs).  
349 
 
Table A4-3: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for the time-updated categorical heart rate patterns ‘high-
low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the PROSPER 
population.   
 Heart Rate 
Category 
Hazard Ratio (95% Confidence 
Interval), p-value 
Primary Composite Endpoint   
CHD death or non-fatal MI or fatal or non-fatal stroke,  
n = 868 
high-low 0.93 (0.70 o 1.23), 0.61 
 low-high 1.33 (1.04 to 1.69), 0.022 
 high-high 1.19 (1.02 to 1.40), 0.025 
Secondary Endpoints   
CHD death or non-fatal MI, n = 639 high-low 0.88 (0.63 to 1.23), 0.45 
 low-high 1.37 (1.03 to 1.81), 0.028 
 high-high 1.27 (1.06 to 1.52), 0.0098 
Fatal or non-fatal stroke, n = 261 high-low 0.95 (0.58 to 1.55), 0.83 
 low-high 1.20 (0.77 to 1.87), 0.41 
 high-high 0.96 (0.72 to 1.29), 0.80 
Other Outcomes 
 
 
Non-fatal MI, n = 471 high-low 0.95 (0.66 to 1.39), 0.81 
 low-high 1.33 (0.96 to 1.85), 0.090 
 high-high 1.15 (0.93 to 1.42), 0.20 
Non-fatal stroke, n = 231 high-low 1.00 (0.60 to 1.65), 0.99 
 low-high 1.22 (0.77 to 1.94), 0.39 
 high-high 0.92 (0.67 to 1.26), 0.60 
TIA, n = 177 high-low 0.63 (0.33 to 1.21), 0.17 
 low-high 0.90 (0.51 to 1.58), 0.71 
 high-high 0.71 (0.49 to 1.03), 0.068 
PTCA or CABG, n = 87 high-low 0.72 (0.29 to 1.83), 0.49 
 low-high 0.88 (0.37 to 2.06), 0.71 
 high-high 0.65 (0.36 to 1.17), 0.15 
Peripheral arterial surgery/angioplasty, n = 79 high-low 0.90 (0.35 to 2.30), 0.82 
 low-high 0.83 (0.32 to 2.12), 0.70 
 high-high 1.01 (0.60 to 1.69), 0.97 
All CV events, n = 963 high-low 0.92 (0.70 to 1.19), 0.51 
 low-high 1.29 (1.02 to 1.63), 0.033 
 high-high 1.15 (1.00 to 1.34), 0.057 
Fatal or non-fatal stroke or TIA, n = 409 high-low 0.81 (0.54 to 1.21), 0.30 
 low-high 1.06 (0.74 to 1.52), 0.77 
 high-high 0.84 (0.67 to 1.07), 0.16 
HF hospitalisation, n = 232 high-low 0.97 (0.55 to 1.21), 0.92 
 low-high 1.88 (1.21 to 2.92), 0.0050 
 high-high 1.84 (1.37 to 2.46), <0.001 
Deaths   
CHD, n = 212 high-low 0.69 (0.36 to 1.34), 0.27 
 low-high 1.94 (1.26 to 2.98), 0.0025 
 high-high 1.65 (1.21 to 2.24), 0.0014 
Stroke, n = 35 high-low 0.74 (0.17 to 3.28), 0.69 
 low-high 0.72 (0.16 to 3.18), 0.66 
 high-high 0.98 (0.46 to 2.09), 0.96 
Vascular, n = 287 high-low 0.75 (0.44 to 1.29), 0.30 
 low-high 1.73 (1.17 to 2.53), 0.0054 
 high-high 1.58 (1.22 to 2.06), <0.001 
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Non-vascular, n = 303 high-low 0.88 (0.54 to 1.46), 0.63 
 low-high 2.24 (1.58 to 3.16), <0.001 
 high-high 1.71 (1.31 to 2.21), <0.001 
Cancer, n = 199 high-low 0.75 (0.40 to 1.41), 0.37 
 low-high 2.51 (1.70 to 3.72), <0.001 
 high-high 1.41 (1.01 to 1.96), 0.043 
All-causes, n = 590 high-low 0.83 (0.57 to 1.18), 0.29 
 low-high 1.99 (1.54 to 2.57), <0.001 
 high-high 1.65 (1.37 to 1.98), <0.001 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs). 
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Table A4-4: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the gender-specific heart rate thirds variables, which produced 
the results shown in Table A4-1 in the PROSPER population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
CHD death or non-fatal MI or fatal or 
non-fatal stroke, n = 868 
Model 0.619  
 Model + Baseline 0.621 3.92, 0.14 
 Model + Time-Updated 0.627 18.26, <0.001 
 Model + Time-Updated 
+ Baseline 
0.629 23.41, <0.001 
 Model + Time-Updated 
+ Previous 
0.628 22.35, <0.001 
Secondary Endpoints    
CHD death or non-fatal MI, n = 639 Model  0.633  
 Model + Baseline 0.635 2.43, 0.30 
 Model + Time-Updated 0.641 20.66, <0.001 
 Model + Time-Updated 
+ Baseline 
0.643 25.05, <0.001 
 Model + Time-Updated 
+ Previous 
0.642 22.90, <0.001 
Fatal or non-fatal stroke, n = 261 Model 0.614  
 Model + Baseline 0.619 3.48, 0.018 
 Model + Time-Updated 0.614 0.29, 0.86 
 Model + Time-Updated 
+ Baseline 
0.620 3.96, 0.41 
 Model + Time-Updated 
+ Previous 
0.619 2.83, 0.59 
Other Outcomes    
Non-fatal MI, n = 471 Model  0.627  
 Model + Baseline 0.627 1.21, 0.55 
 Model + Time-Updated 0.632 8.14, 0.017 
 Model + Time-Updated 
+ Baseline 
0.634 11.50, 0.021 
 Model + Time-Updated 
+ Previous 
0.632 10.66, 0.031 
Non-fatal stroke, n = 231 Model  0.595  
 Model + Baseline 0.601 2.90, 0.23 
 Model + Time-Updated 0.596 0.36, 0.83 
 Model + Time-Updated 
+ Baseline 
0.602 3.41, 0.49 
 Model + Time-Updated 
+ Previous 
0.603 3.45, 0.48 
TIA, n = 177 Model  0.660  
 Model + Baseline 0.665 3.94, 0.14 
 Model + Time-Updated 0.668 5.76, 0.056 
 Model + Time-Updated 
+ Baseline 
0.671 7.57, 0.11 
 Model + Time-Updated 
+ Previous 
0.670 7.82, 0.099 
PTCA or CABG, n = 87 Model  0.769  
 Model + Baseline 0.773 3.96, 0.14 
 Model + Time-Updated 0.772 4.10, 0.13 
 Model + Time-Updated 
+ Baseline 
0.773 5.11, 0.28 
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 Model + Time-Updated 
+ Previous 
0.774 5.00, 0.29 
Peripheral arterial surgery/angioplasty, 
n = 79 
Model  0.755  
 Model + Baseline 0.755 0.86, 0.65 
 Model + Time-Updated 0.756 1.42, 0.49 
 Model + Time-Updated 
+ Baseline 
0.757 1.70, 0.79 
 Model + Time-Updated 
+ Previous 
0.757 1.67, 0.80 
All CV events, n = 963 Model  0.621  
 Model + Baseline 0.623 3.03, 0.22 
 Model + Time-Updated 0.626 14.95, <0.001 
 Model + Time-Updated 
+ Baseline 
0.628 20.17, <0.001 
 Model + Time-Updated 
+ Previous 
0.628 18.36, 0.0010 
Fatal or non-fatal stroke or TIA, n = 409 Model  0.620  
 Model + Baseline 0.625 7.03, 0.030 
 Model + Time-Updated 0.621 1.97, 0.37 
 Model + Time-Updated 
+ Baseline 
0.625 7.83, 0.098 
 Model + Time-Updated 
+ Previous 
0.621 2.16, 0.71 
HF hospitalisation, n = 232 Model 0.699  
 Model + Baseline 0.706 12.17, 0.0023 
 Model + Time-Updated 0.712 22.74, <0.001 
 Model + Time-Updated 
+ Baseline 
0.714 22.77, <0.001 
 Model + Time-Updated 
+ Previous 
0.712 24.43, <0.001 
Deaths    
CHD, n = 212 Model  0.702  
 Model + Baseline 0.703 4.82, 0.90 
 Model + Time-Updated 0.721 22.33, <0.001 
 Model + Time-Updated 
+ Baseline 
0.721 22.89, <0.001 
 Model + Time-Updated 
+ Previous 
0.721 23.31, <0.001 
Stroke, n = 35 Model  0.795  
 Model + Baseline 0.799 0.78, 0.68 
 Model + Time-Updated 0.794 0.24, 0.89 
 Model + Time-Updated 
+ Baseline 
0.799 1.90, 0.75 
 Model + Time-Updated 
+ Previous 
0.795 1.94, 0.75 
Vascular, n = 287 Model  0.701  
 Model + Baseline 0.708 8.48, 0.014 
 Model + Time-Updated 0.720 22.15, <0.001 
 Model + Time-Updated 
+ Baseline 
0.720 22.20, <0.001 
 Model + Time-Updated 
+ Previous 
0.719 22.70, <0.001 
Non-vascular, n = 303 Model  0.667  
 Model + Baseline 0.673 11.52, 0.0031 
 Model + Time-Updated 0.679 26.94, <0.001 
353 
 
 Model + Time-Updated 
+ Baseline 
0.679 27.65, <0.001 
 Model + Time-Updated 
+ Previous 
0.679 26.99, <0.001 
Cancer, n = 199 Model  0.661  
 Model + Baseline 0.666 2.35, 0.31 
 Model + Time-Updated 0.676 15.61, <0.001 
 Model + Time-Updated 
+ Baseline 
0.675 16.02, 0.0030 
 Model + Time-Updated 
+ Previous 
0.675 17.24, 0.0017 
All-causes, n = 590 Model 0.663  
 Model + Baseline 0.669 20.08, <0.001 
 Model + Time-Updated 0.679 49.58, <0.001 
 Model + Time-Updated 
+ Baseline 
0.679 50.13, <0.001 
 Model + Time-Updated 
+ Previous 
0.679 49.96, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; smoking status; diabetes; history of vascular 
disease; hypertension; body mass index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; 
estimated Glomerular Filtration Rate (eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, 
diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).  
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate thirds variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate thirds variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate thirds variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
thirds variable and the previous time-updated heart rate thirds variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
  
354 
 
Table A4-5: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A4-2 in the PROSPER population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
CHD death or non-fatal MI or fatal or 
non-fatal stroke, n = 868 
Model 0.619  
 Model + Baseline 0.619 0.0090, 0.92 
 Model + Time-Updated 0.624 12.94, <0.001 
 Model + Time-Updated 
+ Baseline 
0.628 25.26, <0.001 
 Model + Time-Updated 
+ Previous 
0.625 17.32, <0.001 
Secondary Endpoints    
CHD death or non-fatal MI, n = 639 Model  0.633  
 Model + Baseline 0.633 0.31, 0.58 
 Model + Time-Updated 0.639 13.95, <0.001 
 Model + Time-Updated 
+ Baseline 
0.644 22.56, <0.001 
 Model + Time-Updated 
+ Previous 
0.641 17.12, <0.001 
Fatal or non-fatal stroke, n = 261 Model 0.614  
 Model + Baseline 0.615 1.14, 0.029 
 Model + Time-Updated 0.614 0.037, 0.85 
 Model + Time-Updated 
+ Baseline 
0.617 2.99, 0.22 
 Model + Time-Updated 
+ Previous 
0.617 1.68, 0.43 
Other Outcomes    
Non-fatal MI, n = 471 Model  0.627  
 Model + Baseline 0.627 0.37, 0.55 
 Model + Time-Updated 0.631 3.75, 0.053 
 Model + Time-Updated 
+ Baseline 
0.636 11.83, 0.0027 
 Model + Time-Updated 
+ Previous 
0.632 6.40, 0.50 
Non-fatal stroke, n = 231 Model  0.595  
 Model + Baseline 0.597 0.75, 0.39 
 Model + Time-Updated 0.595 0.058, 0.81 
 Model + Time-Updated 
+ Baseline 
0.599 2.21, 0.33 
 Model + Time-Updated 
+ Previous 
0.599 1.37, 0.50 
TIA, n = 177 Model  0.660  
 Model + Baseline 0.662 0.995, 0.32 
 Model + Time-Updated 0.664 1.73, 0.19 
 Model + Time-Updated 
+ Baseline 
0.664 1.74, 0.42 
 Model + Time-Updated 
+ Previous 
0.665 1.92, 0.38 
PTCA or CABG, n = 87 Model  0.769  
 Model + Baseline 0.777 8.35, 0.0039 
 Model + Time-Updated 0.778 8.27, 0.0040 
 Model + Time-Updated 
+ Baseline 
0.779 9.49, 0.0087 
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 Model + Time-Updated 
+ Previous 
0.778 8.28, 0.016 
Peripheral arterial surgery/angioplasty, 
n = 79 
Model  0.755  
 Model + Baseline 0.755 0.0016, 0.97 
 Model + Time-Updated 0.757 0.31, 0.58 
 Model + Time-Updated 
+ Baseline 
0.757 0.73, 0.69 
 Model + Time-Updated 
+ Previous 
0.756 0.31, 0.85 
All CV events, n = 963 Model  0.621  
 Model + Baseline 0.621 0.070, 0.79 
 Model + Time-Updated 0.624 8.99, 0.0027 
 Model + Time-Updated 
+ Baseline 
0.628 21.29, <0.001 
 Model + Time-Updated 
+ Previous 
0.625 12.01, 0.0025 
Fatal or non-fatal stroke or TIA, n = 409 Model  0.620  
 Model + Baseline 0.621 2.27, 0.13 
 Model + Time-Updated 0.621 0.75, 0.39 
 Model + Time-Updated 
+ Baseline 
0.621 2.37, 0.31 
 Model + Time-Updated 
+ Previous 
0.621 0.95, 0.62 
HF hospitalisation, n = 232 Model 0.699  
 Model + Baseline 0.705 12.69, <0.001 
 Model + Time-Updated 0.718 39.97, <0.001 
 Model + Time-Updated 
+ Baseline 
0.719 40.52, <0.001 
 Model + Time-Updated 
+ Previous 
0.718 40.07, <0.001 
Deaths    
CHD, n = 212 Model  0.702  
 Model + Baseline 0.705 7.70, 0.0055 
 Model + Time-Updated 0.717 20.06, <0.001 
 Model + Time-Updated 
+ Baseline 
0.717 20.12, <0.001 
 Model + Time-Updated 
+ Previous 
0.718 20.37, <0.001 
Stroke, n = 35 Model  0.795  
 Model + Baseline 0.797 1.15, 0.28 
 Model + Time-Updated 0.795 0.43, 0.51 
 Model + Time-Updated 
+ Baseline 
0.797 1.20, 0.55 
 Model + Time-Updated 
+ Previous 
0.796 0.65, 0.72 
Vascular, n = 287 Model  0.701  
 Model + Baseline 0.706 7.77, 0.0053 
 Model + Time-Updated 0.716 19.76, <0.001 
 Model + Time-Updated 
+ Baseline 
0.716 19.83, <0.001 
 Model + Time-Updated 
+ Previous 
0.716 20.05, <0.001 
Non-vascular, n = 303 Model  0.667  
 Model + Baseline 0.674 13.07, <0.001 
 Model + Time-Updated 0.680 30.35, <0.001 
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 Model + Time-Updated 
+ Baseline 
0.680 30.36, <0.001 
 Model + Time-Updated 
+ Previous 
0.680 30.44, <0.001 
Cancer, n = 199 Model  0.661  
 Model + Baseline 0.667 2.88, 0.090 
 Model + Time-Updated 0.676 16.07, <0.001 
 Model + Time-Updated 
+ Baseline 
0.676 17.26, <0.001 
 Model + Time-Updated 
+ Previous 
0.677 17.92, <0.001 
All-causes, n = 590 Model 0.663  
 Model + Baseline 0.669 20.72, <0.001 
 Model + Time-Updated 0.677 50.13, <0.001 
 Model + Time-Updated 
+ Baseline 
0.677 50.15, <0.001 
 Model + Time-Updated 
+ Previous 
0.677 50.51, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; smoking status; diabetes; history of vascular 
disease; hypertension; body mass index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; 
estimated Glomerular Filtration Rate (eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, 
diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).  
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A4-6: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the time-updated categorical heart rate patterns variable, which 
produced the results shown in Table A4-3 in the PROSPER population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
CHD death or non-fatal MI or fatal or non-
fatal stroke, n = 868 
Model 0.619  
 Model + Pattern 0.623 9.62, 0.022 
Secondary Endpoints    
CHD death or non-fatal MI, n = 639 Model 0.633  
 Model + Pattern 0.638 11.47, 0.0095 
Fatal or non-fatal stroke, n = 261 Model 0.614  
 Model + Pattern 0.614 0.89, 0.83 
Other Outcomes    
Non-fatal MI, n = 471 Model 0.627  
 Model + Pattern 0.629 4.06, 0.25 
Non-fatal stroke, n = 231 Model 0.595  
 Model + Pattern 0.596 1.20, 0.75 
TIA, n = 177 Model 0.660  
 Model + Pattern 0.668 4.86, 0.18 
PTCA or CABG, n = 87 Model 0.769  
 Model + Pattern 0.771 2.50, 0.48 
Peripheral arterial surgery/angioplasty, n = 79 Model 0.755  
 Model + Pattern 0.755 0.21, 0.98 
All CV events, n = 963 Model 0.621  
 Model + Pattern 0.624 8.15, 0.043 
Fatal or non-fatal stroke or TIA, n = 409 Model 0.620  
 Model + Pattern 0.622 3.15, 0.37 
HF hospitalisation, n = 232 Model 0.699  
 Model + Pattern 0.709 20.94, <0.001 
Deaths    
CHD, n = 212 Model 0.702  
 Model + Pattern 0.722 18.96, <0.001 
Stroke, n = 35 Model 0.795  
 Model + Pattern 0.795 0.33, 0.95 
Vascular, n = 287 Model 0.701  
 Model + Pattern 0.719 19.20, <0.001 
Non-vascular, n = 303 Model 0.667  
 Model + Pattern 0.681 30.74, <0.001 
Cancer, n = 199 Model 0.661  
 Model + Pattern 0.677 23.05, <0.001 
All-causes, n = 590 Model 0.663  
 Model + Pattern 0.680 49.27, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; smoking status; diabetes; history of vascular 
disease; hypertension; body mass index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; 
estimated Glomerular Filtration Rate (eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, 
diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). 
‘Model + Pattern’ is the multivariate model described above including the time-updated categorical heart rate patterns 
variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
the time-updated categorical heart rate patterns variable to the multivariate model excluding resting heart rate.     
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Table A4-7: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for gender-specific heart rate thirds, relative to the low heart rate third in the 
PROSPER population. 
  Baseline 
Heart Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Heart 
Rate 
Third 
P-value 
Primary Endpoint      
CHD death, non-fatal MI or 
fatal or non-fatal stroke,  
n = 868 
Middle 0.57 0.32 0.83 0.57 
 
High 0.56 0.45 0.99 0.88 
Secondary Endpoints      
CHD death or non-fatal MI,  
n = 639 
Middle 0.88 0.76 0.55 0.95 
 High 0.38 0.67 0.91 0.88 
Fatal or non-fatal stroke,  
n = 261 
Middle 0.42 0.069 0.46 0.52 
 High 0.55 0.81 0.70 0.95 
Other Outcomes      
Non-fatal MI, n = 471 Middle 0.81 0.82 0.68 0.89 
 
High 0.33 0.81 0.99 0.71 
Non-fatal stroke, n = 231 Middle 0.48 0.14 0.64 0.68 
 
High 0.69 0.97 0.50 0.77 
TIA, n = 177 Middle 0.31 0.054 0.054 0.039 
 
High 0.76 0.12 0.16 0.15 
PTCA or CABG, n = 87 Middle 0.31 0.37 0.80 0.96 
 
High 0.41 0.23 0.35 0.52 
Peripheral arterial 
surgery/angioplasty, n = 79 
Middle 0.79 0.82 0.77 0.76 
 
High 0.28 0.40 0.93 0.79 
All cardiovascular events,  
n = 963 
Middle 0.88 0.47 0.84 0.53 
 
High 0.61 0.45 0.97 0.92 
Fatal or non-fatal stroke or 
TIA, n = 409 
Middle 0.81 0.90 0.53 0.43 
 High 0.89 0.38 0.26 0.34 
HF hospitalisation, n = 232 Middle 0.91 0.078 0.099 0.10 
 High 0.86 0.43 0.21 0.12 
Deaths      
CHD, n = 212 Middle 0.46 0.98 0.74 0.93 
 High 0.74 0.83 0.51 0.76 
Stroke, n = 35 Middle 0.62 0.28 0.64 0.69 
 High 0.37 0.77 0.97 0.96 
Vascular, n = 287 Middle 0.64 0.998 0.74 0.89 
 High 0.62 0.91 0.47 0.53 
Non-vascular, n = 303 Middle 0.76 0.71 0.45 0.59 
 High 0.39 0.45 0.17 0.22 
Cancer, n = 199 Middle 0.44 0.79 0.39 0.57 
 High 0.25 0.89 0.48 0.61 
All-causes, n = 590 Middle 0.90 0.78 0.76 0.79 
 High 0.81 0.55 0.66 0.70 
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Male participants with a baseline heart rate less than or equal to 59bpm, between 60 and 68bpm, and greater than 68bpm, 
were classed as being in the ‘low’, ‘medium’ and ‘high’ heart rate thirds, respectively.  Similarly, female participants with a 
baseline heart rate less than or equal to 62bpm, between 63 and 72bpm, and greater than 72bpm were classed as being in 
the ‘low’, ‘medium’ and ‘high’ heart rate thirds. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack.  
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Table A4-8: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for an elevated continuous heart rate in the PROSPER population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Endpoint     
CHD death, non-fatal MI or 
fatal or non-fatal stroke,  
n = 868 
0.26 0.32 0.79 0.72 
Secondary Endpoints     
CHD death or non-fatal MI,  
n = 639 
0.30 0.44 0.90 0.74 
Fatal or non-fatal stroke,  
n = 261 
0.83 0.71 0.90 0.89 
Other Outcomes     
Non-fatal MI, n = 471 0.23 0.70 0.98 0.82 
Non-fatal stroke, n = 231 0.63 0.90 0.93 0.93 
TIA, n = 177 0.66 0.96 0.81 0.58 
PTCA or CABG, n = 87 0.34 0.36 0.67 0.61 
Peripheral arterial 
surgery/angioplasty, n = 79 
0.32 0.33 0.94 0.86 
All CV events, n = 963 0.27 0.35 0.84 0.88 
Fatal or non-fatal stroke or 
TIA, n = 409 
0.88 0.79 0.97 0.75 
HF hospitalisation, n = 232 0.41 0.80 0.51 0.54 
Deaths     
CHD, n = 212 0.71 0.66 0.73 0.78 
Stroke, n = 35 0.52 0.58 0.74 0.78 
Vascular, n = 287 0.41 0.63 0.50 0.80 
Non-vascular, n = 303 0.37 0.27 0.089 0.067 
Cancer, n = 199 0.087 0.76 0.31 0.27 
All-causes, n = 590 0.99 0.24 0.44 0.24 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
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Table A4-9: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for the time-updated categorical heart rate patterns ‘high-low’, ‘low-high’ and ‘high-
high’ relative to the category ‘low-low’ in the PROSPER population.   
 Heart Rate 
Category 
P-value 
Primary Composite Endpoint   
CHD death or non-fatal MI or fatal or non-fatal stroke,  
n = 868 
high-low 0.77 
 low-high 0.91 
 high-high 0.49 
Secondary Endpoints   
CHD death or non-fatal MI, n = 639 high-low 0.56 
 low-high 0.91 
 high-high 0.45 
Fatal or non-fatal stroke, n = 261 high-low 0.76 
 low-high 0.83 
 high-high 0.71 
Other Outcomes 
 
 
Non-fatal MI, n = 471 high-low 0.76 
 low-high 0.91 
 high-high 0.92 
Non-fatal stroke, n = 231 high-low 0.52 
 low-high 0.78 
 high-high 0.49 
TIA, n = 177 high-low 0.47 
 low-high 0.72 
 high-high 0.68 
PTCA or CABG, n = 87 high-low 0.87 
 low-high 0.61 
 high-high 0.37 
Peripheral arterial surgery/angioplasty, n = 79 high-low 0.69 
 low-high 0.40 
 high-high 0.22 
All CV events, n = 963 high-low 0.75 
 low-high 0.79 
 high-high 0.34 
Fatal or non-fatal stroke or TIA, n = 409 high-low 0.50 
 low-high 0.73 
 high-high 0.57 
HF hospitalisation, n = 232 high-low 0.30 
 low-high 0.56 
 high-high 0.29 
Deaths   
CHD, n = 212 high-low 0.31 
 low-high 0.71 
 high-high 0.72 
Stroke, n = 35 high-low 0.26 
 low-high 0.27 
 high-high 0.34 
Vascular, n = 287 high-low 0.077 
 low-high 0.40 
 high-high 0.42 
Non-vascular, n = 303 high-low 0.97 
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 low-high 0.10 
 high-high 0.29 
Cancer, n = 199 high-low 0.84 
 low-high 0.60 
 high-high 0.91 
All-causes, n = 590 high-low 0.20 
 low-high 0.083 
 high-high 0.18 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
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Table A4-10: Results of fitting the time-updated heart rate Cox proportional hazards models.  
Hazard ratios, 95% confidence intervals, and p-values for a 5bpm higher time-updated heart 
rate adjusted for baseline heart rate, in PROSPER subjects who were or were not taking 
anti-arrhyhtmic drugs and/or beta-blockers at randomisaiton. 
 Subgroup Hazard Ratio 
(95% Confidence 
Interval), p-value 
P-value for 
Interaction* 
Primary Endpoints    
CHD death or non-fatal MI or fatal or non-fatal 
stroke, n = 868 
  0.74 
 Beta-blockers or anti-
arrhythmics, n = 283 
1.11 (1.04 to 
1.18), 0.0011 
 
 No beta-blockers or anti-
arrhythmics, n = 585 
1.10 (1.05 to 
1.15), <0.001 
 
Secondary Endpoints    
CHD death or non-fatal MI, n = 639 
 
 0.39 
 Beta-blockers or anti-
arrhythmics, n = 202 
1.08 (1.01 1.16), 
0.036 
 
 No beta-blockers or anti-
arrhythmics, n = 437 
1.12 (1.07 to 
1.18), <0.001 
 
Fatal or non-fatal stroke, n = 261 
 
 0.042 
 
Beta-blockers or anti-
arrhythmics, n = 94 
1.13 (1.03 to 
1.25), 0.013 
 
 
No beta-blockers or anti-
arrhythmics, n = 167 
1.00 (0.91 to 
1.10), 0.99 
 
Other Outcomes    
Non-fatal MI, n = 471 
 
 0.58 
 Beta-blockers or anti-
arrhythmics, n = 153 
1.07 (0.98 to 
1.17), 0.13 
 
 No beta-blockers or anti-
arrhythmics, n = 318 
1.11 (1.04 to 
1.18), <0.001 
 
Non-fatal stroke, n = 231   0.041 
 Beta -blockers or anti-
arrhythmics, n = 83 
1.13 (1.02 to 
1.25), 0.022 
 
 No beta-blockers or anti-
arrhythmics, n = 148 
1.00 (0.90 to 
1.10), 0.93 
 
TIA, n = 177 
 
 0.069 
 Taking beta-blockers or 
anti-arrhythmics, n = 58 
1.07 (0.93 to 
1.23), 0.36 
 
 Not taking beta-blockers 
or anti-arrhythmics, n = 
119 
0.90 (0.80 to 
1.01), 0.081 
 
PTCA or CABG, n = 87 
 
 0.28 
 Beta-blockers or anti-
arrhythmics, n = 41 
1.07 (0.88 to 
1.30), 0.50 
 
 No beta-blockers or anti-
arrhythmics, n = 46 
0.80 (0.65 to 
0.98), 0.033 
 
Peripheral arterial surgery/angioplasty, n = 79 
 
 0.56 
 Beta-blockers or anti-
arrhythmics, n = 23 
1.17 (0.97 to 
1.42), 0.094 
 
 No beta-blockers or anti-
arrhythmics, n = 56 
1.02 (0.86 to 
1.20), 0.86 
 
All CV events, n = 963 
 
 0.42 
 Beta-blockers or anti-
arrhythmics, n = 317 
1.12 (1.05 to 
1.19), <0.001 
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 No beta-blockers or anti-
arrhythmics, n = 646 
1.08 (1.03 to 
1.13), <0.001 
 
Fatal or non-fatal stroke or TIA, n = 409 
 
 0.0078 
 Beta-blockers or anti-
arrhythmics, n = 141 
1.11 (1.02 to 
1.20), 0.017 
 
 No beta-blockers or anti-
arrhythmics, n = 268 
0.95 (0.88 to 
1.03), 0.23 
 
HF hospitalisation, n = 232 
 
 0.43 
 Beta-blockers or anti-
arrhythmics, n = 65 
1.15 (1.02 to 
1.29), 0.023 
 
 No beta-blockers or anti-
arrhythmics, n = 167 
1.20 (1.13 to 
1.28), <0.001 
 
Deaths 
 
  
CHD, n = 212 
 
 0.87 
 Beta-blockers or anti-
arrhythmics, n = 65 
1.13 (1.03 to 
1.25), 0.013 
 
 No beta-blockers or anti-
arrhythmics, n = 147 
1.12 (1.03 to 
1.22), 0.0066 
 
Stroke, n = 35 
 
 0.55 
 Beta-blockers or anti-
arrhythmics, n = 12 
1.17 (0.86 to 
1.60), 0.32 
 
 No beta-blockers or anti-
arrhythmics, n = 23 
0.98 (0.75 to 
1.28), 0.87 
 
Vascular, n = 287 
 
 0.54 
 Beta-blockers or anti-
arrhythmics, n = 87 
1.12 (1.02 to 
1.23), 0.022 
 
 No beta-blockers or anti-
arrhythmics, n = 200 
1.11 (1.03 to 
1.19), 0.0045 
 
Non-vascular, n = 303 
 
 0.53 
 Beta-blockers or anti-
arrhythmics, n = 70 
1.10 (0.99 to 
1.22), 0.075 
 
 No beta-blockers or anti-
arrhythmics, n = 233 
1.14 (1.07 to 
1.21), <0.001 
 
Cancer, n = 199 
 
 0.66 
 Beta-blockers or anti-
arrhythmics, n = 45 
1.14 (1.02 to 
1.28), 0.024 
 
 No beta-blockers or anti-
arrhythmics, n = 154 
1.14 (1.05 to 
1.23), <0.001 
 
All-causes, n = 590 
 
 0.35 
 Beta-blockers or anti-
arrhythmics, n = 157 
1.11 (1.03 to 
1.19), 0.0034 
 
 No beta-blockers or anti-
arrhythmics, n = 433 
1.13 (1.07 to 
1.18), <0.001 
 
*P-values for the likelihood ratio test comparing the model containing the interaction heart rate x use of anti-arrhythmics 
and/or beta-blockers at randomisation, and the model containing only heart rate and use of such drugs additively. 
CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; HF = Heart Failure; MI = Myocardial Infarction; 
PTCA = Percutaneous Transluminal Coronary Angioplasty; TIA = Transient Ischemic Attack. 
Models were additionally adjusted for: age; smoking status; diabetes; history of vascular disease; hypertension; body mass 
index (BMI); high-density lipoprotein (HDL) cholesterol; thyroid stimulating hormones; estimated Glomerular Filtration Rate 
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(eGFR); treatment group (pravastatin or placebo); and intake of aspirin, nitrates, diuretics, angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II receptor blockers (ARBs). 
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Appendix 5 
Supplementary Tables for Chapter 7 
Table A5-1: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a heart rate ≥70bpm compared to a heart rate <70bpm 
in the PERFORM population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Composite Endpoint     
Fatal or non-fatal MI, fatal or non-
fatal ischemic stroke, or other 
vascular death, n = 2141 
1.19 (1.08 to 
1.30), <0.001 
1.23 (1.13 to 
1.35), <0.001 
1.18 (1.08 to 
1.30), <0.001 
1.15 (1.04 to 
1.27), 0.0050 
MI-Related Endpoints     
All fatal or non-fatal MI, n = 285 1.29 (1.01 to 
1.64), 0.044 
1.33 (1.04 to 
1.70), 0.025 
1.25 (0.96 to 
1.62), 0.094 
1.21 (0.92 to 
1.59), 0.18 
Non-fatal MI, n = 251 1.23 (0.95 to 
1.60), 0.11 
1.27 (0.98 to 
1.65), 0.078 
1.20 (0.91 to 
1.59), 0.19 
1.15 (0.86 to 
1.54), 0.33 
Stroke Related Endpoints     
All fatal or non-fatal ischemic stroke, 
n = 1541 
1.07 (0.97 to 
1.19), 0.18 
1.16 (1.04 to 
1.29), 0.0057 
1.15 (1.03 to 
1.29), 0.015 
1.12 (0.99 to 
1.25), 0.069 
Non-fatal ischemic stroke, n = 1446 1.05 (0.94 to 
1.16), 0.42 
1.15 (1.03 to 
1.28), 0.013 
1.15 (1.02 to 
1.29), 0.019 
1.11 (0.99 to 
1.25), 0.085 
All fatal or non-fatal stroke, n = 1667 1.09 (0.99 to 
1.20), 0.095 
1.16 (1.05 to 
1.28), 0.0044 
1.14 (1.03 to 
1.27), 0.016 
1.12 (1.00 to 
1.25), 0.054 
Mortality Related Endpoints     
Vascular death, n = 436 1.71 (1.39 to 
2.10), <0.001 
1.71 (1.38 to 
2.11), <0.001 
1.52 (1.22 to 
1.89), <0.001 
1.51 (1.20 to 
1.89), <0.001 
All-cause mortality, n = 1174 1.41 (1.25 to 
1.60), <0.001 
1.54 (1.36 to 
1.74), <0.001 
1.44 (1.26 to 
1.63), <0.001 
1.40 (1.22 to 
1.60), <0.001 
Cardiac Endpoints     
Cardiac death, n = 103 1.34 (0.88 to 
2.02), 0.172 
1.30 (0.86 to 
1.96), 0.219 
1.22 (0.80 to 
1.87), 0.362 
1.19 (0.76 to 
1.85), 0.450 
Hospitalisation due to cardiac cause,  
n = 887 
1.02 (0.89 to 
1.17), 0.772 
1.11 (0.97 to 
1.28), 0.127 
1.12 (0.97 to 
1.29), 0.135 
1.11 (0.95 to 
1.29), 0.181 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; gender; smoking; body mass index (BMI); prior ischemic stroke; prior myocardial 
infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake of beta-blockers, statins and 
antiplatelet agents after the qualifying event. 
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Table A5-2: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the PERFORM population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Change in 
Heart Rate 
Adjusted for 
Previous 
  
Hazard Ratio (95% Confidence Interval), p-value 
Primary Composite Endpoint     
Fatal or non-fatal MI, fatal or non-
fatal ischemic stroke, or other 
vascular death, n = 2141 
1.04 (1.02 to 
1.06), <0.001 
1.07 (1.05 to 
1.09), <0.001 
1.06 (1.04 to 
1.09), <0.001 
1.05 (1.02 to 
1.07), <0.001 
MI-Related Endpoints     
All fatal or non-fatal MI, n = 285 1.07 (1.01 to 
1.13), 0.013 
1.08 (1.02 to 
1.14), 0.0074 
1.06 (0.99 to 
1.12), 0.077 
1.06 (0.99 to 
1.13), 0.10 
Non-fatal MI, n = 251 1.05 (0.99 to 
1.11), 0.088 
1.07 (1.00 to 
1.13), 0.034 
1.05 (0.99 to 
1.12), 0.13 
1.06 (0.99 to 
1.14), 0.090 
Stroke-Related Endpoints     
All fatal or non-fatal ischemic 
stroke, n = 1541 
1.02 (0.99 to 
1.04), 0.21 
1.05 (1.02 to 
1.07), <0.001 
1.05 (1.02 to 
1.08), <0.001 
1.03 (1.00 to 
1.07), 0.026 
Non-fatal ischemic stroke, n = 1446 1.01 (0.99 to 
1.04), 0.39 
1.04 (1.02 to 
1.07), 0.011 
1.05 (1.02 to 
1.08), 0.012 
1.03 (1.00 to 
1.06), 0.057 
All fatal or non-fatal stroke,  
n = 1667 
1.02 (1.00-
1.04), 0.073 
1.05 (1.02-
1.07), <0.001 
1.05 (1.02-
1.07), <0.001 
1.03 (1.01-
1.06), 0.021 
Mortality-Related Endpoints     
Vascular death, n = 436 1.12 (1.08 to 
1.17), <0.001 
1.16 (1.11 to 
1.21), <0.001 
1.13 (1.08 to 
1.18), <0.001 
1.10 (1.05 to 
1.16), <0.001 
All-cause mortality, n = 1174 1.08 (1.05 to 
1.11), <0.001 
1.16 (1.13 to 
1.19), <0.001 
1.15 (1.11 to 
1.18), <0.001 
1.13 (1.10 to 
1.16), <0.001 
Cardiac Endpoints     
Cardiac death, n = 103 1.12 (1.02 to 
1.22), 0.013 
1.16 (1.07 to 
1.26), <0.001 
1.14 (1.04 to 
1.25), 0.0067 
1.06 (0.96 to 
1.17), 0.26 
Hospitalisation due to a cardiac 
cause, n = 887 
1.02 (0.99 to 
1.05), 0.21 
1.06 (1.03 to 
1.10), <0.001 
1.07 (1.03 to 
1.10), <0.001 
1.06 (1.02 to 
1.11), 0.0014 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; gender; smoking; body mass index (BMI); prior ischemic stroke; prior myocardial 
infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake of beta-blockers, statins and 
antiplatelet agents after the qualifying event. 
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Table A5-3: Results of fitting Cox proportional hazards models.  Hazard ratios 95% 
confidence intervals, and p-values for the time-updated categorical heart rate patterns ‘high-
low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the PERFORM 
population.   
 Heart Rate Category Hazard Ratio (95% 
Confidence Interval), 
p-value 
Primary Composite Endpoint   
Fatal or non-fatal MI, fatal or non-fatal ischemic stroke, 
or other vascular death, n = 2141 
high-low 1.21 (1.04 to 1.40), 
0.014 
 low-high 1.19 (1.02 to 1.38), 
0.026 
 high-high 1.36 (1.22 to 1.51), 
<0.001 
MI-Related Endpoints   
All fatal or non-fatal MI, n = 285 high-low 1.16 (0.77 to 1.75), 
0.49 
 low-high 1.07 (0.70 to 1.64), 
0.75 
 high-high 1.51 (1.12 to 2.03), 
0.0074 
Non-fatal MI, n = 251 high-low 1.14 (0.74 to 1.76), 
0.56 
 low-high 1.01 (0.64 to 1.59), 
0.97 
 high-high 1.43 (1.04 to 1.96), 
0.026 
Stroke-Related Endpoints 
 
 
All fatal or non-fatal ischemic stroke, n = 1541 high-low 1.14 (0.96 to 1.36), 
0.13 
 low-high 1.17 (0.98 to 1.38), 
0.082 
 high-high 1.23 (1.08 to 1.39), 
0.0015 
Non-fatal ischemic stroke, n = 1446 high-low 1.10 (0.92 to 1.32), 
0.29 
 low-high 1.14 (0.96 to 1.37), 
0.14 
 high-high 1.20 (1.05 to 1.36), 
0.0066 
All fatal or non-fatal stroke, n = 1667 high-low 1.15 (0.98 to 1.36), 
0.90 
 low-high 1.19 (1.01 to 1.40), 
0.038 
 high-high 1.22 (1.08 to 1.38), 
0.0012 
Mortality-Related Endpoints   
Vascular death, n = 436 high-low 1.51 (1.06 to 2.16), 
0.022 
 low-high 1.60 (1.12 to 2.27), 
0.0089 
 high-high 2.16 (1.65 to 2.83), 
<0.001 
All-cause mortality, n = 1174 high-low 1.44 (1.17 to 1.77), 
<0.001 
 low-high 1.35 (1.27 to 1.90), 
<0.001 
 high-high 1.86 (1.58 to 2.18), 
<0.001 
Cardiac Endpoints   
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Cardiac death, n = 103 high-low 1.31 (0.67 to 2.56), 
0.42 
 low-high 1.23 (0.62 to 2.43), 
0.55 
 high-high 1.52 (0.90 to 2.56), 
0.11 
Hospitalisation due to a cardiac cause, n = 887 high-low 1.14 (0.91 to 1.42), 
0.26 
 low-high 1.24 (1.00 to 1.54), 
0.054 
 high-high 1.14 (0.96 to 1.35), 
0.12 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on. 
MI = Myocardial Infarction. 
Models were additionally adjusted for: age; gender; smoking; body mass index (BMI); prior ischemic stroke; prior myocardial 
infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake of beta-blockers, statins and 
antiplatelet agents after the qualifying event. 
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Table A5-4: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the heart rate variables that categorised subjects according to 
whether they had a heart rate less than, or greater than or equal to, 70bpm, which produced 
the results shown in Table A5-1 in the PERFORM population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Fatal or non-fatal MI, fatal or non-fatal 
ischemic stroke, or other vascular death,  
n = 2141 
Model 0.630  
 Model + Baseline 0.633 14.18, <0.001 
 Model + Time-Updated 0.634 249.07, <0.001 
 Model + Time-Updated  
+ Baseline 
0.635 254.63, <0.001 
 Model + Time-Updated  
+ Previous 
0.636 399.36, <0.001 
MI-Related Endpoints    
All fatal or non-fatal MI, n = 285 Model 0.676  
 Model + Baseline 0.679 4.13, 0.042 
 Model + Time-Updated 0.677 60.10, <0.001 
 Model + Time-Updated  
+ Baseline 
0.680 62.32, <0.001 
 Model + Time-Updated  
+ Previous 
0.680 99.55, <0.001 
Non-fatal MI, n = 251 Model 0.673  
 Model + Baseline 0.673 2.55, 0.11 
 Model + Time-Updated 0.673 57.59, <0.001 
 Model + Time-Updated  
+ Baseline 
0.674 58.98, <0.001 
 Model + Time-Updated  
+ Previous 
0.675 96.57, <0.001 
Stroke-Related Endpoints    
All fatal or non-fatal ischemic stroke,  
n = 1541 
Model 0.618  
 Model + Baseline 0.619 1.66, 0.20 
 Model + Time-Updated 0.621 139.27, <0.001 
 Model + Time-Updated  
+ Baseline 
0.621 139.36, <0.001 
 Model + Time-Updated + 
Previous 
0.622 227.97, <0.001 
Non-fatal ischemic stroke, n = 1446 Model 0.612  
 Model + Baseline 0.613 0.66, 0.42 
 Model + Time-Updated 0.615 136.36, <0.001 
 Model + Time-Updated  
+ Baseline 
0.615 136.37, <0.001 
 Model + Time-Updated  
+ Previous 
0.616 203.74, <0.001 
All fatal or non-fatal stroke, n = 1667 Model 0.614  
 Model + Baseline 0.615 2.80, 0.094 
 Model + Time-Updated 0.616 140.92, <0.001 
 Model + Time-Updated  
+ Baseline 
0.617 141.40, <0.001 
 Model + Time-Updated  
+ Previous 
0.617 229.80, <0.001 
Mortality-Related Endpoints    
Vascular death, n = 436 Model 0.711  
 Model + Baseline 0.723 26.64, <0.001 
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 Model + Time-Updated 0.723 85.77, <0.001 
 Model + Time-Updated  
+ Baseline 
0.731 100.72, <0.001 
 Model + Time-Updated  
+ Previous 
0.727 113.57, <0.001 
All-cause mortality, n = 1174 Model 0.678  
 Model + Baseline 0.686 31.32, <0.001 
 Model + Time-Updated 0.690 224.39, <0.001 
 Model + Time-Updated  
+ Baseline 
0.694 239.39, <0.001 
 Model + Time-Updated  
+ Previous 
0.692 316.53, <0.001 
Cardiac Endpoints    
Cardiac death, n = 103 Model 0.748  
 Model + Baseline 0.752 1.90, 0.17 
 Model + Time-Updated 0.750 2.66, 0.10 
 Model + Time-Updated  
+ Baseline 
0.753 3.87, 0.14 
 Model + Time-Updated  
+ Previous 
0.753 4.40, 0.11 
Hospitalisation due to a cardiac cause,  
n = 887 
Model 0.662  
 Model + Baseline 0.662 0.085, 0.77 
 Model + Time-Updated 0.662 80.84, <0.001 
 Model + Time-Updated  
+ Baseline 
0.662 80.87, <0.001 
 Model + Time-Updated  
+ Previous 
0.661 120.74, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; gender; smoking; body mass index (BMI); prior 
ischemic stroke; prior myocardial infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake 
of beta-blockers, statins and antiplatelet agents after the qualifying event. 
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate group variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate group variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate group variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
group variable and the previous time-updated heart rate group variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A5-5: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A5-2 in the PERFORM population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Fatal or non-fatal MI, fatal or non-fatal 
ischemic stroke, or other vascular death,  
n = 2141 
Model 0.630  
 Model + Baseline 0.633 14.15, <0.001 
 Model + Time-Updated 0.636 267.28, <0.001 
 Model + Time-Updated  
+ Baseline 
0.637 268.52, <0.001 
 Model + Time-Updated  
+ Previous 
0.638 416.80, <0.001 
MI-Related Endpoints    
All fatal or non-fatal MI, n = 285 Model 0.676  
 Model + Baseline 0.681 5.98, 0.014 
 Model + Time-Updated 0.678 61.87, <0.001 
 Model + Time-Updated  
+ Baseline 
0.681 64.36, <0.001 
 Model + Time-Updated  
+ Previous 
0.679 99.65, <0.001 
Non-fatal MI, n = 251 Model 0.673  
 Model + Baseline 0.676 2.84, 0.092 
 Model + Time-Updated 0.673 58.75, <0.001 
 Model + Time-Updated  
+ Baseline 
0.675 59.68, <0.001 
 Model + Time-Updated  
+ Previous 
0.672 95.38, <0.001 
Stroke-Related Endpoints    
All fatal or non-fatal ischemic stroke,  
n = 1541 
Model 0.618  
 Model + Baseline 0.619 1.75, 0.19 
 Model + Time-Updated 0.622 143.93, <0.001 
 Model + Time-Updated  
+ Baseline 
0.621 144.06, <0.001 
 Model + Time-Updated + 
Previous 
0.623 233.00, <0.001 
Non-fatal ischemic stroke, n = 1446 Model 0.612  
 Model + Baseline 0.613 0.75, 0.39 
 Model + Time-Updated 0.615 140.57, <0.001 
 Model + Time-Updated  
+ Baseline 
0.615 141.10, <0.001 
 Model + Time-Updated  
+ Previous 
0.617 208.40, <0.001 
All fatal or non-fatal stroke, n = 1667 Model 0.614  
 Model + Baseline 0.615 3.18, 0.074 
 Model + Time-Updated 0.617 146.94, <0.001 
 Model + Time-Updated  
+ Baseline 
0.617 146.94, <0.001 
 Model + Time-Updated  
+ Previous 
0.619 235.42, <0.001 
Mortality-Related Endpoints    
Vascular death, n = 436 Model 0.711  
 Model + Baseline 0.725 26.72, <0.001 
 Model + Time-Updated 0.732 101.55, <0.001 
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 Model + Time-Updated  
+ Baseline 
0.737 110.73, <0.001 
 Model + Time-Updated  
+ Previous 
0.737 134.15, <0.001 
All-cause mortality, n = 1174 Model 0.678  
 Model + Baseline 0.685 31.22, <0.001 
 Model + Time-Updated 0.701 291.30, <0.001 
 Model + Time-Updated  
+ Baseline 
0.702 295.00, <0.001 
 Model + Time-Updated  
+ Previous 
0.703 379.04, <0.001 
Cardiac Endpoints    
Cardiac death, n = 103 Model 0.748  
 Model + Baseline 0.758 5.90, 0.015 
 Model + Time-Updated 0.766 11.84, <0.001 
 Model + Time-Updated  
+ Baseline 
0.769 13.82, <0.001 
 Model + Time-Updated  
+ Previous 
0.784 27.09, <0.001 
Hospitalisation due to a cardiac cause,  
n = 887 
Model 0.662  
 Model + Baseline 0.662 1.54, 0.21 
 Model + Time-Updated 0.663 92.03, <0.001 
 Model + Time-Updated  
+ Baseline 
0.663 92.11, <0.001 
 Model + Time-Updated  
+ Previous 
0.663 132.03, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; gender; smoking; body mass index (BMI); prior 
ischemic stroke; prior myocardial infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake 
of beta-blockers, statins and antiplatelet agents after the qualifying event. 
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A5-6: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the time-updated categorical heart rate patterns variable, which 
produced the results shown in Table A5-3 in the PERFORM population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Fatal or non-fatal MI, fatal or non-fatal ischemic 
stroke, or other vascular death, n = 2141 
Model 0.630  
 Model + Pattern 0.636 259.12, <0.001 
MI-Related Endpoints    
All fatal or non-fatal MI, n = 285 Model 0.676  
 Model + Pattern 0.681 63.87, <0.001 
Non-fatal MI, n = 251 Model  0.673  
 Model + Pattern 0.677 60.91, <0.001 
Stroke-Related Endpoints    
All fatal or non-fatal ischemic stroke, n = 1541 Model 0.618  
 Model + Pattern 0.621 141.95, <0.001 
Non-fatal ischemic stroke, n = 1446 Model 0.612  
 Model + Pattern 0.615 137.79, <0.001 
All fatal or non-fatal stroke, n = 1667 Model 0.614  
 Model + Pattern 0.617 143.89, <0.001 
Mortality-Related Endpoints    
Vascular death, n = 436 Model 0.711  
 Model + Pattern 0.727 95.36, <0.001 
All-cause mortality, n = 1174 Model 0.678  
 Model + Pattern 0.693 240.26, <0.001 
Cardiac Endpoints    
Cardiac death, n = 103 Model 0.748  
 Model + Pattern 0.753 3.79, 0.28 
Hospitalisation due to a cardiac cause, n = 887 Model 0.662  
 Model + Pattern 0.663 82.76, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; gender; smoking; body mass index (BMI); prior 
ischemic stroke; prior myocardial infarction (MI); prior transient ischemic attack (TIA); hypertension; diabetes; and the intake 
of beta-blockers, statins and antiplatelet agents after the qualifying event. 
‘Model + Pattern’ is the multivariate model described above including the time-updated categorical heart rate patterns 
variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
the time-updated categorical heart rate patterns variable to the multivariate model excluding resting heart rate.     
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Table A5-7: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a heart rate ≥70bpm compared to a heart rate <70bpm in the PERFORM 
population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Composite Endpoint     
Fatal or non-fatal MI, fatal or non-
fatal ischemic stroke, or other 
vascular death, n = 2141 
0.30 0.64 0.93 0.94 
MI-Related Endpoints     
All fatal or non-fatal MI, n = 285 0.64 0.089 0.047 0.027 
Non-fatal MI, n = 251 0.90 0.080 0.069 0.049 
Stroke Related Endpoints     
All fatal or non-fatal ischemic stroke, 
n = 1541 
0.052 0.43 0.86 0.84 
Non-fatal ischemic stroke, n = 1446 0.051 0.59 0.97 0.89 
All fatal or non-fatal stroke, n = 1667 0.055 0.32 0.74 0.69 
Mortality Related Endpoints     
Vascular death, n = 436 0.48 0.54 0.60 0.32 
All-cause mortality, n = 1174 0.054 0.15 0.44 0.10 
Cardiac Endpoints     
Cardiac death, n = 103 0.98 0.61 0.56 0.48 
Hospitalisation due to cardiac cause,  
n = 887 
0.22 0.36 0.68 0.52 
MI = Myocardial Infarction. 
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Table A5-8: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a 5bpm higher heart rate in the PERFORM population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
in Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Composite Endpoint     
Fatal or non-fatal MI, fatal or non-
fatal ischemic stroke, or other 
vascular death, n = 2141 
0.074 0.29 0.62 0.56 
MI-Related Endpoints     
All fatal or non-fatal MI, n = 285 0.95 0.35 0.30 0.45 
Non-fatal MI, n = 251 0.90 0.32 0.31 0.44 
Stroke-Related Endpoints     
All fatal or non-fatal ischemic 
stroke, n = 1541 
0.032 0.072 0.21 0.30 
Non-fatal ischemic stroke,  
n = 1446 
0.047 0.14 0.31 0.55 
All fatal or non-fatal stroke,  
n = 1667 
0.045 0.053 0.16 0.26 
Mortality-Related Endpoints     
Vascular death, n = 436 0.32 0.46 0.79 0.25 
All-cause mortality, n = 1174 <0.001 0.17 0.76 0.15 
Cardiac Endpoints     
Cardiac death, n = 103 0.34 0.70 0.42 0.56 
Hospitalisation due to a cardiac 
cause, n = 887 
0.99 0.83 0.61 0.57 
MI = Myocardial Infarction. 
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Table A5-9: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for the time-updated categorical patterns ‘high-low’, ‘low-high’ and ‘high-high’ 
relative to the category ‘low-low’ in the PERFORM population.   
 Heart Rate 
Category 
P-value 
Primary Composite Endpoint   
Fatal or non-fatal MI, fatal or non-fatal ischemic stroke, or other 
vascular death, n = 2141 
high-low 0.43 
 low-high 0.38 
 high-high 0.94 
MI-Related Endpoints   
All fatal or non-fatal MI, n = 285 high-low 0.66 
 low-high 0.090 
 high-high 0.31 
Non-fatal MI, n = 251 high-low 0.65 
 low-high 0.049 
 high-high 0.12 
Stroke-Related Endpoints 
 
 
All fatal or non-fatal ischemic stroke, n = 1541 high-low 0.85 
 low-high 0.57 
 high-high 0.47 
Non-fatal ischemic stroke, n = 1446 high-low 0.99 
 low-high 0.43 
 high-high 0.47 
All fatal or non-fatal stroke, n = 1667 high-low 0.80 
 low-high 0.62 
 high-high 0.38 
Mortality-Related Endpoints   
Vascular death, n = 436 high-low 0.040 
 low-high 0.91 
 high-high 0.29 
All-cause mortality, n = 1174 high-low 0.24 
 low-high 0.40 
 high-high 0.95 
Cardiac Endpoints   
Cardiac death, n = 103 high-low 0.33 
 low-high 0.89 
 high-high 0.94 
Hospitalisation due to a cardiac cause, n = 887 high-low 0.76 
 low-high 0.82 
 high-high 0.32 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on. 
MI = Myocardial Infarction. 
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Appendix 6 
Supplementary Tables for Chapter 8 
Table A6-1: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a heart rate ≥70bpm compared to a heart rate <70bpm 
in the BEAUTIFUL placebo population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Composite Endpoint     
Cardiovascular death or admission to 
hospital for myocardial infarction or 
new-onset or worsening heart failure, 
n = 832 
1.40 (1.21 to 
1.61), <0.001 
1.86 (1.61 to 
2.15), <0.001 
1.78 (1.52 to 
2.08), <0.001 
1.61 (1.36 to 
1.89), <0.001 
Mortality Endpoints     
All-cause death, n = 547 1.30 (1.09 to 
1.55), 0.0033 
1.82 (1.52 to 
2.18), <0.001 
1.79 (1.48 to 
2.17), <0.001 
1.70 (1.39 to 
2.08), <0.001 
Cardiovascular death, n = 435 1.35 (1.10 to 
1.64), 0.0032 
1.88 (1.53 to 
2.30), <0.001 
1.83 (1.47 to 
2.27), <0.001 
1.71 (1.36 to 
2.15), <0.001 
Cardiac death, n = 151 1.63 (1.16 to 
2.31), 0.0054 
3.43 (2.33 to 
5.10), <0.001 
3.35 (2.22 to 
5.06), <0.001 
3.17 (2.07 to 
4.86), <0.001 
Heart Failure Endpoints     
Admission to hospital for heart 
failure, n = 427 
1.54 (1.26 to 
1.88), <0.001 
2.27 (1.84 to 
2.81), <0.001 
2.15 (1.72 to 
2.70), <0.001 
1.90 (1.49 to 
2.40), <0.001 
Cardiovascular death or admission to 
hospital for new-onset or worsening 
heart failure, n = 723 
1.43 (1.22 to 
1.66), <0.001 
1.93 (1.65 to 
2.26), <0.001 
1.84 (1.55 to 
2.18), <0.001 
1.66 (1.39 to 
1.99), <0.001 
Coronary Endpoints     
Admission to hospital for myocardial 
infarction, n = 226 
1.47 (1.12 to 
1.92), 0.0063 
1.62 (1.23 to 
2.12), <0.001 
1.48 (1.11 to 
1.99), 0.0084 
1.51 (1.11 to 
2.04), 0.0085 
Admission to hospital for myocardial 
infarction or unstable angina, n = 317 
1.41 (1.12 to 
1.78), 0.0032 
1.37 (1.09 to 
1.72), 0.0065 
1.24 (0.97 to 
1.59), 0.084 
1.23 (0.95 to 
1.58), 0.12 
Coronary revascularisation, n = 186 1.38 (1.02-
1.86), 0.036 
1.37 (1.02 to 
1.84), 0.038 
1.25 (0.91 to 
1.73), 0.17 
1.30 (0.93 to 
1.82), 0.13 
Models were additionally adjusted for: age; smoking; body mass index (BMI); history of diabetes; previous myocardial 
infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); peripheral artery 
disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New 
York Heart Association (NYHA) class; and treatment with aspirin (not including other antithrombotic agents), beta-blockers, 
statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone agents at randomisation. 
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Table A6-2: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the BEAUTIFUL placebo 
population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Composite Endpoint     
Cardiovascular death or admission to 
hospital for myocardial infarction or 
new-onset or worsening heart 
failure, n = 832 
1.11 (1.08 to 
1.15), <0.001 
1.16 (1.13 to 
1.19), <0.001 
1.15 (1.12 to 
1.19), <0.001 
1.13 (1.09 to 
1.17), <0.001 
Mortality Endpoints     
All-cause death, n = 547 1.07 (1.03 to 
1.11), 0.0010 
1.14 (1.10 to 
1.17), <0.001 
1.14 (1.10 to 
1.19), <0.001 
1.12 (1.08 to 
1.17), <0.001 
Cardiovascular death, n = 435 1.08 (1.03 to 
1.13), <0.001 
1.14 (1.10 to 
1.18), <0.001 
1.14 (1.09 to 
1.19), <0.001 
1.12 (1.07 to 
1.17), <0.001 
Cardiac death, n = 151 1.13 (1.05 to 
1.21), 0.0011 
1.26 (1.19 to 
1.33), <0.001 
1.27 (1.20 to 
1.35), <0.001 
1.26 (1.18 to 
1.34), <0.001 
Heart Failure Endpoints     
Admission to hospital for heart 
failure, n = 427 
1.16 (1.11 to 
1.21), <0.001 
1.22 (1.18 to 
1.26), <0.001 
1.20 (1.16 to 
1.25), <0.001 
1.18 (1.13 to 
1.23), <0.001 
Cardiovascular death or admission to 
hospital for new-onset or worsening 
heart failure, n = 723 
1.12 (1.08 to 
1.16), <0.001 
1.16 (1.13 to 
1.20), <0.001 
1.15 (1.11 to 
1.19), <0.001 
1.13 (1.09 to 
1.17), <0.001 
Coronary Endpoints     
Admission to hospital for myocardial 
infarction, n = 226 
1.07 (1.00 to 
1.14), 0.050 
1.14 (1.08 to 
1.20), <0.001 
1.15 (1.08 to 
1.21), <0.001 
1.15 (1.08 to 
1.23), <0.001 
Admission to hospital for myocardial 
infarction or unstable angina, n = 317 
1.07 (1.01 to 
1.13), 0.018 
1.10 (1.05 to 
1.15), <0.001 
1.10 (1.04 to 
1.15), <0.001 
1.09 (1.03 to 
1.15), 0.0023 
Coronary revascularisation, n = 186 1.08 (1.01 to 
1.16), 0.033 
1.13 (1.07 to 
1.19), <0.001 
1.13 (1.05 to 
1.20), <0.001 
1.13 (1.05 to 
1.21), <0.001 
Models were additionally adjusted for: age; smoking; body mass index (BMI); history of diabetes; previous myocardial 
infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); peripheral artery 
disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New 
York Heart Association (NYHA) class; and treatment with aspirin (not including other antithrombotic agents), beta-blockers, 
statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone agents at randomisation. 
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Table A6-3: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for the time-updated categorical heart rate patterns ‘high-
low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the BEAUTIFUL placebo 
population.   
 Heart Rate 
Category 
Hazard Ratio 
(95% Confidence 
Interval),  
p-value 
Primary Composite Endpoint   
Cardiovascular death or admission to hospital for myocardial infarction 
or new-onset or worsening heart failure, n = 832 
high-low 1.29 (1.00 to 
1.66), 0.047 
 low-high 1.54 (1.22 to 
1.94), <0.001 
 high-high 2.17 (1.83 to 
2.57), <0.001 
Mortality Endpoints   
All-cause death, n = 547 high-low 1.29 (0.94 to 
1.76), 0.11 
 low-high 1.83 (1.40 to 
2.41), <0.001 
 high-high 2.01 (1.62 to 
2.48), <0.001 
Cardiovascular death, n = 435 high-low 1.29 (0.91 to 
1.84), 0.15 
 low-high 1.79 (1.31 to 
2.45), <0.001 
 high-high 2.10 (1.65 to 
2.68), <0.001 
Cardiac death, n = 151 high-low 0.81 (0.35 to 
1.85), 0.61 
 low-high 2.61 (1.50 to 
4.53), <0.001 
 high-high 3.56 (2.29 to 
5.55), <0.001 
Heart Failure Endpoints   
Admission to hospital for heart failure, n = 427 high-low 1.43 (0.98 to 
2.08), 0.061 
 low-high 1.85 (1.32 to 
2.59), <0.001 
 high-high 2.78 (1.90 to 
2.75), <0.001 
Cardiovascular death or admission to hospital for new-onset or worsening 
heart failure, n = 723 
high-low 1.39 (1.06 to 
1.82), 0.018 
 low-high 1.68 (1.31 to 
2.16), <0.001 
 high-high 2.29 (1.90 to 
2.75), <0.001 
Coronary Endpoints   
Admission to hospital for myocardial infarction, n = 226 high-low 0.90 (0.55 to 
1.48), 0.69 
 low-high 1.23 (0.80 to 
1.90), 0.34 
 high-high 1.73 (1.27 to 
2.37), <0.001 
Admission to hospital for myocardial infarction or unstable angina, n = 
317 
high-low 0.96 (0.65 to 
1.43), 0.85 
 low-high 0.93 (0.63 to 
1.38), 0.728 
 high-high 1.54 (1.19 to 
2.00), <0.001 
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Coronary revascularisation, n = 186 high-low 0.81 (0.47 to 
1.40), 0.45 
 low-high 0.99 (0.60 to 
1.61), 0.96 
 high-high 1.44 (1.03 to 
2.02), 0.032 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.  
Models were additionally adjusted for: age; smoking; body mass index (BMI); history of diabetes; previous myocardial 
infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); peripheral artery 
disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New 
York Heart Association (NYHA) class; and treatment with aspirin (not including other antithrombotic agents), beta-blockers, 
statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone agents at randomisation. 
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Table A6-4: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the heart rate variables that categorised subjects according to 
whether they had a heart rate less than, or greater than or equal to, 70bpm, which produced 
the results shown in Table A6-1 in the BEAUTIFUL placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Cardiovascular death or admission to 
hospital for myocardial infarction or new-
onset or worsening heart failure, n = 832 
Model 0.689  
 Model + Baseline 0.694 21.54, <0.001 
 Model + Time-Updated 0.705 72.37, <0.001 
 Model + Time-Updated 
+ Baseline 
0.705 74.56, <0.001 
 Model + Time-Updated 
+ Previous 
0.708 86.36, <0.001 
Mortality Endpoints    
All-cause death, n = 547 Model 0.695  
 Model + Baseline 0.698 8.74, 0.0031 
 Model + Time-Updated 0.710 44.40, <0.001 
 Model + Time-Updated 
+ Baseline 
0.710 44.69, <0.001 
 Model + Time-Updated 
+ Previous 
0.710 46.71, <0.001 
Cardiovascular death, n = 435 Model 0.702  
 Model + Baseline 0.706 8.79, 0.003 
 Model + Time-Updated 0.716 38.40, <0.001 
 Model + Time-Updated 
+ Baseline 
0.716 38.88, <0.001 
 Model + Time-Updated 
+ Previous 
0.716 41.46, <0.001 
Cardiac death, n = 151 Model 0.759  
 Model + Baseline 0.773 8.02, 0.0046 
 Model + Time-Updated 0.794 45.40, <0.001 
 Model + Time-Updated 
+ Baseline 
0.795 45.58, <0.001 
 Model + Time-Updated 
+ Previous 
0.795 46.31, <0.001 
Heart Failure Endpoints    
Admission to hospital for heart failure,  
n = 427 
Model 0.753  
 Model + Baseline 0.759 17.80, <0.001 
 Model + Time-Updated 0.769 62.40, <0.001 
 Model + Time-Updated 
+ Baseline 
0.770 64.07, <0.001 
 Model + Time-Updated 
+ Previous 
0.773 73.36, <0.001 
Cardiovascular death or admission to 
hospital for new-onset or worsening heart 
failure, n = 723 
Model 0.714  
 Model + Baseline 0.719 20.66, <0.001 
 Model + Time-Updated 0.729 70.10, <0.001 
 Model + Time-Updated 
+ Baseline 
0.729 72.16, <0.001 
 Model + Time-Updated 
+ Previous 
0.731 82.84, <0.001 
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Coronary Endpoints    
Admission to hospital for myocardial 
infarction, n = 226 
Model 0.661  
 Model + Baseline 0.668 7.56, 0.0060 
 Model + Time-Updated 0.673 12.18, <0.001 
 Model + Time-Updated 
+ Baseline 
0.674 14.59, <0.001 
 Model + Time-Updated 
+ Previous 
0.674 13.19, 0.0014 
Admission to hospital for myocardial 
infarction or unstable angina, n = 317 
Model 0.648  
 Model + Baseline 0.656 8.78, 0.0030 
 Model + Time-Updated 0.653 7.42, 0.0064 
 Model + Time-Updated 
+ Baseline 
0.657 11.78, 0.0028 
 Model + Time-Updated 
+ Previous 
0.657 10.78, 0.0046 
Coronary revascularisation, n = 186 Model 0.651  
 Model + Baseline 0.655 4.44, 0.035 
 Model + Time-Updated 0.654 4.34, 0.037 
 Model + Time-Updated 
+ Baseline 
0.656 6.36, 0.042 
 Model + Time-Updated 
+ Previous 
0.656 4.80, 0.091 
‘Model’ is the multivariate model excluding heart rate which included: age; smoking; body mass index (BMI); history of 
diabetes; previous myocardial infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass 
graft (CABG); peripheral artery disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular 
ejection fraction (LVEF); New York Heart Association (NYHA) class; and treatment with aspirin (not including other 
antithrombotic agents), beta-blockers, statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone 
agents at randomisation. 
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate group variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate group variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate group variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
group variable and the previous time-updated heart rate group variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
 
 
  
384 
 
Table A6-5: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A6-2 in the BEAUTIFUL placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Cardiovascular death or admission to 
hospital for myocardial infarction or new-
onset or worsening heart failure, n = 832 
Model 0.689  
 Model + Baseline 0.696 40.51, <0.001 
 Model + Time-Updated 0.709 111.98, <0.001 
 Model + Time-Updated 
+ Baseline 
0.709 112.93, <0.001 
 Model + Time-Updated 
+ Previous 
0.710 117.48, <0.001 
Mortality Endpoints    
All-cause death, n = 547 Model 0.695  
 Model + Baseline 0.697 10.32, 0.0013 
 Model + Time-Updated 0.707 55.09, <0.001 
 Model + Time-Updated 
+ Baseline 
0.707 55.49, <0.001 
 Model + Time-Updated 
+ Previous 
0.708 56.13, <0.001 
Cardiovascular death, n = 435 Model 0.702  
 Model + Baseline 0.705 10.83, <0.001 
 Model + Time-Updated 0.712 45.13, <0.001 
 Model + Time-Updated 
+ Baseline 
0.712 45.17, <0.001 
 Model + Time-Updated 
+ Previous 
0.712 46.36, <0.001 
Cardiac death, n = 151 Model 0.759  
 Model + Baseline 0.770 9.82, 0.0017 
 Model + Time-Updated 0.790 58.57, <0.001 
 Model + Time-Updated 
+ Baseline 
0.788 59.04, <0.001 
 Model + Time-Updated 
+ Previous 
0.790 58.57, <0.001 
Heart Failure Endpoints    
Admission to hospital for heart failure,  
n = 427 
Model 0.753  
 Model + Baseline 0.762 44.60, <0.001 
 Model + Time-Updated 0.781 113.89, <0.001 
 Model + Time-Updated 
+ Baseline 
0.781 115.35, <0.001 
 Model + Time-Updated 
+ Previous 
0.784 120.21, <0.001 
Cardiovascular death or admission to 
hospital for new-onset or worsening heart 
failure, n = 723 
Model 0.714  
 Model + Baseline 0.721 42.36, <0.001 
 Model + Time-Updated 0.732 103.58, <0.001 
 Model + Time-Updated 
+ Baseline 
0.733 105.36, <0.001 
 Model + Time-Updated 
+ Previous 
0.734 111.41, <0.001 
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Coronary Endpoints    
Admission to hospital for myocardial 
infarction, n = 226 
Model 0.661  
 Model + Baseline 0.666 3.64, 0.056 
 Model + Time-Updated 0.681 22.52, <0.001 
 Model + Time-Updated 
+ Baseline 
0.680 22.74, <0.001 
 Model + Time-Updated 
+ Previous 
0.681 22.95, <0.001 
Admission to hospital for myocardial 
infarction or unstable angina, n = 317 
Model 0.648  
 Model + Baseline 0.654 5.34, 0.021 
 Model + Time-Updated 0.660 16.24, <0.001 
 Model + Time-Updated 
+ Baseline 
0.660 16.35, <0.001 
 Model + Time-Updated 
+ Previous 
0.660 16.48, <0.001 
Coronary revascularisation, n = 186 Model 0.651  
 Model + Baseline 0.657 4.30, 0.038 
 Model + Time-Updated 0.671 15.76, <0.001 
 Model + Time-Updated 
+ Baseline 
0.671 15.77, <0.001 
 Model + Time-Updated 
+ Previous 
0.671 15.78, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; smoking; body mass index (BMI); history of 
diabetes; previous myocardial infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass 
graft (CABG); peripheral artery disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular 
ejection fraction (LVEF); New York Heart Association (NYHA) class; and treatment with aspirin (not including other 
antithrombotic agents), beta-blockers, statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone 
agents at randomisation. 
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A6-6: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the time-updated categorical heart rate patterns variable, which 
produced the results shown in Table A6-3 in the BEAUTIFUL placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Composite Endpoint    
Cardiovascular death or admission to hospital for 
myocardial infarction or new-onset or worsening 
heart failure, n = 832 
Model 0.689  
 Model + Pattern 0.708 86.65, <0.001 
Mortality Endpoints    
All-cause death, n = 547 Model 0.695  
 Model + Pattern 0.710 47.46, <0.001 
Cardiovascular death, n = 435 Model 0.702  
 Model + Pattern 0.716 41.63, <0.001 
Cardiac death, n = 151 Model  0.759  
 Model + Pattern 0.797 47.58, <0.001 
Heart Failure Endpoints    
Admission to hospital for heart failure, n = 427 Model  0.753  
 Model + Pattern 0.773 73.40, <0.001 
Cardiovascular death or admission to hospital for 
new-onset or worsening heart failure, n = 723 
Model 0.714  
 Model + Pattern 0.731 82.85, <0.001 
Coronary Endpoints    
Admission to hospital for myocardial infarction,  
n = 226 
Model 0.661  
 Model + Pattern 0.675 15.07, 0.0018 
Admission to hospital for myocardial infarction or 
unstable angina, n = 317 
Model 0.648  
 Model + Pattern 0.658 14.74, 0.0021 
Coronary revascularisation, n = 186 Model 0.651  
 Model + Pattern 0.662 7.50, 0.058 
‘Model’ is the multivariate model excluding heart rate which included: age; smoking; body mass index (BMI); history of 
diabetes; previous myocardial infarction (MI); previous percutaneous coronary intervention (PCI) or coronary artery bypass 
graft (CABG); peripheral artery disease (PAD); systolic blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular 
ejection fraction (LVEF); New York Heart Association (NYHA) class; and treatment with aspirin (not including other 
antithrombotic agents), beta-blockers, statins, diuretics (excluding anti-aldosterone), organic nitrates and anti-aldosterone 
agents at randomisation. 
‘Model + Pattern’ is the multivariate model described above including the time-updated categorical heart rate patterns 
variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
the time-updated categorical heart rate patterns variable to the multivariate model excluding resting heart rate.     
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Table A6-7: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a heart rate ≥70bpm compared to a heart rate <70bpm in the BEAUTIFUL 
placebo population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Composite Endpoint     
Cardiovascular death or admission to 
hospital for myocardial infarction or 
new-onset or worsening heart failure, 
n = 832 
0.014 0.029 0.15 0.39 
Mortality Endpoints     
All-cause death, n = 547 0.81 0.15 0.12 0.20 
Cardiovascular death, n = 435 0.53 0.12 0.13 0.23 
Cardiac death, n = 151 0.096 0.068 0.15 0.31 
Heart Failure Endpoints     
Admission to hospital for heart 
failure, n = 427 
0.0047 0.0068 0.060 0.20 
Cardiovascular death or admission to 
hospital for new-onset or worsening 
heart failure, n = 723 
0.023 0.0062 0.033 0.10 
Coronary Endpoints     
Admission to hospital for myocardial 
infarction, n = 226 
0.70 0.92 0.94 0.42 
Admission to hospital for myocardial 
infarction or unstable angina, n = 317 
0.83 0.90 0.77 0.41 
Coronary revascularisation, n = 186 0.72 0.91 0.99 0.92 
 
 
Table A6-8: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a 5bpm higher heart rate in the BEAUTIFUL placebo population. 
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Composite Endpoint     
Cardiovascular death or admission to 
hospital for myocardial infarction or 
new-onset or worsening heart 
failure, n = 832 
<0.001 0.015 0.35 0.32 
Mortality Endpoints     
All-cause death, n = 547 0.78 0.46 0.70 0.50 
Cardiovascular death, n = 435 0.72 0.84 0.82 0.87 
Cardiac death, n = 151 0.53 0.68 0.72 0.59 
Heart Failure Endpoints     
Admission to hospital for heart 
failure, n = 427 
<0.001 <0.001 0.017 0.021 
Cardiovascular death or admission to 
hospital for new-onset or worsening 
heart failure, n = 723 
0.0019 0.0034 0.11 0.084 
Coronary Endpoints     
Admission to hospital for myocardial 
infarction, n = 226 
0.60 0.37 0.25 0.23 
Admission to hospital for myocardial 
infarction or unstable angina, n = 317 
0.93 0.37 0.29 0.15 
Coronary revascularisation, n = 186 0.77 0.91 0.97 0.81 
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Table A6-9: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for for the time-updated categorical heart rate patterns ‘high-low’, ‘low-high’ and 
‘high-high’ relative to the category ‘low-low’ in the BEAUTIFUL placebo population.   
 Heart Rate 
Category 
P-value 
Primary Composite Endpoint   
Cardiovascular death or admission to hospital for myocardial infarction 
or new-onset or worsening heart failure, n = 832 
high-low 0.33 
 low-high 0.76 
 high-high 0.0086 
Mortality Endpoints   
All-cause death, n = 547 high-low 0.54 
 low-high 0.68 
 high-high 0.32 
Cardiovascular death, n = 435 high-low 0.55 
 low-high 0.85 
 high-high 0.22 
Cardiac death, n = 151 high-low 0.27 
 low-high 0.33 
 high-high 0.21 
Heart Failure Endpoints   
Admission to hospital for heart failure, n = 427 high-low 0.38 
 low-high 0.64 
 high-high 0.0021 
Cardiovascular death or admission to hospital for new-onset or worsening 
heart failure, n = 723 
high-low 0.95 
 low-high 0.67 
 high-high 0.0077 
Coronary Endpoints   
Admission to hospital for myocardial infarction, n = 226 high-low 0.064 
 low-high 0.81 
 high-high 0.29 
Admission to hospital for myocardial infarction or unstable angina,  
n = 317 
high-low 0.052 
 low-high 0.85 
 high-high 0.57 
Coronary revascularisation, n = 186 high-low 0.73 
 low-high 0.78 
 high-high 0.93 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 70bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 70bpm, and so on.   
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Table A6-10: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a heart rate ≥80bpm compared to a heart rate <80bpm 
in the SHIFT placebo population. 
 Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Endpoint     
Cardiovascular death or hospital admission for 
worsening heart failure, n = 936 
1.74 (1.53 to 
1.98), <0.001 
2.22 (1.95 to 
2.53), <0.001 
1.98 (1.72 to 
2.28), <0.001 
1.84 (1.59 to 
2.15), <0.001 
Mortality Endpoints     
All-cause mortality, n = 551 1.78 (1.50 to 
2.11), <0.001 
2.09 (1.76 to 
2.48), <0.001 
1.83 (1.53 to 
2.20), <0.001 
1.80 (1.48 to 
2.18), <0.001 
Cardiovascular mortality, n = 491 1.81 (1.50 to 
2.17), <0.001 
2.12 (1.78 to 
2.55), <0.001 
1.86 (1.53 to 
2.26), <0.001 
1.86 (1.51 to 
2.28), <0.001 
Death from heart failure, n = 151 2.12 (1.52 to 
2.97), <0.001 
2.32 (1.67 to 
2.32), <0.001 
1.92 (1.34 to 
2.74), <0.001 
1.87 (1.28 to 
2.72), <0.001 
Individual Hospital Admission Endpoints     
All-cause hospital admission, n = 1354 1.37 (1.23 to 
1.53), <0.001 
1.81 (1.62 to 
2.02), <0.001 
1.73 (1.54 to 
1.95), <0.001 
1.69 (1.49 to 
1.92), <0.001 
Hospital admission for worsening heart 
failure, n = 671 
1.68 (1.44 to 
1.96), <0.001 
2.39 (2.05 to 
2.79), <0.001 
2.20 (1.86 to 
2.61), <0.001 
1.96 (1.64 to 
2.34), <0.001 
Any cardiovascular hospital admission,  
n = 1120 
1.38 (1.23 to 
1.56), <0.001 
1.80 (1.60 to 
2.03), <0.001 
1.72 (1.51 to 
1.96), <0.001 
1.64 (1.43 to 
1.89), <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
0.93 (0.60 to 
1.45), 0.750 
1.18 (0.76 to 
1.86), 0.459 
1.25 (0.78 to 
2.02), 0.354 
1.27 (0.77 to 
2.09), 0.359 
Other Composite Endpoints     
Cardiovascular death or hospital admission for 
non-fatal myocardial infarction, n = 550 
1.68 (1.41 to 
1.99), <0.001 
2.00 (1.69 to 
2.37), <0.001 
1.78 (1.48 to 
2.15), <0.001 
1.76 (1.45 to 
2.14), <0.001 
Cardiovascular death, or hospital admission 
for worsening heart failure, or hospital 
admission for non-fatal myocardial infarction, 
n = 977 
1.71 (1.51 to 
1.95), <0.001 
2.18 (1.92 to 
2.48), <0.001 
1.95 (1.70 to 
2.25), <0.001 
1.83 (1.58 to 
2.12), <0.001 
Models were additionally adjusted for: beta-blocker intake; New York Heart Association (NYHA) class; left-ventricular 
ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; age; systolic blood pressure 
(SBP); and estimated Glomerular Filtration Rate (eGFR).   
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Table A6-11: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the SHIFT placebo 
population. 
 Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Primary Endpoint     
Cardiovascular death or hospital admission 
for worsening heart failure, n = 936 
1.15 (1.12 to 
1.18), <0.001 
1.20 (1.17 to 
1.23), <0.001 
1.19 (1.16 to 
1.22), <0.001 
1.16 (1.13 to 
1.20), <0.001 
Mortality Endpoints     
All-cause mortality, n = 551 1.13 (1.09 to 
1.18), <0.001 
1.17 (1.14 to 
1.21), <0.001 
1.16 (1.13 to 
1.20), <0.001 
1.15 (1.11 to 
1.19), <0.001 
Cardiovascular mortality, n = 491 1.14 (1.09 to 
1.18), <0.001 
1.18 (1.14 to 
1.21), <0.001 
1.16 (1.13 to 
1.20), <0.001 
1.15 (1.11 to 
1.20), <0.001 
Death from heart failure, n = 151 1.18 (1.10 to 
1.26), <0.001 
1.24 (1.19 to 
1.30), <0.001 
1.24 (1.17 to 
1.30), <0.001 
1.22 (1.15 to 
1.30), <0.001 
Individual Hospital Admission Endpoints     
All-cause hospital admission, n = 1354 1.09 (1.07 to 
1.12), <0.001 
1.15 (1.13 to 
1.17), <0.001 
1.15 (1.12 to 
1.18), <0.001 
1.14 (1.11 to 
1.17), <0.001 
Hospital admission for worsening heart 
failure, n = 671 
1.15 (1.11 to 
1.19), <0.001 
1.22 (1.19 to 
1.25), <0.001 
1.22 (1.17 to 
1.26), <0.001 
1.18 (1.14 to 
1.22), <0.001 
Any cardiovascular hospital admission,  
n = 1120 
1.10 (1.07 to 
1.13), <0.001 
1.16 (1.14 to 
1.19), <0.001 
1.16 (1.14 to 
1.19), <0.001 
1.15 (1.12 to 
1.18), <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
0.99 (0.88 to 
1.11), 0.829 
1.09 (1.01 to 
1.17), 0.030 
1.12 (1.03 to 
1.21), 0.010 
1.12 (1.02 to 
1.23), 0.016 
Other Composite Endpoints     
Cardiovascular death or hospital admission 
for non-fatal myocardial infarction, n = 550 
1.12 (1.08 to 
1.16), <0.001 
1.17 (1.13 to 
1.20), <0.001 
1.16 (1.12 to 
1.19), <0.001 
1.15 (1.11 to 
1.19), <0.001 
Cardiovascular death, or hospital admission 
for worsening heart failure, or hospital 
admission for non-fatal myocardial 
infarction, n = 977 
1.14 (1.11 to 
1.18), <0.001 
1.20 (1.17 to 
1.22), <0.001 
1.19 (1.16 to 
1.22), <0.001 
1.16 (1.13 to 
1.20), <0.001 
Models were additionally adjusted for: beta-blocker intake; New York Heart Association (NYHA) class; left-ventricular 
ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; age; systolic blood pressure 
(SBP); and estimated Glomerular Filtration Rate (eGFR).   
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Table A6-12: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for time-updated categorical heart rate patterns ‘high-
low’, ‘low-high’ and ‘high-high’ relative to the category ‘low-low’ in the SHIFT placebo 
population.   
 Heart Rate 
Category 
Hazard Ratio (95% 
Confidence 
Interval), p-value 
Primary Endpoint   
Cardiovascular death or hospital admission for worsening heart 
failure, n = 936 
high-low 1.83 (1.49 to 2.26), 
<0.001 
 low-high 2.25 (1.85 to 2.74), 
<0.001 
 high-high 2.68 (2.29 to 3.13), 
<0.001 
Mortality Endpoints   
All-cause mortality, n = 551 high-low 2.09 (1.60 to 2.71), 
<0.001 
 low-high 2.55 (1.99 to 3.25), 
<0.001 
 high-high 2.48 (2.01 to 3.05) 
<0.001 
Cardiovascular mortality, n = 491 high-low 2.07 (1.56 to 2.74), 
<0.001 
 low-high 2.65 (2.05 to 3.43), 
<0.001 
 high-high 2.48 (1.98 to 3.09), 
<0.001 
Death from heart failure, n = 151 high-low 2.45 (1.47 to 4.08), 
<0.001 
 low-high 2.79 (1.71 to 4.55), 
<0.001 
 high-high 3.05 (2.03 to 4.57), 
<0.001 
Individual Hospital Admission Endpoints   
All-cause hospital admission, n = 1354 high-low 1.24 (1.03 to 1.49), 
0.024 
 low-high 1.80 (1.53 to 2.11), 
<0.001 
 high-high 1.92 (1.69 to 2.19), 
<0.001 
Hospital admission for worsening heart failure, n = 671 high-low 1.74 (1.35 to 2.25), 
<0.001 
 low-high 2.21 (1.75 to 2.81), 
<0.001 
 high-high 2.96 (2.46 to 3.55) 
<0.001 
Any cardiovascular hospital admission, n = 1120 high-low 1.40 (1.15 to 1.70) 
<0.001 
 low-high 1.86 (1.56 to 2.22) 
<0.001 
 high-high 1.95 (1.69 to 2.25) 
<0.001 
Hospital admission for non-fatal myocardial infarction, n = 86 high-low 1.39 (0.73 to 2.65) 
0.314 
 low-high 1.83 (1.02 to 3.25) 
0.041 
 high-high 0.95 (0.53 to 1.72) 
0.871 
Other Composite Endpoints   
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Cardiovascular death or hospital admission for non-fatal myocardial 
infarction, n = 550 
high-low 2.05 (1.57 to 2.66) 
<0.001 
 low-high 2.55 (2.00 to 3.25) 
<0.001 
 high-high 2.28 (1.84 to 2.81) 
<0.001 
Cardiovascular death, or hospital admission for worsening heart 
failure, or hospital admission for non-fatal myocardial infarction, n = 
977 
high-low 1.84 (1.50 to 2.26) 
<0.001 
 low-high 2.27 (1.88 to 2.75) 
<0.001 
 high-high 2.60 (2.23 to 3.03) 
<0.001 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 80bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 80bpm, and so on.   
Models were additionally adjusted for: beta-blocker intake; New York Heart Association (NYHA) class; left-ventricular 
ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; age; systolic blood pressure 
(SBP); and estimated Glomerular Filtration Rate (eGFR).   
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Table A6-13: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the heart rate variables that categorised subjects according to 
whether they had a heart rate less than, or greater than or equal to, 80bpm, which produced 
the results shown in Table A6-10 in the SHIFT placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Endpoint    
Cardiovascular death or hospital admission 
for worsening heart failure, n = 936 
Model 0.639  
 Model + Baseline 0.660 68.12, <0.001 
 Model + Time-Updated 0.679 139.75, <0.001 
 Model + Time-Updated 
+ Baseline 
0.683 155.96, <0.001 
 Model + Time-Updated 
+ Previous 
0.687 163.24, <0.001 
Mortality Endpoints    
All-cause mortality, n = 551 Model 0.651  
 Model + Baseline 0.672 43.20, <0.001 
 Model + Time-Updated 0.682 71.17, <0.001 
 Model + Time-Updated 
+ Baseline 
0.689 84.96, <0.001 
 Model + Time-Updated 
+ Previous 
0.690 81.73, <0.001 
Cardiovascular mortality, n = 491 Model 0.658  
 Model + Baseline 0.679 40.52, <0.001 
 Model + Time-Updated 0.689 66.62, <0.001 
 Model + Time-Updated 
+ Baseline 
0.695 79.43, <0.001 
 Model + Time-Updated 
+ Previous 
0.695 74.13, <0.001 
Death from heart failure, n = 151 Model 0.774  
 Model + Baseline 0.792 19.67, <0.001 
 Model + Time-Updated 0.795 25.31, <0.001 
 Model + Time-Updated 
+ Baseline 
0.802 32.59, <0.001 
 Model + Time-Updated 
+ Previous 
0.804 30.96, <0.001 
Individual Hospital Admission Endpoints    
All-cause hospital admission, n = 1354 Model 0.601  
 Model + Baseline 0.610 32.24, <0.001 
 Model + Time-Updated 0.631 108.68, <0.001 
 Model + Time-Updated 
+ Baseline 
0.632 112.02, <0.001 
 Model + Time-Updated 
+ Previous 
0.632 112.84, <0.001 
Hospital admission for worsening heart 
failure, n = 671 
Model 0.646  
 Model + Baseline 0.665 42.58, <0.001 
 Model + Time-Updated 0.691 120.73, <0.001 
 Model + Time-Updated 
+ Baseline 
0.693 126.85, <0.001 
 Model + Time-Updated 
+ Previous 
0.698 140.83, <0.001 
Any cardiovascular hospital admission,  
n = 1120 
Model 0.611  
 Model + Baseline 0.618 27.81, <0.001 
 Model + Time-Updated 0.636 89.15, <0.001 
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 Model + Time-Updated 
+ Baseline 
0.636 92.33, <0.001 
 Model + Time-Updated 
+ Previous 
0.639 95.74, <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
Model 0.713  
 Model + Baseline 0.712 0.10, 0.75 
 Model + Time-Updated 0.712 0.53, 0.46 
 Model + Time-Updated 
+ Baseline 
0.712 0.95, 0.62 
 Model + Time-Updated 
+ Previous 
0.713 0.85, 0.65 
Other Composite Endpoints    
Cardiovascular death or hospital admission 
for non-fatal myocardial infarction, n = 550 
Model 0.657  
 Model + Baseline 0.674 34.93, <0.001 
 Model + Time-Updated 0.684 62.49, <0.001 
 Model + Time-Updated 
+ Baseline 
0.689 72.64, <0.001 
 Model + Time-Updated 
+ Previous 
0.689 69.68, <0.001 
Cardiovascular death, or hospital admission 
for worsening heart failure, or hospital 
admission for non-fatal myocardial 
infarction, n = 977 
Model 0.639  
 Model + Baseline 0.659 67.28, <0.001 
 Model + Time-Updated 0.677 139.64, <0.001 
 Model + Time-Updated 
+ Baseline 
0.681 155.40, <0.001 
 Model + Time-Updated 
+ Previous 
0.684 161.71, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: beta-blocker intake; New York Heart Association 
(NYHA) class; left-ventricular ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; 
age; systolic blood pressure (SBP); and estimated Glomerular Filtration Rate (eGFR).   
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate group variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate group variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate group variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
group variable and the previous time-updated heart rate group variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A6-14: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A6-11 in the SHIFT placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Endpoint    
Cardiovascular death or hospital admission 
for worsening heart failure, n = 936 
Model 0.639  
 Model + Baseline 0.666 80.78, <0.001 
 Model + Time-Updated 0.699 239.06, <0.001 
 Model + Time-Updated 
+ Baseline 
0.700 241.20, <0.001 
 Model + Time-Updated 
+ Previous 
0.703 250.80, <0.001 
Mortality Endpoints    
All-cause mortality, n = 551 Model 0.651  
 Model + Baseline 0.674 39.43, <0.001 
 Model + Time-Updated 0.696 119.86, <0.001 
 Model + Time-Updated 
+ Baseline 
0.697 121.53, <0.001 
 Model + Time-Updated 
+ Previous 
0.698 123.40, <0.001 
Cardiovascular mortality, n = 491 Model 0.658  
 Model + Baseline 0.680 36.32, <0.001 
 Model + Time-Updated 0.701 107.96, <0.001 
 Model + Time-Updated 
+ Baseline 
0.702 109.60, <0.001 
 Model + Time-Updated 
+ Previous 
0.703 111.24, <0.001 
Death from heart failure, n = 151 Model 0.774  
 Model + Baseline 0.798 19.20, <0.001 
 Model + Time-Updated 0.821 68.24, <0.001 
 Model + Time-Updated 
+ Baseline 
0.822 68.60, <0.001 
 Model + Time-Updated 
+ Previous 
0.824 69.19, <0.001 
Individual Hospital Admission Endpoints    
All-cause hospital admission, n = 1354 Model 0.601  
 Model + Baseline 0.615 42.35, <0.001 
 Model + Time-Updated 0.646 179.38, <0.001 
 Model + Time-Updated 
+ Baseline 
0.646 179.42, <0.001 
 Model + Time-Updated 
+ Previous 
0.646 180.45, <0.001 
Hospital admission for worsening heart 
failure, n = 671 
Model 0.646  
 Model + Baseline 0.673 57.83, <0.001 
 Model + Time-Updated 0.715 212.57, <0.001 
 Model + Time-Updated 
+ Baseline 
0.715 212.68, <0.001 
 Model + Time-Updated 
+ Previous 
0.719 223.25, <0.001 
Any cardiovascular hospital admission,  
n = 1120 
Model 0.611  
 Model + Baseline 0.624 39.49, <0.001 
 Model + Time-Updated 0.655 178.31, <0.001 
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 Model + Time-Updated 
+ Baseline 
0.655 178.52, <0.001 
 Model + Time-Updated 
+ Previous 
0.656 179.40, <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
Model 0.713  
 Model + Baseline 0.713 0.047, 0.83 
 Model + Time-Updated 0.714 4.45, 0.035 
 Model + Time-Updated 
+ Baseline 
0.716 6.20, 0.045 
 Model + Time-Updated 
+ Previous 
0.715 5.50, 0.064 
Other Composite Endpoints    
Cardiovascular death or hospital admission 
for non-fatal myocardial infarction, n = 550 
Model 0.657  
 Model + Baseline 0.675 31.66, <0.001 
 Model + Time-Updated 0.695 106.80, <0.001 
 Model + Time-Updated 
+ Baseline 
0.696 107.53, <0.001 
 Model + Time-Updated 
+ Previous 
0.696 108.87, <0.001 
Cardiovascular death, or hospital admission 
for worsening heart failure, or hospital 
admission for non-fatal myocardial 
infarction, n = 977 
Model 0.639  
 Model + Baseline 0.665 78.92, <0.001 
 Model + Time-Updated 0.696 241.03, <0.001 
 Model + Time-Updated 
+ Baseline 
0.697 242.76, <0.001 
 Model + Time-Updated 
+ Previous 
0.700 249.81, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: beta-blocker intake; New York Heart Association 
(NYHA) class; left-ventricular ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; 
age; systolic blood pressure (SBP); and estimated Glomerular Filtration Rate (eGFR).   
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A6-15: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the time-updated categorical heart rate patterns variable, which 
produced the results shown in Table A6-12 in the SHIFT placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Primary Endpoint    
Cardiovascular death or hospital admission for 
worsening heart failure, n = 936 
Model 0.639  
 Model + Pattern 0.687 171.56, <0.001 
Mortality Endpoints    
All-cause mortality, n = 551 Model 0.651  
 Model + Pattern 0.693 98.22, <0.001 
Cardiovascular mortality, n = 491 Model 0.658  
 Model + Pattern 0.699 90.06, <0.001 
Death from heart failure, n = 151 Model 0.774  
 Model + Pattern 0.805 35.96, <0.001 
Individual Hospital Admission Endpoints    
All-cause hospital admission, n = 1354 Model 0.601  
 Model + Pattern 0.632 141.11, <0.001 
Hospital admission for worsening heart failure, n = 
671 
Model 0.646  
 Model + Pattern 0.698 143.05, <0.001 
Any cardiovascular hospital admission, n = 1120 Model 0.611  
 Model + Pattern 0.638 99.92, <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
Model 0.713  
 Model + Pattern 0.724 4.75, 0.19 
Other Composite Endpoints    
Cardiovascular death or hospital admission for non-
fatal myocardial infarction, n = 550 
Model 0.657  
 Model + Pattern 0.694 89.12, <0.001 
Cardiovascular death, or hospital admission for 
worsening heart failure, or hospital admission for 
non-fatal myocardial infarction, n = 977 
Model 0.639  
 Model + Pattern 0.684 172.23, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: beta-blocker intake; New York Heart Association 
(NYHA) class; left-ventricular ejection fraction (LVEF); whether the primary cause of heart failure (HF) was ischemic or not; 
age; systolic blood pressure (SBP); and estimated Glomerular Filtration Rate (eGFR).   
‘Model + Pattern’ is the multivariate model described above including the time-updated categorical heart rate patterns 
variable. 
The likelihood ratio test statistic and corresponding p-value were computed by comparing the multivariate model including 
the time-updated categorical heart rate patterns variable to the multivariate model excluding resting heart rate.     
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Table A6-16: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a heart rate ≥80bpm compared to a heart rate <80bpm in the SHIFT placebo 
population. 
 Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Endpoint     
Cardiovascular death or hospital admission for 
worsening heart failure, n = 936 
0.019 0.21 0.72 0.50 
Mortality Endpoints     
All-cause mortality, n = 551 0.28 0.64 0.98 0.67 
Cardiovascular mortality, n = 491 0.34 0.36 0.61 0.41 
Death from heart failure, n = 151 0.77 0.42 0.28 0.38 
Individual Hospital Admission Endpoints     
All-cause hospital admission, n = 1354 0.0086 0.29 0.85 0.46 
Hospital admission for worsening heart 
failure, n = 671 
0.022 0.83 0.27 0.52 
Any cardiovascular hospital admission,  
n = 1120 
0.030 0.89 0.50 0.82 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
0.48 0.045 0.067 0.26 
Other Composite Endpoints     
Cardiovascular death or hospital admission for 
non-fatal myocardial infarction, n = 550 
0.54 0.71 0.93 0.58 
Cardiovascular death, or hospital admission 
for worsening heart failure, or hospital 
admission for non-fatal myocardial infarction, 
n = 977 
0.020 0.30 0.90 0.51 
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Table A6-17: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a 5bpm higher heart rate in the SHIFT placebo population. 
 Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Primary Endpoint     
Cardiovascular death or hospital admission 
for worsening heart failure, n = 936 
0.042 0.11 0.38 0.37 
Mortality Endpoints     
All-cause mortality, n = 551 0.11 0.16 0.41 0.40 
Cardiovascular mortality, n = 491 0.061 0.065 0.25 0.16 
Death from heart failure, n = 151 0.46 0.33 0.39 0.75 
Individual Hospital Admission Endpoints     
All-cause hospital admission, n = 1354 0.028 0.15 0.39 0.48 
Hospital admission for worsening heart 
failure, n = 671 
0.34 0.99 0.91 0.77 
Any cardiovascular hospital admission,  
n = 1120 
0.047 0.62 0.90 0.84 
Hospital admission for non-fatal myocardial 
infarction, n = 86 
0.15 0.12 0.069 0.066 
Other Composite Endpoints     
Cardiovascular death or hospital admission 
for non-fatal myocardial infarction, n = 550 
0.11 0.22 0.49 0.31 
Cardiovascular death, or hospital admission 
for worsening heart failure, or hospital 
admission for non-fatal myocardial 
infarction, n = 977 
0.046 0.20 0.56 0.56 
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Table A6-18: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for time-updated categorical heart rate patterns ‘high-low’, ‘low-high’ and ‘high-
high’ relative to the category ‘low-low’ in the SHIFT placebo population.   
 Heart Rate 
Category 
P-value 
Primary Endpoint   
Cardiovascular death or hospital admission for worsening heart 
failure, n = 936 
high-low 0.81 
 low-high 0.997 
 high-high 0.17 
Mortality Endpoints   
All-cause mortality, n = 551 high-low 0.92 
 low-high 0.56 
 high-high 0.77 
Cardiovascular mortality, n = 491 high-low 0.94 
 low-high 0.42 
 high-high 0.48 
Death from heart failure, n = 151 high-low 0.67 
 low-high 0.87 
 high-high 0.60 
Individual Hospital Admission Endpoints   
All-cause hospital admission, n = 1354 high-low 0.22 
 low-high 0.55 
 high-high 0.22 
Hospital admission for worsening heart failure, n = 671 high-low 0.43 
 low-high 0.13 
 high-high 0.95 
Any cardiovascular hospital admission, n = 1120 high-low 0.30 
 low-high 0.18 
 high-high 0.55 
Hospital admission for non-fatal myocardial infarction, n = 86 high-low 0.55 
 low-high 0.60 
 high-high 0.0047 
Other Composite Endpoints   
Cardiovascular death or hospital admission for non-fatal myocardial 
infarction, n = 550 
high-low 0.76 
 low-high 0.61 
 high-high 0.99 
Cardiovascular death, or hospital admission for worsening heart 
failure, or hospital admission for non-fatal myocardial infarction,  
n = 977 
high-low 0.66 
 low-high 0.99 
 high-high 0.29 
Patients were classified as being in the low-low category if their heart rate measurement at both the current and previous 
visit was below 80bpm.  Similarly, patients were classified as being in the high-high category if their heart rate measurement 
at both the current and previous visit was greater than or equal to 80bpm, and so on.   
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Table A6-19: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for each of the five or six heart rate groups greater than 
or equal to 65bpm, or 60bpm, relative to a heart rate <65bpm, or <60bpm, for the baseline 
and time-updated models, respectively, in the pooled left-ventricular dysfunction placebo 
population.   
 Heart 
Rate 
Group 
Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
adjusted for 
Previous 
  Hazard Ratio (95% Confidence Interval), p-value 
Individual Endpoints      
All-cause death, n = 1098 60-
64bpm 
- 1.14 (0.85 to 
1.53), 0.38 
1.15 (0.85 to 
1.54), 0.36 
1.15 (0.85 to 
1.55), 0.38 
 65-
69bpm 
1.00 (0.77 to 
1.30), 0.98 
1.27 (0.96 to 
1.69), 0.094 
1.29 (0.97 to 
1.72), 0.082 
1.29 (0.95 to 
1.74), 0.097 
 70-
74bpm 
1.06 (0.84 to 
1.35), 0.61 
1.66 (1.26 to 
2.19), <0.001 
1.67 (1.26 to 
2.22), <0.001 
1.64 (1.21 to 
2.21), 0.0013 
 75-
79bpm 
1.18 (0.92 to 
1.51), 0.20 
1.81 (1.36 to 
2.39), <0.001 
1.79 (1.34 to 
2.38), <0.001 
1.74 (1.28 to 
2.36), <0.001 
 80-
84bpm 
1.55 (1.20 to 
2.00), <0.001 
2.08 (1.56 to 
2.78), <0.001 
2.01 (1.49 to 
2.70), <0.001 
1.91 (1.39 to 
2.64), <0.001 
 ≥85bpm 1.89 (1.49 to 
2.39), <0.001 
3.14 (2.43 to 
4.06), <0.001 
2.91 (2.21 to 
3.84), <0.001 
2.66 (1.97 to 
3.61), <0.001 
Cardiovascular mortality, n = 
926 
60-
64bpm 
- 1.20 (0.86 to 
1.67), 0.28 
1.19 (0.86 to 
1.66), 0.30 
1.20 (0.86 to 
1.68), 0.29 
 65-
69bpm 
1.19 (0.88 to 
1.60), 0.26 
1.33 (0.97 to 
1.82), 0.081 
1.31 (0.95 to 
1.80), 0.099 
1.34 (0.96 to 
1.87), 0.090 
 70-
74bpm 
1.21 (0.92 to 
1.59), 0.17 
1.71 (1.26 to 
2.33), <0.001 
1.67 (1.22 to 
2.29), 0.0013 
1.67 (1.19 to 
2.34), 0.0027 
 75-
79bpm 
1.30 (0.97 to 
1.72), 0.077 
1.90 (1.39 to 
2.60), <0.001 
1.83 (1.33 to 
2.51), <0.001 
1.81 (1.29 to 
2.55), <0.001 
 80-
84bpm 
1.77 (1.32 to 
2.36), <0.001 
2.11 (1.53 to 
2.91), <0.001 
1.96 (1.41 to 
2.74), <0.001 
1.92 (1.34 to 
2.74), <0.001 
 ≥85bpm 2.16 (1.64 to 
2.83), <0.001 
3.33 (2.50 to 
4.44), <0.001 
2.99 (2.20 to 
4.06), <0.001 
2.80 (2.00 to 
3.92), <0.001 
Hospital admission for heart 
failure, n = 1098 
60-
64bpm 
- 1.45 (1.01 to 
2.08), 0.043 
1.45 (1.01 to 
2.08), 0.045 
1.28 (0.88 to 
1.85), 0.19 
 65-
69bpm 
1.21 (0.88 to 
1.65), 0.25 
1.72 (1.22 to 
2.43), 0.0020 
1.70 (1.20 to 
2.41), 0.0026 
1.43 (0.99 to 
2.05), 0.054 
 70-
74bpm 
1.24 (0.94 to 
1.64), 0.13 
2.13 (1.52 to 
2.99), <0.001 
2.11 (1.50 to 
2.97), <0.001 
1.67 (1.16 to 
2.39), 0.0054 
 75-
79bpm 
1.62 (1.23 to 
2.15), <0.001 
3.12 (2.25 to 
4.34), <0.001 
3.04 (2.17 to 
4.25), <0.001 
2.30 (1.61 to 
3.29), <0.001 
 80-
84bpm 
1.76 (1.31 to 
2.35), <0.001 
2.98 (2.11 to 
4.20), <0.001 
2.86 (2.01 to 
4.07), <0.001 
2.09 (1.43 to 
3.04), <0.001 
 ≥85bpm 2.59 (1.97 to 
3.40), <0.001 
5.65 (4.13 to 
7.73), <0.001 
5.23 (3.76 to 
7.27), <0.001 
3.74 (2.62 to 
5.34), <0.001 
Hospital admission for non-fatal 
myocardial infarction, n = 312  
60-
64bpm 
- 1.24 (0.78 to 
1.99), 0.36 
1.24 (0.77 to 
1.98), 0.37 
1.22 (0.75 to 
1.98), 0.42 
 65-
69bpm 
0.85 (0.56 to 
1.28), 0.44 
1.21 (0.76 to 
1.92), 0.43 
1.19 (0.74 to 
1.91), 0.47 
1.17 (0.71 to 
1.91), 0.54 
 70-
74bpm 
1.28 (0.88 to 
1.84), 0.19 
1.54 (0.97 to 
2.45), 0.066 
1.49 (0.93 to 
2.40), 0.097 
1.48 (0.90 to 
2.44), 0.13 
 75-
79bpm 
1.48 (1.01 to 
2.19), 0.047 
1.72 (1.07 to 
2.75), 0.025 
1.64 (1.00 to 
2.68), 0.048 
1.64 (0.97 to 
2.75), 0.063 
 80-
84bpm 
1.41 (0.91 to 
2.18), 0.12 
1.73 (1.04 to 
2.88), 0.035 
1.68 (0.99 to 
2.86), 0.055 
1.66 (0.94 to 
2.91), 0.080 
 ≥85bpm 1.34 (0.88 to 
2.04), 0.17 
2.36 (1.50 to 
3.71), <0.001 
2.40 (1.47 to 
3.92), <0.001 
2.36 (1.39 to 
4.01), 0.016 
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Combined Endpoints      
Cardiovascular mortality or 
hospital admission for heart 
failure, n = 1659 
60-
64bpm 
- 1.18 (0.91 to 
1.53), 0.20 
1.18 (0.91 to 
1.52), 0.22 
1.07 (0.82 to 
1.40), 0.61 
 65-
69bpm 
1.24 (0.98 to 
1.57), 0.070 
1.35 (1.06 to 
1.73), 0.017 
1.33 (1.04 to 
1.71), 0.024 
1.18 (0.91 to 
1.53), 0.22 
 70-
74bpm 
1.24 (1.01 to 
1.54), 0.044 
1.77 (1.40 to 
2.25), <0.001 
1.74 (1.36 to 
2.24), <0.001 
1.46 (1.13 to 
1.90), 0.0039 
 75-
79bpm 
1.42 (1.14 to 
1.77), 0.0017 
2.25 (1.78 to 
2.85), <0.001 
2.17 (1.70 to 
2.77), <0.001 
1.78 (1.37 to 
2.30), <0.001 
 80-
84bpm 
1.75 (1.40 to 
2.19), <0.001 
2.24 (1.75 to 
2.87), <0.001 
2.10 (1.62 to 
2.71), <0.001 
1.67 (1.27 to 
2.20), <0.001 
 ≥85bpm 2.39 (1.94 to 
2.95), <0.001 
3.80 (3.04 to 
4.75), <0.001 
3.40 (2.68 to 
4.31), <0.001 
2.64 (2.03 to 
3.42), <0.001 
Cardiovascular mortality or 
hospital admission for non-fatal 
myocardial infarction, n = 1143 
60-
64bpm 
- 1.24 (0.93 to 
1.64), 0.14 
1.24 (0.93 to 
1.64), 0.14 
1.23 (0.92 to 
1.65), 0.16 
 65-
69bpm 
1.03 (0.80 to 
1.33), 0.81 
1.28 (0.97 to 
1.68), 0.079 
1.28 (0.97 to 
1.69), 0.081 
1.27 (0.95 to 
1.70), 0.10 
 70-
74bpm 
1.14 (0.91 to 
1.43), 0.26 
1.69 (1.30 to 
2.21), <0.001 
1.68 (1.28 to 
2.20), <0.001 
1.64 (1.23 to 
2.20), <0.001 
 75-
79bpm 
1.23 (0.97 to 
1.57), 0.090 
1.83 (1.40 to 
2.40), <0.001 
1.79 (1.35 to 
2.36), <0.001 
1.74 (1.29 to 
2.35), <0.001 
 80-
84bpm 
1.59 (1.24 to 
2.03), <0.001 
1.98 (1.50 to 
2.63), <0.001 
1.89 (1.41 to 
2.53), <0.001 
1.81 (1.32 to 
2.48), <0.001 
 ≥85bpm 1.88 (1.49 to 
2.37), <0.001 
3.03 (2.36 to 
3.89), <0.001 
2.79 (2.13 to 
3.66), <0.001 
2.60 (1.94 to 
3.50), <0.001 
Cardiovascular mortality or 
hospital admission for heart 
failure or non-fatal myocardial 
infarction, n = 1809 
60-
64bpm 
- 1.18 (0.93 to 
1.49), 0.18 
1.17 (0.93 to 
1.49), 0.19 
1.08 (0.85 to 
1.38), 0.53 
 65-
69bpm 
1.15 (0.93 to 
1.43), 0.19 
1.26 (1.00 to 
1.58), 0.047 
1.25 (0.99 to 
1.58), 0.056 
1.12 (0.88 to 
1.43), 0.35 
 70-
74bpm 
1.17 (0.96 to 
1.42), 0.12 
1.68 (1.35 to 
2.10), <0.001 
1.67 (1.33 to 
2.09), <0.001 
1.42 (1.12 to 
1.81), 0.0039 
 75-
79bpm 
1.37 (1.12 to 
1.67), 0.0025 
2.10 (1.69 to 
2.62), <0.001 
2.04 (1.63 to 
2.56), <0.001 
1.70 (1.34 to 
2.17), <0.001 
 80-
84bpm 
1.65 (1.34 to 
2.04), <0.001 
2.11 (1.67 to 
2.66), <0.001 
2.00 (1.57 to 
2.55), <0.001 
1.63 (1.26 to 
2.11), <0.001 
 ≥85bpm 2.18 (1.80 to 
2.65), <0.001 
3.54 (2.88 to 
4.36), <0.001 
3.24 (2.59 to 
4.04), <0.001 
2.57 (2.01 to 
3.28), <0.001 
Models were additionally adjusted for: age; sex; smoking; body mass index (BMI); systolic blood pressure (SBP); diastolic 
blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association (NYHA) class; previous 
myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-converting enzyme (ACE) 
inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
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Table A6-20: Results of fitting Cox proportional hazards models.  Hazard ratios, 95% 
confidence intervals, and p-values for a 5bpm higher heart rate in the pooled left-ventricular 
dysfunction placebo population.   
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 Hazard Ratio (95% Confidence Interval), p-value 
Individual Endpoints     
All-cause death, n = 1098 1.10 (1.08 to 
1.13), <0.001 
1.16 (1.14 to 
1.19), <0.001 
1.16 (1.13 to 
1.19), <0.001 
1.14 (1.11 to 
1.17), <0.001 
Cardiovascular death, n = 926 1.11 (1.08 to 
1.14), <0.001 
1.17 (1.14 to 
1.19), <0.001 
1.16 (1.13 to 
1.19), <0.001 
1.14 (1.11 to 
1.18), <0.001 
Hospital admission for heart failure,  
n = 1098 
1.15 (1.12 to 
1.18), <0.001 
1.22 (1.20 to 
1.25), <0.001 
1.21 (1.18 to 
1.24), <0.001 
1.18 (1.15 to 
1.21), <0.001 
Hospital admission for non-fatal 
myocardial infarction, n = 321 
1.05 (0.99 to 
1.11), 0.085 
1.12 (1.08 to 
1.17), <0.001 
1.14 (1.08 to 
1.19), <0.001 
1.14 (1.09 to 
1.20), <0.001 
Combined Endpoints     
Cardiovascular death or hospital 
admission for heart failure, n = 1659 
1.13 (1.11 to 
1.16), <0.001 
1.19 (1.17 to 
1.21), <0.001 
1.17 (1.15 to 
1.20), <0.001 
1.15 (1.12 to 
1.18), <0.001 
Cardiovascular death or hospital 
admission for non-fatal myocardial 
infarction, n = 1143 
1.10 (1.07 to 
1.13), <0.001 
1.15 (1.13 to 
1.18), <0.001 
1.15 (1.12 to 
1.18), <0.001 
1.14 (1.11 to 
1.17), <0.001 
Cardiovascular death or hospital 
admission for heart failure or non-fatal 
myocardial infarction, n = 1809 
1.13 (1.10 to 
1.15), <0.001 
1.18 (1.16 to 
1.20), <0.001 
1.17 (1.15 to 
1.19), <0.001 
1.15 (1.13 to 
1.18), <0.001 
Models were additionally adjusted for: age; sex; smoking; body mass index (BMI); systolic blood pressure (SBP); diastolic 
blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association (NYHA) class; previous 
myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-converting enzyme (ACE) 
inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
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Table A6-21: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the model including the heart rate groups variable, which produced the results shown 
in Table A6-19 in the pooled left-ventricular dysfunction placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Individual Endpoints    
All-cause death, n = 1098 Model 0.681  
 Model + Baseline 0.692 59.25, <0.001 
 Model + Time-Updated 0.706 148.68, <0.001 
 Model + Time-Updated 
+ Baseline 
0.707 156.41, <0.001 
 Model + Time-Updated 
+ Previous 
0.711 168.68, <0.001 
Cardiovascular death, n = 926 Model 0.692  
 Model + Baseline 0.704 56.84, <0.001 
 Model + Time-Updated 0.715 132.61, <0.001 
 Model + Time-Updated 
+ Baseline 
0.717 140.12, <0.001 
 Model + Time-Updated 
+ Previous 
0.720 149.25, <0.001 
Hospital admission for heart failure,  
n = 1098 
Model 0.739  
 Model + Baseline 0.751 95.29, <0.001 
 Model + Time-Updated 0.772 289.16, <0.001 
 Model + Time-Updated 
+ Baseline 
0.773 294.29, <0.001 
 Model + Time-Updated 
+ Previous 
0.777 319.00, <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 321 
Model 0.661  
 Model + Baseline 0.666 9.15, 0.10 
 Model + Time-Updated 0.673 20.30, 0.0024 
 Model + Time-Updated 
+ Baseline 
0.675 25.60, 0.0074 
 Model + Time-Updated 
+ Previous 
0.675 22.71, 0.030 
Combined Endpoints    
Cardiovascular death or hospital admission 
for heart failure, n = 1659 
Model 0.708  
 Model + Baseline 0.719 120.23, <0.001 
 Model + Time-Updated 0.735 297.63, <0.001 
 Model + Time-Updated 
+ Baseline 
0.736 309.17, <0.001 
 Model + Time-Updated 
+ Previous 
0.740 339.52, <0.001 
Cardiovascular death or hospital admission 
for non-fatal myocardial infarction, n = 1143 
Model 0.663  
 Model + Baseline 0.674 52.06, <0.001 
 Model + Time-Updated 0.687 132.93, <0.001 
 Model + Time-Updated 
+ Baseline 
0.688 138.54, <0.001 
 Model + Time-Updated 
+ Previous 
0.690 144.05, <0.001 
Cardiovascular death or hospital admission 
for heart failure or non-fatal myocardial 
infarction, n = 1809 
Model 0.690  
 Model + Baseline 0.702 113.53, <0.001 
 Model + Time-Updated 0.719 300.01, <0.001 
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 Model + Time-Updated 
+ Baseline 
0.719 309.07, <0.001 
 Model + Time-Updated 
+ Previous 
0.723 334.66, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; smoking; body mass index (BMI); systolic 
blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association 
(NYHA) class; previous myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-
converting enzyme (ACE) inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
‘Model + Baseline’ is the multivariate model described above including the baseline heart rate groups variable. 
‘Model + Time-Updated’ is the multivariate model described above including the time-updated heart rate groups variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the baseline and the time-
updated heart rate groups variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the time-updated heart rate 
groups variable and the previous time-updated heart rate groups variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A6-22: C-statistics and likelihood ratio tests for the model excluding resting heart rate 
and the models including the continuous heart rate variables, which produced the results 
shown in Table A6-20 in the pooled left-ventricular dysfunction placebo population. 
  C-statistic Likelihood Ratio Test 
Statistic, p-value 
Individual Endpoints    
All-cause death, n = 1098 Model 0.681  
 Model + Baseline 0.691 48.11, <0.001 
 Model + Time-Updated 0.708 181.90, <0.001 
 Model + Time-Updated 
+ Baseline 
0.709 182.20, <0.001 
 Model + Time-Updated 
+ Previous 
0.710 186.65, <0.001 
Cardiovascular death, n = 926 Model 0.692  
 Model + Baseline 0.703 46.28, <0.001 
 Model + Time-Updated 0.718 159.12, <0.001 
 Model + Time-Updated 
+ Baseline 
0.718 159.77, <0.001 
 Model + Time-Updated 
+ Previous 
0.719 163.65, <0.001 
Hospital admission for heart failure,  
n = 1098 
Model 0.739  
 Model + Baseline 0.752 97.25, <0.001 
 Model + Time-Updated 0.776 319.19, <0.001 
 Model + Time-Updated 
+ Baseline 
0.776 320.07, <0.001 
 Model + Time-Updated 
+ Previous 
0.778 335.38, <0.001 
Hospital admission for non-fatal myocardial 
infarction, n = 321 
Model 0.661  
 Model + Baseline 0.664 2.86, 0.091 
 Model + Time-Updated 0.674 26.62, <0.001 
 Model + Time-Updated 
+ Baseline 
0.673 27.39, <0.001 
 Model + Time-Updated 
+ Previous 
0.674 27.91, <0.001 
Combined Endpoints    
Cardiovascular death or hospital admission 
for heart failure, n = 1659 
Model 0.708  
 Model + Baseline 0.720 118.40, <0.001 
 Model + Time-Updated 0.739 337.77, <0.001 
 Model + Time-Updated 
+ Baseline 
0.739 341.41, <0.001 
 Model + Time-Updated 
+ Previous 
0.741 357.48, <0.001 
Cardiovascular death or hospital admission 
for non-fatal myocardial infarction, n = 1143 
Model 0.663  
 Model + Baseline 0.674 44.34, <0.001 
 Model + Time-Updated 0.689 161.28, <0.001 
 Model + Time-Updated 
+ Baseline 
0.689 161.65, <0.001 
 Model + Time-Updated 
+ Previous 
0.690 163.66, <0.001 
Cardiovascular death or hospital admission 
for heart failure or non-fatal myocardial 
infarction, n = 1809 
Model 0.690  
 Model + Baseline 0.703 113.55, <0.001 
 Model + Time-Updated 0.722 345.80, <0.001 
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 Model + Time-Updated 
+ Baseline 
0.722 348.28, <0.001 
 Model + Time-Updated 
+ Previous 
0.724 360.11, <0.001 
‘Model’ is the multivariate model excluding heart rate which included: age; sex; smoking; body mass index (BMI); systolic 
blood pressure (SBP); diastolic blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association 
(NYHA) class; previous myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-
converting enzyme (ACE) inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
‘Model + Baseline’ is the multivariate model described above including the continuous baseline heart rate variable. 
‘Model + Time-Updated’ is the multivariate model described above including the continuous time-updated heart rate 
variable. 
‘Model + Time-Updated + Baseline’ is the multivariable model described above including both the continuous baseline and 
time-updated heart rate variables. 
‘Model + Time-Updated + Previous’ is the multivariate model described above including both the continuous time-updated 
heart rate variable and the previous time-updated heart rate variable. 
The likelihood ratio test statistics and corresponding p-values were computed by comparing the multivariate models 
including the different heart rate variables to the multivariate model excluding resting heart rate.     
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Table A6-23: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for each of the five or six heart rate groups greater than or equal to 65bpm, or 
60bpm, relative to a heart rate <65bpm, or <60bpm, for the baseline and time-updated 
models, respectively, in the pooled left-ventricular dysfunction placebo population.   
 Heart 
Rate 
Group 
Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
adjusted for 
Previous 
  P-value    
Individual Endpoints      
All-cause death, n = 1098 60-
64bpm 
- 0.99 0.96 0.95 
 65-
69bpm 
0.29 0.32 0.30 0.34 
 70-
74bpm 
0.94 0.80 0.77 0.69 
 75-
79bpm 
0.60 0.62 0.70 0.81 
 80-
84bpm 
0.24 0.87 0.99 0.92 
 ≥85bpm 0.52 0.71 0.61 0.44 
Cardiovascular mortality,  
n = 926 
60-
64bpm 
- 0.55 0.54 0.51 
 65-
69bpm 
0.72 0.29 0.27 0.31 
 70-
74bpm 
0.81 0.66 0.63 0.56 
 75-
79bpm 
0.48 0.83 0.94 0.995 
 80-
84bpm 
0.39 0.96 0.86 0.86 
 ≥85bpm 0.44 0.79 0.59 0.55 
Hospital admission for heart 
failure, n = 1098 
60-
64bpm 
- 0.71 0.64 0.60 
 65-
69bpm 
0.24 0.46 0.63 0.67 
 70-
74bpm 
0.076 0.79 0.93 0.86 
 75-
79bpm 
0.030 0.98 0.58 0.57 
 80-
84bpm 
0.0077 0.70 0.82 0.85 
 ≥85bpm <0.001 0.29 0.85 0.82 
Hospital admission for non-fatal 
myocardial infarction, n = 312  
60-
64bpm 
- 0.95 1.00 0.97 
 65-
69bpm 
0.89 0.90 0.80 0.74 
 70-
74bpm 
0.75 0.89 0.71 0.57 
 75-
79bpm 
0.35 0.79 0.53 0.47 
 80-
84bpm 
0.26 0.85 0.57 0.53 
 ≥85bpm 0.97 0.45 0.28 0.35 
      
Combined Endpoints      
Cardiovascular mortality or 
hospital admission for heart 
failure, n = 1659 
60-
64bpm 
- 0.86 0.80 0.78 
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 65-
69bpm 
0.29 0.70 0.88 0.84 
 70-
74bpm 
0.29 0.69 0.93 0.995 
 75-
79bpm 
0.046 0.73 0.89 0.87 
 80-
84bpm 
0.031 0.33 0.76 0.71 
 ≥85bpm <0.001 0.11 0.61 0.51 
Cardiovascular mortality or 
hospital admission for non-fatal 
myocardial infarction, n = 1143 
60-
64bpm 
- 0.50 0.50 0.47 
 65-
69bpm 
0.77 0.20 0.20 0.19 
 70-
74bpm 
0.71 0.46 0.43 0.31 
 75-
79bpm 
0.56 0.78 0.64 0.54 
 80-
84bpm 
0.44 0.66 0.47 0.42 
 ≥85bpm 0.53 0.44 0.26 0.23 
Cardiovascular mortality or 
hospital admission for heart 
failure or non-fatal myocardial 
infarction, n = 1809 
60-
64bpm 
- 0.93 0.89 0.89 
 65-
69bpm 
0.079 0.80 0.93 0.93 
 70-
74bpm 
0.053 0.99 0.79 0.68 
 75-
79bpm 
0.012 0.88 0.88 0.73 
 80-
84bpm 
0.0056 0.38 0.91 0.77 
 ≥85bpm <0.001 0.19 0.52 0.68 
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Table A6-24: P-values for the Grambsch and Therneau 1994 test for non-proportionality of 
hazards for a 5bpm higher heart rate in the pooled left-ventricular dysfunction placebo 
population.   
 Baseline Heart 
Rate 
Time-Updated 
Heart Rate 
Time-Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-Updated 
Heart Rate 
Adjusted for 
Previous 
 P-value    
Individual Endpoints     
All-cause death, n = 1098 0.32 0.58 0.65 0.85 
Cardiovascular death, n = 926 0.089 0.20 0.41 0.32 
Hospital admission for heart failure,  
n = 1098 
<0.001 0.025 0.21 0.32 
Hospital admission for non-fatal 
myocardial infarction, n = 321 
0.85 0.27 0.31 0.28 
Combined Endpoints     
Cardiovascular death or hospital 
admission for heart failure, n = 1659 
<0.001 0.0012 0.067 0.075 
Cardiovascular death or hospital 
admission for non-fatal myocardial 
infarction, n = 1143 
0.13 0.67 0.96 0.97 
Cardiovascular death or hospital 
admission for heart failure or non-fatal 
myocardial infarction, n = 1809 
<0.001 0.0068 0.23 0.25 
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Table A6-25: Likelihood ratio test results comparing the models containing the interaction, 
heart rate group x study, and the models containing only heart rate and study additively in 
the pooled left-ventricular dysfunction placebo population. 
  Baseline 
Heart Rate 
Time-
Updated 
Heart Rate 
Time-
Updated 
Heart Rate 
Adjusted for 
Baseline 
Time-
Updated 
Heart Rate 
Adjusted for 
Previous 
 Model P-values for Interaction 
Individual Endpoints      
All-cause death,  
n = 1098 
Categorical Heart 
Rate Groups 
0.27 0.092 0.10 0.094 
 Continuous Heart 
Rate 
0.11 0.26 0.25 0.26 
Cardiovascular 
death, n = 926 
Categorical Heart 
Rate Groups 
0.36 0.20 0.21 0.20 
 Continuous Heart 
Rate 
0.24 0.35 0.32 0.35 
Hospital admission 
for heart failure,  
n = 1098 
Categorical Heart 
Rate Groups 
0.60 0.89 0.88 0.90 
 Continuous Heart 
Rate 
0.39 0.70 0.73 0.60 
Hospital admission 
for non-fatal 
myocardial 
infarction,  
n = 321 
Categorical Heart 
Rate Groups 
0.99 0.11 0.13 0.12 
 Continuous Heart 
Rate 
0.49 0.58 0.56 0.60 
Combined Endpoints      
Cardiovascular death 
or hospital admission 
for heart failure,  
n = 1659 
Categorical Heart 
Rate Groups 
0.48 0.61 0.65 0.56 
 Continuous Heart 
Rate 
0.63 0.29 0.26 0.35 
Cardiovascular death 
or hospital admission 
for non-fatal 
myocardial 
infarction, n = 1143 
Categorical Heart 
Rate Groups 
0.21 0.12 0.11 0.12 
 Continuous Heart 
Rate 
0.12 0.10 0.094 0.10 
Cardiovascular death 
or hospital admission 
for heart failure or 
non-fatal myocardial 
infarction,  
n = 1,809 
Categorical Heart 
Rate Groups 
0.38 0.38 0.42 0.35 
 Continuous Heart 
Rate 
0.29 0.14 0.12 0.17 
Models were additionally adjusted for: age; sex; smoking; body mass index (BMI); systolic blood pressure (SBP); diastolic 
blood pressure (DBP); left-ventricular ejection fraction (LVEF); New York Heart Association (NYHA) class; previous 
myocardial infarction (MI); diabetes; previous stroke; and intake of beta-blockers; angiotensin-converting enzyme (ACE) 
inhibitors; diuretics; and anti-aldosterone agents at randomisation; and study. 
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Appendix 7 
Supplementary Tables for Chapter 9 
Table A7-1: PRISMA 2009 checklist94 for the meta-analyses of the predictive value of resting heart rate measured at a single point in time, and time-updated 
resting heart rate measurements, for all-cause and cardiovascular mortality. 
Section/Topic Item 
No. 
Checklist Item Reported On Page No. 
Title    
Title 1 Identify the report as a systematic review, meta-analysis, or both. 228 
Abstract    
Structured 
summary 
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review 
registration number. 
N/A as thesis chapter as 
opposed to journal article 
Introduction    
Rationale 3 Describe the rationale for the review in the context of what is already known. 228 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes and study 
design (PICOS).   
228 
Methods    
Protocol and 
registration 
5 Indicate if a review protocol exists, if and where it can be accessed (such as Web address), and, if available, provide registration 
information including registration number. 
No review protocol, noted 
as limitation in discussion  
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication 
status) used as criteria of eligibility, giving rationale. 
229 and 240 
Information 
sources 
7 Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched. 
229 and 240 
See 22-3 for details of the 
initial search 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. N/A 
See 22-3 and Table A1-2 
provided in Appendix 1 for 
details of the initial 
electronic search strategy 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis). 
229 and 240 
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Data collection 
process 
10 Describe the method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators. 
229 and 240-1 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made. 229 and 240-1 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias in individual studies (including specification of whether this was done at study or outcome 
level), and how this information is to be used in any data synthesis 
85 
Summary 
measures 
13 State the principal summary measures (such as risk ratio, difference in means). 229 and 240 
Synthesis of 
results 
14 Describe the method of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistics) for 
each meta-analysis. 
85-7 
Risk of bias 
across studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selecting reporting within studies). 87 
Additional 
analyses 
16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-
specified. 
232-3 
Results    
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with 
a flow diagram. 
229-231 and 241-2, Figure 
9-1 and Figure 9-7 
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the 
citations. 
Tables A7-2 to A7-5 
Risk of bias 
within studies 
19 Present data on risk bias of each study and, if available, any outcome-level assessment (see item 12). 230 and 241, Tables A7-2 
and A7-4 
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study: (a) simple summary data for each intervention group and (b) effect 
estimates and confidence intervals, ideally with a forest plot. 
Tables A7-2 to A7-5, Figures 
9-2, 9-4, 9-8 and 9-9 
Synthesis of 
results 
21 Present the main results of the review.  If meta-analyses are done, include for each, confidence intervals and measures of inconsistency. 231-3, 242 and 244, Figures 
9-2, 9-4, 9-8 and  
9-9 
Risk of bias 
across studies 
22 Present results of any assessment of risk of bias across studies (see item 15). 238-240 and 244 
Additional 
analysis 
23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) (see item 16). 232-3, Figures 9-3 and 9-5 
Discussion    
Summary of 
evidence 
24 Summarise the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as 
health care providers, uses, and policy makers). 
246-250 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, 
reporting bias). 
250-1 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 251 
Funding    
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Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic 
review 
PhD funded by Servier; 
meta-analyses not 
specifically funded 
Table A7-2: An overview of studies which investigated baseline heart rate as a risk marker and satisfied the inclusion criteria to be included in the meta-
analysis, along with the hazard ratios and 95% confidence intervals for a 5bpm higher baseline heart rate for all-cause and/or cardiovascular death.   
Study Population Number of 
Subjects 
included in 
Study 
Follow-Up Study Quality 
Based on the 
Newcastle-
Ottawa 
Scale96 
Type of Heart Rate Model and Associated Adjusters Hazard Ratio (95% 
Confidence Interval), 
and the Corresponding 
Number of First Events 
that Occurred 
       All-Cause 
Death 
CV Death 
Legeai et al. 
2011206 
General 7147 6 years 7 Baseline resting heart 
rate measured using a 
validated digital 
electronic tensiometer 
Model 2: age; sex; study centre; SBP; smoking status; wine 
consumption; regular fish consumption; BMI; total and HDL 
cholesterol; diabetes status; previous CV disease; living 
alone; disability status; and beta-blocker and calcium 
antagonist use 
1.10 (1.05 
to 1.14) 
n = 615 
1.09 (1.00 
to 1.20) 
n = 110 
Jensen et al. 
2012128 
General 6518 14 years 8 Baseline resting heart 
rate measured by ECG 
Model adjusting for conventional CV risk factors, figrinogen 
and high-sensitive C-reactive protein: blood pressure; BMI; 
smoking; drinking habits; log(FEV1), log(triglycerides); 
physical activity; log(high-senstivie C-reactive protein); and 
fibrinogen 
1.04 (1.02 
to 1.07) 
n = 1923 
1.07 (1.03 
to 1.10) 
n = 634 
Johansen et al. 
2013132 
General 653 6.3 years 7 Baseline resting heart 
rate 
Model 5: SBP; age; sex; smoking; diabetes; total cholesterol; 
high-sensitive C-reactive protein; NT-proBNP; use of beta-
blockers; ACE-inhibitors/ARBs; diuretics; and calcium 
channel blockers 
1.11 (1.01 
to 1.22) 
n = 80 
- 
Wang et al. 
2014134 
General 92562 4 years 7 Baseline resting heart 
rate measured by ECG 
Model 3: age; sex; average monthly income of each family 
member; education level; marital status; BMI; waist 
circumference; smoking status; drinking status; physical 
activity; high-sensitive C-reactive protein; hypertension; 
diabetes; and dyslipidaemia 
1.09 (1.06 
to 1.11) 
n = 1589 
- 
Ho et al. 
2014204 
General 4058 19 years 8 Baseline resting heart 
rate measured by ECG 
Multivariable model: age; sex; SBP; use of antihypertensive 
treatment; BMI; diabetes; smoking status; physical activity 
index; valvular heart disease; ECG LV hypertrophy; total/HDL 
cholesterol ratio; minor CV disease; and PR and QRS duration 
1.07 (1.05 
to 1.10) 
n = 1186 
1.08 (1.02 
to 1.14) 
n = 252 
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Hillis et al. 
2012141 
Type 2 
Diabetes 
11138 4.4 years 7 Baseline resting heart 
rate measured using a 
digital monitor 
Multiple covariate adjusted model: age; sex; ADVANCE Study 
BP treatment arm; ADVANCE Study glycaemic control arm; 
BMI; duration of diabetes; HbA1c; urinary albumin/creatinine 
ratio; eGFR; SBP; DBP; history of hospitalisation for HF; 
participation in moderate and/or vigorous exercise for >15 
min at least once weekly; total cholesterol; triacylglycerol 
level; AF; treatment with calcium channel blockers and 
treatment with beta-blockers 
1.07 (1.04 
to 1.10) 
n = 879 
1.08 (1.03 
to 1.12) 
n = 468 
Palatini et al. 
2002147 
Hypertensive 4682 2 years 7 Baseline resting heart 
rate, referred to as 
clinical heart rate in the 
paper 
 
Sex; age; CV complications at entry; diabetes at entry; 
smoking and drinking habits; SBP; and haemoglobin levels 
1.18 (1.08 
to 1.30) 
n = 145 
1.11 (0.97 
to 1.26) 
n = 80 
Julius et al. 
2012212 
Hypertensive 15193 5 years 7 Baseline resting heart 
rate measured by ECG 
Model 3: SBP; age; gender; race; BMI; total cholesterol; 
smoking; diabetes mellitus; history of CHD; history of 
cerebrovascular disease; history of PAD; LV hypertrophy; use 
of beta-blockers, calcium antagonists or other 
antihypertensive drugs 
1.09 (1.07 
to 1.11) 
n = 1612 
- 
Ortiz et al. 
2010151 
CHD 1264 2.1 years 8 Baseline resting heart 
rate measured by ECG 
Final multivariable model also adjusted for LVEF: age; DBP; 
AF; treatment with beta-blockers, diuretics or digoxin; LVEF  
1.05 (0.86 
to 1.22) 
n = 33 
- 
Parodi et al. 
2010159 
Post-MI/ACS 2477 0.5 years 7 Presenting/baseline 
heart rate assessed by a 
calliper in the patient 
diagnostic ECG 
Age; peak creatinine-kinase value; cardiogenic shock; 
suboptimal PCI result; previous infarction 
1.32 (1.23 
to 1.42) 
n = 174 
- 
Timoteo et al. 
2011161 
Post-MI/ACS 1126 1 year 7 Admission heart rate Age; previous PCI; smoking; diabetes; SBP; ACE inhibitors; 
beta-blocker; statins; LVEF <35%; STEMI; PCI; and natural 
log(CK) 
1.05 (1.02 
to 1.12) 
n = 120 
- 
Antoni et al. 
2012169 
Post-MI/ACS 1429 1 year and 
4 years 
8 Discharge heart rate 
measured by ECG 
Age; Killip class ≥2; the left anterior descending coronary 
artery as culprit vessel; and LVEF 
1-Year 
1.35 (1.22 
to 1.50) 
n = 44 
1-Year 
1.29 (1.13 
to 1.46) 
n = 32 
       4- Years 
1.26 (1.16 
to 1.36) 
n = 83 
4-Years 
1.24 (1.12 
to 1.37) 
n = 52 
Noman et al. 
2013164 
Post-MI/ACS 2310 1.6 years 8 Admission heart rate 
measured by ECG 
Age; sex; haemoglobin; creatinine; diabetes; previous MI; 
anterior MI; SBP; multivessel disease; onset to balloon; TIMI 
3-flow post-primary PCI 
1.08 (1.04 
to 1.12) 
n = 236 
- 
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Jensen et al. 
2013170 
Post-MI/ACS 2029 2 years 7 Discharge heart rate 
measured by ECG 
Age; sex; HF at admission; indication for PCI; and use of ACE-
inhibitors/ARBs at discharge 
1.22 (1.10-
1.36) 
n missing 
- 
Seronde et al. 
2013171 
Post-MI/ACS 3079 1 year and 
5 years 
8 Discharge heart rate Type of infarction (STEMI or NSTEMI); age; sex; previous 
infarction; previous stroke; previous HF; history of cancer or 
chronic pulmonary disease; eGFR; SBP; Killip Class; 
haemoglobin level; LV dysfunction; treatments; use of 
coronary angiography; revascularisation; and the TIMI risk 
score 
1-Year 
1.06 (1.01 
to 1.11) 
n = 242 
- 
       5-Years 
1.04 (1.01 
to 1.08) 
n = 643 
- 
Vazir et al. 
2014215 
HF 7599 3.17 years 7 Baseline resting heart 
rate recorded by 
palpation, or from 
auscultation of the 
heart, or from ECG 
Age; sex; randomisation to candesartan; ejection fraction; 
previous hospitalisation for HF; history of diabetes; BMI; DBP; 
NYHA class; beta-blocker dose and digoxin use; cardiomegaly 
on chest X-ray; AF 
1.03 (1.01 
to 1.05) 
n = 1831 
1.03 (1.01 
to 1.05) 
n = 1460 
Fox et al. 
2008184 
(equivalent to 
BEAUTIFUL in 
Table A7-2) 
LV Dysfunction 
and CHD 
5438 1.58 years 7 Baseline resting heart 
rate measured by ECG 
Age, smoking, body mass index, history of diabetes, previous 
MI, previous PCI or CABG, PAD, SBP, DBP, LVEF, NYHA class, 
and treatment with aspirin, beta-blocker, statin, diuretics 
(excluding anti-aldosterone), organic nitrates, and anti-
aldosterone agents at randomisation 
- 1.08 (1.03 
to 1.12) 
n = 435 
Fosbol et al. 
2010183 
(DIAMOND-HF) 
LV Dysfunction 
and HF 
1518 10 years 7 Baseline resting heart 
rate measured by ECG 
Age; sex; history of CHD; smoke status; QRS duration; PR-
interval; history of diabetes; renal function (creatinine 
clearance); AF; Wall Motion Index; NYHA class; haemoglobin 
levels; and presence of clinical HF 
1.04 (1.02 
to 1.07) 
n = 1336 
- 
Fosbol et al. 
2010183 
(DIAMOND-MI) 
LV Dysfunction 
and Post-
MI/ACS 
1510 10 years 7 Baseline resting heart 
rate 
Age; sex; history of CHD; smoke status; QRS duration; PR-
interval; history of diabetes; renal function (creatinine 
clearance); AF; Wall Motion Index; NYHA class; haemoglobin 
levels; and presence of clinical HF 
1.08 (1.05 
to 1.11) 
n = 2412 
- 
Bemelmans et 
al. 2013188 
Vascular 
Disease 
4272 4.4 years 8 Baseline resting heart 
rate measured by ECG 
Age; gender; beta-blockers; calcium channel blockers; alpha-
blockers; diuretics; current smoking; inclusion diagnosis 
(CHD, AAA, PAD or CV disease); BMI; eGFR; type 2 diabetes; 
SBP 
1.07 (1.04 
to 1.10) 
n = 513 
- 
Nanchen et al. 
2013138 
(equivalent to 
PROSPER in 
Table A7-2) 
Vascular 
Disease 
4084 3.2 years 7 Baseline resting heart 
rate measured by ECG 
Multivariate basic model: age; smoking status; baseline 
diabetes; history of vascular disease; history of angina; 
hypertension; BMI; HDL-cholesterol; TSH; and eGFR 
- 1.11 (1.05 
to 1.16) 
n = 200 
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Lonn et al. 
2014216 
Vascular 
Disease 
31531 4.7 years 7 Baseline resting heart 
rate measured using an 
automated validated 
device 
Model 3: age; sex; diabetes; hypertension; dyslipidaemia; 
current smoking; creatinine; use of beta-blocker; use of 
diltiazem/verapamil; and stratified by treatment allocation 
in the trial 
1.07 (1.05 
to 1.08) 
n = 3779 
1.08 (1.06 
to 1.09) 
n = 2269 
Fox et al. 
2013191 
(equivalent to 
PERFORM in 
Table A7-2)  
Post-Stroke 18980 2.4 years 7 Baseline resting heart 
rate measured by 
palpitation, 
auscultation, or 12-lead 
ECG 
Country; age; gender; smoking; BMI; previous ischemic 
stroke; previous MI; previous TIA; hypertension; diabetes; 
and beta-blockers; statins; and antiplatelet agents after 
qualifying event 
1.08 (1.05 
to 1.11) 
n = 1174 
1.11 (1.07 
to 1.15) 
n = 683 
Note that the result for: Noman et al. 2013164 is the long-term result, not the in-hospital result; Seronde et al. 2013171 does not include the result that excluded patients who had died in the first year of follow-up; 
Bemelmans et al. 2013188 is the result for all of the patients.  Follow-up duration for each study is median or mean follow-up depending on what was stated in the publication; if follow-up was given in months or 
days it was converted to the approximate time in years.   
AAA = Abdominal Aortic Aneurysm; ACE = Angiotensin-Converting Enzyme; ACS = Acute Coronary Syndrome; AF = Atrial Fibrillation; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass Index; CABG = 
Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; CK = Creatin Kinase; CV = Cardiovascular; DBP = Diastolic Blood Pressure; ECG = Electrocardiography; eGFR = estimated Glomerular 
Filtration Rate; FEV = Forced Expiratory Volume; HDL = High-Density Lipoprotein; HF = Heart Failure; HbA = Glycated Haemoglobin;  LV = Left-Ventricular; LVEF= Left-Ventricular Ejection Fraction; MI = 
Myocardial Infarction; NSTEM = Non-ST-Segment Elevation MI; NYHA = New York Heart Association; PAD = Peripheral Artery Disease; PCI = Percutaneous Coronary Intervention; SBP = Systolic Blood 
Pressure; STEMI = ST-Segment Elevation MI; TIA = Transient Ischemic Attack; TIMI = Thrombolysis in Myocardial Infarction; TSH = Thyroid-Stimulating Hormone.   
  
418 
 
Table A7-3: An overview of studies conducted in this thesis which investigated baseline heart rate as a risk marker and satisfied the inclusion criteria to be 
included in the meta-analysis, along with the hazard ratios and 95% confidence intervals for a 5bpm higher baseline heart rate for all-cause and/or 
cardiovascular death.   
Study Population Number of 
Subjects 
included in 
Study 
Follow-Up Type of Heart Rate Adjusters Hazard Ratio (95% 
Confidence Interval), and 
the Corresponding 
Number of First Events 
that Occurred 
      All-Cause 
Death 
CV Death 
EUROPA CHD 12208 4.2 years Baseline resting heart rate 
(measured at Study Visit 3) 
Age; sex; history of PCI; history of CABG; peripheral vascular disease; 
diabetes mellitus; hypercholesterolemia; treatment with platelet 
inhibitors; lipid-lowering therapies; beta-blockers; calcium channel 
blockers; and diuretics (potassium-sparing and other); and SBP and DBP 
1.09 (1.05 
to 1.13) 
n = 795 
1.06 (1.02 
to 1.11) 
n = 464 
CAPRICORN  Post-MI with 
LVSD 
981 (Placebo 
Population 
Only) 
1.3 years Baseline resting heart rate Sex, previous diabetes, LVEF, site of MI, and treatment for MI with 
intravenous diuretics 
1.05 (0.98 
to 1.12) 
n = 150 
1.05 (0.98 
to 1.12) 
n = 138 
EPHESUS Post-MI with 
HF or LVSD 
6606 1.33 years Baseline resting heart rate Age; sex; race; BMI; smoking history; diabetes; hypertension; angina; 
prior MI; AF; dyslipidaemia; HF; COPD; DBP; Killip class; and intake of 
certain drugs at randomisation which were aspirin, statins, vitamin K 
antagonists, diuretics and digitalis cardiac glycosides 
1.08 (1.05 
to 1.11) 
n = 1028 
1.08 (1.05 
to 1.11) 
n = 887 
OPTIMAAL Post-MI with 
HF or LVSD 
5461 2.7 years Baseline resting heart rate Age; sex; race; BMI; smoking history; diabetes; hypertension; angina; 
prior MI; AF; dyslipidaemia; HF; COPD; DBP; Killip class; and intake of 
certain drugs at randomisation which were aspirin, statins, vitamin K 
antagonists, diuretics and digitalis cardiac glycosides 
1.09 (1.07 
to 1.11) 
n = 944 
1.10 (1.07 
to 1.12) 
n = 781 
VALIANT Post-MI with 
HF or LVSD 
14669 2.06 years Baseline resting heart rate Age; sex; race; BMI; smoking history; diabetes; hypertension; angina; 
prior MI; AF; dyslipidaemia; HF; COPD; DBP; Killip class; and intake of 
certain drugs at randomisation which were aspirin, statins, vitamin K 
antagonists, diuretics and digitalis cardiac glycosides 
1.07 (1.05 
to 1.08) 
n = 2870 
1.07 (1.06 
to 1.09) 
n = 2477 
BEAUTIFUL 
(equivalent to 
Fox et al. 2008184 
in  Table A7-1) 
LV 
Dysfunction 
and CHD 
5438 1.58 years Baseline resting heart rate 
measured by ECG 
Age, smoking, BMI, history of diabetes, previous MI, previous PCI or 
CABG, PAD, SBP, DBP, LVEF, NYHA class, and treatment with aspirin 
(not including other antithrombotic agents as it was not available in the 
dataset used for the current analysis), beta-blocker, statin, diuretics 
(excluding anti-aldosterone), organic nitrates, and anti-aldosterone 
agents at randomisation 
1.07 (1.03 
to 1.11) 
n = 547 
 
1.08 (1.03 
to 1.13) 
n = 435 
 
SHIFT LV 
Dysfunction 
and HF 
3261 1.91 years Baseline resting heart rate 
measured by ECG 
Beta-blocker intake; NYHA class; LVEF; whether the primary cause of HF 
was ischemic or not; age; SBP; and estimated glomerular filtration rate 
1.13 (1.09 
to 1.18) 
n = 551 
1.14 (1.09 
to 1.18) 
n = 491 
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PROSPER 
(equivalent to 
Nanchen et al. 
2013138 in Table 
A7-1) 
Vascular 
Disease 
5680 3.2 years Baseline resting heart rate 
measured by ECG 
Age; smoking status; diabetes; history of vascular disease; hypertension; 
BMI; HDL-cholesterol; thyroid stimulating hormones; estimated 
glomerular filtration rate eGFR; treatment group (pravastatin or 
placebo); and intake of aspirin, nitrates, diuretics, ACE inhibitors and 
ARBs 
1.08 (1.05 
to 1.12) 
n = 590 
1.07 (1.02 
to 1.13) 
n = 287 
PERFORM 
(equivalent to 
Fox et al. 2013191 
in  
Table A7-1) 
 
Post-Stroke 18993 2.4 years Baseline resting heart rate 
measured by palpitation, 
auscultation, or 12-lead 
ECG, according to the 
investigator’s decision 
Age, gender, smoking, BMI, prior ischemic stroke, prior MI, prior TIA, 
hypertension, diabetes and the intake of beta-blockers, statins, and 
antiplatelet agents after the qualifying event 
1.08 (1.05 
to 1.11) 
n = 1174 
1.12 (1.08 
to 1.17) 
n = 436 
Note that the CAPRICORN results are taken from the time-updated CAPRICORN analysis (Chapter 4 Section 4.2) that included only the placebo patients. 
ACE = Angiotensin-Converting Enzyme; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass Index; CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; COPD = Chronic Obstructive 
Pulmonary Disease; DBP = Diastolic Blood Pressure; HF = Heart Failure; LV = Left-Ventricular; LVEF = Left-Ventricular Ejection Fraction; MI = Myocardial Infarction; NYHA = New York Heart Association; PCI 
= Percutaneous Coronary Intervention; TIA = Transient Ischemic Attack. 
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Table A7-4: An overview of studies which investigated time-updated heart rate as a risk marker and satisfied the inclusion criteria to be included in the 
meta-analysis, along with the hazard ratios and 95% confidence intervals for a 5bpm higher time-updated heart rate for all-cause and/or cardiovascular 
death.   
Study Population Number of 
Subjects 
included in 
Study 
Follow-Up Study Quality 
Based on the 
Newcastle-
Ottawa 
Scale96 
Type of Heart Rate Model and Associated Adjusters Hazard Ratio (95% 
Confidence Interval), 
and the Corresponding 
Number of First Events 
that Occurred 
       All-Cause 
Death 
CV Death 
Ho et al. 
2014204 
General 4058 19 years 8 Time-updated resting 
heart rate measured at 
baseline and updated 
over 8 years post-
baseline, measured using 
an ECG 
Multivariable-adjusted model for heart rate as a time-dependent 
variable: age; sex; SBP; use of antihypertensive treatment; BMI; 
diabetes; smoking status; physical activity index; valvular heart 
disease; ECG LV hypertrophy; total/HDL cholesterol ratio; minor 
CV disease; and PR and QRS duration 
1.08 (1.05 
to 1.11) 
n = 1186 
1.08 (1.02 
to 1.13) 
n = 252 
O’Hartaigh 
et al. 
2015207 
General 5691 7.9 years 8 Time-updated resting 
heart rate measured at 
baseline and at 6 annual 
assessments post-
baseline 
Multivariable model: age; sex; smoke; exercise intensity; 
education level; BMI; type 2 diabetes mellitus; C-reactive 
protein; interleukin-6; CHD; congestive HF; race; hypertension; 
HDL and LDL cholesterol; AF; ACE-inhibitors; aspirin; beta-
blocker; and calcium channel blocker therapy 
1.15 (1.12 
to 1.18) 
n = 974 
- 
Okin et al. 
2010210 
Hypertensive 9190 4.8 years 7 Time-updated heart rate 
measured at baseline and 
throughout follow-up, 
using an ECG 
Multivariable model: baseline heart rate; treatment with losartan 
vs. atenolol; age; gender; race; prevalent diabetes; history of 
CHD; AF; congestive HF; stroke; peripheral vascular disease; 
smoking; albumin/creatinine ratio; total and HDL cholesterol; 
serum creatinine; BMI; incident MI; baseline and time-updated 
systolic and diastolic blood pressure; QRS duration; Sokolow-Lyon 
voltage; and Cornell voltage-duration product 
1.12 (1.08 
to 1.15) 
n = 814 
1.08 (1.03 
to 1.13) 
n = 438 
Vazir et al. 
2014215 
HF 7599 3.17 years 7 Time-updated heart rate 
measured at baseline and 
throughout follow-up, 
recorded by palpation, or 
from auscultation of the 
heart, or from ECG 
Age; sex; randomisation to candesartan; ejection fraction; 
previous hospitalisation for HF; history of diabetes at baseline; 
BMI; DBP; NYHA functional class; beta-blocker dose; and digoxin 
use at any time during the study; cardiomegaly on chest X-ray; AF 
at baseline; and baseline heart rate 
1.09 (1.07 
to 1.11) 
n = 1831 
1.08 (1.06 
to 1.10) 
n = 1460 
ACE = Angiotensin Converting Enzyme; AF = Atrial Fibrillation; BMI = Body Mass Index; CHD = Coronary Heart Disease; CV = Cardiovascular; DBP = Diastolic Blood Pressure; ECG = 
Electrocardiographic/Electrocardiography; HDL = High Density Lipoprotein; HF = Heart Failure; LDL = Low Density Lipoprotein; LV = Left-Ventricular; MI = Myocardial Infarction; NYHA = New York Heart 
Association.  
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Table A7-5: An overview of studies conducted in this thesis which investigated time-updated heart rate as a risk marker and satisfied the inclusion criteria 
to be included in the meta-analysis, along with the hazard ratios and 95% confidence intervals for a 5bpm higher time-updated heart rate for all-cause 
and/or cardiovascular death.   
Study Population Number of 
Subjects 
included in 
the Study 
Follow-Up Type of Heart Rate Adjusters Hazard Ratio (95% 
Confidence Interval), and 
the Corresponding 
Number of First Events 
that Occurred 
      All-Cause 
Death 
CV Death 
EUROPA Stable CHD 12208 4.2 years Baseline (measured at Study 
Visit 3) and time-updated 
resting heart rate measured 
at 3, 6 and 12 months after 
randomisation, and at 6-
montly intervals thereafter 
Age; sex; history of PCI; history of CABG; peripheral vascular disease; 
diabetes mellitus; hypercholesterolemia; treatment with platelet 
inhibitors; lipid-lowering therapies; beta-blockers; calcium channel 
blockers; and diuretics (potassium-sparing and other); and SBP and DBP 
1.17 (1.13 
to 1.20) 
n = 795 
1.11 (1.07 
to 1.16) 
n = 464 
     Additionally adjusted for baseline heart rate 1.16 (1.13 
to 1.20) 
n = 795 
1.10 (1.06 
to 1.15) 
n = 464 
BEAUTIFUL CHD with LV 
Dysfunction 
5438 1.58 years Baseline and time-updated 
resting heart rate measured 
at 2 weeks, 1, 3 and 6 months 
after randomisation, and 
every 6 months thereafter 
Age, smoking, BMI, history of diabetes, previous MI, previous PCI or CABG, 
PAD, SBP, DBP, LVEF, NYHA class, and treatment with aspirin (not including 
other antithrombotic agents as it was not available in the dataset used for 
the current analysis), beta-blocker, statin, diuretics (excluding anti-
aldosterone), organic nitrates, and anti-aldosterone agents at 
randomisation 
1.14 (1.10 
to 1.17) 
n = 547 
1.14 (1.10 
to 1.18) 
n = 435 
     Additionally adjusted for baseline heart rate 1.14 (1.10 
to 1.19) 
n = 547 
1.14 (1.09 
to 1.19) 
n = 435 
CAPRICORN Post-Acute MI 
with LV 
Dysfunction 
981 1.3 yeras Baseline and time-updated 
resting heart rate measured 
at 3-month intervals during 
the first year of follow-up, 
and at 4-month intervals 
thereafter 
Sex, previous diabetes, LVEF, site of MI, and treatment for MI with 
intravenous diuretics 
1.12 (1.06 
to 1.18) 
n = 150 
1.10 (1.04 
to 1.07) 
n = 138 
     Additionally adjusted for baseline heart rate 1.12 (1.06 
to 1.18) 
n = 150 
1.10 (1.03 
to 1.17) 
n = 138 
SHIFT HF with LV 
Dysfunction 
3261 1.91 years Baseline and time-updated 
resting heart rate measured 
at 28 days post-baseline, and 
every four months thereafter 
Beta-blocker intake; NYHA class; LVEF; whether the primary cause of heart 
failure was ischemic or not; age; SBP; and estimated glomerular filtration 
rate 
1.17 (1.14 
to 1.21) 
n = 551 
1.18 (1.14 
to 1.21) 
n = 491 
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     Additionally adjusted for baseline heart rate 1.16 (1.13 
to 1.20) 
n = 551 
1.16 (1.13 
to 1.20) 
n = 491 
PROSPER Vascular 
Disease 
5680 3.2 years Baseline and time-updated 
resting heart rate measured 
annually  
Age; smoking status; diabetes; history of vascular disease; hypertension; 
BMI; HDL-cholesterol; thyroid stimulating hormones; estimated glomerular 
filtration rate; treatment group (pravastatin or placebo); and intake of 
aspirin, nitrates, diuretics, ACE inhibitors and ARBs 
1.12 (1.09 
to 1.15) 
n = 590 
1.11 (1.06 
to 1.16) 
n = 287 
     Additionally adjusted for baseline heart rate 1.12 (1.08 
to 1.17) 
n = 590 
1.11 (1.05 
to 1.18) 
n = 287 
PERFORM Post-Stroke 18993 2.4 years Baseline and time-updated 
resting heart rate measured 
at 1, 3 and 6 months after 
randomisation, and at 6-
monthly intervals thereafter 
Age, gender, smoking, BMI, prior ischemic stroke, prior MI, prior TIA, 
hypertension, diabetes and the intake of beta-blockers, statins, and 
antiplatelet agents after the qualifying event 
1.16 (1.13 
to 1.19) 
n = 1174 
1.16 (1.11 
to 1.21) 
n = 436 
     Additionally adjusted for baseline heart rate 1.15 (1.11 
to 1.18) 
n = 1174 
1.13 (1.08 
to 1.16) 
n = 436 
ACE = Angiotensin Converting Enzyme; ARB = Angiotensin II Receptor Blocker; BMI = Body Mass Index; CABG = Coronary Artery Bypass Graft; CHD = Coronary Heart Disease; DBP = Diastolic Blood 
Pressure; HDL = High Density Lipoprotein; HF = Heart Failure; LV = Left-Ventricular; MI = Myocardial Infarction; NYHA = New York Heart Association; PAD = Peripheral Artery Disease; PCI = Percutaneous 
Coronary Intervention; SBP = Systolic Blodd Pressure; TIA = Transient Ischemic Attack.   
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